


International Agency for Research on Cancer



BIENNIAL REPORT



20/21

BIENNIAL REPORT

2020–2021

INTERNATIONAL AGENCY FOR RESEARCH ON CANCER

LYON, FRANCE

2021

© International Agency for Research on Cancer 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 IGO licence (CC BY-NC-ND 3.0 IGO; <https://creativecommons.org/licenses/by-nc-nd/3.0/igo/>).

Under the terms of this licence, you may copy and redistribute the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products, or services. The use of the WHO logo is not permitted.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation.

IARC (2021). IARC Biennial Report 2020–2021. Lyon, France: International Agency for Research on Cancer. Available from: <https://publications.iarc.fr/607>. Licence: CC BY-NC-ND 3.0 IGO.

Sales, rights and permissions.

To purchase print copies distributed by WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland, see <http://apps.who.int/bookorders>. Tel.: +41 22 791 3264; Fax: +41 22 791 4857; email: bookorders@who.int.

To purchase IARC publications in electronic format, see the IARC Publications website (<https://publications.iarc.fr>).

To submit requests for adaptations or commercial use and queries on rights and licensing, see the IARC Publications website (<https://publications.iarc.fr/Rights-And-Permissions>).

Third-party materials.

If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO or contributing agencies concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO or contributing agencies in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO or contributing agencies be liable for damages arising from its use.

Cover image: © AdobeStock.com/Goinky.

IARC Library Cataloguing in Publication Data

Names: International Agency for Research on Cancer.

Title: IARC biennial report 2020–2021 | International Agency for Research on Cancer.

Description: Lyon: International Agency for Research on Cancer, 2021. | Series: IARC biennial reports, ISSN 0250-8613. | Includes bibliographical references.

Identifiers: ISBN 978-92-832-1106-8 (ebook)

Subjects: MESH: Annual Report.

Classification: NLM W2

TABLE OF CONTENTS

Introduction	1
Scientific Structure	3
IARC Lectures	4
Section of Cancer Surveillance	7
Section of Evidence Synthesis and Classification	13
IARC Monographs Group	15
IARC Handbooks Group	17
WHO Classification of Tumours Group	19
Section of Mechanisms of Carcinogenesis	22
Epigenetics Group	23
Molecular Mechanisms and Biomarkers Group	27
Section of Infections	31
Infections and Cancer Biology Group	33
Infections and Cancer Epidemiology Group	34
Section of Environment and Radiation	39
Section of Nutrition and Metabolism	46
Biomarkers Group	48
Nutritional Epidemiology Group	50
Nutritional Methodology and Biostatistics Group	51
Section of Genetics	54
Genetic Epidemiology Group	56
Genetic Cancer Susceptibility Group	58
Section of Early Detection and Prevention	62
Prevention and Implementation Group	64
Screening Group	66
Office of the Director	70
New IARC Initiatives	73
Communications Group	75
Education and Training Group	78
Laboratory Services and Biobank Group	85
Section of Support to Research	89
Committees	92
Laboratory Steering Committee	92
Biobank Steering Committee	92
Computational Biology, Bioinformatics, and Biostatistics Committee	93
Ethics Committee	93
Occupational Health and Safety Committee	93
Governing and Scientific Councils	94
Staff Publications	108
Collaborators	144
Acknowledgements	154



INTRODUCTION – FROM THE IARC DIRECTOR

This Biennial Report covers the period 2020–2021 and showcases a selection of the work conducted by the International Agency for Research on Cancer (IARC) in collaboration with its global network of experts. This time, the Biennial Report has an associated webpage (<https://www.iarc.who.int/biennial-report-2020-2021web/>) that highlights key cancer data and key figures on IARC. Furthermore, in line with the changing environment and the Agency's efforts to “green the blue”, IARC is no longer providing paper copies of its Governance documents, and this Biennial Report is the first to be produced in electronic format only.

IARC's latest estimates show that the global cancer burden rose to 19.3 million new cases and 10.0 million cancer deaths in 2020. Cancer is expected to surpass cardiovascular disease as the leading cause of premature death in most countries during this century. One of IARC's most striking discoveries is that, for the first time, female breast cancer has overtaken lung cancer as the most commonly diagnosed cancer worldwide. IARC predicts that by 2040 cancer incidence will almost double, to 30.2 million new cases. This Biennial Report highlights several studies that show the long-term beneficial impacts of preventive interventions, emphasizing

the tremendous potential for prevention to invert the projected trends in cancer incidence and mortality.

Because of the COVID-19 pandemic, the past two unprecedented years have brought IARC many challenges. From March to May 2020, we adapted to working remotely. IARC's operations continued thanks to the outstanding commitment of its personnel and significant investment in the digitalization of its activities. Subsequently, there was a gradual return to on-site operations, with most personnel (~70%) working remotely for the following months. Despite the challenges, IARC successfully conducted most of its research remotely and deployed innovative tools and technologies such as digital signatures and online conferencing solutions. For the first time in IARC's history, all meetings were successfully transformed into virtual meetings, including five *Mono-graphs* meetings, two *Handbooks of Cancer Prevention* meetings, the IARC Scientific Council session in 2021 and the IARC Governing Council sessions in 2020 and 2021, in addition to various other scientific events. Unfortunately, the COVID-19 pandemic had a negative impact on IARC's fundraising activities and resulted in the suspension of certain activities and projects that could not be conducted remotely, such as fieldwork.

In response to the pandemic, IARC assessed its impact on health at the national level and on the outcomes of current and future patients with cancer. IARC participated in the COVID-19 and Cancer Global Taskforce and became a founding partner of the COVID-19 and Cancer Global Modelling Consortium, with a remit to co-develop tools and provide evidence to aid decision-making during and after the pandemic. IARC was able to clearly assess the negative impact that the pandemic has had; it interrupted registry operations, disrupted screening programmes, and delayed patient diagnosis and initiation of treatment. The long-term, large-scale cancer aftershock will be strongly felt in the coming years.

Despite the pandemic, IARC continued to fulfil its mission, and after more than a year of external consultation, reflection, and discussion, the IARC Medium-Term Strategy 2021–2025 was finalized and adopted by the IARC Governing Council in May 2021. This exciting new roadmap will guide IARC for the next 5 years. The Medium-Term Strategy is based on the IARC Statute and an objective that has guided IARC's work since 1965: *to promote international collaboration in cancer research*. In 2021–2025, IARC will focus its work on areas where it has the greatest public health impact and where it can make the biggest difference to

people's lives. This ambition has forged IARC's future strategy and defined its fundamental and emerging priorities.

IARC continues to address its *fundamental priorities*: Data for Action (to describe the occurrence of cancer), Understanding the Causes (to identify cancer risk factors), From Understanding to Prevention (to effectively implement cancer research), and Knowledge Mobilization (to share knowledge about cancer). In addition to its fundamental priorities, IARC has identified three *emerging priorities* that are important and evolving global issues for cancer prevention research: Evolving Cancer Risk Factors and Populations in Transition, Implementation Research, and Economic and Societal Impacts of Cancer. IARC will gradually strengthen

its engagement in these three emerging priorities, increasing its activity in *implementation research*.

Aiming for a more agile organization, IARC's organizational structure was reviewed and revised to enable greater flexibility in resource management and to promote collaboration across the Agency. In 2021, the former Section and Group structure (as reflected in this Biennial Report) was replaced by a Branch structure. This structure is complemented by the conceptual idea of four scientific Pillars representing IARC's four fundamental research priorities, as described above.

The adoption of the Medium-Term Strategy was a major milestone, and one of IARC's greatest achievements during

this biennium was to welcome China as a new Participating State in May 2021. I am confident that this engagement will further strengthen international cooperation and the strategic coordination of scientific research for cancer prevention and control.


With a new Medium-Term Strategy and a new Participating State, IARC looks forward to an exciting move to its Nouveau Centre building, a new state-of-the-art headquarters from which to undertake its mission to reduce the burden of and suffering from cancer, now and for future generations. Cancer research that matters.



Dr Elisabete Weiderpass. © IARC.

International Agency for Research on Cancer World Health Organization

1 December 2020



IARC LECTURES

In 2020 and 2021, IARC was honoured and delighted to host seminars that were delivered by some of the world's most eminent speakers in the fields of cancer research, prevention, implementation science, and health inequalities, as well as cancer initiatives currently under way at both the European and global levels.

7TH IARC CANCER AND SOCIETY LECTURE

March 2020 Emily Banks (Australian National University, Australia) – Cancer control: public health solutions to our greatest challenges




Professor Emily Banks

IARC DISTINGUISHED SPEAKER SERIES

These distinguished speakers were invited to present topics of interest within the framework of regular Town Hall meetings, which were broadcast online after March 2020 because of the COVID-19 pandemic.

- January 2020 Rashmi Sinha (National Cancer Institute, USA and IARC Senior Visiting Scientist Awardee, NME) – New Year Lecture: moving microbiome research into population studies
- February 2020 Lin Fritschi (Curtin University, Australia and IARC Senior Visiting Scientist Awardee, IMO) – Occupational cancer epidemiology
- June 2020 Christine Friedenreich (Cancer Control Alberta and University of Calgary, Canada) – Physical activity across the cancer continuum: epidemiologic evidence and biologic mechanisms
- January 2021 Paolo Vineis (Imperial College London, United Kingdom and the Italian Institute of Technology, Italy) – Cancer and the Green New Deal
- February 2021 Benjamin O. Anderson (World Health Organization (WHO), Breast Health Global Initiative (BHGI), Fred Hutchinson Cancer Research Center, and University of Washington, USA) – Global Breast Cancer Initiative (GBCI): a catalyst for change in global oncology and noncommunicable diseases (NCDs)

April 2021	David A. Chambers (National Cancer Institute, USA) – Advancing implementation science in cancer: progress, assumptions, and next steps	September 2021	Véronique Trillet-Lenoir (European Parliament, Belgium) – Strengthening Europe in the fight against cancer: towards a comprehensive and coordinated strategy
April 2021	Anne F. Rositch (Johns Hopkins Bloomberg School of Public Health, USA) – Dissemination and implementation science: research to reduce the global burden of cancer	October 2021	Christine Chomienne (Institute de Recherche Saint Louis, Université de Paris) – Horizon Europe Cancer Mission: preparation and launch of the implementation plan
May 2021	Karen Canfell (The Daffodil Centre and University of Sydney, Australia) – The journey towards cervical cancer elimination: how far have we come, and how far is there to go?	November 2021	Ophira Ginsburg (New York University Grossman School of Medicine, USA and IARC Senior Visiting Scientist Awardee, CSU) – Women, power, and the cancer divide
June 2021	Michael G. Marmot (University College London, United Kingdom) – Social justice and health equity	November 2021	Arash Etemadi (National Cancer Institute, USA) – Biomarkers: the lingua franca of global cancer research
September 2021	Mark Jonathan Caulfield (Queen Mary University of London, United Kingdom) – Transforming cancer genomics in healthcare		




■ No data □ Not applicable

The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Data source: GHE 2016
Map production: CSU
World Health Organization

World Health Organization
© WHO 2020. All rights reserved



SECTION OF CANCER SURVEILLANCE (CSU)

Section head

Dr Freddie Bray

Deputy section head

Dr Isabelle Soerjomataram

Professional staff

Dr Melina Arnold
Dr Hadrien Charvat
(until March 2020)
Mr Morten Ervik
Mr Jacques Ferlay
Dr Claire Marant-Micallef
(until June 2020)
Dr Filip Meheus (until August 2021)
Mr Les Mery
Dr Marion Piñeros-Petersen
Dr Eva Steliarova-Foucher
Dr Salvatore Vaccarella
Dr Ariana Znaor

Technical and administrative staff

Ms Aude Bardot
Ms Murielle Colombet
Ms Anastasia Dolya
Ms Maria Fernan
Mr Frédéric Lam
Mr Mathieu Laversanne
Ms Fatiha Louled
Mr Eric Masuyer
Ms Sarah Sherwood
Ms Katuska Veselinović
Mr Jérôme Vignat

Visiting scientists

Dr Therese Andersson
(until December 2021)
Dr Hadrien Charvat
(until September 2021)
Dr Katie Connor (until June 2020)
Dr Ophira Ginsburg
Dr Tor Åge Myklebust
(until December 2020)
Dr Max Parkin (until December 2021)
Dr Mark Rutherford
(until December 2021)
Dr Kamal Seneviratne
Dr Anne Julie Tybjerg
(until March 2021)

Postdoctoral fellows and doctoral students

Dr Manushak Avagyan
Dr Citadel Cabasag
Dr Neimar de Paula Silva
Dr Andrea Gini
Dr Meng Meng Li
(until September 2020)
Dr Joannie Lortet-Tieulent
(until February 2020)
Dr Allini Mafra (until July 2021)
Dr Adalberto Miranda Filho
(until November 2020)
Dr Eileen Morgan
Dr Jean Niyigaba
Ms Harriet Rungay
Dr Richa Shah
Dr Raphaël Simon
(until November 2020)
Dr Deependra Singh
Dr Patumrat Sripan
Dr Andras Weber

Students

Mr Javier Benitez Fuentes
(until November 2021)
Ms Paula Fagan
Ms Clara Frick (until December 2021)
Ms Mirjam Kohls (until July 2020)
Mr Oliver Langselius
(until August 2021)
Ms Katarina Malakova
(until June 2020)
Ms Margherita Pizzato
Ms Yaqi Su (until September 2021)
Ms Odayar Varsini (until August 2021)

With long-standing expertise in cancer registration and descriptive epidemiology, the Section of Cancer Surveillance (CSU) serves as a reference to the global cancer community in the provision of national cancer indicators, developed through a collaborative research programme. The research activities are complemented by support and advocacy for local data collection, and a key aim of CSU is the provision of measurable improvements in the coverage, quality, and networking capacity of population-based cancer registries (PBCRs) in low- and middle-income countries (LMICs). The core priorities of CSU are:

- to consolidate the role of IARC as a definitive source of data and statistics describing the global cancer burden in children, adolescents, and adults;
- to ensure that locally recorded high-quality cancer data are available to governments in LMICs, to inform priorities for national cancer control;
- to describe and interpret the changing magnitude and the transitional nature of cancer profiles around the world; and
- to advocate the health, social, and economic benefits of cancer prevention, through a systematic quantification of the future impact of effective interventions.

With the start of the new IARC Medium-Term Strategy 2021–2025 and the new organizational structure as of 1 January 2021, CSU was renamed as the Cancer Surveillance Branch. A brief summary of CSU activities during the 2020–2021 biennium is provided here.

CANCER REGISTRY SUPPORT AND COLLABORATION

CSU provides the Secretariat for the International Association of Cancer Registries (IACR; <http://www.iacr.com.fr>), the professional society dedicated to fostering the aims of PBCRs worldwide through meetings, advocacy, and developing registry standards and tools. An IACR survey revealed the operational impact of the COVID-19 pandemic on PBCRs in the early months of the crisis; two thirds of the respondents reported disruptions. With international travel on hold, the 42nd IACR Annual Scientific Conference was held virtually over 3 days in October 2021; this free event was attended by more than 400

members worldwide. A major focus was facilitating the recording of comparable cancer staging data internationally.


The Global Initiative for Cancer Registry Development (GICR; <https://gicr.iarc.fr/>) brings together agencies committed to working collaboratively to improve surveillance worldwide. A virtual IARC–GICR course on tumour–node–metastasis (TNM) staging and the Essential TNM was held for participants from 11 Eastern Mediterranean countries in November 2020. The CanStaging⁺ tool was launched by IARC in August 2021 (Figure 1) (Ervik et al., 2021) as part of the International Cancer Benchmarking Partnership (ICBP SURVMARK-2), and a Perspective was published in *The Lancet Oncology* (Soerjomataram et al., 2021b). Several ICBP SURVMARK-2 studies sought to better understand variations in staging, histology, and registry practices in the context of international survival comparisons (Cabasag et al., 2020a, 2021; Myklebust et al., 2020; Andersson et al., 2021a; Araghi et al., 2021a; Morgan et al., 2021a). CSU participated in the IARC/WHO Committee for the International Classification of Diseases for Oncology (ICD-O), tasked with updating the ICD-O-3 morphology included in revised editions of the *WHO Classification of Tumours* (also known as the WHO Blue Books), and disseminating

the resulting changes to the registry community. Finally, the call for data for Volume XII of the joint IACR–IARC publication *Cancer Incidence in Five Continents* (covering diagnoses made during 2013–2017) was launched in July 2021, combined with the SURVCAN-4 call for selected registries.

The GICR^{Net} continued to expand its network of IARC–GICR Regional Trainers. To compensate for the limited opportunities to meet in person during the biennium, 14 e-learning modules were developed together with Vital Strategies and the African Cancer Registry Network (AFCRN), supported by Bloomberg Philanthropies. In July 2021, the second IARC–GICR Summer School was held virtually in collaboration with the National Cancer Center of the Republic of Korea. The introduction of GICR Partner Countries provided greater focus on registries, and there are strong prospects for further improvement. In addition, regional support was increased through the integration of IARC–GICR Collaborating Centres to complement the work of the Regional Hubs.

From June 2020, IARC entered into a bilateral agreement with St. Jude Children’s Research Hospital (USA) to implement the Targeting Childhood Cancer through the GICR (ChildGICR) project, an

Figure 1. Screenshot of the CanStaging⁺ tool (<https://canstaging.org/>). © IARC.



extension of the GICR programme to build national childhood cancer surveillance capacity in LMICs via implementation, education, and research. Networking workshops involving local stakeholders were held virtually in four target countries: Georgia, Mexico, South Africa, and Viet Nam. An educational highlight was the online ChildGICR Masterclass that started in April 2021. Over 12 weeks, 22 GICRNet participants worked together with global leaders to jointly co-develop educational materials on the principles of childhood cancer registration (Figure 2); the participants continue to actively network to build regional capacity.

In collaboration with WHO regional offices, CSU developed several position papers discussing surveillance data to inform policies in Latin America (Piñeros et al., 2021a) and the Eastern Mediterranean (Znaor et al., 2021a). CSU also developed roadmaps for the surveillance of cervical cancer (Figure 3) (Piñeros et al., 2021b) and childhood cancer (Piñeros et al., 2021c), to complement the scale-up of the respective WHO signature initiatives. Collaborative studies examining the status of registration in China (Wei et al., 2020) and the Russian Federation (Barchuk et al., 2021a) were published. CSU also participated in the *Lancet Oncology* Commission on sustainable

care for children with cancer (Atun et al., 2020).

THE GLOBAL CANCER OBSERVATORY: LINKING RESEARCH TO ACTION

CSU disseminates global cancer statistics through the Global Cancer Observatory (<https://gco.iarc.fr/>), an interactive web-based platform comprising multiple subsites. The Cancer Today subsite was updated with the GLOBOCAN estimates of national incidence, mortality, and prevalence in 185 countries for 2020. Studies reviewing data sources and methods and regional variations in cancer profiles worldwide (Sung et al., 2021) were published, the latter in *CA: A Cancer Journal for Clinicians*, which retains the highest impact factor of all journals ranked by the International Scientific Indexing (ISI) server.

The Cancer Tomorrow subsite provides tools to predict future cancer incidence and mortality up to 2040, and it was updated to incorporate user-defined trends-based projections of the future burden. The Cancer Causes subsite provides estimates of population attributable fractions (PAFs) for major risk factors, to assist national decision-makers in setting priorities for cancer prevention; alcohol consumption was

added in 2021, based on a recent collaborative publication (Rumgay et al., 2021). In collaboration with WHO regional offices, updates of the alcohol-related burden were disseminated in various media formats (Figure 4). The Cancer Survival subsite has been continuously updated over the biennium to incorporate recent site-specific results from numerous studies published as part of ICBP SURVMARK-2 (Cabasag et al., 2020a, 2021; Araghi et al., 2021a; Rutherford et al., 2021).

In collaboration with the Association of the Nordic Cancer Registries (ANCR), a complete revamp of the NORDCAN website was undertaken; NORDCAN 2.0 (<https://nordcan.iarc.fr/>) enables dynamic comparisons of cancer statistics for the Nordic countries, supported by the Nordic Cancer Union (NCU). Harnessing some of the same technology, the Cancer Over Time subsite was launched in November 2021 to enable joint analyses of cancer incidence and mortality trends in about 60 countries around the world.

DESCRIPTIVE STUDIES: A FOCUS ON IMPACT, TO AID DECISION-MAKING

CSU expanded its research programme to ask questions that support the commitments of countries to tackle

Figure 2. Trainers participating in the online ChildGICR Masterclass, in April 2021. Over a period of 12 weeks, working groups developed the necessary teaching materials to cover seven key topics in childhood cancer registration. © IARC.





Figure 3. A framework for the surveillance and monitoring of a scaled-up cervical cancer control programme, including the central role of population-based cancer registries. Reproduced with permission from Piñeros et al. (2021b). © 2020 The Authors. Published by Elsevier Inc.



the rising cancer burden. A focus was the measurement of the impact of the COVID-19 pandemic on the health of nations and on the outcomes of current and future patients with cancer. CSU participated in the COVID-19 and Cancer Global Taskforce and in spring 2021 became a founding partner of the COVID-19 and Cancer Global Modelling Consortium (<https://ccgmc.org/>), with a remit to co-develop tools and provide evidence to aid decision-making during and after the pandemic (Figure 5).

CSU continued to highlight cancer transitions worldwide. Cancer is expected to surpass cardiovascular disease as the leading cause of premature death in most countries during this century (Bray et al., 2021a). Furthermore, a recent study compared trends in premature death from cardiovascular disease and cancer during 2000–2019 in 20 diverse countries to examine whether the countries will meet Target 3.4 of the United Nations

Sustainable Development Goals: a reduction by one third in premature deaths from noncommunicable diseases by 2030. National progress was highly variable and tended to be more apparent in high-income countries compared with middle-income countries, and for the control of cardiovascular disease compared with cancer (Bray et al., 2021b).

With IARC's unique focus on cancer prevention, several studies have highlighted the long-term beneficial impact of preventive interventions. As well as predicting the future burden up to 2070, CSU recently quantified the long-term impact on global cancer incidence of a reduction in the prevalence of tobacco smoking, overweight and obesity, and human papillomavirus (HPV) infection in different settings (Soerjomataram and Bray, 2021). Recent estimates of the impact of tobacco use and alcohol consumption on the cancer burden

sought to advocate the prioritization of their control; CSU has shown that optimal implementation of evidence-based tobacco control policies could prevent 1.65 million new cases of lung cancer in Europe by 2037 (Gredner et al., 2021). CSU also estimated that almost 750 000 (~4%) of the new cases of cancer worldwide in 2020 could be attributed to alcohol consumption (Figure 4) (Rumgay et al., 2021a); this figure could be reduced by various control strategies, including increasing alcohol taxation.

CSU continued to develop in-depth collaborative assessments of the descriptive epidemiology of specific cancer types, including cancers of the oral cavity (Miranda-Filho and Bray, 2020) and gastrointestinal tract (Arnold et al., 2020a, 2020b; Rumgay et al., 2021b; Rutherford et al., 2021), and sex-specific cancers (Bray et al., 2020a; Znaor et al., 2020a). CSU also published the results of several studies examining the current

and future burden of cervical cancer in relation to scaling up the WHO global initiative to eliminate cervical cancer as a public health problem (Arbyn et al., 2020a; Brisson et al., 2020; Canfell et al., 2020; Pilleron et al., 2020; Bonjour et al., 2021; Ryzhov et al., 2021; Stelzle et al., 2021; Znaor et al., 2021b), as well as the impact of overdiagnosis on thyroid cancer incidence and mortality (Li et al., 2020a, 2020b, 2021a; Miranda-Filho et al., 2021a; Vaccarella and Dal Maso, 2021; Vaccarella et al., 2021a). Specific in-country studies examined the current and future patterns of cancer in the Islamic Republic of Iran (Roshandel et al., 2020, 2021), Thailand (Sangrajrang et al., 2020), Ukraine (Ryzhov et al., 2020), and Uruguay (Musetti et al., 2021).

In line with the emerging priority areas as set out in the IARC Medium-Term Strategy 2021–2025, CSU developed two teams in 2021 that aim to develop and expand cancer research activities that focus on social inequalities (Lortet-Tieulent et al., 2020) and on descriptive economics.

Figure 4. Infographic on alcohol and cancer produced as part of the release of the publication on the global cancer burden attributable to alcohol. © IARC.








Figure 5. The COVID-19 and Cancer Global Modelling Consortium. This infographic was designed by CSU. For more information about the consortium, please visit <https://ccgmc.org/>.





SECTION OF EVIDENCE SYNTHESIS AND CLASSIFICATION (ESC)

Section head

Dr Ian A. Cree

Secretary

Ms Anne-Sophie Bres

IARC Monographs Group (IMO)

Group head

Dr Mary Schubauer-Berigan

Scientists

Dr Lamia Benbrahim-Tallaa
 Dr Aline De Conti
 Dr Nathan DeBono
 Dr Fatiha El Ghissassi
 Dr Jennifer Girschik (until April 2020)
 Dr Yann Grosse
 Dr Kathryn Guyton (until April 2021)
 Dr Daniel Middleton
 (until November 2021)
 Dr Adalberto Miranda Filho
 Dr Mary Schubauer-Berigan
 Dr Roland Wedekind

Scientific editor

Dr Heidi Mattock

Secretary

Ms Jennifer Nicholson

Technical assistants

Ms Marieke Dusenberg
 (until March 2021)
 Ms Niree Kraushaar
 Ms Solène Quennehen
 Ms Sandrine Ruiz

Senior visiting scientists and visiting scientists

Dr Lin Fritschi (until March 2020)
 Dr William Gwinn
 Dr Jérôme Lavoué
 (until December 2021)

Dr Bradley Reifeld
 Dr David Richardson
 Dr Michelle Turner
 (until October 2021)
 Dr Susana Viegas

Postdoctoral fellow

Dr Adalberto Miranda Filho
 (until August 2021)

Students

Mr Tarek Eleiwy (until July 2020)
 Ms Samantha Goodman
 (until October 2021)
 Mr Yaqi Liu (until December 2020)
 Ms Samantha Vega
 (until December 2020)

IARC Handbooks Group (IHB)

Group head

Dr Béatrice Lauby-Secretan

Scientist

Dr Véronique Bouvard

Secretary/technical assistant

Ms Marieke Dusenberg

Technical assistants

Ms Niree Kraushaar
 Ms Solène Quennehen

Visiting scientist

Dr Suzanne Nethan

WHO Classification of Tumours Group (WCT)

Group head

Dr Ian A. Cree

Scientists

Dr Iciar Indave (systematic reviewer)
 Dr Valerie White (pathologist)
 (until March 2021)

Secretary

Ms Anne-Sophie Bres

Clerk secretary

Ms Laura Brispot

Technical editor

Ms Jessica Cox

Senior information assistant

Ms Asiedua Asante

Principal information assistant

Mr Alberto Machado

Information assistants

Ms Meaghan Fortune
 Ms Catarina Marques

Research assistant

Ms Christine Carreira

Senior visiting scientists and visiting scientists

Dr Subasri Armon (until July 2021)
 Dr Anil Fonseca
 Dr Daphne Fonseca
 Dr Dilani Lokuhetty
 (until October 2020)
 Dr Vishal Rao (until July 2021)
 Dr Valerie White

Students

Mr Zi Long Chow
 (until January 2020)
 Mr Ramon Cierco Jiménez

Trainee

Mr Javier Del Aguila

The Section of Evidence Synthesis and Classification (ESC) comprises three Groups: the IARC Monographs Group (IMO), the IARC Handbooks Group (IHB), and the WHO Classification of Tumours Group (WCT). With the start of the new IARC Medium-Term Strategy 2021–2025 and the new organizational structure as of 1 January 2021, ESC was renamed as the Evidence Synthesis and Classification Branch.

The IARC Monographs Group (IMO) produces the *IARC Monographs on the Identification of Carcinogenic Hazards to Humans*, a series of systematic scientific reviews that identify environmental

factors that may cause cancer in humans. IMO also organizes advisory groups and international scientific workshops on key issues pertaining to the assessment of carcinogens and their mechanisms.

The IARC Handbooks Group (IHB) produces the *IARC Handbooks of Cancer Prevention*. This series of systematic scientific reviews identifies interventions and strategies that can reduce the risk of cancer or mortality from cancer.

The WHO Classification of Tumours Group (WCT) produces the *WHO Classification of Tumours* series (also known as the WHO Blue Books). Now in its

fifth edition as a series of 14 volumes, it provides the definitive and internationally accepted standards for the diagnosis of tumours.

For each volume of the *IARC Monographs*, the *IARC Handbooks*, and the *WHO Classification of Tumours*, IARC convenes international, interdisciplinary groups of expert scientists and physicians to systematically review the pertinent scientific literature and develop consensus evaluations and classifications. IARC selects these experts on the basis of their knowledge and experience as well as an absence of conflicting interests.

IARC HANDBOOK ON CERVICAL CANCER SCREENING

At the World Health Assembly in May 2018, WHO Director-General Dr Tedros Adhanom Ghebreyesus made a global call for action towards the elimination of cervical cancer. The *IARC Handbooks* programme responded to this call with the preparation of Volume 18: Cervical Cancer Screening. This volume updates the evaluations of the effectiveness of the current methods of cervical cancer screening and provides statements of the comparative effectiveness of these methods.

This *Handbook* was prepared in close collaboration with WHO headquarters, for the updating of the *WHO Screening and Treatment Recommendations to Prevent Cervical Cancer*. Preliminary steps involved the identification of topics for contribution to the recommendations, harmonization of the protocols for systematic review, and coordination of the calendars so that the two projects would evolve in parallel. The outcome of the collaboration was that the *IARC Handbooks* evaluations of the effectiveness of screening with human papillomavirus (HPV) DNA testing, cytology, and visual inspection with acetic acid (VIA), and the statements of their comparative effectiveness, served as a basis for the WHO recommendations.

Announcement of the webinar held on 6 July 2021. Reproduced from <https://www.who.int/news-room/events/detail/2021/07/06/default-calendar/reaching-2030-cervical-cancer-elimination-targets>, Copyright 2021.

The graphic features a teal background with a stylized illustration of a woman's head and neck in profile on the right. On the left, there are two dark teal boxes containing text about the WHO guideline and the IARC Handbooks. The top left corner includes logos for the World Health Organization and the International Agency for Research on Cancer (IARC). The text 'Save the date: 6 July 2021' is prominently displayed in the upper right. Below the main title, it says 'Join the launch of these two new products'. At the bottom, it provides the time (09:00-10:30 CET, repeated at 14:30-16:00 CET), states 'No registration required', and provides a link to join and a password (LAUNCH123). A contact email address is also listed.

World Health Organization
IARC
Save the date: 6 July 2021

Reaching the 2030 targets for cervical cancer elimination: New WHO recommendations for screening and treatment

Join the launch of these two new products

- WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition
- IARC Handbooks of Cancer Prevention Volume 18 – Cervical Cancer Screening

Time: 09:00-10:30 CET, repeated at 14:30-16:00 CET

No registration required
Link to join: bit.ly/cervicalcancerGL
Password: LAUNCH123

Contact: corroamy@who.int

Such collaboration represents a major milestone for the *IARC Handbooks* programme, and a similar collaboration is currently under way with the WHO Regional Office for South-East Asia for the preparation of Volume 19: Oral Cancer Prevention.

IARC MONOGRAPHS GROUP (IMO)


The IARC Monographs Group (IMO) is responsible for producing the *IARC Monographs on the Identification of Carcinogenic Hazards to Humans*. The *IARC Monographs* are fundamental to the Agency's mission of identifying the preventable causes of cancer in humans. Since the inception of the *Monographs* programme in 1971, 1032 agents have been evaluated one or more times for carcinogenicity. This international, interdisciplinary endeavour provides an authoritative reference for researchers, health authorities, and the public. Health agencies worldwide rely on the *Monographs* for the scientific support of actions to control exposures and prevent cancer. In addition to producing this important resource, the scientific personnel of IMO contribute to the scientific literature on topics related to the methodology and contents of the *Monographs*.

MAJOR ACCOMPLISHMENTS

IMO organized five Working Group meetings during the 2020–2021 biennium. Because of the travel restrictions put in place during the COVID-19 pandemic, all of the meetings were held fully remotely, and they were extended beyond 8 days to accommodate the time zones associated with global remote participation. The agents evaluated at the five Working Group meetings included several that had been recommended as priorities for evaluation:

- Volume 127: Some Aromatic Amines and Related Compounds (25 May–12 June 2020)
- Volume 126: Opium Consumption (11–20 September 2020)
- Volume 128: Acrolein, Crotonaldehyde, and Arecoline (29 October–13 November 2020)
- Volume 129: Gentian Violet, Leucogentian Violet, Malachite Green, Leucomalachite Green, and CI Direct Blue 218 (22 February–5 March 2021)

Figure 1. *IARC Monographs Volume 126: Opium Consumption*. © IARC.



• Volume 130: 1,1,1-Trichloroethane and Four Other Industrial Chemicals (7–22 October 2021).

Table 1 presents the results of these meetings, highlighting the important contribution of the *Monographs* in evaluating the carcinogenicity of diverse agents. These agents range from chemicals tested only in animal bioassays to complex exposures that have been evaluated in epidemiological and mechanistic studies, such as opium consumption (Figure 1).

The evaluations reached in these meetings included 20 classifications, comprising 14

agents never before evaluated by IARC and re-evaluations of 6 agents considered previously.

A concise summary of each evaluation with the classification, accompanying rationale, and key references is published in *The Lancet Oncology* within several weeks of each meeting. Full details and supporting data are provided in the complete *Monographs* volume, which is expected to be published about a year after each meeting. Both are available to download for free from the IARC Publications website (<https://publications.iarc.fr/>).

PUBLICATIONS

During the 2020–2021 biennium, the following *IARC Monographs* volumes were published:

Volume 128: Acrolein, Crotonaldehyde, and Arecoline (2021)

Volume 127: Some Aromatic Amines and Related Compounds (2021)

Volume 126: Opium Consumption (2021)

Volume 125: Some Industrial Chemical Intermediates and Solvents (2020)

Volume 124: Night Shift Work (2020)

Volume 123: Some Nitrobenzenes and Other Industrial Chemicals (2020).

Table 1. Summary of evaluations from the five *Monographs* meetings held in 2020–2021

Agent (Volume)	Evaluation ^a	Strength of evidence of cancer in humans (tumour type provided for <i>limited or sufficient</i> evidence)	Strength of evidence for carcinogenicity in experimental animals	Key characteristics of carcinogens with strong evidence ^b
<i>Opium Consumption (Volume 126)</i>				
Opium consumption	Group 1	<i>Sufficient</i> (larynx, lung, urinary bladder) <i>Limited</i> (oesophagus, stomach, pancreas, pharynx)	<i>Sufficient</i>	2
<i>Some Aromatic Amines and Related Compounds (Volume 127)</i>				
Aniline ^c	Group 2A	<i>Inadequate</i>	<i>Sufficient</i>	Multiple (1, 2, 5, 10)
Aniline hydrochloride ^c	Group 2A	<i>Inadequate</i>	<i>Sufficient</i>	Multiple (1, 2, 5, 10)
<i>ortho</i> -Anisidine ^c	Group 2A	<i>Inadequate</i>	<i>Sufficient</i>	Multiple (1, 2, 10)
<i>ortho</i> -Anisidine ^c hydrochloride	Group 2A	<i>Inadequate</i>		Multiple (1, 2, 10)
<i>ortho</i> -Nitroanisole ^c	Group 2A	<i>Inadequate</i>	<i>Sufficient</i>	Multiple (1, 2, 10)
Cupferron	Group 2B	<i>Inadequate</i>	<i>Sufficient</i>	2
<i>Acrolein, Crotonaldehyde, and Arecoline (Volume 128)</i>				
Acrolein	Group 2A	<i>Inadequate</i>	<i>Sufficient</i>	Multiple (1, 2, 3, 5, 6, 7, 10)
Crotonaldehyde	Group 2B	<i>Inadequate</i>	<i>Limited</i>	Multiple (1, 2, 5, 6)
Arecoline	Group 2B	<i>Inadequate</i>	<i>Limited</i>	Multiple (1, 2, 3, 5)
<i>Gentian Violet, Leucogentian Violet, Malachite Green, Leucomalachite Green, and CI Direct Blue 218 (Volume 129)</i>				
Gentian Violet	Group 2B	<i>Inadequate</i>	<i>Sufficient</i>	None
Leucogentian Violet	Group 3	<i>Inadequate</i>	<i>Inadequate</i>	None
Malachite Green	Group 3	<i>Inadequate</i>	<i>Limited</i>	None
Leucomalachite Green	Group 2B	<i>Inadequate</i>	<i>Sufficient</i>	None
CI Direct Blue 218	Group 2B	<i>Inadequate</i>	<i>Sufficient</i>	None
<i>1,1,1-Trichloroethane and Four Other Industrial Chemicals (Volume 130)</i>				
1,1,1-Trichloroethane	Group 2A	<i>Limited</i>	<i>Sufficient</i>	None
Hydrazobenzene	Group 2B	<i>Inadequate</i>	<i>Sufficient</i>	None
<i>N</i> -Methylolacrylamide	Group 2B	<i>Inadequate</i>	<i>Sufficient</i>	None
Diphenylamine	Group 2B	<i>Inadequate</i>	<i>Sufficient</i>	None
Isophorone	Group 2B	<i>Inadequate</i>	<i>Sufficient</i>	None

^a Group 1, carcinogenic to humans; Group 2A, probably carcinogenic to humans; Group 2B, possibly carcinogenic to humans; Group 3, not classifiable as to its carcinogenicity to humans.

^b Numbers correspond to one or more of the 10 key characteristics of carcinogens, as identified by Smith et al. (2016; <https://www.ncbi.nlm.nih.gov/pubmed/?term=26600562>) and described in the Preamble to the *IARC Monographs* (<https://monographs.iarc.fr/preamble-to-the-iarc-monographs/>).

^c This agent was determined to belong to a class of aromatic amines for which several members (including *ortho*-toluidine, 2-naphthylamine, and 4-aminobiphenyl) have been classified as *carcinogenic to humans* (Group 1).

IARC HANDBOOKS GROUP (IHB)

The IARC Handbooks Group (IHB) is responsible for producing the *IARC Handbooks of Cancer Prevention*. The objective of the *IARC Handbooks* is to publish critical reviews and evaluations of interventions and strategies that can reduce the burden of cancer. The principles of systematic review are applied to the identification, screening, synthesis, and evaluation of the evidence. Interventions or strategies are selected for evaluation on the basis of published scientific evidence of preventive effects and potential public health relevance. *Handbook* evaluations have included chemopreventive agents, preventive actions, effectiveness of screening, and effectiveness of tobacco control measures. The *Handbooks* are used worldwide by public health representatives to set guidelines and recommendations for cancer prevention.

MAJOR ACCOMPLISHMENTS

IHB organized two meetings during the 2020–2021 biennium: the Working Group meetings for *IARC Handbooks* Volume 18 (Cervical Cancer Screening) and Volume 19 (Oral Cancer Prevention). Because of the COVID-19 pandemic, both meetings were held fully remotely.

VOLUME 18: CERVICAL CANCER SCREENING (JUNE–OCTOBER 2020)

Cervical cancer screening was re-evaluated by the *IARC Handbooks*. The Working Group considered new screening technologies, including human papillomavirus (HPV) testing, and provided statements of the comparative effectiveness of established screening methods (Figure 2). This *Handbook* was published in response to the WHO Cervical Cancer Elimination Initiative, which was launched after the WHO Director-General's call for action at the World Health Assembly in May 2018. This was the first close collaboration between the *Handbooks* programme and WHO headquarters, and it enabled the development and updating of WHO recommendations.


A summary of the outcome of the meeting, which took place remotely between June and October 2020, was published in *The New England Journal of Medicine* in November 2021 (Bouvard et al., 2021).

VOLUME 19: ORAL CANCER PREVENTION (SEPTEMBER–DECEMBER 2021)

This *Handbook* is a first-time evaluation of all approaches to oral cancer prevention, with a special emphasis on low- and middle-income countries and on oral cancer associated with the use of smokeless tobacco and products derived from the areca nut. This *Handbook* will cover primary prevention through the evaluation of whether reduction of exposure to the established (IARC Group 1) risk factors leads to reduced incidence or mortality, primary prevention through interventions aiming to reduce exposure to smokeless tobacco or products derived from the areca nut, and secondary prevention through screening.

A scoping meeting for Volume 19 took place in February 2021, and the meeting took place fully remotely between September and December, first in subgroups and then in plenary sessions. The evaluations reached at this *Handbooks* meeting will lead to the development of tools and recommendations for the implementation of prevention measures in those countries most in need.

Figure 2. The Working Group for IARC Handbooks Volume 18: Cervical Cancer Screening, the geographical distribution of the participants, and the summarized outcomes of the meeting. All © IARC.



International Agency for Research on Cancer

**IARC Handbooks Volume 18:
Cervical Cancer Screening**

Estimated age-standardized incidence rates (World) in 2020, cervix uteri, all ages

Data source: GLOBOCAN 2020
 Graph production: IARC
 Map production: IARC
 © International Agency for Research on Cancer 2021

EVALUATIONS OF SCREENING METHODS

<div style="background-color: #0070C0; color: white; padding: 5px; font-weight: bold; font-size: small;">Conventional cytology</div>	<div style="background-color: #0070C0; color: white; padding: 5px; font-weight: bold; font-size: small;">Liquid-based cytology</div>	<div style="background-color: #0070C0; color: white; padding: 5px; font-weight: bold; font-size: small;">HPV nucleic acid testing</div>	<div style="background-color: #0070C0; color: white; padding: 5px; font-weight: bold; font-size: small;">Visual inspection with acetic acid (VIA)</div>	<div style="background-color: #0070C0; color: white; padding: 5px; font-weight: bold; font-size: small;">Cytology based on Romanowsky-Giemsa staining</div>
Group A	Group A	Group A	Group A/B	Group C
Benefits outweigh the harms for women aged 30 years and older. There is less certainty for women younger than 30 years and for women older than 65 years.	Benefits outweigh the harms for women aged 30 years and older. Benefits and harms are very similar to those of conventional cytology, owing to a reduced proportion of inadequate results but slightly higher referral rates.	Benefits outweigh the harms for women aged 30 years and older. There is less certainty for women younger than 30 years, especially when triage testing of HPV-positive women is not in place.	Benefits may outweigh harms, but only in VIA screening programmes implemented by well-trained providers, with quality assurance and with appropriate treatment of lesions and follow-up care.	No comparative study on accuracy, efficacy, and effectiveness of the technique in cervical cancer screening was available to the Working Group.

COMPARATIVE EFFECTIVENESS OF SCREENING METHODS

HPV DNA testing versus VIA	HPV DNA testing versus cytology	HPV DNA testing alone versus co-testing
HPV DNA testing showed higher reduction in cervical cancer incidence and mortality than VIA, which outweighed the potential increase in positive tests and colposcopy referrals.	HPV DNA testing showed higher reduction in cervical cancer incidence and mortality than cytology, which outweighed the increase in positive tests and colposcopy referrals, and potential increase in psychological harms.	Compared with HPV DNA testing, co-testing (HPV DNA + cytology) showed minimal increase in sensitivity and lower specificity for precancerous lesions, resulting in increased colposcopy referrals and decreased positive predictive value.

https://handbooks.iarc.fr

WHO CLASSIFICATION OF TUMOURS GROUP (WCT)

The work of the WHO Classification of Tumours Group (WCT) encompasses the *WHO Classification of Tumours* series (also known as the WHO Blue Books), the IARC histopathology laboratory, and the International Collaboration for Cancer Classification and Research (IC³R).

WHO BLUE BOOKS

Tumour classification is a major scientific endeavour of considerable importance, underpinning the diagnosis of all cancer worldwide. In recent years, the series' adoption of a relational database approach and a hierarchical classification according to Linnaean principles has vastly improved the standardization of tumour classification across anatomical sites, requiring authors to consider all

characteristics of each tumour and highlighting the increasingly multidisciplinary nature of cancer diagnosis.

During the 2020–2021 biennium, the following volumes were published:

- *Soft Tissue and Bone Tumours*, fifth edition (2020)
- *Female Genital Tumours*, fifth edition (2020)
- *Thoracic Tumours*, fifth edition (2021).


A fourth volume (*Central Nervous System Tumours*, fifth edition) is almost complete. The 14-volume fifth edition of the *WHO Classification of Tumours* series is well under way, with a further five volumes in various stages of production. The books and the accompanying website (WHO Classification of Tumours Online; <https://tumourclassification.iarc.who.int/>) have both been very well received, and

use of the classification is expanding in the wider biomedical community (e.g. among radiologists). Production of the *WHO Classification of Tumours* series continues to be funded by book sales and website subscriptions alone.

HISTOPATHOLOGY LABORATORY

During this biennium, thanks to the IARC Scientific Council and Governing Council Special Funds (2021), the histopathology laboratory has modernized its equipment, with a corresponding increase in capacity and capability. It continues to operate with a single scientist but provides technical support to a wide range of projects across the Agency, including providing whole slide images for the WHO Blue Books (Figure 3). The laboratory is increasingly involved in

Figure 3. A lymphoepithelial carcinoma of the lung showing a syncytial growth pattern of tumour cells with large vesicular nuclei (whole slide image). © IARC.



all aspects of digital and computational pathology, including artificial intelligence and machine learning projects. Its capacity to produce high-quality immunohistochemistry for research projects has been enhanced by the acquisition of an automated immunostainer, and older equipment used to produce slides and frozen sections is being updated. All of the laboratory's equipment will eventually be moved to the Nouveau Centre building, which will have a dedicated histopathology laboratory similar to the one currently in use. Collaborations with Centre Léon Bérard and other institutions continue to expand.


INTERNATIONAL COLLABORATION FOR CANCER CLASSIFICATION AND RESEARCH (IC³R)

The translation of research findings into practice is never easy, and the sheer volume of information produced each year can be daunting for those involved. Crucially, scientific information must be of high quality to be of use. Unlike in other branches of medicine, the translation of cancer research into diagnostic practice is largely in the hands of its users, through incorporation into the WHO Classification of Tumours (with the exception of health technology assess-


ment, which is the remit of health-care services within individual countries).

The International Collaboration for Cancer Classification and Research (IC³R; <https://ic3r.iarc.who.int/>) was established to bring cancer research institutions together to improve research quality and to meet the need for evaluation and synthesis of research findings (Figure 4). Currently, 22 institutions are involved in IC³R, and it is funded by membership dues.

Figure 4. The WHO Classification of Tumours (WCT) is run by an Editorial Board composed of standing members nominated by major societies, and expert members selected for each volume. The International Collaboration for Cancer Classification and Research (IC³R) has been formed to bring together cancer research institutes around the world interested in diagnosis to improve the evidence base for the classification. The classification can also be used to identify gaps and priorities for future research. © IARC.



Studying (epi)genome deregulation and environmental origins of cancer



SECTION OF MECHANISMS OF CARCINOGENESIS (MCA)

Section head

Dr Zdenko Herceg

Epigenetics Group (EGE)

Group head

Dr Zdenko Herceg

Scientists

Dr Rosita Accardi (died 13 May 2020)

Dr Akram Ghantous

Dr Rita Khoueiry

Secretariat

Ms Elizabeth Page

Postdoctoral fellows

Dr Zainab Awada

Dr Felicia Chung (until April 2021)

Dr Andrea Halaburkova

(until November 2020)

Dr Farah Nassar

Dr Alexei Novoloaca

(until December 2020)

Dr Grace Akinyi Odongo

Dr Alexandra Sexton-Oates

(until January 2020)

Dr Natalia Spitz Toledo Dias

Dr Fazlur Talukdar (until August 2020)

Doctoral students

Ms Maria Boskovic

Ms Mariana Gomes da Silva Araujo

Mr Antonin Jay

(until November 2020)

Ms Francesca Manara

Mr Thanos Mouchtaris-Michailidis

Mr Alexei Novoloaca

(until June 2020)

Ms Anna-Luiza Vicente

(until May 2020)

Research assistants

Mr Cyrille Cuenin

Ms Aurélie Salle

Senior research assistant, data management/analysis

Mr Vincent Cahais

Trainees

Ms Cédrine Milesi

(until September 2020)

Ms Farah Ramadan

(until December 2020)

Ms Ling Wei (until March 2020)

Molecular Mechanisms and Biomarkers Group (MMB)

Group head

Dr Jiri Zavadil

Scientists

Dr Michael Korenjak

Dr Magali Olivier (until August 2020)

Senior research assistant, data management/analysis

Dr Claire Renard

Senior research assistant

Ms Marie-Pierre Cros

(until June 2021)

Secretariat

Ms Karine Racinoux

Postdoctoral fellow

Dr Samrat Das

Students

Ms Liesel Claeys

(until November 2021)

Ms Shefali Thakur

Trainees

Ms Bérénice Chavanel

(until August 2021)

Ms Xinyue Jiang (until August 2020)

Mr Stéphane Keita

(until August 2021)

Identifying the causal pathways that link environmental or lifestyle exposures to tumorigenesis and gaining insights into the molecular mechanisms that underlie the associations observed in epidemiological studies (biological plausibility) provide a foundation for studies of cancer etiology, carcinogen evaluation and classification, and ensuring evidence-based cancer prevention. The Section of Mechanisms of Carcinogenesis (MCA) conducts hypothesis-driven and data-driven studies aimed at advancing the understanding of cancer causation and the mechanisms of tumorigenesis, as well as promoting

international collaborations, as the core mission of IARC.

The studies of MCA are interdisciplinary in nature, and the major MCA programmes promote and advance synergistic collaborations with other IARC scientists and evidence synthesis experts. Key elements of MCA's strategy include developing innovative state-of-the-art molecular and cell biology and functional epigenomics research methodologies, and bioinformatics and biostatistics tools, applicable to experimental cancer models and human samples from population-

based studies. The Section comprises two Groups – the Epigenetics Group (EGE) and the Molecular Mechanisms and Biomarkers Group (MMB) – whose corresponding research programmes are complementary with respect to methodological approaches and the shared ultimate objective of identifying causal links between environmental factors and cancer. With the start of the new IARC Medium-Term Strategy 2021–2025 and the new organizational structure as of 1 January 2021, MCA was renamed as the Epigenomics and Mechanisms Branch.

EPIGENETICS GROUP (EGE)

The overarching aim of the Epigenetics Group (EGE) is to advance the understanding of the role of epigenetic changes and pathways induced by environmental factors and endogenous processes in cancer causation, underpinning studies of etiology, carcinogen evaluation, and prevention. EGE exploits new concepts in cancer epigenetics, the availability of unique population-based cohorts, and recent technological advances in epigenomics (Halaburkova et al., 2020; Pashayan et al., 2020; Ghantous et al., 2021; Sklias et al., 2021). EGE also develops epigenomic methodologies, profiling strategies, and bioinformatics tools applicable to population-based cohorts and molecular epidemiology studies coordinated by IARC researchers and external collaborators (Merid et al., 2020; Karabegović et al., 2021; Sorroche et al., 2021; Talukdar et al., 2021).

EPIGENOME-WIDE PROFILING OF OESOPHAGEAL SQUAMOUS CELL CARCINOMA FROM HIGH-INCIDENCE REGIONS IDENTIFIES CRUCIAL GENES AND POTENTIAL CANCER MARKERS

Oesophageal squamous cell carcinoma (ESCC) is one of the most aggressive and lethal forms of cancer in the world, with the highest incidence rates in low- and middle-income countries. EGE

conducted the largest epigenome-wide (DNA methylome, DNAm) profiling of the collection of ESCC samples from high-incidence populations worldwide (Figure 1), with the aim of understanding ESCC etiology and identifying early biomarkers. DNAm changes in ESCC samples and normal tissue adjacent to the tumours (NAT) from patients with cancer in nine high-incidence countries in Africa, Asia, and South America were studied by using the Infinium MethylationEPIC array (Talukdar et al., 2021). Methylome analysis comparing tumour tissue and NAT identified 6796 differentially methylated positions (DMPs) and 866 differentially methylated regions (DMRs). Most of the identified DMPs and DMRs were hypermethylated in tumours. Top genes identified in the discovery phase were prioritized for validation, and their putative functional impact on gene transcription was analysed using RNA-seq data from The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) project. The specificity and sensitivity of these DNAm events in discriminating tumours from NAT were then assessed. EGE identified and prioritized genes and pathways involved in the development of ESCC, and proposed an early detection marker panel, which could serve as a reference for tests to improve the early detection of

this cancer type in low-resource settings (Talukdar et al., 2021).

EPIGENETIC MARKERS OF BREAST CANCER RISK IN A PROSPECTIVE COHORT STUDY

Epigenetic alterations are a near-universal feature of malignancy; however, much of the current evidence is based on findings in retrospective studies, which may reflect epigenetic patterns influenced by the onset of the disease. Studying breast cancer, EGE established genome-scale DNA methylation profiles of prospectively collected buffy coat samples from a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) study using reduced representation bisulphite sequencing (RRBS) (Figure 2). For a subset of these individuals, EGE also profiled primary tumours and tumour-adjacent tissue samples. EGE observed cancer-specific DNA methylation events in both the breast tissue and buffy coat samples, each characterized by sample type-specific differences but with a shared enrichment for genes in specific biological pathways. Notably, increased DNA methylation in genomic regions associated with specific genes was linked to the length of time to diagnosis in prospectively collected buffy coat DNA from individuals who subsequently developed breast cancer

(Figure 2). Using machine learning methods, EGE piloted a DNA methylation-based classifier that predicted case-control status in a held-out validation set with high accuracy, in some cases

up to 15 years before diagnosis. The findings suggest a model of gradual accumulation of cancer-associated epigenetic patterns in peripheral blood, which may be detected long before the

clinical manifestation of cancer. Such changes may provide useful markers for risk stratification and, ultimately, personalized cancer prevention.

Figure 1. Genome-wide DNA methylation profiling of oesophageal squamous cell carcinoma (ESCC) from high-incidence populations of the world enables the identification of functionally relevant and robust DNA methylation markers for early detection in low-resource settings. (a) Overview of study design and sample characteristics. Country-wise sample distribution in percentages. Dots in the map showing sample collection sites and their respective countries are coloured. Reprinted from Talukdar et al. (2021), with permission from the American Association for Cancer Research. (b) Collaborators attending the Oesophageal Squamous Cell Carcinoma African Prevention research (ESCAPE) network meeting (coordinated by Dr Valerie McCormack, IARC) held in Eldoret, Kenya. © IARC.





Figure 3. Understanding estrogen receptor (ER) pathway regulation in breast cancer cells and revealing potential mechanisms underlying the roots of resistance to anti-estrogen therapy. (a) Breast cancers are classified into different molecular subtypes mainly according to the presence of ER, progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), and their expression tends to determine the treatment approach. Most (70%) breast cancers are ER-positive (ER+) and are subjected to anti-estrogen therapy. However, patients regularly develop a non-reversible resistance to anti-estrogen therapy. (b) In vitro optimized protocol adapted for studying estrogen deprivation and re-stimulation using MCF-7 breast cancer cells. MCF-7 cells cultured in control conditions (CTR, charcoal-stripped serum + estradiol E2) were deprived of E2 for 4 and 14 days (E2D) or deprived of E2 for 4 days then re-stimulated with E2 for 10 days (ReSt, blue dashed line). (c) Heat map of differentially methylated positions (DMPs) between CTR and E2-deprived (E2D) MCF-7 cells with at least 10% differential methylation ($\Delta\beta$) detected after methylome analyses using an 850K array, which measures the DNAm levels across more than 850 000 CpGs. (d) Analyses of histone post-translational modification (PTM) by ChIP-sequencing of H3K27 acetylation (H3K27ac), a mark associated with enhancer regions. Analysis showed a global decrease of histone acetylation in E2D compared with CTR. (e) Results of transcriptome analysis (RNA-sequencing). Upper left: Distribution of $-\log_{10}(P)$ of differentially expressed genes (DEGs) in E2D versus CTR according to \log_2 fold change (FC) of expression. Coloured dots represent downregulated and upregulated DEGs with an absolute $\log_2(FC) > 1$ (blue and red) and a false discovery rate (FDR) < 0.05 (dashed horizontal). DEGs that were differentially expressed with an absolute $\log_2(FC) < 1$ are shaded dark grey. Upper right: Gene set enrichment analysis of downregulated and upregulated DEGs (MSigDB, database H, hypergeometric test). Lower: Significant differential expression of three epigenetic remodelling factors, HDAC9, PADI4, and TET2, in response to E2 deprivation. (f) Partial reversibility of epigenomic and transcriptomic changes after E2 deprivation and re-stimulation. Left: Distribution of hypermethylated DMPs in response to E2 deprivation and re-stimulation for CTR, E2D, and ReSt at day 14 (CTR vs E2D, $n = 950$; FDR < 0.05 , $\Delta\beta > 10\%$). Box plot: centre lines, median (Q2); box boundaries, 25% and 75% quartiles (Q1 and Q3); top and bottom whiskers, minimum and maximum (Q0 and Q4). For each pairwise comparison (ReSt–CTR and CTR–E2D), the quartiles are connected with red lines. In each interquartile range, the mean $\Delta\beta$ between the compared interquartile groups is shown in red. The mean of each group is shown with a red cross. Asterisks mark significant differences of ReSt and E2D means compared with CTR. Upper centre: Overlap of differential H3K27ac regions between CTR versus E2D and CTR versus ReSt regions, showing 207 common peaks. Lower centre: H3K27ac signal in \log_2 -normalized reads of the 207 peaks. Right: Non-reversibility of expression of AP-1 transcription factor inducer TNIK and AP-1 target gene MMP13 for CTR condition (green squares), E2D (orange diamonds), and ReSt (blue triangles) on day 14. Differential expression analysis was performed after RNA-sequencing by contrasting CTR versus ReSt groups among E2-deprivation DEGs with FDR < 0.05 and $|\log_2FC| > 1$. Reproduced from Sklias et al. (2021). © 2021, Oxford University Press.



EPIGENETIC CHANGES INDUCED BY ESTROGEN HORMONES AS A POTENTIAL MECHANISM UNDERLYING ENDOCRINE RESISTANCE IN ER-POSITIVE BREAST CANCER

Estrogen hormones are implicated in the development of most breast cancers, and estrogen receptor (ER) alpha, the main nuclear factor that mediates estrogen signalling, orchestrates a complex molecular circuitry, which is poorly understood. EGE combined a novel in vitro protocol

adapted for studying estrogen deprivation and re-stimulation with the latest epigenomics and bioinformatics tools, which enabled a genome-wide interrogation of the epigenome and transcriptome changes associated with modifications in ER pathways. The results showed that prolonged estrogen deprivation and re-stimulation result in time-dependent epigenetic changes across diverse genomic regions and changes in gene expression associated with specific biological pathways (Figure 3). Remark-

ably, many of the observed changes upon estrogen deprivation were also detected in breast cancer cells that developed resistance in response to anti-estrogen therapy (Sklias et al., 2021). Finally, the study revealed a selective reversibility and persistence of epigenetic and gene transcription changes observed after estrogen deprivation and re-stimulation, suggesting a potential mechanism underlying the roots of endocrine resistance that develops in response to anti-estrogen therapy (Figure 3) (Sklias et al., 2021).

MOLECULAR MECHANISMS AND BIOMARKERS GROUP (MMB)

The overarching objective of the Molecular Mechanisms and Biomarkers Group (MMB) is to improve the knowledge base for mechanistic molecular studies of modifiable cancer causes and for relevant cancer prevention measures. Innovative experimental approaches assist in the discovery of molecular cancer markers (Melki et al., 2020). MMB conducts molecular cancer epidemiological studies (Karabegović et al., 2021; the MODARC study on the role of dietary acrylamide in renal carcinogenesis; the EVAMOVAIRE2 study) and participates in IARC's carcinogen evaluation (Samet et al., 2020) and cancer classification efforts (Cree et al., 2021a). During the biennium, MMB performed integrative toxicogenomic analyses of selected candidate carcinogens and their roles in oncogenesis (Claeys et al., 2020). MMB also collaborated with the IARC Monographs on systematic cancer hazard assessments (Barupal et al., 2021).

EVAMOVAIRE2: MUTATIONAL SIGNATURES OF ASBESTOS EXPOSURE IN OVARIAN TUMOURS

Epidemiological studies of geographical variations in ovarian cancer incidence

have suggested a causal role for environmental factors, prompting the IARC Monographs to classify asbestos fibres as an ovarian carcinogen in 2009. MMB explored the link between asbestos exposure and ovarian cancer histological subtypes by integrating epidemiological data, exposure assessment, and whole-genome sequencing to determine the potentially carcinogenic effects of exposure to asbestos. Among 254 patients with ovarian cancer in the study, 13.4% had been exposed to asbestos occupationally and 16.5% had possibly been exposed indirectly, via a close relative. The direct exposure prevalence appeared to be higher than in the general population.


MMB conducted whole-genome sequencing of tumour-normal tissue pairs of 25 cases with established exposure mode, probability, and levels. Several exposure-specific mutational signatures were observed, all of an endogenous nature, alongside a signature of BRCA1/2 deficiency and lower rates of the *TP53* gene mutations associated with tumours of unexposed patients (Figure 4). Chrysotile asbestos treatment of cell model systems induced prominent, dose-dependent

cytotoxicity and genome-wide mutagenesis indicative of oxidative DNA damage (Figure 4). The EVAMOVAIRE2 study has provided new insights into environmental and occupational exposure to asbestos as an important risk factor for ovarian carcinogenesis.

GENOMIC DNA DAMAGE INDUCED BY TOBACCO-SPECIFIC NITROSAMINES

Epidemiological studies have linked tobacco use to numerous cancer types, including cancer of the lung, oral cavity, pharynx, larynx, oesophagus, pancreas, urinary bladder, and liver. The tobacco-specific nitrosamines (TSNAs) 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) and *N'*-nitrosonornicotine (NNN) are recognized human carcinogens (IARC Group 1). However, the complex composition of tobacco smoke and a lack of molecular exposure markers mask the precise roles of TSNAs in human oncogenesis. NNK and NNN might contribute to the mutagenic effects of tobacco smoke, but the mutational signatures of TSNAs have not yet been described.

Figure 4. Mechanisms of asbestos-associated ovarian carcinogenesis investigated in 25 patients with epithelial ovarian cancer, using whole-genome sequencing of DNA derived from the formalin-fixed, paraffin-embedded (FFPE) tumour specimens. (a) In the included exposed patients ($n = 17$), enrichments of mutational signatures were observed, indicating increased cell proliferation (SBS1, SBS5), fingerprints of APOBEC-driven mutagenesis (SBS2, SBS13), higher rates of DNA replication errors (ID1, ID2), and ovarian-specific signature ID16. (b) Mutational signature SBS3 and TP53 mutations were enriched in the unexposed patients compared with the exposed patients. (c) Acute and chronic effects of chrysotile asbestos treatment on mutagenesis in cultured cells manifested through elevated mutational signature SBS18 (red arrows) formed by oxidated deoxyguanosines (8-oxo-2'-deoxyguanosine, 8-oxo-dG), consistent with increased exposure-related oxidative DNA damage. The top panel shows a background signature SBS17, and the bar graph shows the increase in the SBS18 versus SBS17 ratio after treatment with chrysotile. © IARC.



MMB characterized such mutational signatures induced by TSNA in a human lung cell line and in a rat bioassay. DNA adduct analysis revealed major damage on thymidine (O2-POBdT) and guanine (7-POBG) residues (Figure 5). Genome-scale sequencing of TSNA cell clones and of rat tumours yielded highly

similar mutational signatures (Figure 5), indicating the convergent effects of the two related nitrosamine compounds. The hallmark T > N mutations enriched on the untranscribed strand are consistent with the thymidine damage via O2-POBdT adduct formation. The newly identified signatures provide a valuable molecular

marker for follow-up in silico studies of the mutagenic effect of TSNA exposure in thousands of human cancer genomes, to ultimately address the contribution of TSNA to the mutation spectra of tobacco-related cancers.



SECTION OF INFECTIONS (INF)

Section head

Dr Massimo Tommasino

Infections and Cancer Biology Group (ICB)

Group head

Dr Massimo Tommasino

Scientist

Dr Tarik Gheit

Technical assistants

Ms Sandrine McKay-Chopin
Ms Cécilia Sirand

Secretariat

Ms Nicole Suty

Visiting scientists

Dr Abbas Karimi Postakan
(until May 2020)
Dr Vanessa Salete de Paula
Dr Valerio Taverniti (until March 2020)
Dr Assunta Venuti
(until November 2021)

Postdoctoral fellows

Dr Racheal Dube Mandishora
(until September 2021)
Dr Purnima Gupta
(until January 2020)

Students

Mr Rosario Brancaccio
(until December 2020)
Ms Irena Dus-Ilnika
Mr David Ismael Escobar Marcillo
(until April 2020)
Ms Luisa Galati
Ms Simone Gobbato (until April 2020)
Ms Hanna Krynska
Ms Eugénie Lohmann
(until December 2020)
Ms Aline Lopes-Ribeiro
(until September 2021)
Ms Grete Privitera
(until August 2021)
Mr Mathis Ratel
(until September 2021)
Mr Alexis Robitaille
(until March 2020)
Ms Maria del Carmen Romero
Medina (until December 2020)
Mr Rajdip Sen (until December 2020)
Ms Maria Tolomeo (until April 2020)

Infections and Cancer Epidemiology Group (ICE)

Group head

Dr Gary Clifford

Scientists

Dr Iacopo Baussano
Dr Jean-Damien Combes
Dr Catherine de Martel
Dr Jin Young Park

Visiting scientists

Dr Robert Newton (until March 2020)
Dr Guglielmo Ronco
(until September 2021)

Data managers

Mr Damien Georges
Ms Vanessa Tenet

Project assistants

Ms Philippine Gason
Ms Viktoria Knaze

Secretariat

Ms Susan Gamon

Postdoctoral fellows

Dr Catherina J. Alberts
Dr Ahmad Fuady
Dr Mayo Hirabayashi
Dr Ahmadaye Ibrahim Khalil
(until October 2021)
Dr Irene Man
Dr Feixue Wei

Students

Mr Kueshivi M. Atsou
(until July 2020)
Mr Maxime Bonjour
Ms Séphora Campoy
Ms Marie Chantal Umulisa
(until January 2020)
Mr Nicolas Voisin (until June 2020)

The Section of Infections (INF) has two groups: the Infections and Cancer Biology Group (ICB) and the Infections and Cancer Epidemiology Group (ICE). The research activities of both Groups aim to evaluate the role of infectious agents in human cancers through biological and epidemiological studies.

The functional studies of ICB during the 2020–2021 biennium were focused on the characterization of the biological properties of oncoproteins from several human viruses, in particular cutaneous beta human papillomavirus (HPV) types (Gupta et al., 2020a; Minoni et al., 2020; Romero-Medina et al., 2020; Magnotti et al., 2021). With regard to epidemiological studies, ICB developed a highly sensitive diagnostic assay for a large number of infectious agents, with the final aim of (i) evaluating the contribution of infections to human carcinogenesis; and (ii) identifying novel algorithms for early

diagnosis of human cancers driven by infections (Amorrortu et al., 2020, 2021; Galati et al., 2020a, 2021; Tagliabue et al., 2020; Rollison et al., 2021; Simoens et al., 2021).

The overall strategy of ICE is to improve the epidemiological evidence base with respect to prevention of infection-attributable cancer. This strategy relies on obtaining both high-quality data and biological samples from populations that have been well characterized epidemiologically. Although the strategy of ICE is global, work is naturally focused on low- and middle-income countries (LMICs), which have a disproportionate burden of infection-attributable cancers, and particularly on countries in Africa and Asia. There are currently 11 infectious agents that are classified as carcinogenic by the IARC Monographs, and they are at different stages along the pathway from discovery to public health intervention.

Correspondingly, ICE research includes a wide portfolio of study designs that are tailored to specific infectious agents across a spectrum of epidemiological research, from etiology or natural history through global burden assessment to evaluation and modelling of the impact of interventions and/or policy.

ICB and ICE are also participating in several collaborative studies to assess the impact of HPV vaccine in LMICs and to characterize the role of mucosal high-risk (HR) HPV infection in the etiology of head and neck cancer.

With the start of the new IARC Medium-Term Strategy 2021–2025 and the new organizational structure as of 1 January 2021, INF became part of the newly created Early Detection, Prevention, and Infections Branch.

GASTRIC CANCER PREVENTION IN THE REPUBLIC OF KOREA: THE HELPER STUDY

Helicobacter pylori is the most important infectious cause of cancer worldwide. In 2013, IARC and the National Cancer Center of Korea launched the HELPER study, a multicentre double-blind randomized controlled trial in the Republic of Korea, to assess the effect of *H. pylori* eradication in gastric cancer prevention. HELPER has recruited about 12 000 middle-aged participants from the general population, including 5269 *H. pylori*-positive participants, who were subsequently randomized to eradication with bismuth quadruple therapy or placebo. Biennial endoscopic follow-up is continuing within the Korean National Cancer Screening Programme, and an interim analysis is planned for 2026.

HELPER Investigators' Workshop, Seoul, Republic of Korea. © IARC.



This trial is expected to determine to what extent *H. pylori* eradication reduces the risk of gastric cancer in the general population, while also providing important data on how to optimize the allocation of the resources devoted to gastric cancer control in the Republic of Korea. Globally, the study will have major public health implications by providing leads for gastric cancer prevention in populations with elevated rates of gastric cancer, particularly in Asian countries.

ROLE OF BETA HPV TYPES IN THE DEVELOPMENT OF CUTANEOUS SQUAMOUS CELL CARCINOMA

A large number of HPV types have been isolated and fully characterized so far. They are subdivided into genera and species in the HPV phylogenetic tree according to the DNA genome sequence. A subgroup genus alpha, referred to as mucosal HR HPV types, infect the epithelia of the anogenital tract as well as the upper respiratory tract; these HR HPV types have been clearly associated with a broad spectrum of human cancers, including cervical and oropharyngeal cancers. In addition to the HR HPV types, cutaneous beta HPV types also appear to be implicated in carcinogenesis, although by different mechanisms. Using *in vitro* and *in vivo* experimental models, studies by ICB and other groups have highlighted the transforming properties of E6 and E7

from several cutaneous beta HPV types. In a recent study, ICB characterized a novel mechanism of virus-mediated p53 inactivation. Beta HPV38 E6 and E7 promote accumulation of a wild-type p53 form in human keratinocytes, promoting cellular proliferation. Inactivation of p53 by different means strongly decreases the proliferation of HPV38 E6 and E7 human keratinocytes. This p53 form is phosphorylated at S392 by the double-stranded RNA-dependent protein kinase PKR, which is highly activated by HPV38. PKR-mediated S392 p53 phosphorylation promotes the formation of a p53–DNMT1 complex, which inhibits expression of integrin alpha 1 (ITGA1), a repressor of epidermal growth factor receptor (EGFR) signalling (Romero-Medina et al., 2020) (Figure 1). These findings reveal the existence of a specific wild-type p53 form that displays pro-proliferation properties and are in agreement with a model in which beta

HPV E6 and E7 proteins and ultraviolet (UV) radiation intimately cooperate in promoting skin carcinogenesis (Figure 2). A recent study by ICB showed that UV irradiation per se increases the beta HPV positivity in the skin, most likely because of its inhibitory activity on the immune system. In turn, by targeting key cellular pathways, beta HPV types act as facilitators of HPV UV-induced DNA mutations. However, after the accumulation of DNA mutations and the development of skin lesions, the expression of the HPV38 E6 and E7 genes is dispensable for the maintenance of the malignant phenotype of skin cancer cells (Lambert et al., 2020a).

In agreement with this working model, a prospective study showed that baseline beta HPV detection significantly predicted the development of cutaneous squamous cell carcinoma (Rollison et al., 2021).

Figure 1. HPV38 alters wild-type p53 activity to promote cell proliferation via the downregulation of integrin alpha 1 (ITGA1) expression. EGFR, epidermal growth factor receptor. © IARC.





Figure 2. Model for cooperation between some beta human papillomavirus (HPV) types and ultraviolet (UV) radiation in promoting cutaneous squamous cell carcinoma (cSCC). Under physiological conditions, UV irradiation of the skin induces DNA mutations in keratinocytes and immunosuppression. The UV-induced damage results in (i) cell-cycle arrest and repair of DNA mutations or (ii) apoptosis if the DNA damage is unreparable. Beta HPV early proteins, E6 and E7, can alter the cellular response to UV-induced stress, maintaining alive DNA-damaged cells that have a high risk of evolving into cancer cells. After accumulation of mutations in oncogenic driver genes (e.g. cellular tumour suppressor genes or oncogenes), the expression of the viral genes becomes dispensable. Reproduced from Lambert et al. (2020a). Copyright © 2020, The Authors, under exclusive licence to Springer Nature Limited.



INFECTIONS AND CANCER EPIDEMIOLOGY GROUP (ICE)

GLOBAL BURDEN OF CANCER ATTRIBUTABLE TO INFECTIOUS AGENTS

Given the amenability of infections to prevention, estimates of infection-attributable cancer burden are key public health indicators. ICE updated estimates of infection-attributable cancer burden at the country, regional, and global level with the most pertinent exposure assessment tools and the latest global cancer incidence data for 11 infectious carcinogens (viruses, bacteria, and parasites) (de Martel et al., 2020) (Figure 3). This work estimated that in 2018, 2.2 million infection-attributable cancer cases were diagnosed worldwide, corresponding to an age-standardized incidence rate (ASIR) of 25.0 cases per 100 000 person-years. Primary causes were *H. pylori* (810 000 cases; ASIR, 8.7), HPV (690 000 cases; ASIR, 8.0), hepatitis B virus (360 000 cases; ASIR, 4.1), and hepatitis C virus (160 000 cases; ASIR, 1.7). The infection-attributable

ASIR was highest in eastern Asia (37.9) and sub-Saharan Africa (33.1) and lowest in northern Europe (13.6) and western Asia (13.8) (de Martel et al., 2020) (Figure 3). China accounted for one third of global cancer cases attributable to infection, driven by the high ASIR of *H. pylori* (15.6) and hepatitis B virus (11.7) infections. HPV-attributable cancer incidence showed the strongest relationship with income level, from ASIR of 6.9 in high-income countries to ASIR of 16.1 in low-income countries. Follow-up analyses focused on the global burden of cervical cancer attributable to HIV infection (Stelzle et al., 2021) and on the HPV-related cancer burden in China (Duan et al., 2020). These findings are important to raise awareness for the control of oncogenic infections, particularly in an era where global cancer prevention is seen within the context of noncommunicable diseases.

ANAL CANCER EPIDEMIOLOGY AND PREVENTION

Understanding the burden and natural history of HPV-related anal squamous cell carcinoma (ASCC) is needed to raise awareness and inform prevention initiatives. Globally every year, an estimated 29 000 people, predominantly women, are diagnosed with ASCC (de Martel et al., 2020). An ASCC risk scale was developed, based on a meta-analysis of anal cancer incidence, to help prioritize high-risk groups for anal cancer prevention programmes, most notably people living with HIV, men who have sex with men, women diagnosed with HPV-related gynaecological precancerous lesions or cancer, and recipients of solid organ transplants (Clifford et al., 2021) (Figure 4). A collaborative re-analysis of individual-level data of almost 30 000 men from 64 studies comprehensively described the age-specific epidemiology of anal HPV infection and high-grade

Figure 3. Global burden of cancer attributable to infections in 2018: 2.2 million cases (13% of all cancers). HBV, hepatitis B virus; HCV, hepatitis C virus; HPV, human papillomavirus. Reproduced from de Martel et al. (2020). © 2019 International Agency for Research on Cancer; licensee Elsevier.





Figure 4. Anal cancer risk scale, showing estimates for people living with HIV, men who have sex with men (MSM), women diagnosed with HPV-related gynaecological precancerous lesions or cancer for different age groups, and solid organ transplant recipients (SOTR) for different periods since transplant; yrs, years; yst, years since transplant. Reproduced from Clifford et al. (2021). © 2020 International Agency for Research on Cancer (IARC/WHO); licensed by John Wiley & Sons Ltd on behalf of Union for International Cancer Control.




precancerous lesions according to the main known determinants of male ASCC risk, namely HIV status and sexuality (Wei et al., 2021a). Another meta-analysis focused on describing anal HPV, anal lesions, and cancer in recipients of solid organ transplants (Albuquerque et al., 2020). Clinical studies also continue to provide information about natural history in these high-risk groups, including anal HPV prevalence in HIV-positive women in China, the utility of HPV16 E6 antibodies to stratify people living with HIV for risk of anal cancer in the Swiss HIV Cohort Study (Combes et al., 2020), and a longitudinal study of anal HPV16 and HPV18 incidence and clearance in the APACHES study of 500 HIV-positive men who have sex with men in France (Alberts et al., 2020a).

HPV VACCINATION IMPACT IN LMICs:
PUBLIC HEALTH DECISION MODELLING

Effective prophylactic vaccines against HR HPV types have shown high safety and efficacy, and vaccination programmes are cost-effective in high-income countries. However, the introduction of HPV vaccination in LMICs remains challenging and requires the long-lasting commitment of local public health authorities. To support HPV vaccination in LMICs, ICE is conducting field studies to monitor the local impact of HPV vaccination and is developing predictive algorithms to project, at a global scale, the expected reduction in cervical cancer incidence as a result of vaccination. In Rwanda and Bhutan, ICE has demonstrated HPV vaccination effectiveness through urine-based HPV prevalence surveys in schools (Baussano et al., 2021) and cytology-based surveys in

Figure 5. Type- and age-specific HPV prevalence in baseline and repeated surveys in Bhutan. Vaccine types are HPV6, HPV11, HPV16, and HPV18; non-vaccine types are 42 types detected by GP5+/6+, excluding the 4 vaccine types. Error bars represent 95% confidence intervals. From Baussano et al. (2020a). Copyright © 2020 American College of Physicians. All Rights Reserved. Reprinted with the permission of American College of Physicians, Inc.



the general population (Baussano et al., 2020a) (Figure 5). In Rwanda, ICE has concomitantly assessed the nationwide cohort-specific coverage of vaccination (Sayinzoga et al., 2020). Meanwhile, to support the introduction of HPV vaccination at a global scale, ICE has estimated expected and preventable cervical cancers among women born between 2005 and 2014 in 185 countries (Bonjour et al., 2021; Piñeros et al., 2021b) (Table 1). To assess the local burden of cervical cancer in settings where

cancer registry data are not available, ICE has also developed a procedure to estimate cervical cancer incidence from population-based HPV prevalence data. Finally, in collaboration with colleagues from other leading institutions worldwide, ICE has assessed optimal HPV vaccination strategies to prevent cervical cancer in limited-resource settings (Drolet et al., 2021). These studies support the WHO global initiative to eliminate cervical cancer as a public health problem.

Table 1. Number of women at risk and number of expected and preventable cervical cancer cases among women born between 2005 and 2014 by continent, cervical cancer burden category, and 2018 Human Development Index

	Number of women at risk	Cases expected in the absence of vaccination		Cases preventable through vaccination	
		Number (95% UI)	Percentage of total cases in each category	Number (95% UI)	Percentage of total cases in each category
<i>Continent</i>					
Africa	165 606 523	5 648 149 (5 428 370–6 021 112)	48.7	4 162 782 (4 000 569–4 437 821)	73.7
Asia	344 978 554	4 486 109 (4 372 716–4 643 003)	38.7	3 480 802 (3 380 678–3 608 856)	77.6
Europe	38 508 937	416 241 (410 384–423 343)	3.6	332 124 (327 352–337 944)	79.8
Latin America	52 222 051	863 532 (835 639–919 393)	7.4	605 918 (586 145–644 957)	70.2
North America	22 124 133	140 961 (137 550–144 461)	1.2	111 009 (107 869–114 330)	78.8
Oceania	3 061 127	42 855 (39 073–47 384)	0.4	35 485 (32 318–39 271)	82.8
<i>Cervical cancer burden^a</i>					
Very high	292 719 493	5 949 749 (5 745 857–6 186 696)	51.3	4 568 726 (4 405 526–4 755 927)	76.8
High	136 428 165	2 808 840 (2 671 891–3 045 844)	24.2	2 062 358 (1 961 833–2 236 491)	73.4
Medium	77 561 473	1 697 817 (1 597 925–1 890 372)	14.6	1 231 586 (1 158 349–1 372 443)	72.5
Low	106 942 955	1 027 948 (992 516–1 118 556)	8.9	778 124 (752 326–844 285)	75.7
Very low	12 849 239	113 492 (109 602–120 963)	1.0	87 326 (84 360–93 058)	76.9
<i>Human Development Index^b</i>					
Low–middle	352 464 260	8 025 880 (7 794 459–8 447 380)	69.2	6 117 421 (5 939 136–6 430 904)	76.2
High	186 108 791	2 775 193 (2 720 782–2 837 271)	23.9	1 994 697 (1 954 640–2 039 514)	71.9
Very high	87 928 274	796 774 (786 593–810 166)	6.9	616 002 (607 835–626 440)	77.3
Total	626 501 325	11 597 847 (11 366 107–12 027 739)	100.0	8 728 120 (8 549 700–9 049 217)	75.3

UI, uncertainty interval.

^a Individual countries were sorted according to the expected number of cervical cancer cases, then grouped into the following categories: very high burden (8 countries accounting for up to 50% of all cases worldwide), high burden (17 countries accounting for the next 25% of all cases), medium burden (25 countries accounting for the next 15%), low burden (68 countries accounting for the next 9%), and very low burden (67 countries accounting for the remaining 1%).

^b Low–middle, < 0.70; high, 0.70–0.79; very high, ≥ 0.80.

Source: Reproduced from Bonjour et al. (2021). © 2021 World Health Organization; licensee Elsevier.



SECTION OF ENVIRONMENT AND RADIATION (ENV)

Section head

Dr Joachim Schüz

Deputy section head

Dr Valerie McCormack

Scientists

Dr Graham Byrnes

Dr Isabelle Deltour

Dr Carolina Espina

Dr Florence Guida

Dr Ann Olsson

Dr Evgenia Ostroumova

Dr Kayo Togawa (until October 2021)

Staff

Ms Christine Bassier

Mr Liacine Bouaoun

Ms Catherine Chassin

Mr Gilles Ferro

Ms Véronique Luzon

Ms Monika Moissonnier

Visiting scientists

Dr Friederike Erdmann

Dr Kirsten Frederiksen

(until June 2021)

Dr Ausrele Kesminiene

Dr Noriko Kojimahara

(until February 2020)

Dr Clement Tetteh Narh

Dr Kayo Togawa

Postdoctoral fellows

Dr Shukrullah Ahmadi

Dr Pauline Boucheron

Dr Amandine Busson

Dr Aurélie Danjou

Dr Ariadna Feliu Josa

Dr Milena Foerster

Dr Joanne Kim

Dr Gwinyai Masukume

(until November 2021)

Dr Daniel Middleton

(until December 2020)

Dr Clement Tetteh Narh

(until August 2021)

Dr Felix Onyije

Dr Hannah Simba

Dr Ljubica Zupunski

Students

Ms Kenza Abdelmalki

(until October 2021)

Ms Kristina Betts

(until February 2020)

Ms Bayan Hosseini

The main programme of work of the Section of Environment and Radiation (ENV) encompasses environmental, occupational, and radiation-related cancer, and lifestyle and cancer etiology and prognosis in low- and middle-income countries (LMICs), as well as the implementation of cancer prevention research. With the start of the new IARC Medium-Term Strategy 2021–2025 and the new organizational structure as of 1 January 2021, ENV was renamed as the Environment and Lifestyle Epidemiology Branch, to better capture its broad scope of activities.

ENV focuses its endeavours on four main areas: (i) research in settings where levels of exposure to putative or established carcinogens in the environment, in the workplace, or related to people's lifestyles are high, and research is thus warranted; (ii) studies of common cancer types and of specific environmental, occupational, or lifestyle exposures that occur in underresearched settings; (iii) studies evaluating the role of broader social and biological factors throughout the course of the disease and its prognosis; and (iv) catalysing all new knowledge on lifestyle, environmental, occupational, and radiation-related risk

factors, and on screening and vaccination with the respective collaborators, into recommendations at the individual and population level. The objectives of ENV are achieved through the conduct of collaborative international epidemiological studies, including coordination of international consortia or through the initiation of focused individual and multicountry analytical epidemiological studies. In selecting programmes of research, an effort is made to ensure that the involvement of the Agency serves a specific and substantial function, by facilitating international collaboration, by overcoming political barriers, by

initiating new studies through assisting local collaborators with IARC's unique expertise in and beyond ENV and increasing local visibility and trust in their work, and by using the general expertise, international network, and special function of the Agency as part of the World Health Organization (WHO).

With a strong focus on environmental (including occupational and radiation-related) and lifestyle risk factors, ENV fills a major research gap to further identify factors and to understand the cancer burden attributed to these factors. ENV

has steered its research focus to LMICs in particular, a direction that is consistent with the Agency's international remit and is warranted because in these settings, levels of environmental pollution are often higher and protection measures are often less developed. Another focus of ENV is to identify and investigate previously unstudied lifestyle habits and exposures unique to LMICs and other settings that may affect carcinogenesis. Capacity-building, as well as establishing research platforms, is another mission of IARC to which ENV contributes extensively. ENV also plays

a key role in the translation of research findings into applied cancer prevention by, for example, informing the respective international and national authorities on worker protection, especially against radiation. Most directly, ENV is conducting cancer prevention research through the World Code Against Cancer initiative, which is developing sets of regional recommendations on primary and secondary prevention of cancer, and by chairing the newly established Cancer Prevention Europe platform, which had an influential role in shaping Europe's Beating Cancer Plan.

MANUS SORDIDAE, MENS PURA (DIRTY HANDS, BUT A CLEAN MIND)

At the heart of the cancer studies carried out by ENV is the conduct of fieldwork in underresearched areas of the world, in particular in low-income countries that have a scarcity of available data but unique and never-studied exposures (many not yet even identified as candidates) and combinations of exposures, higher exposures in workplaces and in the environment, and less protection of workers, communities, and environments compared with high-income countries. High-quality studies in these settings can be initiated only if the collaboration between the local and international scientists is respectful and is driven by shared scientific curiosity and open-mindedness and addresses questions, exposures, and exposure circumstances relevant to the local setting. This requires not only a mutual understanding of each group's expertise and how it contributes to the joint success of the project but also an appreciation of how epidemiological methods from


A scene from ESCCAPE fieldwork, illustrating the challenge of percentage ethanol estimation in local distillations. This is an artisanal *kachasu* (maize-based) distillation setup in Malawi. The ethanol content of this unregulated spirit varies according to the distillation process and between distillers, and differs between the regular and *mutu* (strong) *kachasu*. Although the first research implicating the role of *kachasu* in the incidence of oesophageal cancer was published in 1969, evidence of its contribution to the oesophageal cancer burden in East Africa is only now beginning to emerge. © IARC.



textbooks are put into practice and, for the international scientists, an appreciation of the local context, culture, and environment. The setting up of protocols, including methods of study conduct and interpretation of results, is full of pitfalls and barriers. However, more than 50 years of experience has shown IARC that such barriers can be minimized by regular and frequent mutual visits and joint explorations, which no virtual platform in the world can replace. With such a focus on hands-on studies, ENV is closely following Geoffrey Rose's motto of *manus sordidae, mens pura* ("dirty hands, but a clean mind"; <https://www.bmj.com/content/bmj/2/6143/1006.full.pdf>). The continuing COVID-19 pandemic has had a large impact on such activities. ENV pledges to make all efforts to enable fieldwork research that is informative and scientifically sound, and not diluted and misleading.

The African Breast Cancer – Disparities in Outcomes (ABC-DO) study is an ENV-initiated programme of work aimed at addressing multiple dimensions of a major cause of cancer death in women in sub-Saharan Africa: low breast cancer survival. This common cancer type in women has a very good prognosis in high-income settings; therefore, improving survival should be a priority in cancer control plans in all LMICs. To examine the major barriers to improving

Figure 1. Three-year overall survival (%) of patients with breast cancer in sub-Saharan Africa. Observed survival (blue) and predicted survival if the following improvements had been made, by site and race: downstaging to improved distributions of earlier stage at diagnosis (green), improved treatment so that all women receive surgery and systemic therapy (red), reduction in survival deficits attributed to social inequalities (orange), and elimination of survival deficits attributed to increased mortality in HIV-positive women (dark grey), being young (< 30 years) (purple), and not having estrogen receptor (ER)-positive or progesterone receptor (PR)-positive, human epidermal growth factor receptor 2 (HER2)-negative tumour subtypes (light blue). Reproduced from McCormack et al. (2020), Copyright Elsevier (2020).



breast cancer survival, ENV set up a five-country breast cancer cohort (<https://abc-do.iarc.who.int>), which continues to follow up 2200 women who were newly diagnosed with breast cancer during 2014–2017. Mobile-health (mHealth) real-time data collection and follow-up protocols were uniquely adopted in this study, ensuring few losses to follow-up (Foerster et al., 2020a). Recent findings showed that breast cancer survival is alarmingly low in Black African women (Figure 1). At 3 years after diagnosis, survival was 90% in White Namibian women, 58% in Black Namibian and Black South African women, 46% in Ugandan and Zambian women, and 36% in Nigerian women (McCormack et al., 2020). The largest contributors to low survival were late stage at diagnosis and a lack of access to surgery and systemic therapy, which particularly affected women in lower socioeconomic groups. In contrast, the relatively high proportions of young-onset breast cancer (age < 30 years at diagnosis), HIV-positive women, and more aggressive tumour subtypes made only a small contribution to low overall survival (McCormack et al., 2020).

The drivers of late stage at diagnosis have also been identified and include extensive delays between presentation at a first-line health provider and diagnosis (Foerster et al., 2021), as well as the geospatial element driving later stage at diagnosis in women living farther away from diagnostic centres (Togawa et al., 2021a). ABC-DO has also, for the first time, revealed the extent of the inter-generational effect of such high patient mortality rates by quantifying the number of maternal orphans associated with each breast cancer death (Galukande et al., 2021). The ABC-DO cohort continues to be followed up, and current research is studying the impact of additional morbidities (hypertension, HIV, and obesity) on survival (Ayeni et al., 2021). The comprehensive multidimensional insights gained through ABC-DO are helping to show the impact of breast cancer deaths and to shed light on the most effective pathways to improving survival, as part of WHO's 2021 launch of the Global Breast Cancer Initiative.

The European Code Against Cancer was launched in 1986, and IARC was mandated to lead the development of its fourth edition. The IARC methodology to develop the cancer prevention recommendations has been refined and expanded to include information on successful interventions, as described in a roadmap laid out within the European Union (EU) Innovative Partnership for Action Against Cancer (iPAAC); this roadmap now forms the basis for the development of the fifth edition within Europe's Beating Cancer Plan (Espina et al., 2021). The need for better dissemination across Europe was identified from surveys showing that too few Europeans are well informed on how to reduce their risk of cancer (Ritchie et al., 2021). The strengthening of primary, secondary, and tertiary cancer prevention has also been achieved through the newly established Cancer Prevention Europe network, chaired by ENV, and its role in shaping the EU Cancer Mission and Europe's Beating Cancer Plan (Berns et al., 2020).

Inspired by the European Code Against Cancer, IARC called for this model to be extended to other world regions to achieve a World Code Against Cancer. In 2021, this process has begun with the preparation of the first Latin American and Caribbean Code Against Cancer, in collaboration with the Pan American Health Organization and several regional partners. In parallel, the use of more modern technologies (mHealth) to spread knowledge on cancer prevention through mobile phone messages has been explored in this region through dissemination research. The importance of, and barriers to, cancer prevention were discussed in a Special Issue of the journal *Molecular Oncology*, coordinated by guest editors in ENV (Schüz and Espina, 2021).

RECENT RESEARCH FINDINGS

Whether and to what extent the increasing use of pesticides contributes to the global cancer burden remains a major environmental health concern, and ENV is involved in several activities to study cancer risk in relation to pesticide

use. A study of the incidence of cancer in farmers and agricultural workers, compared with the general population, in eight countries within the AGRICOH consortium (<https://agricoh.iarc.fr/>) has illustrated that these occupational groups generally have reduced incidence rates, in particular for cancer types associated with unhealthy lifestyle factors such as smoking or physical inactivity (Togawa et al., 2021b); increased incidence rates were found only for skin melanoma and multiple myeloma in women, and for prostate cancer. These findings confirm the challenges of studying a factor such as exposure to pesticides in an otherwise relatively healthy population. In other pesticide-related research, there was little evidence that the exposure of parents to pesticides increases the subsequent risk of testicular cancer in their male offspring, perhaps with the exception of fungicides (Danjou et al., 2021), as seen in a large-scale case-control study in France. A systematic review confirmed concerns that the exposure of parents to pesticides increases the risk of leukaemia in their offspring (Karalexi et al., 2021).

Lung cancer is the most common occupationally related cancer type. An analysis by the ENV-coordinated SYNERGY consortium of 16 case-control studies of lung cancer confirmed that working as a painter, which is among the jobs that require respective preventive measures, was associated with a 30% increase in the risk of lung cancer (Guha et al., 2021). Using the same data source for an advanced dose-response analysis showed the critical roles of diesel motor exhaust (Ge et al., 2020a) and respirable crystalline silica (Ge et al., 2020b) in causing occupationally related lung cancers. In a different occupational cancer study, ENV determined that four well-known lung carcinogens (asbestos, respirable crystalline silica, chromium VI, and nickel) also increase the risk of laryngeal cancer (Hall et al., 2020).

Another large employment sector worldwide is the petroleum industry; a systematic review by ENV highlighted the limited scientific knowledge on cancer risks because of the lack of systematic epidemiological studies, both on a global scale (Onyije et al., 2021) and within major oil-producing countries such as the Islamic

Figure 2. Although tattoos are common, public awareness of the possible related health hazards and risks is low. In addition to the possibility of skin irritation, the potential threat from subcutaneous exposure to chemicals in the tattoo ink, which have proven to be carcinogenic by dermal or respiratory uptake, remains widely neglected. Lymphatic accumulation of such toxins could pose an unknown risk of immune-related cancers, particularly the group of non-Hodgkin lymphomas. © IARC.



Republic of Iran (Hosseini et al., 2021). In further occupational studies, valuable insights for worker protection are expected to be gained from the large-scale historical cohort study of almost 36 000 miners and millers exposed to chrysotile (asbestos) in the Russian Federation, working in the world's largest active chrysotile mine and enrichment factory; fieldwork was completed in late 2019 (Schüz et al., 2020a), and reports on measures to ensure high data quality have been published (Olsson et al., 2020; Schüz et al., 2020b). Finally, many substances used in the traditional art of tattooing, a practice that has increased substantially in popularity, are established occupational carcinogens. Therefore, an increased risk of some cancer types, in particular lymphomas, is not implausible (Figure 2), and ENV has just started the first prospective investigations with collaborators in France and Germany (Foerster et al., 2020b).

Another example of a collaborative focused research programme where fieldwork studies were needed is the case of oesophageal cancer in East

Africa and southern Africa. Through the Oesophageal Squamous Cell Carcinoma African Prevention Research (ESCAPE) study, ENV and a network of African institutions (Figure 3) completed case-control studies in Kenya, Malawi, and the United Republic of Tanzania in 2021. The findings so far indicate the presence of multiple risk factors, notably the considerable role of tobacco use and alcohol consumption in men and of consumption of hot beverages in both sexes. Poor oral health and hygiene are also implicated, and studies of the pathways driving these associations, such as constituents of the oral microbiome, are under way. The ESCAPE study also includes investigations of the impact of geophagia, the intentional consumption of non-food items (typically soil, a very common practice during pregnancy, potentially causing irritation to the mucosa), an example of a never-studied factor. This habit was not found to increase risk of oesophageal squamous cell cancer (Narh et al., 2021).

Protection from radiation at low doses still needs to be optimized, and data from the aftermath of nuclear accidents remain the most informative source. Therefore, ENV researchers observed with concern a lack of funding for previously developed research strategies related to the Chernobyl nuclear accident, which should have been implemented with urgency, given that the affected populations are ageing and the possibility of their participation in studies is decreasing (Ostroumova et al., 2020). Recent IARC-led research on Chernobyl showed no statistically significantly increased risk of breast cancer in association with district-averaged accumulated breast radiation dose after adjustment for age, time, and urbanicity in female populations of the most radioactively contaminated areas of Belarus (1978–2010) and Ukraine (1990–2010) (Zupunski et al., 2021) (Figure 4), but detailed analytical studies on breast cancer are warranted. The gold mine tailings in South Africa are also of concern, because of their contamination with uranium; a study of hair samples confirmed elevated levels in residents of various neighbourhoods, highlighting the need for studies of possible adverse health effects in humans.

Figure 3. Meeting of the Oesophageal Squamous Cell Carcinoma African Prevention Research (ESCAPE) study team of collaborators from IARC, Kenya (Moi University, Eldoret), Malawi (College of Medicine, Blantyre), the United Kingdom (University of Liverpool), and the United Republic of Tanzania (Kilimanjaro Clinical Research Institute/Kilimanjaro Christian Medical Centre, Moshi), held in Blantyre, Malawi, in February 2020. © IARC.




Because mobile phone use is ubiquitous and technologies change regularly, the monitoring of potential adverse health effects associated with their use remains important. ENV has compared the incidence rates of the most common type of brain tumour – glioma – in men in the Nordic countries with projections of increased risk scenarios related to mobile phone use; the results suggest that if there is a risk, it is very small. These recent population findings are not compatible with the results of previous case-control studies, indicating that the




effects have at least been overestimated. Continued monitoring is warranted, and ENV is participating in the multinational prospective cohort study of mobile phone users (Cohort Study of Mobile Phone Use and Health [COSMOS]; Tettamanti et al., 2020).

Childhood cancer remains a priority research area of ENV. In 2021, ENV coordinated a Special Issue of the journal *Cancer Epidemiology* describing the situation with respect to awareness, diagnosis, referral, and treatment of

childhood cancer around the world, showing disparities between high- and low-income countries of greater magnitude than for most adult cancer types (Schüz and Roman, 2021). An assessment of the impact of the COVID-19 pandemic on paediatric oncology diagnoses in Germany in 2020 revealed a significantly higher incidence of all childhood cancers and in all childhood age ranges (Erdmann et al., 2021); the underlying reasons for this increase are not known, and close monitoring is warranted.

Figure 4. Breast cancer relative risk (RR) estimates by 5-year-lagged cumulative absorbed breast dose categories compared with the reference category (< 5.0 mGy; RR = 1.00) adjusted for attained age and urban or rural status, and stratified by 5-year intervals in (a) Belarus and (b) Ukraine. Reproduced with permission from Zupunski et al. (2021), © John Wiley & Sons.





SECTION OF NUTRITION AND METABOLISM (NME)

Section head

Dr Marc Gunter

Biomarkers Group (BMA)

Group head

Dr Augustin Scalbert

Scientists

Dr Laure Dossus
Dr Pekka Keski-Rahkonen
Dr Sabina Rinaldi
Dr Reza Salek (until September 2021)

Research assistants

Mr David Achaintre
Ms Vanessa Neveu
Ms Geneviève Nicolas
Ms Béatrice Vozar

Laboratory technicians

Ms Audrey Gicquiau
Ms Anne-Sophie Navionis
Ms Nivonirina Robinot
Ms Amarine Trolat
(until February 2021)

Secretariat

Ms Karine Racinoux

Postdoctoral fellows

Dr Adam Amara
Dr Chrysovalantou Chatziioannou
Dr Mathilde His
Dr Mira Merdas
Dr Jodi Rattner

Students

Ms Manon Cairat
Mr Roland Wedekind

Trainees

Mr Ngoc-Minh-Quan Nguyen
(until September 2021)
Mr Maxime Vincent

Nutritional Epidemiology Group (NEP)

Group head

Dr Marc Gunter

Scientists

Dr Inge Huybrechts
Dr Mazda Jenab
Dr Neil Murphy

Visiting scientists

Dr Kristen Benjaminsen Borch
Ms Elodie Faure
Dr Agnès Fournier
Dr Hwayoung Noh
Dr Rashmi Sinha
(until February 2020)

Secretariat

Ms Tracy Lignini
Ms Sally Moldan

Postdoctoral fellows

Dr Elom Aglago (until August 2021)
Dr Jessica Blanco
Dr Niki Dimou
Dr Nathalie Kliemann
(until October 2020)
Dr Ruhina Laskar
Dr Matthew Lee
Dr Nagisa Mori
Dr Nikolaos Papadimitriou

Students

Ms Aline Al Nahas
Ms Liesel Claeys
(until February 2021)
Ms Kim Maasen
(until November 2021)
Ms Michèle Matta
(until November 2021)
Dr Mohammad Sediq Sahrai
(until October 2020)
Ms Heleen Van Puyvelde
(until November 2020)

Ms Sahar Yammine
(until November 2020)
Mr Sémi Zouiouich
(until March 2021)

Trainees

Ms Ines Ramos
Dr Mirna Sabra

Nutritional Methodology and Biostatistics Group (NMB)

Group head

Dr Pietro Ferrari

Scientists

Dr Heinz Freisling
Dr Vivian Viallon

Research assistants

Ms Carine Biessy
Ms Corinne Casagrande
Mr Bertrand Hemon
Dr Aurélie Moskal (until June 2021)

Secretariat

Ms Karina Zaluski

Postdoctoral fellows

Dr Veronica Davila Batista
Dr Hannah Lennon (until April 2020)
Dr Komodo Matta
Dr Ana-Lucia Mayen-Chacon
Dr Martina Recalde

Students

Ms Marie Breeur
Ms Reynalda Cordova
(until August 2020)
Ms Emma Fontvieille
Ms Laia Peruchet Noray

Trainees

Ms Clarisse Pont
Ms Léa Regazzetti

The Section of Nutrition and Metabolism (NME) comprises three highly integrated groups: the Biomarkers Group (BMA), the Nutritional Epidemiology Group (NEP), and the Nutritional Methodology and Biostatistics Group (NMB). The Section combines large-scale population-based studies with laboratory and biostatistical expertise to identify causal links between nutrition, metabolic factors, and cancer. The goal of the Section is to provide robust evidence of the role of nutrition in cancer development that can be translated to clinical interventions and public health policy. NME aims to go beyond what may be considered the traditional

domains of nutrition in cancer research and to fully exploit methodological advances in -omics and molecular profiling techniques to implement an integrated, multidisciplinary programme of research. The overall strategic vision of NME is based on three major research themes: (i) understanding the role of obesity and metabolic dysfunction in cancer development, (ii) identification of biomarkers of diet and nutrition and their application within studies of cancer, and (iii) multimorbidity and biological pathways common to cancer, diabetes, and cardiovascular disease. Within these themes, NME focuses on a core set of

cancer sites, primarily gastrointestinal cancers, as well as hormone-related cancers such as breast cancer and endometrial cancer. A particular emphasis is placed on cancer types that have clear links to nutrition and metabolic abnormalities and for which much remains to be discovered about disease etiology.

With the start of the new IARC Medium-Term Strategy 2021–2025 and the new organizational structure as of 1 January 2021, NME was renamed as the Nutrition and Metabolism Branch.

ESTABLISHING AN EPIDEMIOLOGICAL STUDY IN AFGHANISTAN: KANDAHAR OBESITY RESEARCH

As a result of rapid economic, social, and cultural changes, the prevalence of obesity in Afghanistan is increasing and dietary habits are shifting from the traditional pattern to a pattern more typical of industrialized countries, with concomitant increases in the incidence of noncommunicable diseases (NCDs).

A population-based cross-sectional study was designed in Kandahar city, and data were collected on sociodemographic characteristics, health history, anthropometry, physical activity, and diet. NME used stratified sampling to recruit an equal number of participants in the normal-weight, overweight, and obese categories. Body fat composition was analysed using bioelectric impedance analysis, and dried blood, urine, and stool samples were collected for biomarker analyses.

The study included 712 participants (411 men and 301 women); 92% lived in urban areas, 73% were married, 42% were aged 20–30 years, 51% were not formally educated, 79% were never-smokers, and 68% had central obesity. With respect to NCDs, 38% were hypertensive, 18% were diabetic, 30% had dyslipidaemia, 36% had fatty liver disease, and 50% were symptomatic for anxiety and/or depression.

This is the first study that will assess dietary patterns, lifestyle factors, and their association with obesity and metabolic health in Afghanistan. The data collected will be an invaluable resource for future studies on biomarkers or the microbiome, and could be used to train future public health scientists in Afghanistan.

Kandahar Obesity Research. © IARC.



BIOMARKERS GROUP (BMA)

METABOLOMICS REVEALS NEW BIOMARKERS FOR INTAKE OF PROCESSED MEAT

Processed meat has been associated with a higher risk of colorectal cancer; however, identification of the etiologically relevant components of this heterogeneous food group remains challenging. The Biomarkers Group (BMA) applied an untargeted metabolomic approach to identify novel biomarkers of intake for processed meat products in a randomized cross-over dietary intervention and in 474 participants in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Several pepper-derived alkaloids were positively associated with intake of sausage and processed meat and may be used as biomarkers to improve assessment of intake of processed meat in epidemiological studies (Figure 1) (Wedekind et al., 2021).

NEW DATA ON BIOMARKERS OF EXPOSURE AND THEIR ASSOCIATIONS WITH DISEASE RISK COLLECTED IN THE EXPOSOME-EXPLORER DATABASE

The Exposome-Explorer database (<http://exposome-explorer.iarc.fr>) provides detailed information on more than 1000 biomarkers of dietary and pollutant exposures as measured in various populations.

New information on their associations with cancer risk in relevant epidemiological studies, derived from more than 300 scientific papers, has now been collated (Neveu et al., 2020).

IDENTIFICATION OF BIOMARKERS TO EXPLORE NOVEL ETIOLOGICAL HYPOTHESES IN BREAST CANCER

BMA applied targeted metabolomics to identify novel metabolites associated with breast cancer, breast density, and potential modifiable determinants.

In premenopausal Mexican women from the Mexican Teachers Cohort, sphingomyelin (SM) C16:1 and phosphatidylcholine (PC) ae C30:2 were inversely associated with percentage mammographic density and were positively associated with cholesterol and metabolic syndrome components (His et al., 2021a).

As part of the EPIC study, BMA observed novel associations between circulating concentrations of acetylcarnitine, arginine, asparagine, and PCs, and breast cancer. Correlates of these biomarkers were investigated (His et al., 2021b), and PCs were observed to be inversely associated with adiposity and positively associated with total and saturated fat intakes. PC ae C36:2 was inversely associated with


alcohol consumption and positively associated with healthy lifestyle. Asparagine was inversely associated with adiposity. These findings suggest possible mechanisms for novel etiological hypotheses on breast cancer.

OBESITY AND ENDOMETRIAL CANCER: DISENTANGLING UNDERLYING MECHANISMS

Obesity is a major risk factor for endometrial cancer, but the underlying pathways and their relative contribution are still unclear. In a study conducted as part of EPIC, pathways characterized by reduced adiponectin and increased inflammatory biomarkers, insulin, and estrogen explained about 70% of the association between endometrial cancer and obesity (Dashti et al., 2021).

Using metabolomics, BMA discovered alterations in concentrations of glycine, serine, SM C18:0, and free carnitine associated with endometrial cancer (Figure 2) (Dossus et al., 2021). BMA also identified a metabolic signature of obesity among more than 4000 EPIC participants that was more predictive of endometrial cancer risk than anthropometric measures (Kliemann et al., 2021).

Figure 1. Scaled relative intensities of pepper alkaloid metabolites in plasma samples associated with intake of several processed food products in a dietary intervention study (n = 12). Reproduced from Wedekind et al. (2021). © John Wiley & Sons.



Dysregulation of tryptophan metabolism has been linked to the development of colorectal cancer, but few epidemiological studies have addressed this hypothesis. BMA studied associations between tryptophan metabolites and colon cancer risk in the ColoCare, Colorectal Cancer Study of Austria (CORSA), and EPIC cohorts (Papadimitriou et al., 2021). Tryptophan levels were inversely associated and serotonin levels positively associated with colon cancer risk (Figure 3). These results support earlier studies on the role of tryptophan metabolism in colon cancer and offer new insights into changes in the metabolic flux of tryptophan before and after diagnosis of colon cancer.

Figure 2. Odds ratios (ORs) and *P* values for the associations between metabolites and risk of endometrial cancer in models adjusted for body mass index (BMI). ORs are estimated per standard deviation (SD) increase in log-transformed metabolite concentrations, from logistic regression conditional on matching variables. The figure shows statistical significance based on *P* values (significant metabolites above the dotted line). SM, sphingomyelin. Reproduced from Dossus et al. (2021). © 2021, Published by Elsevier Inc.





Figure 3. Associations of tryptophan, serotonin, kynurenine, and kynurenine-to-tryptophan ratio with colon cancer in the Colorectal Cancer Study of Austria (CORSA), ColoCare, and European Prospective Investigation into Cancer and Nutrition (EPIC) studies. The odds ratios (ORs) correspond to a 1 standard deviation difference in concentration levels of the biomarkers, except for serotonin where the comparison was made between detectable and undetectable concentration levels. CI, confidence interval. Reproduced with permission from Papadimitriou et al. (2021a), John Wiley & Sons.



NUTRITIONAL EPIDEMIOLOGY GROUP (NEP)

INSULIN, INSULIN-LIKE GROWTH FACTORS, AND BREAST AND COLORECTAL CANCERS

Experimental and epidemiological evidence has implicated the insulin and insulin-like growth factor (IGF) axis in breast and colorectal cancer development, but causality of these relationships is uncertain. In observational and Mendelian randomization (MR) analyses, the Nutritional Epidemiology Group (NEP) investigated the role of circulating IGF-1 and fasting insulin in breast and colorectal cancer development. In the UK Biobank, higher IGF-1 concentrations were associated with greater breast (hazard ratio [HR] per 5 nmol/L, 1.11; 95% confidence interval [CI], 1.07–1.16) and colorectal cancer risk (HR per 1 standard deviation [SD], 1.11; 95% CI, 1.05–1.17). In MR analyses, genetically predicted IGF-1 concentrations were positively associated with breast (odds ratio [OR] per 5 nmol/L, 1.05; 95% CI, 1.01–1.10) and colorectal cancer risk (OR per 1 SD increment, 1.08; 95% CI, 1.03–1.12). Genetically predicted fasting insulin levels were positively associated with colorectal cancer risk (OR per 1 SD, 1.65; 95% CI, 1.15–2.36) (Murphy et al., 2021a). These results support probable causal relationships and suggest that targeting the insulin–IGF axis may be beneficial in preventing breast and colorectal tumorigenesis (Murphy et al., 2020a, 2020b).

EXPLORING THE ROLE OF IRON IN COLORECTAL CANCER

Iron is hypothesized to play a role in colorectal tumorigenesis; however, epidemiological evidence is limited. NEP examined the association between dietary and circulating iron and colorectal cancer via genetically predicted circulating iron using MR in 58 221 cases of colorectal cancer and 67 694 controls, and dietary total, haem, and non-haem iron assessed using dietary questionnaires within the EPIC cohort (6162 cases of colorectal

cancer, 450 101 non-cases). A positive association was observed for genetically predicted circulating iron and colon cancer risk (OR per SD, 1.08; 95% CI, 1.00–1.17; *P* value, 0.05) (Tsilidis et al., 2021). In the EPIC study, haem iron was positively associated with colorectal cancer in men (HR Q5 vs Q1, 1.13; 95% CI, 0.99–1.29) but not in women. These findings support a possible causal association between circulating iron and haem iron and the development of colorectal cancer.

FOOD PROCESSING AND CANCER RISK AND MORTALITY

Global industrialization has increased the consumption of ultra-processed foods (UPFs) while reducing food biodiversity. Recent analyses by NEP as part of the EPIC cohort examined the associations between processed food consumption and cancer risk. Positive associations between UPFs and several cancer sites were found, and an inverse association was observed for minimally processed foods in relation to most of the cancer outcomes.

Evidence suggests that UPFs may increase cancer risk via their obesogenic properties and their poor nutritional value, as well as through exposure to potentially carcinogenic compounds such as certain food additives and neoformed processing contaminants. The increase in UPF consumption parallels a steady decrease in food biodiversity as a result of industrialization. The continuing studies of NEP have already demonstrated an increased risk of premature death and cancer risk with lower species diversity in the diet (Hanley-Cook et al., 2021).

METABOLIC PROFILING AND COLORECTAL CANCER

Risk of colorectal cancer can be lowered by adherence to the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) guidelines. NEP derived metabolic signatures

of adherence to these guidelines and tested their associations with colorectal cancer risk as part of the EPIC cohort. Higher WCRF/AICR scores were characterized by metabolic signatures of increased odd-chain fatty acids, serine, glycine, and specific PCs. These signatures were more strongly inversely associated with colorectal cancer risk (OR, 0.62 per unit change; 95% CI, 0.50–0.78) than the WCRF/AICR score (OR, 0.93 per unit change; 95% CI, 0.86–1.00) overall. Measuring a specific panel of metabolites representative of a healthy or unhealthy lifestyle may identify strata of the population at higher risk of colorectal cancer.

NUTRITIONAL METHODOLOGY AND BIOSTATISTICS GROUP (NMB)

BIOSTATISTICAL ACTIVITIES


The increasing availability of molecular data in large epidemiological studies requires the development and application of ad hoc statistical methodology. The Nutritional Methodology and Biostatistics Group (NMB) has implemented a new pipeline for the normalization and pooling of metabolomics data (Viallon et al., 2021). A new machine-learning method based on an extension of the lasso penalty was developed to analyse

large-dimension data in (nested) case-control studies with several disease subtypes (Ballout et al., 2021). In line with recent developments in the field of causal inference, NMB applied modern causal mediation analysis to investigate the biological processes underlying the carcinogenic effect of obesity and alcohol (Assi et al., 2020; Dashti et al., 2021), and MR analysis was applied to investigate the causality of bilirubin on cancer occurrence (Seyed Khoei et al., 2020a, 2021).

LIFESTYLE AND RISK OF MULTIMORBIDITY

Improvements in longevity have increased the likelihood of an individual developing two or more diseases, referred to as multimorbidity. Cardiovascular diseases, type 2 diabetes, and cancer are the most common NCDs and represent major causes of morbidity, disability, and impaired quality of life. Limited evidence exists on how established risk factors for single NCDs are related to the clustering

Figure 4. Cumulative incidence functions (CIFs) describing the development of cancer, cardiovascular disease (CVD), and type 2 diabetes (T2D), and subsequent cancer-cardiometabolic multimorbidity (MM). Cancer refers to first malignant tumours at any site excluding non-melanoma skin cancer. CIFs are plotted for men (dotted) and women (continuous) aged 65 years for healthy lifestyle index (HLI) values of 15 (healthy, 85th percentile in green) and 5 (unhealthy, 4th percentile in red). HLI ranges from 0 to 20 units; higher scores indicate healthier lifestyles. Reproduced from Freisling et al. (2020a). © 2020, Freisling et al.



of NCDs within individuals. Within a large cohort of 300 000 participants from seven European countries, NMB showed that favourable lifestyle habits reduced the risk of incident multimorbidity from cancer and cardiometabolic diseases (Freisling et al., 2020a). In particular, NMB's absolute risk model assessed the burden of multimorbidity among participants who experienced a first disease, and quantified the preventive potential of healthy lifestyle habits with regard to multimorbidity of cancer and cardiometabolic diseases. For example, after diagnosis with type 2 diabetes, the 10-year absolute risks

of multimorbidity were 40% for men and 30% for women with an unhealthy lifestyle, and 25% for men and 18% for women with a healthy lifestyle (Figure 4) (Freisling et al., 2020a).

ALCOHOL AND CANCER

Modest associations between alcohol consumption and cancer, particularly for light and moderate intakes, may be missed as a result of measurement error in self-reported assessments. NMB identified 2-hydroxy-3-methylbutyric acid as a novel biomarker of alcohol consumption in the EPIC study and the Alpha-Tocopher-

ol, Beta-Carotene Cancer (ATBC) study (Lofffield et al., 2021). Higher levels of 2-hydroxy-3-methylbutyric acid were positively associated with risk of hepatocellular carcinoma, pancreatic cancer, and liver disease mortality. These metabolites could help advance the study of alcohol and cancer risk in population-based studies.

In a pooled analysis of EPIC and Melbourne Cohort Collaborative Study (MCCS) data, a novel positive association between lifetime alcohol intake and risk of noncardia stomach cancer was identified (Jayasekara et al., 2021).



SECTION OF GENETICS (GEN)

Section head

Dr Paul Brennan

Genetic Epidemiology Group (GEP)

Group head

Dr Paul Brennan

Scientists

Dr Estelle Chanudet-van den Brink
(until July 2020)
Dr Ana Carolina de Carvalho Peters
Dr Aida Ferreira-Iglesias
Dr Mattias Johansson
Dr Sandra Perdomo Velasquez
Dr Hilary Robbins
Dr Mahdi Sheikh
Dr Shama Virani

Technical assistants

Ms Karine Alcala
Ms Valérie Gaborieau
Ms Sandrine Magat
(until January 2020)
Ms Hélène Renard

Laboratory technician

Ms Priscilia Chopard

Project assistant

Ms Laurène Bouvard

Secretariat

Ms Juliette Prazak
Ms Aurélie Rosado
(until October 2021)
Ms Andreea Spanu
Ms Charlotte Volatier
(until January 2020)

Visiting scientist

Dr Emily Banks (until March 2020)

Postdoctoral fellows

Dr Ricardo Cortez Cardoso Penha
Dr Xiaoshuang Feng
Dr Aida Ferreira-Iglesias
(until July 2020)
Dr Florence Guida
(until August 2021)
Dr Jean-Noël Hubert
(until December 2020)
Dr Daniela Mariosa
Dr Maja Milojevic
Dr Dariush Nasrollahzadeh Nesheli
(until July 2021)
Dr Justina Onwuka
Dr Fadoua Rafii
(until September 2021)
Dr Sergey Senkin
Dr Mahdi Sheikh (until June 2021)
Dr Karl Smith-Byrne
(until November 2021)

Students

Ms Elmira Ebrahimi
Mr Luis Enrique Romero Cruz
Ms Hana Zahed

Genetic Cancer Susceptibility Group (GCS)

Group head

Dr James McKay

Scientists

Dr Behnoush Abedi-Ardekani
Dr Nicolas Alcala
Dr Lynnette Fernandez-Cuesta
Dr Matthieu Foll
Dr Florence Le Calvez-Kelm

Visiting scientists

Dr Arash Nikmanesh
Dr Dariush Nasrollahzadeh Nesheli

Laboratory technicians

Ms Amélie Chabrier
Ms Nathalie Forey

Bioinformatician

Dr Catherine Voegele

Secretariat

Ms Isabelle Rondy

Postdoctoral fellows

Dr Nicolas Alcala
(until March 2020)
Dr Joshua Atkins
Dr Alex Di Genova Bravo
Dr Alexandra Sexton-Oates

Students

Mr Ricardo Blazquez Encinas Rey
(until December 2021)
Mr Antoine Boureille
(until August 2020)
Ms Virginia Diez-Obrero
(until December 2020)
Ms Aurélie Gabriel
(until January 2021)
Mr Colin Giacobi
(until August 2020)
Mr Boris Lipinski
(until August 2020)
Ms Lise Mangiante
Ms Emilie Mathian
Ms Mathilde Persch
(until September 2021)

The Section of Genetics (GEN) includes the Genetic Epidemiology Group (GEP) and the Genetic Cancer Susceptibility Group (GCS). The work of the Section combines large population-based studies as well as laboratory and bioinformatics expertise to identify specific genes and genetic profiles that contribute to the development of cancer and to elucidate how they exert their effect along with environmental factors. GEN also tries to identify individuals who are at high enough risk that they are likely to benefit from potential screening strategies.

GEN projects usually involve extensive fieldwork in collaboration with external investigators to develop large-scale epidemiological studies with appropriate clinical and exposure data, as well as

biosample collection. This typically occurs within GEP. Germline genetic analysis usually comprises genome-wide genotyping studies, as well as extensive sequencing work. GEP studies also assess non-genetic exposures, partly in recognition of the importance of non-genetic factors in driving cancer incidence, and also to facilitate accurate assessment of gene–environment interactions. In contrast, GCS places more focus on identification of uncommon or rare genetic variants that may have a larger effect than common single-nucleotide polymorphisms but that are not sufficiently frequent to be captured by current genome-wide association genotyping arrays. The approach of GCS has been to use genomics and bioinformatics techniques to comple-

ment more traditional approaches for the study of rare genetic variants. GCS also uses genomics to explore how variants may be conferring genetic susceptibility to cancer. Thus, the research programme of GCS complements that of GEP, and also provides a facility for high-throughput genomics techniques and the related bioinformatics to support GEN's molecular epidemiology projects and other IARC genomics projects.

With the start of the new IARC Medium-Term Strategy 2021–2025 and the new organizational structure as of 1 January 2021, GEN was renamed as the Genomic Epidemiology Branch, to better capture the broad range of scientific activities under way.

MUTOGRAPHS: BUILDING UP A LARGE CANCER BIOREPOSITORY ACROSS FIVE CONTINENTS

GEP, in collaboration with GCS and the Section of Environment and Radiation (ENV), the Laboratory Services and Biobank Group (LSB), and the Section of Support to Research (SSR), has devoted substantial resources to recruiting large series of cancer cases, comprising extensive questionnaire information and biological samples, as part of the Mutographs Grand Challenge project. Delays due to the COVID-19 pandemic in 2020 and 2021 had a major impact on recruitment and timelines. However, GEP has worked closely with all centres participating in the project, has adapted the recruitment and processing protocols to comply with COVID-19 restrictions, and continues to support the progress of the project locally.

Ontario Institute for Cancer Research, Toronto, Canada. Courtesy of Pancreatic Cancer Toronto, Canada.



Digestive Diseases Research Institute, Tehran, Islamic Republic of Iran. Courtesy of Digestive Diseases Research Institute, Tehran University of Medical Sciences, Islamic Republic of Iran.



Hospital Italiano de Buenos Aires, Argentina. Courtesy of Hospital Italiano de Buenos Aires, Argentina.



GENETIC EPIDEMIOLOGY GROUP (GEP)

During the 2020–2021 biennium, the Genetic Epidemiology Group (GEP) has continued research efforts on how genomics can be used to understand the causes of cancer, as well as how genomics can contribute to the early

detection and outcome prediction of cancer (Ginsburg et al., 2021a). Some prominent examples of the work of the Group over the biennium are described here.

IDENTIFYING NOVEL CAUSES OF MULTIPLE CANCER TYPES THROUGH ANALYSIS OF MUTATION SIGNATURES: THE MUTOGRAPHS STUDY

The Mutographs project aims to understand the causes of five different cancer types across five continents by generating mutational signature profiles. The initial recruitment of approximately 6000 cases has been completed, and 3000 cases have been successfully processed at IARC and sent to the Wellcome Sanger Institute for whole-genome sequencing (Table 1). GEP completed the first group of 1552 cancers sequenced in 2021, and genomic, exposure, and clinical data will be publicly available through the International Cancer Genome Consortium Accelerating Research in Genomic Oncology (ICGC ARGO) platform. The analysis of 552 cases of oesophageal cancer from eight countries with varying incidence rates showed the high prevalence of APOBEC signatures in all cases, as well as specific mutation signatures linked to opium consumption and alcohol consumption, as well as to homologous DNA repair deficiency (Figure 1) (Moody et al., 2021). Analysis of approximately 1000 kidney cancers is continuing, and preliminary results are shedding light on the contribution of environmental causes to the high risk of kidney cancer in central Europe. Most of the processing and sequencing efforts are now focused on cases of head and neck cancer, colorectal cancer, gastro-oesophageal adenocarcinoma, and pancreatic adenocarcinoma. Based on the same design and methodology as the Mutographs project, three additional side studies investigating specific geographical exposures of interest have been initiated. For example, GEP is studying the plausible sources of aristolochic acid exposure that could cause renal and urinary tract cancers in the Balkan region. The Group also aims to elucidate the role of opium consumption in the development of bladder cancer in the Kerman province of the Islamic Republic of Iran, and to

Table 1. Current progress on sample collection and processing by cancer type in the Mutographs project

Sample type	Samples and data at IARC	Samples shipped to Wellcome Sanger Institute	Whole-genome sequencing released	Target	Proportion of target achieved (%)
Oesophageal squamous cell carcinoma	1482	671	552	552	100
Renal cell carcinoma	1261	1141	594	1000	59
Colorectal cancer	1378	386	150	1000	15
Head and neck cancer	622	186	0	300	0
Pancreatic ductal adenocarcinoma	693	297	115	650	18
Oesophageal adenocarcinoma	704	262	110	650	17
Total	6140	2943	1521	3852	39

Figure 1. Average relative attributions of single-base substitution (SBS) COSMIC signatures are broadly similar between all countries. Signatures accounting for less than 5% on average (with the exception of SBS3 and SBS16) are grouped together into the “other” category. Reproduced with permission from Moody et al. (2021). © 2021, The Author, under exclusive licence to Springer Nature America, Inc.





Figure 2. Volcano plot depicting proteins associated with lung cancer risk after accounting for multiple comparisons in both the initial discovery phase and the replication phase. SD, standard deviation. © IARC.



investigate the mutational profile differences in gallbladder cancer cases from regions of high and low incidence in India.

EVALUATING STRATEGIES TO IMPROVE EARLY DETECTION AND OUTCOME IN LUNG CANCER

The overall goal of GEP is to identify individuals at sufficiently high risk of developing lung cancer to justify screening and early detection. The initial approach of the Group was to develop and validate lung cancer risk prediction models using the vast information harmonized in the Lung Cancer Cohort Consortium (LC3), including lung cancer risk factors and outcomes from more than 20 cohorts around the world, representing more than 2.5 million individuals in 15 countries (Robbins et al., 2021). In addition, using the framework of the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) study, GEP is actively investigating the potential of a wide range of biomarker types for lung cancer

risk prediction; initial studies indicate that circulating protein biomarkers have the most promising potential to improve the identification of individuals most likely to benefit from screening. The Group completed the initial discovery scan of 1200 proteins on 252 case–control pairs from two LC3 cohorts. This enabled the identification of the five most informative protein panels, which were assayed in 477 case–control pairs from four additional cohorts (Figure 2).

QUITTING SMOKING AFTER DIAGNOSIS OF LUNG CANCER IMPROVES SURVIVAL


The effect of smoking cessation in lung cancer survival was evaluated using information collected as part of the 15-year collaborative study with the N.N. Blokhin National Medical Research Centre of Oncology of the Russian Academy of Medical Sciences. GEP showed that smoking cessation after lung cancer diagnosis substantially improved overall and progression-free survival among current smokers with early-stage lung

cancer; similar effects were observed among mild to moderate smokers and heavy smokers, and among patients with earlier-stage and later-stage tumours (Figure 3) (Sheikh et al., 2021).

PROGRESS INVESTIGATING ETIOLOGICAL AND PROGNOSTIC FACTORS IN HEAD AND NECK CANCERS

Two main collaborative projects have showed important evidence of the role of human papillomavirus (HPV) infection in the development of oropharyngeal cancer. Recent evidence from the work in the HPV Cancer Cohort Consortium (HPVC3) has shown that HPV16 E6 is easily detectable in blood and is highly sensitive (> 90%) and specific (> 99%), and that seropositivity can occur decades before cancer is detectable. As part of the VOYAGER study, GEP conducted the largest genome-wide association study analysis with a focus on oropharyngeal cancer. After stratifying by HPV status, a protective effect was shown for one human leukocyte antigen

Figure 3. Association between quitting smoking after diagnosis of lung cancer and the probability of overall survival (left) and progression-free survival (right). © IARC.



locus (rs4713462) against HPV-positive oropharyngeal cancer, which also correlated with low antibody levels against HPV16 E6 (Ferreiro-Iglesias et al., 2021). Furthermore, the first survival analysis in

1463 patients with head and neck cancer in South America after completion of a 3-year follow-up confirmed that survival was better for HPV-related than for HPV-unrelated oropharyngeal cancer,

as well as the negative prognostic effect of advanced clinical stage and alcohol consumption (Abrahão et al., 2020).

GENETIC CANCER SUSCEPTIBILITY GROUP (GCS)

The Genetic Cancer Susceptibility Group (GCS) is a multidisciplinary scientific group, covering genetics, genomics, bioinformatics, and pathology. These combined skills are used to undertake genetics and genomics research to identify cancer-related genes, explore their mechanisms of action, and contribute to how tumours are classified and detected. GCS works within international consortia to assemble the large sample sizes needed for informative genetics and genomics studies. GCS's multifaceted genomic analysis and multidisciplinary team provide additional depth to these consortia-based studies.

In the context of early biomarkers, GCS has explored highly recurrent telomerase reverse transcriptase (*TERT*) gene promoter mutations as biomarkers for the early detection of urothelial cancer,

and developed assays for the detection of low-abundance *TERT* promoter mutations (Zvereva et al., 2020a). This assay was used in a nested case-control study within a longitudinal population-based prospective cohort of 50 000 individuals in the Islamic Republic of Iran, and demonstrated that *TERT* mutations could be detected in urine samples obtained up to 10 years before the primary diagnosis of bladder cancer, and were not detected in matched controls (100% specificity and 46.6% sensitivity) (Figure 4) (Hosen et al., 2020a). The study demonstrated the presence of these mutations in urine in asymptomatic individuals who later developed bladder cancer, highlighting the potential of urinary *TERT* promoter mutations to be used as a simple, inexpensive, and non-invasive early detection biomarker. These results received broad coverage by international media,

including the United Nations News, France Info, the La Chaîne Info news channel, and the *Daily Mail* (in the United Kingdom), as well as science magazines and specific urology websites.

The Rare Cancers Genomics initiative aims at the molecular characterization of rare cancers (<http://rarecancersgenomics.com/>), including malignant pleural mesothelioma (MESOMICS) and lung neuroendocrine neoplasms (lungNENomics). In the MESOMICS project, GCS has contributed to the comprehensive molecular and pathological evaluation of transitional mesothelioma assisted by a deep learning approach (Galateau Salle et al., 2020) and provided an overview of molecular advances in the classification of pleural mesotheliomas (Fernandez-Cuesta et al., 2021). In the lungNENomics project, GCS generated

Figure 4. Association between *TERT* promoter mutation mutant allelic fractions (MAFs, %) and the time interval from urine collection to clinical diagnosis of bladder cancer. The MAFs of the mutations detected by the UroMuTERT assay (next-generation sequencing-based assay) in the 14 urine samples of the asymptomatic subjects from the Golestan Cohort Study are plotted against the time in years from urine collection to diagnosis of bladder cancer. Reproduced from Hosen et al. (2020a). © 2020 Published by Elsevier B.V.





Figure 5. Schematic representation of the different classifications of malignant pleural mesothelioma and their key molecular features. The front face of the pyramid represents the current WHO classifications (top) and the different discrete (middle) and continuous (bottom) molecular classifications that have been proposed. For discrete molecular classifications, the proposed molecular clusters are reported. For Blum et al., a gradient between the epithelioid score (E-score) and the sarcomatoid score (S-score) is depicted. For Alcala et al., the association between the first dimension of the molecular classification and the WHO histological type is shown. The side face of the pyramid represents features and subtypes mentioned in each study that have not been reported to be significantly correlated with the histological types; for Alcala et al., the second molecular dimension is represented, which was shown to summarize features independent of the WHO classification. Colours represent the association between features and the different types: red, sarcomatoid or sarcomatoid-like profiles; orange, biphasic or biphasic-like profiles; green, epithelioid or epithelioid-like profiles; and grey, no proven association with the WHO classification. Reprinted by permission from Fernandez-Cuesta et al. (2021), © 2021.



the first molecular map of lung neuroendocrine neoplasms (Gabriel et al., 2020), led (Foll and Fernandez-Cuesta, 2020) and contributed (Lantuejoul et al., 2020) to reviews in the field of lung neuroendocrine neoplasms, and contributed (Dr Fernandez-Cuesta) to the 2021 fifth edition of the WHO Classification of Tumours of the lung, pleura, thymus, and heart. The Rare Cancers Genomics initiative has a strong computational biology component, particularly for the analysis and integration of -omics data (including whole-genome and/or transcriptome sequencing and methylation arrays), interpretation of histopathological images with deep learning algorithms, and modelling of evolutionary processes associated with tumour progression. GCS actively shares these tools as open-source packages (<https://github.com/IARCbioinfo>) and maximizes their reuse potential by providing reproducible analyses and online training, ultimately building capacity for cancer genomics (Figure 5).

In the context of how germline variation influences cancer susceptibility, GCS has worked within the International Lung Cancer Consortium (ILCCO) to identify a lung cancer susceptibility variant in the DNA repair gene *ATM*. This variant is a missense variant in *ATM* and has an important genetic effect, with allele carriers having an up to 3–4-fold increase in the risk of lung cancer relative to non-carriers. It also appears to be most relevant to lung cancer in women and lung adenocarcinomas in never-smokers; although it is very rare in most parts of the world, it approaches frequen-

cies of 3% in Ashkenazi Jewish populations (Ji et al., 2020a). GCS leads the pathology workflow for the Mutographs of Cancers project, a continuing large-scale international study that aims to unveil the carcinogenic role of environmental exposures by analysing the mutational signatures through whole-genome sequencing (<https://www.mutographs.org/>). GCS also investigated the morphological features of 1000 non-tumoral renal tissues from patients with renal cell carcinoma, and found that the frequency of chronic renal parenchymal changes with the predominance of chronic interstitial nephritis pattern in patients with renal cell carcinoma varies by country; these changes are more frequent in Romania and Serbia (Table 2) (Abedi-Ardekani et al., 2021).

GCS leads the pathology workflow for the Mutographs of Cancers project, a continuing large-scale international study that aims to unveil the carcinogenic role of environmental exposures by analysing the mutational signatures through whole-genome sequencing (<https://www.mutographs.org/>). GCS also investigated the morphological features of 1000 non-tumoral renal tissues from patients with renal cell carcinoma, and found that the frequency of chronic renal parenchymal changes with the predominance of chronic interstitial nephritis pattern in patients with renal cell carcinoma varies by country; these changes are more frequent in Romania and Serbia (Table 2) (Abedi-Ardekani et al., 2021).

cies of 3% in Ashkenazi Jewish populations (Ji et al., 2020a). GCS leads the pathology workflow for the Mutographs of Cancers project, a continuing large-scale international study that aims to unveil the carcinogenic role of environmental exposures by analysing the mutational signatures through whole-genome sequencing (<https://www.mutographs.org/>). GCS also investigated the morphological features of 1000 non-tumoral renal tissues from patients with renal cell carcinoma, and found that the frequency of chronic renal parenchymal changes with the predominance of chronic interstitial nephritis pattern in patients with renal cell carcinoma varies by country; these changes are more frequent in Romania and Serbia (Table 2) (Abedi-Ardekani et al., 2021).

Table 2. Odds ratios and 95% confidence intervals (CIs) for association between country and observation of moderate to severe chronic renal parenchymal changes in non-neoplastic kidney tissues of patients with renal cell carcinoma

Recruiting country	Odds ratio (95% CI)			
	Unadjusted	Model 1 ^a	Model 2 ^b	Model 3 ^c
Russian Federation	Reference	Reference	Reference	Reference
United Kingdom	0.84 (0.25–2.76)	0.64 (0.19–2.16)	0.59 (0.17–2.01)	0.39 (0.10–1.49)
Czechia	1.79 (0.82–3.92)	1.34 (0.59–3.00)	1.54 (0.67–3.57)	1.28 (0.56–2.91)
Romania	3.40 (1.41–8.18)	3.12 (1.26–7.74)	3.16 (1.24–8.03)	2.67 (1.07–6.67)
Serbia	4.63 (1.33–16.08)	5.06 (1.39–18.44)	6.27 (1.40–28.02)	4.37 (1.20–15.96)
Romania and Serbia	3.62 (1.57–8.32)	3.42 (1.44–8.12)	3.53 (1.45–8.58)	2.96 (1.24–7.03)

^a Adjusted for age, sex, and percentage of medulla.

^b Adjusted for age, sex, percentage of medulla, stage, and tumour size.

^c Adjusted for age, sex, diabetes, hypertension, and use of non-steroidal anti-inflammatory drugs (NSAIDs).

Source: Reproduced from Abedi-Ardekani et al. (2021). Copyright © 2021, Abedi-Ardekani et al.



SECTION OF EARLY DETECTION AND PREVENTION (EDP)

Section head

Dr Joachim Schüz (acting)

Prevention and Implementation Group (PRI)

Group head

Dr Maribel Almonte

Scientists

Dr Armando Baena

Dr Hugo De Vuyst

Dr Mathilde Forestier

Dr Jin Young Park

(until December 2020)

Dr Mary Luz Rol

Dr Vitaly Smelov (until June 2020)

Secretariat

Ms Karima Bendeddouche

Research assistants for data management/analysis

Ms Sylvaine Barbier

(until September 2020)

Ms Viktoria Knaze

(until December 2020)

Mr Ravi Shankar

Postdoctoral fellows

Dr Armando Baena

(until October 2021)

Dr Vernon Mochache

Dr Arianis Tatiana Ramirez Pineda

Senior visiting scientists and visiting scientists

Dr Isabelle Heard

Dr Rolando Herrero

Dr David Mesher

Dr Rodica Mindruta-Stratan

(until July 2020)

Dr Raúl Murillo

Dr Ana Patricia Ortiz

(until October 2020)

Dr Marievelisse Soto Salgado

(until November 2020)

Dr Joan Valls Marsal

Student

Ms Laura Downham

Screening Group (SCR)

Group head

Dr Partha Basu

Scientists

Dr Andre Carvalho

Dr Richard Muwonge

Dr Catherine Sauvaget

Dr Farida Selmouni

Dr Patricia Villain

Health information systems specialist

Mr Eric Lucas

Secretary

Ms Lobna Boulegroun

Project assistant

Ms Cecile Le Duc

Information assistant

Ms Krittika Guinot

Senior visiting scientists

Professor Walter Prendiville
(until July 2021)

Dr Rengaswamy

Sankaranarayanan

Professor Yelena Tarasenko

(until August 2021)

Dr Olga Trusova

Postdoctoral fellows

Dr Charlotte Marie Bauquier

(until March 2020)

Dr Alice Le Bonniec

(until March 2021)

Dr Isabel Maria Mosquera Metcalfe

Dr Li Zhang

Students

Ms Thea Brevik (until July 2021)

Ms Lara Calegari (until May 2020)

Mr Sander De Souza

(until April 2021)

Ms Laureline Guigon

(until February 2021)

Ms Xuelian Zhao (until March 2020)

The Section of Early Detection and Prevention (EDP) conducts research on the efficacy, safety, and cost-effectiveness of cancer prevention and early detection interventions to guide rational cancer control policies, with a particular emphasis on low- and middle-income countries (LMICs). With the start of the new IARC Medium-Term Strategy 2021–2025 and the new organizational

structure as of 1 January 2021, EDP became part of the newly created Early Detection, Prevention, and Infections Branch.

One of the principles that continue to guide EDP's work is the search for simplified, affordable technology adaptable to LMICs. EDP provides technical support to current and planned population-based

prevention and screening programmes in LMICs in the context of cancer control, conducts clinical and screening trials, and carries out implementation and health economics research. In addition, EDP develops educational materials and conducts training activities for cancer control. EDP has established extensive networks involving highly skilled clinicians, epidemiologists, and other

personnel. These networks facilitate the transfer of research technology to the local researchers and often their students, who participate actively in study design and conduct, and data analysis. An important part of the work

of EDP is the dissemination of the scientific evidence base and the provision of technical assistance to governments and policy-makers in countries developing cancer control programmes.

The multicentre and multidisciplinary studies of EDP are conducted within two separate Groups: the Prevention and Implementation Group (PRI) and the Screening Group (SCR).


TRAINING OF TRAINERS IN CELAC WITHIN CANSCREEN5

The objective of the Screening Group project “Reduction of inequalities in cancer screening: a case study in the Community of Latin American and Caribbean States (CELAC)” is to examine policies in CELAC aimed at reducing inequalities in effective participation of the eligible population in cancer screening. The project, implemented in collaboration with the Centre for Global Health Inequalities Research (CHAIN) in Norway (supported by the Research Council of Norway) and the Pan American Health Organization (PAHO), also aims to enhance the capacity of the cancer screening programme managers in CELAC to implement quality-assured screening programmes. This has become an integral part of the IARC project Cancer Screening in Five Continents (CanScreen5) (<https://canscreen5.iarc.fr>).


This Training of Trainers programme is a package of e-learning modules and live sessions. E-learning modules cover principles of cancer screening, planning and implementing screening programmes, and ensuring quality. Live sessions include keynote lectures and group discussions. Among other topics, lectures cover cancer control in the region, indicators in cervical cancer screening, social inequalities, and implementation science.

The first phase of Training of Trainers in CELAC has been carried out and involved 65 participants from 22 countries. After the training, participants reported that their knowledge had been increased by more than 50%, and this learning will be reinforced during face-to-face workshops. Using the CanScreen5 self-paced learning programme, participants will be able to train colleagues in their respective countries.

Countries contributing to the Cancer Screening in Five Continents (CanScreen5) initiative, with their stage in the process indicated. © IARC.



“Keep holding our hand” (quote from a Training of Trainers participant from Honduras). © IARC.



PREVENTION AND IMPLEMENTATION GROUP (PRI)

HPV VACCINE EFFICACY

In collaboration with the United States National Cancer Institute, the ESCUDDO randomized trial comparing one dose versus two doses of the bivalent and nonavalent human papillomavirus (HPV) vaccines among 20 000 adolescent girls (aged 12–16 years) is continuing in Costa Rica. Recruitment has been completed, and follow-up has been extended to 5 years to account for the possible impact of the COVID-19 pandemic, which may change exposure to HPV through changes in social interactions. In the Costa Rica HPV vaccine trial (CVT) study, the Prevention and Implementation Group (PRI) has demonstrated that one dose is still highly protective and immunogenic 11 years after vaccination (Kreimer et al., 2020a) and that three doses are protective against high-grade lesions during long-term follow-up (Porrás et al., 2020).

CERVICAL SCREENING IN LATIN AMERICA

Despite steady reductions in cervical cancer incidence and mortality in Latin America over the past decades, the incidence rates are still above the elimination threshold (age-standardized incidence rate of 4 cases per 100 000 women per year) (Figure 1) (Pilleron et al., 2020), highlighting the need for effective strategies to achieve the elimination goals.

The ASCUS-COL trial in Colombia investigated the efficacy to prevent precancerous cervical lesions of HPV testing compared with the usual care (immediate colposcopy and repeat Pap smear) in 2661 women with atypical squamous cells of undetermined significance (ASCUS) Pap results. HPV testing was found to reduce the burden of cervical lesions by 65% and colposcopy referral by 41% (Baena et al.,

2020). No differences in health-related quality of life were observed by HPV positivity status (Urrea Cosme et al., 2020). When collected samples were used, the performance of the recently developed S5-methylation test (United Kingdom) to triage HPV-positive women (with ASCUS Pap results) highlighted the potential role of S5-methylation in HPV-based cervical screening (Ramirez et al., 2021).

The ESTAMPA study investigates cervical cancer screening and triage techniques in women (aged 30–64 years) in nine countries in Latin America. HPV-positive women receive colposcopy, biopsy, and treatment and a second screen after 18 months as needed. The main outcome is advanced cancer precursors (Almonte et al., 2020). More than 42 000 women have been recruited, and a high adherence to the screening process has been reported; 95% of

Figure 1. Distribution of age-standardized incidence rates of cervical cancer per 100 000 women per year in 2018 by country and subregion, compared with the elimination threshold defined by WHO of 4 per 100 000 women per year. Reproduced with permission from Pilleron et al. (2020), © John Wiley and Sons.





Figure 2. Progress of the ESTAMPA study as at July 2021. * Percentage computed after excluding 270 women who withdrew from the study. ** Percentage computed among women eligible to attend the 18-month visit (i.e. without cervical intraepithelial neoplasia grade 2 [CIN2] and in the study for at least 18 months). HPV, human papillomavirus. © IARC.



high-grade lesions detected have been treated (Figure 2). Results are supported by a study network promoting the sharing of experiences among more than 200 multidisciplinary professionals (Figure 3). In addition, the Psycho-ESTAMPA tool to assess the psychosocial impact of an HPV-positive screening result was developed and validated and will be used to measure the impact of various methods of communicating HPV test results (Arrossi et al., 2020).

To further support the implementation of HPV screening in the region, PRI is also conducting formative research on barriers to and facilitators of adoption of the WHO cervical screening guidelines, in the GUIDES project.

CERVICAL SCREENING AND TREATMENT IN AFRICA

The CESTA study compares the efficacy of cervical screening by (i) HPV

detection with visual inspection with acetic acid (VIA) triage of HPV-positive women and ablative treatment of women who are both HPV-positive and VIA-positive, with (ii) HPV detection followed by ablative treatment of HPV-positive women. In Senegal, 18% of 350 HIV-negative women (aged 30–54 years) were HPV-positive, compared with 62% of 400 women living with HIV (aged 25–54 years) in South Africa; an additional 1200 women living with HIV are being recruited in South Africa to enable the evaluation of other, more suitable screening techniques.

A collaborative randomized trial in women living with HIV in Kenya previously reported that recurrent high-grade cervical disease (cervical intraepithelial neoplasia grade 2 or worse [CIN2+]) was lower after treatment by the loop electro-surgical excision procedure (LEEP) than after cryotherapy. Secondary data analyses demonstrated that endocervical

curettage does not increase detection of CIN2+ (Chung et al., 2021a) and that the reduction in recurrence was associated with a decrease in HPV persistence in LEEP-treated women (Chung et al., 2021b).

HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER

The HELPER study, a continuing collaboration with the National Cancer Center of Korea, has enrolled 11 799 participants, and 5269 participants who tested positive for *H. pylori* were randomized to eradication or placebo to investigate the reduction in the incidence of gastric cancer. All participants are being endoscopically followed up within the Korean National Cancer Screening Program.


The GISTAR study, a collaboration with the University of Latvia, is investigating whether *H. pylori* test-and-treat and endoscopic follow-up of subjects with serological evidence of atrophic gastritis reduces gastric cancer mortality. Recruitment is continuing, with more than 10 000 participants included and followed up so far.

The prevalence of *H. pylori* and gastric lesions in low-risk and high-risk areas for gastric cancer is being investigated in the ENIGMA studies. In ENIGMA-Chile, the prevalence of serologically determined atrophic gastritis was significantly higher in the high-risk area, although comparable *H. pylori* prevalence is observed in both areas (Herrero et al., 2020).

BREAST CANCER SCREENING IN BELARUS

Within the joint European Union and United Nations project BELMED (Preventing noncommunicable diseases, promoting healthy lifestyle, and support to modernization of the health system in Belarus), PRI supported the breast mammography screening component, particularly by ensuring the quality of the programme through training of health-care professionals and the establishment of monitoring processes. The final report of the BELMED screening component is expected in early 2022.

Figure 3. The ESTAMPA study network. EQA, external quality assessment; GCPs, good clinical practices; HPV, human papillomavirus. © Almonte et al. (2020). Re-use permitted under CC BY. Published by BMJ. <https://creativecommons.org/licenses/by/4.0/>.



SCREENING GROUP (SCR)

Studies led by the Screening Group (SCR) during the 2020–2021 biennium have generated valuable evidence to support the development of resource-appropriate policies to deliver effective cancer prevention and early detection services in the following domains.

EVALUATION OF HPV VACCINE

The SCR study under way in India recently reported that the vaccine efficacy of a single dose of quadrivalent HPV vaccine was as high as that of two doses and three doses at a median follow-up of 9.0 years. Vaccine efficacy against persistent HPV16/18 infection was 95.4% in recipients of a single dose, 93.1% in recipients of two doses, and 93.3% in recipients of three doses (Table 1) (Basu et al., 2021c).

SCR evaluated a new quadrivalent HPV vaccine produced by the Serum Institute of India (SII) in a phase II randomized trial that included female and male participants in two age cohorts: 9–14 years ($n = 300$) and 15–26 years ($n = 300$). The participants received

either Gardasil or the SII vaccine (CTRI/2018/06/014601). Neutralizing antibody titre against vaccine-targeted genotypes (HPV6, HPV11, HPV16, and HPV18) was very high 7 months after vaccination, with 100% seroconversion irrespective of the vaccine type, indicating that the new vaccine is as immunogenic as Gardasil. A recommendation of a single dose and the use of a locally manufactured vaccine will significantly improve the affordability of vaccination programmes against HPV.

CERVICAL CANCER SCREENING AND MANAGEMENT OF PRECANCERS

In a study in rural China, 9526 women (aged 30–65 years) were screened for cervical cancer on self-collected vaginal samples using the *careHPV* test (a signal amplification test) and a locally developed polymerase chain reaction (PCR)-based HPV test. The PCR-based test had significantly higher sensitivity in detecting high-grade precancers and/or cancers compared with the *careHPV* test (96.7% vs 72.5%) but lower specificity (82.1% vs 86.0%). Triaging with

HPV16/18 genotyping considerably improved the specificity (97.0%), with some reduction in sensitivity (73.6%) (Zhao et al., 2020a).

In a study in Zambia aiming to evaluate thermal ablation for treatment of cervical precancer, 2456 VIA-positive women were randomized to be treated with thermal ablation, cryotherapy, or loop excision. Treatment success rates were similar for the three techniques, although they were significantly lower in HIV-positive women than in HIV-negative women (49% vs 83%). Data from the studies were shared with WHO for guideline development.

ORAL CANCER SCREENING

SCR assessed a risk prediction model for oral cancer screening. The model showed that screening with visual examination of ever-users of tobacco and/or alcohol with no additional risk stratification would achieve a reduction of 23.3% in oral cancer mortality. Screening would be highly efficient, and the model indicated that screening of only 50% of ever-

Table 1. Efficacy of a single dose of quadrivalent human papillomavirus (HPV) vaccine compared with that of two doses and three doses (all vaccines given at age 10–18 years) for the prevention of incident and persistent HPV infections; 10-year follow-up data from IARC HPV vaccine study in India

	Unvaccinated	Single dose	Two doses (days 1 and ≥ 180)	Three doses (days 1, 60, and ≥ 180)
<i>HPV incidence</i>				
Number of women assessed	1479	2858	2166	2019
Incident HPV16 and/or HPV18 infections				
Observed events	138	92	59	59
Adjusted vaccine efficacy ^a (%) (95% CI)		63.5 (51.2 to 73.1)	67.7 (55.2 to 77.2)	66.4 (53.6 to 76.3)
Incident HPV31, HPV33, and/or HPV45 infections				
Observed events	148	136	89	86
Adjusted vaccine efficacy ^a (%) (95% CI)		43.5 (25.4 to 56.5)	54.0 (38.5 to 66.5)	54.6 (38.3 to 66.6)
<i>HPV persistence</i>				
Number of women assessed	1260	2135	1452	1460
Persistent HPV16 and/or HPV18 infections				
Observed events	32	1	1	1
Adjusted vaccine efficacy ^a (%) (95% CI)		95.4 (85.0 to 99.9)	93.1 (77.3 to 99.8)	93.3 (77.5 to 99.7)
Persistent HPV31, HPV33 and/or HPV45 infections				
Observed events	14	14	11	7
Adjusted vaccine efficacy ^a (%) (95% CI)		8.8 (–230.8 to 62.6)	8.4 (–239.3 to 65.7)	38.8 (–124.4 to 80.2)

CI, confidence interval; HPV, human papillomavirus.

^a Adjusted through direct standardization on the five strata created from the disease risk score estimates.

Source: Reprinted from Basu P et al. (2021c). © 2021. World Health Organization. Licensee Elsevier.

users of tobacco and/or alcohol would lead to a similar reduction in mortality (19.7%) (Cheung et al., 2021).

SCREENING AND EARLY DIAGNOSIS OF BREAST CANCER

To investigate the variability in the performance of screening mammography across the European Union, SCR estimated breast cancer detection rates adjusted by age, screening interval, and positive predictive value. For women aged 50–69 years, the detection rate of invasive cancers ranged between 3.8 and 7.4 per 1000 and that of ductal carcinoma in situ ranged between 0.7 and 2.7 per 1000 across countries (Armaroli et al., 2020). The remarkable heterogeneity was due to different background risk and differences in the quality and organization of programmes.

The SCR patterns-of-care study, involving 2120 patients with breast cancer registered during 2008–2017 at two publicly funded oncology centres in Morocco, reported a median delay of 6 months between symptom onset and physician consultation (Mrabti et al., 2021). A total of 45% of the patients presented with

stage III or IV cancer. The median delay between registration at an oncology centre and the initiation of treatment was 1.5 months. Disparities in the quality of care between the two oncology centres resulted in a 25% difference in 5-year disease-free survival for early-stage breast cancers.

COLORECTAL CANCER SCREENING

SCR published comparative data on the performance of colorectal cancer screening programmes across the European Union. The participation rate was higher in countries that have adopted faecal immunochemical testing (FIT) (range, 22.8–71.3%) than in those using guaiac faecal occult blood testing (gFOBT) (range, 4.5–66.6%). Large variations in screening performance were observed. Compliance with referral for colonoscopy ranged between 64% and 92%. The detection rates of advanced adenomas and colorectal cancer were higher with FIT than with gFOBT, and higher in men than in women.


SCR implemented a demonstration project in Morocco to screen 9763 men and women for colorectal cancer using FIT

through routine primary-care facilities. Of the 4.7% of participants who tested positive, only 62.6% underwent colonoscopy, highlighting the challenges of implementing colorectal cancer screening in the country. The detection rate of colorectal cancer was low (0.7 per 1000).

IMPACT OF COVID-19 ON CANCER DETECTION

SCR published a commentary on best practices to continue with cancer screening during the advancing and receding COVID-19 pandemic. SCR has also conducted studies to assess the impact of the pandemic on cancer screening programmes, especially in LMICs (Figure 4) (Basu et al., 2021a; Villain et al., 2021). These studies have also highlighted how some LMICs have leveraged the vertical investments made to mitigate the COVID-19 pandemic to improve the quality and reach of cancer screening programmes (Basu et al., 2021b).

Figure 4. IARC evaluated the impact of the COVID-19 pandemic on cancer screening programmes in several countries. The figure shows the significant decrease in the number of women screened for cervical cancer per month in Bangladesh in 2020 compared with previous years. The figure also shows how the programme recovered from the impact of lockdown within a few months as a result of planned measures. The bars indicate the number of COVID-19 cases detected by months in 2020. VIA, visual inspection with acetic acid. Reprinted from Basu et al. (2021b), © 2021, with permission from Elsevier.





OFFICE OF THE DIRECTOR

<p>Director Dr Elisabethe Weiderpass</p>	<p>Communications officer Ms Véronique Terrasse (from January 2021)</p>	<p>Secretaries Ms Laurence Marnat Ms Sylvie Nouveau (from January 2021)</p>
<p>Director's Office team</p>	<p>Information assistants Mr Nicholas O'Connor (from January 2021) Ms Morena Sarzo (from January 2021)</p>	<p>Consultants Ms Laure Bernou (until May 2021) Mr Olivier Exertier Ms Beatrix Lahoupe (until November 2020)</p>
<p>Programme officer Dr Véronique Chajès</p>		
<p>Bioethics and compliance officer Dr Chiara Scoccianti</p>	<p>Executive assistant to the Director Ms Nadia Akel</p>	<p>Trainees Ms Houda Bouabdallah Mr Tarek Eleiwy (until July 2020) Ms Camille Mebarkia (until March 2021)</p>
<p>Strategic Engagement and External Relations (SEE)</p>		
<p>Strategic engagement and resource mobilization officer Mr Clément Chauvet</p>		

The Office of the Director is composed of a team that provides scientific and administrative support to the Agency, specialist knowledge in strategic engagement, resource mobilization, and external relations, and expertise in bioethics and compliance. The bioethics and compliance team is an integral part of the Director's Office, to ensure its independence in the evaluation of the Agency's scientific work.

The team in the Director's Office supports the IARC Director in the implementation of the Agency's strategic priorities, as described in the IARC Medium-Term Strategy 2021–2025. This strategic roadmap was formulated by a Working Group including members of the IARC Scien-

tific Council and Governing Council, and WHO, and was fully endorsed by the IARC Scientific Council and Governing Council in 2021. The guiding objective of IARC – the promotion of international collaboration in cancer research – has remained unchanged since 1965, but the focus has been shifted to ensure the greatest public health impact of the Agency's work. IARC continues to address its fundamental priorities and will gradually strengthen its engagement in three emerging priorities, notably implementation research. Progress in the implementation of the IARC Medium-Term Strategy 2021–2025 will be assessed within an evaluation framework composed of pertinent key performance indicators (KPIs).

The organizational structure of IARC was revised during the biennium to promote collaboration across the Agency. The former Sections and Groups have been replaced by scientific Branches. The new structure is complemented by the conceptual idea of four scientific Pillars, representing IARC's four fundamental research priorities. A Nordic Research Leadership Training course was offered to senior scientific personnel to strengthen the Agency's strategic and scientific leadership.

In 2021, the Senior Leadership Team (SLT) was reviewed and replaced by a Senior Advisory Team on Management (SAT), whose purpose is to provide senior advisory support to the Director on



Centre building. The Agency has strengthened its collaboration with Centre Léon Bérard and is already engaging with more than 50 local actors. This engagement is very important, not only for IARC's relationship with local authorities but also to boost local participation in the Nouveau Centre campaign.

STRATEGIC ENGAGEMENT AND EXTERNAL RELATIONS (SEE)

The IARC Resource Mobilization strategy relies on four focus areas, as shown in the diagram. During the 2020–2021 biennium, important milestones have been achieved in each of these areas.

At the Sixty-third Session of the Governing Council in May 2021, IARC welcomed a new Participating State: China. The Secretariat has also engaged very closely with other potential new Participating States, including Portugal and Saudi Arabia, and is on track to meet the target of welcoming one new Participating State per biennium.

The Agency continued to be successful in attracting funding through research grants, with an average success rate of 27%

strategic, management, and operational policy matters for decision-making.

Strategic scientific discussions now take place within the IARC Science Forum and Open Forum to stimulate new and exciting scientific and creative ideas. The IARC Cross-Cutting Working Group on Cancer Prevention Knowledge Translation and Transfer was created to accelerate the adoption and implementation of evidence-based cancer prevention and control strategies among stakeholders.


The Director's Office team is also responsible for strengthening and expanding the Agency's network of Participating States, governmental and nongovernmental partners, funding agencies, and collaborators.

The Agency signed five Memoranda of Understanding (MoU), with the Beijing Genomics Institute at Shenzhen/China National GeneBank in China, the Sociedade Beneficente Israelita Brasileira Albert Einstein in Brazil, the National Center for Disease Control and Public Health in Georgia, the Trustees of Columbia University in the City of New York in the USA, and the National Cancer Registry operated by the National Institute of Oncology in Hungary. IARC also renewed its MoU with the National Cancer Center Japan.

IARC and WHO re-engaged in a structured dialogue to develop a joint action plan to identify areas of cooperation. The plan will help bring to fruition the imple-

mentation of key global cancer initiatives towards better public health.


During the 2020–2021 biennium, the Director's Office had some important achievements. In May 2021, China joined IARC, bringing the total number of Participating States to 27. IARC is in contact with partners in Lyon to increase awareness of the fundraising campaign for the Nouveau



on 2019 applications. In 2020, 236 new grant applications and funding requests were submitted and the Agency signed extrabudgetary contracts amounting to a total value of €20.07 million, of which €12.34 million was attributed to IARC. Novel funding sources are being systematically identified and funding opportunities are closely monitored by a dedicated team, which continuously screens more than 130 funders; in 2020, more than 340 funding opportunities were posted on the intranet Resource Mobilization pages for IARC colleagues to consider.

IARC has been officially recognized by the Organisation for Economic Co-operation and Development (OECD) as an international organization eligible to receive official development assistance (ODA), with a coefficient of 51%. This means that 51% of Participating States' assessed contributions to IARC can be reported by them to the OECD as ODA. In addition, because IARC has a strong focus on cancer prevention research in low- and middle-income countries (LMICs), the Secretariat has developed a set of projects that are 100% ODA-compliant; this is often an advantage when seeking funding from development agencies and/or philanthropic organizations. The Secretariat is currently discussing such projects with different potential donors to substantially enlarge the direct funding component received by the Agency.

The Secretariat was able to attract funding from non-state actors during this biennium. For example, the European Society for Medical Oncology (ESMO) provided the funding to create and maintain the *World Cancer Report* Updates learning platform. Children with Cancer UK and the Terry Fox Foundation have funded fellowships for postdoctoral scientists from LMICs and thus helped to fulfil the capacity-building mission of IARC. Thanks to the support of the Sociedade Beneficente Israelita Brasileira Albert Einstein, IARC has started the development of a Latin America Code Against Cancer, similar to the European Code Against Cancer.



IARC has launched a three-pronged fundraising campaign for the Nouveau Centre building. This campaign focuses on attracting large gifts from ultra-high-net-worth individuals (during this biennium, the Secretariat was able to secure a gift of €1 million from Mr Alain Mérieux) and obtaining in-kind donations of equipment for the Nouveau Centre (IARC has signed in-kind donation agreements with several companies, including Office Concept, Froilabo, and Comadequat). The Secretariat also launched a crowdfunding campaign during the Sixty-third Session of the Governing Council. Through a web-based platform (<https://isupport.iarc.fr/>), IARC supporters can have their name, or that of a loved one, inscribed on the glass

doors of the Nouveau Centre building in exchange for an affordable donation.

In January 2021, a new unit was created that includes both Strategic Engagement and External Relations (SEE). SEE will ensure that IARC's communications reach a wider and more diverse audience, promoting the concept of open science as advocated by the Director. By reaching out to a very diverse range of potential partners and audiences, SEE will ensure that IARC's brand recognition improves and that, as a result, IARC becomes more attractive to potential partners.

NEW IARC INITIATIVES

IARC EQUITY AND DIVERSITY ADVISORY GROUP (EDAG)

The IARC Equity and Diversity Advisory Group (EDAG) was formed in November 2018. It was originally known as the Women in Science Advisory Group (WiSA). One year later, it was decided to expand the scope of the group to cover equity and diversity in general, and hence the name was changed. The EDAG currently has eight members, who represent all the different types of IARC personnel, including professional staff, administrative staff, early career scientists, and visiting scientists.

The aim of the EDAG, which advises the Director, is to ensure that individuals or groups of individuals within the Agency are not treated differently or less favourably on the basis of race, sex, disability, religion or belief, sexual orientation, or age.

The members of the Equity and Diversity Advisory Group.



Equity and diversity are promoted by:

- treating all IARC personnel fairly;
- enabling all IARC personnel to develop to their full potential;
- creating an inclusive culture;
- ensuring equal access to opportunities for learning and career development;
- ensuring that IARC/WHO policies, procedures, and processes do not result in discrimination; and
- equipping personnel to recognize and challenge inequality and discrimination in the workplace.

Recent EDAG initiatives include a virtual happy hour for LGBTQ+ personnel and friends, the creation of an award scheme for prominent female scientists, and a workshop followed by discussions on implicit bias.

IARC CROSS-CUTTING WORKING GROUP ON CANCER PREVENTION KNOWLEDGE TRANSLATION AND TRANSFER (KTT WG)

The IARC Cross-Cutting Working Group on Cancer Prevention Knowledge Translation and Transfer (KTT WG) was created in 2020. The vision of the KTT WG is to build bridges and create links so that the scientific knowledge produced by IARC and its collaborators reaches important decision-makers in cancer prevention. The aim of the KTT WG is to translate and transfer high-quality evidence on cancer prevention to stakeholders for their benefit and use, by connecting researchers and research users.

The KTT WG is composed of a dynamic interdisciplinary group of scientists and experts in strategy and communication, who catalyse efforts and stimulate cross-Agency synergies to deliver the latest scientific results to the target audience: stakeholders, decision-makers, and policy-makers from public health institutions, ministries of health, civil society organizations, noncommunicable disease networks, health professionals' societies, and philanthropic organizations. The immediate goals of the KTT WG are to develop a set of targeted resources in the form of comprehensive packages on selected topics, by summarizing the outcomes of projects that can have an impact on recommendations, actions, and policies, and also to raise awareness.

In the first year of its existence, the KTT WG has established the IARC Evidence Summary Brief series, which has received much media attention, and launched a website dedicated to this series. It is anticipated that the Evidence Summary Briefs will help to accelerate the adoption and implementation of evidence-based strategies, while also creating new opportunities for capacity-building and research. The KTT WG is currently conducting a pilot survey and interviews of key stakeholders to obtain advice on broad dissemination strategies and on evaluation of the impact of such strategies.

The dedicated webpage of the IARC Evidence Summary Briefs series (<https://iarc.fr/evidence-summary-briefs-series/>) shows the first two Briefs to be launched: "Breast Cancer Outcomes in Sub-Saharan Africa" and "The Nutri-Score: A Science-Based Front-of-Pack Nutrition Label".

International Agency for Research on Cancer
World Health Organization

MEDIA CENTRE RESEARCH PUBLICATIONS TRAINING EVENTS JOBS & CAREERS ABOUT IARC

Evidence Summary Briefs series

IARC Evidence Summary Briefs

The International Agency for Research on Cancer (IARC) is publishing a series of scientific Evidence Summary Briefs to call attention to the findings of evidence-based studies in important aspects of cancer prevention. As this series grows, IARC will build up and disseminate a portfolio of Evidence Summary Briefs on key cancer prevention topics.

The IARC Evidence Summary Briefs series is the first output of the IARC cross-cutting Working Group on Cancer Prevention Knowledge Translation and Transfer. The aim of this cross-cutting Working Group is to build bridges between the scientific and decision-making arenas by translating and transferring high-quality evidence in cancer prevention, produced by IARC and its collaborators, to stakeholders for their benefit and use.

IARC EVIDENCE SUMMARY BRIEF NO. 2
THE NUTRI-SCORE: A SCIENCE-BASED FRONT-OF-PACK NUTRITION LABEL
[READ REPORT](#)
[READ MORE](#)

IARC EVIDENCE SUMMARY BRIEF NO. 1
BREAST CANCER OUTCOMES IN SUB-SAHARAN AFRICA
[READ REPORT](#)
[READ MORE](#)

COMMUNICATIONS GROUP (COM)

Group head

Dr Nicolas Gaudin (until March 2020)
Dr Tamás Landesz
(acting, until December 2020)
Ms Teresa Lee
(acting, until September 2020)

Secretary

Ms Sylvie Nouveau
(until December 2020)

Knowledge manager

Ms Teresa Lee

Managing editor

Dr Karen Müller

Scientific editor

Dr Heidi Mattock
(until December 2020)

Technical editor

Ms Jessica Cox
(until December 2020)

Communications officer

Ms Véronique Terrasse
(until December 2020)

Institutional webmaster

Ms Maria de la Trinidad Valdivieso
Gonzalez

Web architect

Mr Danil Kister (until April 2020)

Information assistants

Ms Latifa Bouanzi
Ms Meaghan Fortune
(until December 2020)
Ms Fiona Gould (until January 2020)
Ms Sylvia Lesage
Mr Nicholas O'Connor
(until December 2020)
Ms Solène Quennehen
(until December 2020)
Ms Morena Sarzo
(until December 2020)
Mr Othman Yaquoubi

The Communications Group (COM) has been an integral part of the Director's Office, aiming to present a clear and cohesive image of IARC and its work to the scientific community, the media, and the general public. The role of COM has also encompassed information- and publication-related services to the research Sections, and the work of the COM Group Head as the External Relations Officer and Liaison with WHO headquarters. COM was restructured in January 2021 as part of the broader reorganization of the Agency. Publishing, library, and web services became part of the Services to Science and Research Branch (SSR), whereas media and

external communications remained in the Director's Office as part of the Strategic Engagement and External Relations team.

DIGITAL STRATEGY AND DISSEMINATION

Stewarding the IARC e-bookshop, and in particular the WHO Classification of Tumours Online annual subscription, which was launched in September 2019, was the focus of the 2020–2021 biennium. The digital subscription website currently offers the complete contents of the 11 most recent volumes of this renowned series, along with whole slide images. The number of subscriptions has grown

steadily throughout the biennium, complementing the sale of print books by WHO Press. The current total of digital subscriptions stands at 4200. Hospital libraries, pathology units, and other institutional subscribers are offered a bulk discount model.

The 2020–2021 biennium was also a period of intense behind-the-scenes work to make the Agency's publications compliant with the technical standards of the United States National Library of Medicine (NLM), whose Bookshelf database serves as a repository and additional dissemination channel for many IARC titles.

CORPORATE VISUAL IDENTITY

COM spearheaded the commissioning of a new corporate visual identity that expresses the principles and values crystallized in the IARC Medium-Term Strategy 2021–2025. The new visual identity, comprising a graphic charter and templates for a wide variety of communications materials, was announced in September 2021. Implementation will be carried out in stages, with the goal of full cohesion in the Agency's visual branding.

PUBLICATIONS KEY PERFORMANCE INDICATORS AND BIBLIOMETRICS

The IARC Medium-Term Strategy 2021–2025 prompted a revision of COM's key performance indicators (KPIs) reporting on publications. Moving away from metrics predominantly driven by impact factor, COM strives for a more complete and well-rounded view of the impact of the Agency's scientific publishing by considering the *h*-index, altmetrics, and collaboration with countries.

INFORMATION SERVICES

The provision of information services to IARC personnel and external visitors via the Agency's library is less publicly visible but serves an important function. In addition to providing access to journals and other materials in print and digital formats, the information services team plays a key role in training IARC personnel. Instructional sessions on PubMed, in-depth searching for systematic reviews, copyright, and publishing issues were successfully conducted online during the biennium.

Although the COVID-19 pandemic has led to an even greater emphasis on digital formats and access, for the IARC library this biennium also prompted a review of its legacy print collection in anticipation of the Agency's move to the Nouveau Centre building, where shelving capacity will be significantly reduced. Deselection of materials has been conducted in consultation with IARC scientists and will result in a leaner and refreshed physical collection.

OPEN ACCESS

In terms of the broader Open Access landscape, this biennium witnessed the January 2021 launch of Plan S, an Open Access initiative supported by an international consortium of research funders. Open Access compliance with funding authorities, including Plan S members, is a priority for the Agency, and an information session for IARC scientists was co-presented with a WHO Press staff member in December 2020.

The IARC Governing Council Special Fund for Open Access, which earmarks €50 000 per annum for journal article processing charges, supported 25 articles in 2020 and 21 articles to date in 2021.

During the 2020–2021 biennium, IARC published the following reference publications:

WHO CLASSIFICATION OF TUMOURS

- [WHO Classification of Soft Tissue and Bone Tumours, 5th edition](#) (print)
- [WHO Classification of Female Genital Tumours, 5th edition](#) (print)
- [WHO Classification of Thoracic Tumours, 5th edition](#) (print)

IARC MONOGRAPHS

- [Volume 120, Benzene](#) (print)
- [Volume 121, Styrene, Styrene-7,8-Oxide, and Quinoline](#) (print)
- [Volume 122, Isobutyl Nitrite, \$\beta\$ -Picoline, and Some Acrylates](#) (print)
- [Volume 123, Some Nitrobenzenes and Other Industrial Chemicals](#) (PDF and print)
- [Volume 124, Night Shift Work](#) (PDF and print)
- [Volume 125, Some Industrial Chemical Intermediates and Solvents](#) (PDF and print)
- [Volume 126, Opium Consumption](#) (PDF)
- [Volume 127, Some Aromatic Amines and Related Compounds](#) (PDF)
- [Volume 128, Acrolein, Crotonaldehyde, and Arecoline](#) (PDF)

IARC SCIENTIFIC PUBLICATIONS

- [Cancer Incidence in Five Continents, Volume XI, IARC Scientific Publication No. 166](#) (PDF and print)

BIENNIAL REPORT

- [Biennial Report 2018–2019](#) (print)
- [Rapport biennal 2018–2019](#) (PDF)

NON-SERIES PUBLICATIONS

- [World Cancer Report: Cancer Research for Cancer Prevention](#) (PDF and print)
- [A Checklist for Dad](#) (print)
- [Patterns of Care for Women with Breast Cancer in Morocco: An Assessment of Breast Cancer Diagnosis, Management, and Survival in Two Leading Oncology Centres](#) (PDF)

ELECTRONIC RESOURCES

- [Atlas of Visual Inspection of the Cervix with Acetic Acid for Screening, Triage, and Assessment for Treatment](#), IARC CancerBase No. 16

EDITING, LAYOUT, TRANSLATION, AND LANGUAGE SERVICES

The COM Editing and Layout team is responsible for the editing and layout of established IARC Publications series and non-series publications. The team helps to maintain the reputation and image of the Agency by ensuring high corporate standards. COM also helps to produce various promotional materials about the Agency and its publications.

In addition, COM presents training on writing and publishing and provides English editing services for various materials for the IARC website, as well as articles for submission to peer-reviewed journals, book chapters, and other manuscripts. COM provides translation services for short documents and coordinates external translation services for longer documents. COM also organizes language courses for the Agency's personnel in English, French, and Spanish.

MEDIA SERVICES

The IARC Communications strategy aims to increase the Agency's visibility among scientists, researchers, and the cancer community, as well as among policy-makers, the media, and the general public.

From January 2020 to September 2021, efforts to design and develop a wide range of visuals led to an increase in activities on IARC's social media platforms. During this period, 534 tweets were posted to the IARC Twitter account and 41 new videos were published on the IARC YouTube channel. This increase in activity was reflected by an increase in the audience: the IARC Twitter account gained more than 3500 followers, surpassing 10 000 followers in May 2021, and the IARC YouTube channel gained 1245 subscribers, about three quarters of the total number who have subscribed to date.

Full communications packages were systematically developed to mark key events such as World Cancer Day, Cervical Cancer Awareness Month, World Cancer Research Day, and Breast Cancer Awareness Month. These packages included videos, Q&As, interviews, news items, infographics, and animations. Specific themes were regularly developed as Featured News topics on the IARC website. From January 2020 to August 2021, almost 250 news items were published on the IARC website.

Media activities continued to grow, with regular interactions with journalists. Interviews with IARC scientists appeared in a wide range of media. Much of this media coverage arose from one of the 23 press releases published to highlight IARC's scientific results. For example, IARC Press Release No. 299 on alcohol and cancer was covered by the BBC, *The Guardian*, Sky News, *Le Monde*, *El País*, and other top-tier international media outlets.

In 2020–2021, communications activities also supported the Agency's resource mobilization efforts and, in particular, the progress of the construction of the Nouveau Centre building, in order to

increase IARC's visibility among the public and the Agency's partners at the local level in Lyon. To this end, a press conference was held in July 2021 and marketing materials were disseminated with the support of local communications companies.

Several activities and events, including webinars, were organized with key partners in Lyon to highlight IARC's role as a core player in cancer research, not only at the international level but also at the local and national levels.

Finally, interactions with international partners increased significantly throughout this biennium, including regular communications and coordination meetings with WHO teams at the headquarters and regional levels, active participation by IARC in various major communication events and campaigns with the Union for International Cancer Control (UICC), and IARC's driving role in the promotion and design of the World Cancer Research Day campaign.

WEB SERVICES

The key aim of the Web services team is to harness web technology to ensure the timely dissemination of the Agency's scientific activities (cancer statistics, publications, meetings, courses, fellowships, etc.) and the complete integration of this information across IARC's newly developed communication channels.

To further the Agency's Internet presence, the Web services team in collaboration with Information Technology Services (ITS) and an external contractor focused on enhancing the look and feel of the IARC website and adding specific features. These included, for example, the implementation of vertical scrolling on the IARC homepage (<https://www.iarc.who.int/>) as well as the creation of Research Branch webpages

(<https://www.iarc.who.int/branches/>) that reflect the new IARC organizational structure, which took effect in January 2021. In addition, and in close collaboration with the Office of the Director of Administration and Finance (DAF) and the Resource Mobilization Office, specific webpages were created in support of resource mobilization activities (<https://www.iarc.who.int/about-iarc-newbuilding/>, <https://www.iarc.who.int/donations-nc/>).

As part of the broader goal of promoting IARC's research, the Web services team in collaboration with ITS and an external contractor coordinated the development of a new look and feel for IARC's Research Project websites in a new content management system (CMS), and migrated 35 existing websites into the CMS in a cloud-based solution.

In addition, during the biennium the Web services team developed or validated and launched nine websites:

- International Collaboration for Cancer Classification and Research (IC³R): <https://ic3r.iarc.who.int>
- Cancer Risk in Childhood Cancer Survivors (CRICCS): <https://criccs.iarc.who.int/>
- NORDCAN 2.0: Comparable cancer statistics: <https://nordcan.iarc.fr/en>
- Human Exposome Assessment Platform (HEAP): <https://heap-exposome.eu/>
- *World Cancer Report* Updates learning platform: <https://learning.iarc.fr/wcr/>
- Cancer Prevention Europe Learning Centre: <https://cancerpreventioneuropa.iarc.fr/learning-centre/>
- Cancers Attributable to Alcohol: <https://gco.iarc.fr/causes/alcohol/home>
- IARC Cervical Cancer Image Bank: <https://screening.iarc.fr/cervicalimagebank.php>
- Cancer Over Time: <https://gco.iarc.fr/vertime>

EDUCATION AND TRAINING GROUP (ETR)

Group head

Ms Anouk Berger

Assistant, fellowship programme

Ms Isabelle Battaglia

Assistant, courses programme

Ms Sandrine Montigny

Project assistants

Ms Heather Coombs

Ms Dominique Meunier

Secretary

Ms Mira Delea

Administrative clerks

Ms Nadia Ben Amara (until July 2021)

Ms Elke Niehaus

Students

Mr Bastien Boisjot

(until August 2021)

Ms Pauline Buosi (until August 2020)

Ms Amélie Labaume

(until August 2020)

Ms Carla Reyes (until July 2021)

Consultant

Ms Amélie Labaume

Affiliated staff

Dr Maribel Almonte (Scientific director, Summer School module on Implementing Cancer Prevention and Early Detection)

Dr Armando Baena Zapata (Scientific director, Summer School module on Implementing Cancer Prevention and Early Detection)

Dr Partha Basu (Scientific director, Summer School module on Implementing Cancer Prevention and Early Detection)

Dr Andre Carvalho (Scientific director, Summer School module on Implementing Cancer Prevention and Early Detection)

Dr Laure Dossus (Scientific director, Summer School module on Introduction to Cancer Epidemiology)

Dr Pietro Ferrari (Scientific director, Summer School module on Introduction to Cancer Epidemiology)

Dr Zdenko Herceg (Scientific officer, fellowship programme) (until December 2020)

Dr Valerie McCormack (Scientific officer, fellowship programme)

As a core function of the Agency, IARC's education and training programme has made a substantial contribution to the development of human resources for cancer research worldwide and has also helped to widen the Agency's network of collaborators.

Key achievements of IARC's education and training programme during 2020–2021 are presented here. Whereas the Education and Training Group (ETR) coordinates the Agency's activities in these areas, many initiatives are led by the research Groups.

With the start of the new IARC Medium-Term Strategy 2021–2025 and the new organizational structure as of 1 January 2021, ETR was renamed as the Learning and Capacity-Building Branch.

RESEARCH TRAINING AND FELLOWSHIP PROGRAMME

The programme offers researchers at different stages of their career (collectively referred to as Early Career and Visiting Scientists) opportunities to receive training at IARC by participating in collaborative research projects. These Early

Career and Visiting Scientists are supported either by project funds from IARC Groups or by IARC Fellowships. A total of 254 Early Career and Visiting Scientists from 58 different countries worked at IARC during the biennium. This represents a 13.9% decrease compared with the previous biennium, which is directly related to reduced mobility resulting from the travel restrictions imposed during the COVID-19 pandemic.

The internal programme of generic skills courses, jointly managed by ETR and the Human Resources Office, offered 30 courses to Early Career and Visiting Scientists in 2020–2021 (Table 1), which were attended by more than 200 people. Because of the COVID-19 pandemic, the courses offered were reduced to high-priority events and were held online. In addition, Early Career and Visiting Scientists accessed 97 learning resources from the WHO iLearn learning platform. An IARC Mentoring Programme was developed with a group of volunteers from across the Agency as part of the IARC Quality of Work Life initiative (Figure 1).

ETR continued to work closely with the Early Career Scientists Association (ECSA). Among other activities, ECSA successfully held online events, including a Career Day, featuring a career panel and a seminar on working efficiently from home, and a Scientific Week, enabling the presentation of work to peers from IARC, the Cancéropôle Lyon Auvergne Rhône-Alpes, the United States National Cancer Institute, and the German Cancer Research Center.

POSTDOCTORAL FELLOWSHIPS

The Agency awarded seven IARC Postdoctoral Fellowships to candidates from low- and middle-income countries (LMICs) for projects in line with IARC's emerging priorities or on the relationship between cancer and COVID-19. In addition, as part of efforts to identify complementary sources of funding for the programme, negotiations with Children with Cancer UK led to a call for IARC Postdoctoral Fellowships for scientists wishing to carry out research on paediatric cancers or cancer in teenagers and young adults. Two such fellowships were awarded.

Three return grants were awarded, to assist former IARC Postdoctoral Fellows in the establishment of research activities in their home countries.

Table 1. Generic courses for Early Career Scientists, 2020 and 2021

Research skill development	Writing skills
Multivariate analysis for -omics data integration: principles and applications Tidyverse fundamentals with R	Copyright issues (twice) Effective scientific posters Publications catch-all/catch-up Publishing in scientific journals PubMed workshop: search efficiently Systematic reviews search methodology
IT skills	Communication skills
Electronic Laboratory Notebook REDCap for data collection REDCap for surveys	Effective interpersonal communication techniques (four times) Social media
Career management and development	Leadership and management
Career Compass webinar Career Compass follow-up webinar Confident career conversations Creating and maintaining high performance Giving and receiving feedback (twice) Motivation and focus (twice)	Efficient communication between team member and supervisor: being on the same page Research leadership training course (twice) Task management Teamwork and collaboration

Figure 1. Flyer to promote the concept of the IARC Mentoring Programme. © IARC.



Figure 2. Cancer Screening in Five Continents (CanScreen5) Train the Trainers live session. © IARC.



SHORT-TERM FELLOWSHIPS

In collaboration with the Union for International Cancer Control (UICC), the UICC-IARC Development Fellowship enables a selected number of IARC Summer School participants from LMICs to visit IARC for a period of 1 month for further training and collaboration. Seven UICC-IARC Development Fellowships were awarded.

COURSES PROGRAMME

The courses programme is designed to enhance the capacity of the global research community, in particular in LMICs, through lifelong learning in the areas of the Agency's expertise.

LEARNING EVENTS

The Agency organized 37 courses or webinars targeting researchers and health professionals from many countries, in particular LMICs (Table 2). Because of the COVID-19 pandemic, courses were offered online, were redesigned to combine live sessions with facilitated self-learning, and lasted from a period of a few days, for example the

cancer staging course, to several months, for example the IARC Summer School 2021, the ChildGICR Masterclass, and the Cancer Screening in Five Continents (CanScreen5) Train the Trainers course (Figure 2). More than 2700 scientists and health professionals benefited from these learning events during the biennium.

SELF-LEARNING RESOURCES

As a key complement to live events, IARC continued to produce self-learning resources. A new self-paced learning programme on cancer screening and early diagnosis was launched in the framework of the CanScreen5 project. This resource was translated into Russian and will soon be available in Spanish (<https://learning.iarc.fr/edp/resources/pgm-cancer-screening/>).

As part of the Cancer Prevention Europe consortium, self-learning modules on the fourth edition of the European Code Against Cancer were produced and were translated into French, Hungarian, Polish, and Spanish (<https://learning.iarc.fr/edp/cpe/>) (Figure 3).

LEARNING PORTAL

Launched in 2019, the IARC Learning portal (<https://learning.iarc.fr>) enables access to several thematic learning platforms (Biobanking, Cancer Prevention and Early Detection, and *World Cancer Report* Updates). It also provides access to IARC WebTV, including the IARC Summer School video channel, as well as to the websites of other IARC-led projects with learning materials on cancer surveillance and on the exposome (the Human Exposome Assessment Platform). The IARC Learning portal continues to attract an increasing audience. Since November 2019, 1554 people (1423 during 2020–2021) have created an account on the portal to freely access learning resources.

Table 2. Learning events, 2020 and 2021

Course title	Location	Number of participants	External collaborations
Cancer surveillance			
Cancer registration: basic principles and methods for the Organisation of Eastern Caribbean States (OECS)	Online	46	IARC Caribbean Hub for Cancer Registration – Martinique Cancer Registry – OECS Health Unit Joint Virtual Caribbean Course
GICR Childhood cancer	Online	25	St. Jude Children's Research Hospital
GICR-WHO EMRO Basic cancer registration course	Online	45	WHO Regional Office for the Eastern Mediterranean
GICR-WHO EMRO Data quality course	Online	20	WHO Regional Office for the Eastern Mediterranean
GICR Staging and Essential TNM course	Online	15	Union for International Cancer Control (UICC)
IARC-National Cancer Center Korea Joint Summer School on Cancer Registration: Principles and Methods	Online	32	GICR, National Cancer Center of the Republic of Korea and its Graduate School of Cancer Science and Policy (NCC-GCSP)
Cancer prevention and early detection			
CanScreen5 – Train the Trainers – African region	Online	32	American Cancer Society (ACS), Medical Research Council (United Kingdom)
CanScreen5 – Train the Trainers – Pan American Health Organization – Community of Caribbean and Latin American States (CELAC) countries (3 sessions)	Online	79	American Cancer Society (ACS), Centre for Global Health Inequalities Research (CHAIN) of Norway
IARC-Centre Léon Bérard Série d'échanges – Bouger contre le cancer (in French)	Online	220	Centre Léon Bérard, Lyon, France
IARC-Centre Léon Bérard Série d'échanges – Mieux manger pour ma santé (in French)	Online	121	Centre Léon Bérard, Lyon, France
IARC Summer School: Implementing Cancer Prevention and Early Detection	Online	34	Union for International Cancer Control (UICC)
Precision oncology	Online	40	European Scientific Institute, University of Grenoble
Prevention and screening to control chronic diseases: an illustration with cancer – Master of Public Health: Epidemiology of Chronic Diseases	Online	15	French National School of Public Health
Projet Care4Afrique – Benin – IVA et thermo-coagulation (in French)	Online	17	
Running 8-HPV type OncoE6/E7 Cervical Test for ESTAMPA (2 series)	Online	8	
Stakeholder analysis of barriers to cancer screening	Online	25	Pan American Health Organization
The contribution of the Innovative Partnership for Action Against Cancer (iPAAC) Joint Action to building capacity for cancer prevention	Online	87	Cancer Society of Finland, Association of European Cancer Leagues
<i>World Cancer Report</i> webinar series – HPV vaccination	Online	288	European Society for Medical Oncology (ESMO)
<i>World Cancer Report</i> webinar series – Obesity and cancer	Online	351	European Society for Medical Oncology (ESMO)
<i>World Cancer Report</i> webinar series – Social inequalities and cancer	Online	282	European Society for Medical Oncology (ESMO)
<i>World Cancer Report</i> webinar series – COVID-19 and cancer screening	Online	391	European Society for Medical Oncology (ESMO)

Table 2. Learning events, 2020 and 2021 (continued)

Course title	Location	Number of participants	External collaborations
<i>World Cancer Report</i> webinar series – Challenges and opportunities for primary cancer prevention	Online	261	European Society for Medical Oncology (ESMO)
Cancer research infrastructure and methods			
Biobank ethics and governance, for BCNet members (2 webinars)	Online	27	National Cancer Institute (NCI) Center for Global Health (CGH)
Human exposome “Bring your own data workshop” for HEAP consortium	Online	20	Human Exposome Assessment Platform (HEAP) consortium members
IARC Summer School: Introduction to Cancer Epidemiology	Online	39	Union for International Cancer Control (UICC)
Multivariate analysis for -omics data integration: principles and applications	IARC, Lyon	30	Swiss Institute of Biostatistics
Safe handling of biological samples, for BCNet members (4 webinars)	Online	55	National Cancer Institute (NCI) Center for Global Health (CGH)
Scientific writing for peer-reviewed publications, for scientists from African and Latin American countries	Online	16	
UiT Winter School on Cancer Epidemiology	Norway and online	43 + 40	The Arctic University of Norway (UiT)
Leadership and management			
Research Leadership Training Programme (2 series)	Online	15	Mobilize Strategy Consulting

Figure 3. Self-paced e-learning module for the European Code Against Cancer, fourth edition. © IARC.



As part of the IARC Learning portal, and with the support of and in collaboration with the European Society for Medical Oncology (ESMO), IARC launched the *World Cancer Report Updates* learning platform (<https://learning.iarc.fr/wcr/>) (Figure 4). This provides learning resources and opportunities related to selected content from the 2020 *World Cancer Report*, as well as on developments in cancer research for cancer prevention. Five live webinars provided the opportunity to 2008 researchers and health professionals from 140 countries to interact with international experts. Four e-learning modules were created from the webinar recordings, including short video teasers, quizzes,

questions and answers, and certificates of completion.


KEY PARTNERSHIPS

Relationships between IARC and academic institutions continued to be strengthened during the 2020–2021 biennium. For example, an agreement was reached with the Italian Istituto Superiore di Sanità for the joint supervision and hosting of three PhD students. IARC was also invited to partner with the German Cancer Research Center for the development of a Cancer Prevention Graduate School. In addition, ETR collaborated with the Karolinska

Institutet and other European institutions in the Human Exposome Assessment Platform consortium, funded by the European Union.

IARC has been involved in the development of the WHO Academy at several levels. As well as contributing to governance and infrastructure aspects, two IARC learning programmes were selected as part of the development of the first courses of the Academy: the Comprehensive Learning Programme on Screening, Diagnosis, and Management of Cervical Precancer; and the Managing Infrastructure for Medical Research Learning Programme.

Figure 4. The *World Cancer Report Updates* learning platform. © IARC.



IARC SUMMER SCHOOL IN CANCER EPIDEMIOLOGY 2021

The IARC Summer School in Cancer Epidemiology aims to improve the methodological and practical skills of cancer researchers and health professionals. Because of the COVID-19 pandemic, the 2021 course was redesigned and conducted entirely online, while maintaining the features that make the course unique: the fostering of international collaboration, the provision of multiple opportunities for interaction, and the delivery of high-quality multidisciplinary lectures and practical activities to facilitate the learning process of participants.

Two modules were offered: Introduction to Cancer Epidemiology, and Implementing Cancer Prevention and Early Detection. A blended learning approach was adopted for both modules, including 4 weeks of self-paced activities (recorded lectures and assignments, punctuated by two or three live sessions and networking events), followed by 2 weeks of daily live sessions and group work activities. A total of 73 cancer researchers and health professionals from more than 45 countries (the vast majority of which were LMICs) participated in the two modules.

All the resources used to deliver the 2021 Summer School are available from the IARC Learning portal (<https://learning.iarc.fr>).

Participants were invited to report their impressions and experience of the 2021 Summer School. The recorded testimonials perfectly illustrate the spirit of the IARC Summer School: the shared learning, sharing of experiences, and the international networking for cancer prevention across countries. The feedback from participants and the assessment of the course directors will be taken into consideration in the design of future IARC Summer Schools and other similar events, to ensure that, when on-site events are again permitted, potential on-site components of courses will be even more focused on the practical and networking aspects.

IARC tweet with IARC Summer School 2021 participants. © IARC.



LABORATORY SERVICES AND BIOBANK GROUP (LSB)

Group head

Dr Zisis Kozlakidis

Secretary

Ms Charlotte Volatier
(until December 2020)
Ms Tracy Wootton

Biobank process management assistant

Dr Elodie Caboux

Laboratory services management assistant

Dr Stéphanie Villar

Senior biobank technician

Mr Christophe Lallemand

Biobank technicians

Ms Elodie Colney
Mr Henri Cordier
Ms Sophie Guillot
Ms Gertrude Tchoua

Students and visiting scientists

Dr Subasri Armon
Ms Mathilde Benoit
Dr Koh Furuta
Ms Léa Marchand
Mr Morten Øien
Ms Julie Roux
Dr Daniel Simeon-Dubach
Mr Pierre Vodossin
Ms Maissa Zeghidi

The Laboratory Services and Biobank Group (LSB) (Figure 1) works with IARC's Administrative Services Office (ASO) and research Groups to provide core laboratory and biobanking services to support the Agency's research activities. LSB also leads national and international research projects on biobanking and medical research infrastructure. In addition, LSB provides technical and safety advice to the Nouveau Centre project for the future laboratories and biobank, in alignment with the IARC Medium-Term Strategy 2021–2025.

Within the new organizational structure as of 1 January 2021, LSB was renamed as Laboratory Support, Biobanking, and Services.

Figure 1. Laboratory Services and Biobank Group team photo. Courtesy of Xuexun Zhou.



LABORATORY SERVICES

LSB ensures that optimal laboratory services are available, including a laboratory store that provides consumables, glass-washing facilities, mycoplasma testing and quarantine for cell cultures, pipette checking, and the freezing and/or retrieval of cell lines in nitrogen gas. In conjunction with the Laboratory Steering Committee (LSC), LSB oversees the common laboratory platforms and ensures that equipment is well maintained. Interaction between laboratory-based and epidemiological research is enhanced through the upgrading, updating, and acquisition of state-of-the-art scientific instruments and the provision of sample storage capacity.

HEALTH AND SAFETY

Health and safety issues are managed in collaboration with the Occupational Health and Safety Committee (OHSC). The IARC safety manual, a key document, is now available online; it is updated regularly and is aligned with the latest national and international guidelines. The first section of the manual describes the role of all personnel and service providers involved in safety and security at IARC, access conditions, general rules, emergency procedures, and medical services. The second section covers laboratory safety, including personal and collective protection guidelines, management of equipment and cold storage, transport procedures between laboratory floors, laboratory services offered, and good laboratory practice. Information

is provided on biological and chemical risks, including risks related to the handling of carcinogens, liquid nitrogen, and laboratory waste.

IARC authorizations for the restricted use of genetically modified organisms (GMOs) are handled by LSB. Radio-nuclide experimentation has ceased entirely, and the relevant authorizations have not been renewed. LSB initiated the declaration of the biological collections stored at IARC and the authorization to import and/or export biological samples in accordance with CODECOH; this authorization is valid until 2025.

During the biennium, LSB provided 124 safety briefings for newcomers and 28 training sessions for newcomers working in laboratories. LSB made more than 10 presentations to 93 laboratory personnel, covering new guidelines linked to COVID-19 constraints; working with liquid nitrogen, with carcinogens, and with the Fusion FX system; working in the L3 or L2+ laboratories; and completing the Electronic Laboratory Notebook. LSB also published a report on biosafety, describing gaps in current knowledge (Roux et al., 2021).

LSB plays many important roles in the preparation for the move to the Nouveau Centre building, including participating in the laboratory working group, the biobank working group, and the transfer and move working group; several calls for tender; the donation campaign; and the implementation of new procedures.

BIOBANK SERVICES

The IARC Biobank maintains biological sample collections from international studies and operates a service platform for sample retrieval, inventory, aliquoting, DNA extraction and quantification, and reception or shipment of biological material worldwide.


The IARC sample management database (SAMI) stores information on more than 6 million biological specimens. During the biennium, more than 363 000 new samples were imported into SAMI and more than 65 000 samples were accessed for collaborators. SAMI is continuously being upgraded, and version 2.0 was launched in 2020.

The standard procedures that govern sample transfer to and from the Agency and the management of samples were updated (e.g. the new sample disposal policy). During the biennium, 106 Material Transfer Agreements for incoming and outgoing samples were technically validated. LSB supervised the replacement of obsolete equipment and the purchase of new units to increase cold storage capacity to meet future needs as well as provide adequate back-up facilities. A new freezer-temperature monitoring system was validated and installed on cold storage equipment, anticipating the move to and expansion within the Nouveau Centre building.

The Biobank continues to provide pre-analytical services on a cost-recovery basis. During the biennium, 18 projects were serviced, all of which related to requests from international institutions. This resulted in more than 12 000 sample retrievals from liquid nitrogen, 5133 DNA extractions, 7162 DNA aliquots, 5034 plasma and serum aliquots, and 205 receptions or shipments of samples from or to 23 countries worldwide. The Biobank inventoried more than 67 000 individual samples and provided support across the continuum, from reception to data upload into SAMI (Figure 2).

The Biobank continues to participate in international proficiency testing schemes and scored highly in the programmes of DNA extraction from whole blood, frozen tissue, and formalin-fixed, paraffin-embedded tissue and DNA quantification.

Figure 2. An overview of the services provided by the IARC Biobank as at September 2021. © IARC.



BCNet


LSB participates in several research programmes, in line with IARC's mission of cancer research for cancer prevention. To address the underrepresentation of biological resources in low- and middle-income countries (LMICs) in research, the LMICs Biobank and Cohort Building

Network (BCNet; <https://bcnet.iarc.fr/>) was established by IARC in 2013. Currently, 42 institutions in 23 countries are members of BCNet (Figure 3). During the biennium, BCNet delivered four presentations to external collaborators (in Nigeria, Kenya, the Philippines, and Macao Special Administrative Region, China) and published several seminal

articles (Henderson et al., 2020; Kozlakidis, 2020; Vodossin et al., 2021).

BCNet direct funding is provided by the Center for Global Health, National Cancer Institute, National Institutes of Health, USA. LSB gratefully acknowledges all the members of BCNet and their active discussions and exchanges, which have enriched our scientific world as well as our contextual understanding of global research.

Figure 3. Map of BCNet member countries as at September 2021. © IARC.



COLLABORATIONS

With regard to infrastructure research, LSB represents IARC at the International Organization for Standardization (ISO; <https://www.iso.org/>) and at the Biobanking and BioMolecular resources Research Infrastructure–European Research Infrastructure Consortium (BBMRI-ERIC; <https://www.bbMRI-eric.eu/>) (Figure 4). LSB participated in infrastructure research from the perspective of operational readiness and responsiveness (Henderson and Kozlakidis, 2020; Aisyah et al., 2021; Wei et al., 2021b). LSB also contributed to the development of further recommendations and guidelines (Jazieh and

Figure 4. The Biobanking and BioMolecular resources Research Infrastructure–European Research Infrastructure Consortium (BBMRI-ERIC), together with IARC, launched an initiative on better understanding the landscape of paediatric biobanking (<https://iarc.who.int/news-events/call-for-participation-and-resource-landscaping-on-elsi-issues-for-biobanking-with-children/>). © Adobe Stock.



Kozlakidis, 2020; Vandenberg et al., 2020; Cree et al., 2021a), with a particular emphasis on data and artificial intelligence (Eklund et al., 2020; Kozlakidis, 2020; Kozlakidis and Nigam, 2020), and to the development of a future WHO Academy course.

During the biennium, LSB investigated the impact of the COVID-19 pandemic on infrastructures and cancer patients (Allocca et al., 2020a, 2020b; Di Lorenzo et al., 2020a, 2020b; Aisyah et al., 2021). This research will continue as part of the regional project “Impact of COVID-19 on Cancer” (IMCOCA), a *Projet Structurant* funded by Cancéropôle Lyon Auvergne Rhône-Alpes (CLARA; <https://www.canceropole-clara.com/>),

awarded jointly to Centre Léon Bérard (CLB; <https://www.centreleonberard.fr/en>) and LSB (Figure 5).

LSB participates in projects funded by the European Commission: the Human Exposome Assessment Platform (HEAP) project (grant no. 874662) (<https://heap-exposome.eu/>) and the Twinning for the Armenian Research Infrastructure on Cancer Research (ARICE) project (grant no. 952417) (<https://www.arice.am/>). Funding is provided by BBMRI-ERIC for the European Paediatric Translational Research Infrastructure (<https://eptri.eu/>) and the Center of Excellence in Biobanking and Biomedical Research at the University of Cyprus (<https://biobank.cy/>).

Figure 5. The “Impact of COVID-19 on Cancer” (IMCOCA) *Projet Structurant* is funded by Cancéropôle Lyon Auvergne Rhône-Alpes (CLARA) and was awarded jointly to Centre Léon Bérard (CLB) and LSB. Courtesy of CLARA.



SECTION OF SUPPORT TO RESEARCH (SSR)

OFFICE OF DIRECTOR OF ADMINISTRATION AND FINANCE

Director of administration and finance

Dr Tamás Landesz

Administrative officer (Legal/contracts)

Ms Virginie Vocanson

Assistant (Documents)

Ms Agnès Meneghel

Administrative assistant

Ms Nathalie Lamandé

Secretary

Ms Séverine Coutelier

ADMINISTRATIVE SERVICES OFFICE

Administrative services officer

Ms Elisabeth Françon

Project manager

Mr Sylvain Lubiato

Administrative assistant

Ms Sophie Servat

Principal assistant (Procurement)

Ms Fabienne Lelong

Assistants (Procurement)

Ms Sandra Lejeune

Mr Didier Louis

Ms Sandrine Macé

Assistant (Registry)

Mr François Deloche

Assistant

(Security and building management)

Mr Jean-Alain Pedil

Secretary

Ms Valérie Rut

Support staff

Mr Bruno Amara (Maintenance)

Mr Thomas Cler

(Laboratory maintenance)

Mr Yannick Condomines (Reception)

Mr Henri Cordier

(Laboratory and administration)

Mr William Goudard

(Space maintenance)

Mr Antoine Hernandez (Driver)

Mr Michel Javin (Reprography)

Mr Hafed Lamouchi

(Electronic maintenance)

RESOURCE MOBILIZATION, BUDGET, AND FINANCE OFFICE

Administration and finance officer

Ms Angkana Santhiprechachit

(until November 2021)

Resource mobilization and grant officer

Dr Olaf Kelm (until February 2020)

Ms Claire Salignat

Budget officer

Ms Editta Odame

Finance officers

Ms Julie Goux

Mr Rommel Nidea

Assistants (Budget)

Mr Thomas Odin

Ms Madeleine Ongaro

Mr Franck Rousset

Assistants (Accounts)

Ms Belinda Annibaldi

Mr Samuel Billard

Mr Pascal Binet

Mr Christian Mah (until February 2021)

Ms Laurence Piau (until January 2021)

Ms Adèle Séguret

Mr Nils Viala

Assistants (Resource mobilization)

Ms Maud Bessenay

Ms Véronique Chabanis

Ms Claire Salignat

(until November 2020)

Trainees

Ms Coline Bancel

Ms Emmanuelle Gaucherand

Ms Amel Mesbah

Ms Anna Schmutz

Ms Mahée-Théa Viton

HUMAN RESOURCES OFFICE

Human resources officer

Ms Dina D'Amico (until January 2020)

Mr David Kavanagh

Associate human resources officer

Ms Catherine Bassompierre

Assistants (Human resources)

Ms Julie Buguet

Ms Julianna Soos (Training)

Secretary

Ms Sophie Sibert

Central Secretarial Services (CSS)

Ms Severine Coutelier

Ms Nandini Deleu

Ms Andreea Spanu

(until February 2020)

Staff physician

Dr Michel Baduraux (until July 2021)

Secretary to IARC Staff Association Committee and Staff physician

Ms Isabelle Poncet

Relocation assistant

Ms Christine Astier

INFORMATION TECHNOLOGY SERVICES

Head, Information Technology Services

Mr Francisco Lozano

IT officers

Mr Philippe Boutarin

Mr Christopher Jack (until August 2021)

Assistants (IT support/development)

Mr Sébastien Agathe

Ms Lucile Alteyrac

Mr Benjamin Danet

Mr Hafed Lamouchi

Mr Nicolas Tardy (Bioinformatics)

Mr Rémi Valette

The main role of the Section of Support to Research (SSR) is to ensure the smooth operations of IARC and to enable the achievement of the Agency's scientific objectives. With the start of the new IARC Medium-Term Strategy 2021–2025 and the new IARC organizational structure as of 1 January 2021, SSR was renamed as the Services to Science and Research Branch.

SSR is made up of six specialized operational units, which provide services intrinsic to the successful implementation of the Agency's scientific programmes: (i) Office of the Director of Administration and Finance, including legal support and data protection; (ii) Budget and Finance Office, including supporting resource mobilization activities; (iii) Human Resources Office, including staff training and capacity-building; (iv) Administrative Services Office, including procurement, conference services, building management, and security; (v) Information Technology Services, including telecommuni-

cations; and (vi) Publishing, Library, and Web Services, including publications production and copyright management (which became part of SSR in January 2021 as part of the restructuring). SSR ensures that the Agency's activities meet the highest sector standards of resource management, operational efficiency, and accountability in the use of the funding made available by its Participating States and donors.

In addition to the regular provision of daily operational services, during 2020–2021 the following achievements of SSR contributed substantively to maintaining IARC's leadership status in the ever-changing international research environment.

SSR continued to spearhead the review of IARC's core values, which represent the Agency's DNA, and helped embed these values in every aspect of the Agency's work. During the biennium the Quality of Work Life initiative was launched;

this is an important programme that aims to ultimately improve the quality of science at IARC. Based on broad consultation with IARC personnel, multiple working groups, involving volunteers from across the Agency, have been set up in four target areas: (i) working in a respectful and harmonious environment, (ii) opportunities for growth, training, and development, (iii) well-being and work–life balance, and (iv) team and performance management.

Notable progress has been made, in close cooperation with our host country, in the construction of a new state-of-the-art IARC headquarters in Lyon: the Nouveau Centre building. The First Stone Ceremony was held in February 2020 with the participation of the IARC Scientific Council and local dignitaries. Work on the building has progressed well since then, despite the challenges created by the COVID-19 pandemic. The new building is scheduled to be finished in time to enable its occupation



by the end of 2022. As well as working towards the construction of IARC's future premises, SSR has continued to ensure that the Agency's scientific activities are not significantly interrupted by the continued technical failures experienced in the current premises.


As a result of the COVID-19 pandemic, SSR activated the Agency's Business Continuity Management Team to guide IARC personnel through the various periods of lockdown, applying a phased approach. SSR adapted the current premises to be compliant with WHO and host country health and safety measures as well as health protocols, while ensuring that daily operations and scientific work can continue uninterrupted. Effective teleworking was enabled through the use of the latest cloud-based communications, collaboration, and productivity platforms, and the expansion of the virtual private network (VPN) technology to all IARC personnel. Several additional services for virtual meetings, electronic workflows, and electronic signatures made it possible for work to continue seamlessly.

The IARC Specific Guide on Engagement with Non-State Actors was updated and further simplified to provide clear operational guidance, complementing the WHO Framework of Engagement with Non-State Actors (FENSA).

SSR supported the Director in efforts to mobilize additional external financial resources to deliver the approved programme of work, in developing an IARC Investment Case to help resource mobilization efforts, and in launching the new IARC Medium-Term Strategy 2021–2025.

SSR continued to ensure effective management of IARC accounts, retaining compliance with the International Public Sector Accounting Standards (IPSAS), validated by WHO external auditors on an annual basis. The Agency continued to receive unqualified (or fully compliant) audit opinions from the External Auditors throughout the biennium. In 2021, for the first time, IARC received no recommendations from the External Auditors and managed to close all prior year recommendations successfully.


Enable and support continuous Learning and Development (L&D)



In addition, SSR continued to put in place measures aimed at maximizing the professional and personal potential of personnel, and fostering a work environment that supports collaboration and excellence. Because of constraints resulting from the COVID-19 pandemic, face-to-face training sessions were replaced by online courses and novel group-based learning methods.

An innovative scientific leadership programme comprising various modules was launched in 2021. The first cohort of students included senior and mid-level scientific managers at IARC. The second cohort also included external scientists from low- and middle-income countries as well as scientists nominated by IARC Participating States.

SSR remains committed to the principle of continuous quality improvement, striving to further enhance the Agency's processes and support services by, among others, collecting feedback through regular service surveys. Five impact areas devised by SSR to enable IARC to fulfil the IARC Medium-Term Strategy 2021–2025 and to help build a learning and adaptive organization fit for the 21st century are (i) faster delivery of results, (ii) pooling of resources, (iii) technological innovation and advancement, (iv) fit for Open Science, and (v) culture shift and personal growth. SSR holds monthly Administrative Town Hall meetings to communicate SSR objectives and planned activities and to explain new operational policies and administrative procedures of general interest.



COMMITTEES

LABORATORY STEERING COMMITTEE (LSC)

Laboratory research is essential for IARC to conduct studies on the causes and mechanisms of cancer, to support cancer prevention. Research laboratories are embedded within five Branches within the new IARC organizational structure (Genomic Epidemiology; Nutrition and Metabolism; Epigenomics and Mechanisms; Early Detection, Prevention, and Infections; and Evidence Synthesis and Classification), and LSB provides global laboratory services, including biobanking. The IARC Labora-

tory Steering Committee (LSC) oversees the IARC core laboratory facilities and advises the Director on their most efficient use.

Significant tasks of the LSC during the 2020–2021 biennium, conducted in close collaboration with LSB and ASO, have concerned the establishment of rules for laboratory activities under COVID-19 constraints, the coordination of the acquisition of new equipment for the histopathology laboratory (one

automated slide staining system [Histo-stainer], one cryostat, and an upgrade of the digital scanner), the creation (with the Director's Office) of a decision-making framework for in-house laboratory capacity versus outsourcing, the overall maintenance of laboratory equipment, the contribution to the IARC donation campaign for laboratory equipment, the logistical preparation for the move to the Nouveau Centre building, and the organization of seminars on new laboratory technologies.

BIOBANK STEERING COMMITTEE (BSC)

The role of the IARC Biobank Steering Committee (BSC) is to support biobanking activities at the Agency and advise the Director regarding the strategic development of the Biobank.

During the 2020–2021 biennium, the BSC renewed its membership, welcomed a new chairperson, and completed the acquisition of a semi-automated liquid

nitrogen storage platform dedicated to cell line preservation. Other tasks during the biennium include the expansion of remote temperature monitoring capabilities for freezers, a review of operations under COVID-19 constraints, the creation of an Agency policy for the disposal of samples, operational alignment to the updated CODECOH regulations, the contribution to the

IARC donation campaign for laboratory equipment, and visits to the Nouveau Centre construction site.

The BSC has initiated planning for the move of the IARC Biobank to the Nouveau Centre building (in close collaboration with ASO) and has identified sample collections to be disposed of before the move.

COMPUTATIONAL BIOLOGY, BIOINFORMATICS, AND BIostatISTICS COMMITTEE (C3B)

The IARC Computational Biology, Bioinformatics, and Biostatistics Committee (C3B) has continued to oversee the Agency's activities in these areas.

The overall structure of the C3B was changed, with the creation of the roles of responsible officers in bioinformatics, biostatistics, and scientific information technology (IT), carried out by Dr Matthieu Foll (GCS), Dr Vivian Viallon (NMB), and Mr Christopher Jack (ITS), respectively. These individuals take the primary responsibility for these activities across IARC.

The main activity of the C3B during the 2020–2021 biennium was the creation of the IARC Scientific IT platform, which provides access to shared centralized computing and storage resources. This shared and centralized approach has several advantages: the data are stored in a secure environment on the IARC premises, the platform facilitates collaborative work, it is cost-effective, and it helps data owners to comply with best practices required to store sensitive or personal data. This system has also been crucial during the COVID-19 pandemic, to enable IARC personnel to

work remotely. Scientific opportunities will be associated with further developments; in particular, IARC will become a data hub for some projects, with external collaborators able to use the platform remotely.

The C3B acknowledges the departure of Mr Christopher Jack (ITS) to pursue professional opportunities elsewhere. Mr Jack was instrumental in scientific computing at the Agency, and the C3B sincerely thanks him for his efforts and wishes him well in his future post.

ETHICS COMMITTEE (IEC)

The IARC Ethics Committee (IEC) ensures that research conducted or supported by IARC conforms to international ethical standards for research involving humans. The IEC ethical review is complementary to local and/or national ethical approval. Over the 2020–2021 biennium, the IEC was composed of 11 senior individuals from diverse backgrounds and nationalities. The IEC is chaired by Professor Samar Al-Homoud, supported by Dr Hans Storm (vice-chair from February 2020 to February 2021) and Dr Angeliki

Kerasidou (vice-chair in January 2020 and since February 2021) and assisted by Dr Chiara Scoccianti as secretary. An external Ethics Advisory Group (EAG) provides guidance on an ad hoc basis on areas where specialist expertise is required.

During the biennium (up to June 2021), the IEC evaluated 69 new projects and 52 resubmissions of projects previously reviewed by the IEC. During the COVID-19 lockdowns in 2020, the IEC strongly supported the IARC

principal investigators with its procedure for expedited review between official meetings, clearing 40% more projects than in 2019. The IEC updated its rules and procedures (RAPs) and standard operating procedures (SOPs) with changes to the procedures for regular submission and expedited review, to further facilitate clearance between IEC meetings by the IEC chairs with the support of the secretary. The IEC questionnaire and annual report template were also updated.

OCCUPATIONAL HEALTH AND SAFETY COMMITTEE (OHSC)

The mission of the IARC Occupational Health and Safety Committee (OHSC) is to ensure, in close collaboration with the Staff Physician, the IARC administration, and LSB, that optimal working conditions are provided for all IARC personnel.

Some of the main activities of the OHSC during the 2020–2021 biennium included

the replacement of old laboratory chairs, to improve working conditions in the laboratories, and the implementation of a fall detection sensor system in isolated areas of the IARC premises. In addition, the OHSC was involved in reviewing guidelines prepared by LSB for the reception of biological samples potentially contaminated with SARS-

CoV-2, and was part of a working group on the prevention and treatment of psychosocial risks, as part of the Quality of Work Life initiative. The OHSC also organized first aid training for personnel, to complement the role of the IARC Safety Team and help create a safer working environment.

GOVERNING AND SCIENTIFIC COUNCILS

The International Agency for Research on Cancer (IARC) was established in May 1965, through a resolution of the Eighteenth World Health Assembly, as an extension of the World Health Organization, after a French initiative. Its governance is effected through the IARC Governing Scientific Councils.

GOVERNING COUNCIL

IARC's general policy is directed by a Governing Council, composed of the Representatives of Participating States and of the Director-General of the World Health Organization. It meets every year in ordinary session in Lyon, usually the week before the World Health Assembly. The Governing Council elects IARC's Director for a 5-year term. The Council elected Dr Elisabete Weiderpass in May

2018 to serve for a 5-year term as from 1 January 2019. The chairperson of the Governing Council prepares the meetings together with the Secretariat and advises the Director throughout the year.

SCIENTIFIC COUNCIL

The Scientific Council consists of highly qualified scientists selected on the basis of their technical competence in cancer research and allied fields. Members of the Scientific Council are appointed as experts and not as representatives of Participating States. When a vacancy arises on the Scientific Council, the Participating State that nominated the departing member may nominate up to two experts to replace that member. Scientific Council members are appointed for 4-year terms by the Governing

Council. The Scientific Council reviews the scientific activities of the Agency and makes recommendations on its programme of permanent activities and priorities. The Scientific Council meets every year in ordinary session in late January/early February.

BUDGET

IARC activities are partially funded by the regular budget contributions paid by its Participating States. In addition, substantial funding comes from extrabudgetary sources, mainly grant awards, both national and international. The regular budget for the 2022–2023 biennium was approved in May 2021 at a level of €45 371 329.

PARTICIPATING STATES AND REPRESENTATIVES AT IARC GOVERNING COUNCIL'S
SIXTY-SECOND SESSION, 11–12 MAY 2020 (HELD REMOTELY)

CANADA

Dr Stephen M. Robbins, Chairperson
Scientific Director, Institute of Cancer
Research
Canadian Institutes of Health Research
Calgary, Alberta

Ms Lucero Hernandez
Manager, Multilateral Relations Division
Office of International Affairs for the
Health Portfolio
Ottawa, Ontario

Ms Jennifer Izaguirre
Policy Analyst, Multilateral Relations
Division
Office of International Affairs for the
Health Portfolio
Ottawa, Ontario

SWEDEN

Dr Karin Schmekel, Vice-Chairperson
Deputy Director, Ministry of Education
and Research
Stockholm

Professor Jan-Ingvar Jönsson
Secretary General, Medicine and Health
Swedish Research Council
Stockholm

SWITZERLAND

Dr Diane Steber Büchli, Rapporteur
Senior Advisor, Federal Office of Public
Health
Division of International Affairs
Bern

AUSTRALIA

Professor Dorothy Keefe
Chief Executive Officer, Cancer
Australia
New South Wales

Ms Emma Wood
Assistant Secretary, International
Strategies Branch
Department of Health
Canberra

Ms Bronwyn Adams
Director, Cancer Services
Canberra

AUSTRIA

Ms Elisabeth Tischelmayer
Austrian Federal Ministry of Education,
Science and Research
Vienna

BELGIUM

Mr Lieven De Raedt
Conseiller Stratégiques, Relations
Internationales
SPF Santé publique, Sécurité de la
Chaîne Alimentaire et Environnement
Brussels

Dr Marc Van den Bulcke
Chef du Centre du Cancer
Brussels

BRAZIL

Dr Ana Cristina Pinho Mendes Pereira
Director-General, National Cancer
Institute (INCA)
Rio de Janeiro

Dr Livia De Oliveira Pasqualin
International Affairs Analyst, National
Cancer Institute (INCA)
Rio de Janeiro

Dr João Ricardo Rodrigues Viegas
International Affairs Analyst, National
Cancer Institute (INCA)
Rio de Janeiro

DENMARK

Professor Mads Melbye (unable to
attend)
Chief Executive Officer, Statens Serum
Institute
Copenhagen

Professor Tine Jess
Statens Serum Institute
Copenhagen

FINLAND

Dr Markku Tervahauta
Director General, National Institute for
Health and Welfare (THL)
Helsinki

Ms Tuula Helander
Senior Advisor, Personalized Medicine
Ministry of Social Affairs and Health
Permanent Secretary's Cabinet
Helsinki

FRANCE

Professor Norbert Ifrah
President, Institut national du Cancer
(INCa)
Boulogne-Billancourt

Dr Jocelyne Bérille
Chargée de mission, Direction générale
de la recherche et de l'innovation
Paris

Ms Christine Berling
Cheffe, Mission des affaires
européennes et internationales
Direction générale de la Santé (DGS/
MAEI)
Ministère des Solidarités et de la Santé
Paris

Mr Thomas Dubois
Responsable du Département des
Relations internationales
Institut national du Cancer (INCa)
Boulogne-Billancourt

GERMANY

Ms Elisabeth Schulte
Senior Adviser, Federal Ministry of
Health
Berlin

Mr Thomas Iffland
Senior Adviser, Federal Ministry of
Health
Bonn

HUNGARY

Professor Ildikó Horváth
Minister of State for Health of Hungary
Ministry of Human Capacities
Budapest

Professor Péter Nagy
Scientific Director, National Institute of
Oncology
Budapest



Dr Edit Marosi
Department Head, National Institute of
Oncology
Budapest

INDIA
Ms Vandana Gurnani
Additional Secretary and Mission
Director, National Health Mission
Ministry of Health and Family Welfare
New Delhi

Mr Nilambuj Sharan
Economic Adviser, Ministry of Health
and Family Welfare
New Delhi

Ms Vidushi Chaturvedi
Director, Ministry of Health and Family
Welfare
New Delhi

IRAN (ISLAMIC REPUBLIC OF)
Professor Reza Malekzadeh
Vice Minister for Research and
Technology
Acting Chairperson, National Cancer
Control Committee
Ministry of Health and Medical
Education
Tehran

IRELAND
Mr Ciarán Murphy
Department of Health
Dublin

ITALY
Professor Silvio Brusaferrero (unable to
attend)
Commissioner, Istituto Superiore di
Sanità
Rome

Dr Mauro Biffoni
Director, Department of Oncology and
Molecular Medicine
Istituto Superiore di Sanità
Rome

JAPAN
Dr Yosuke Kita
Senior Coordinator for Global Health
International Affairs Division, Minister's
Secretariat
Ministry of Health, Labour and Welfare
Tokyo

Dr Hitoshi Nakagama
President, National Cancer Center
Japan
Tokyo

Dr Teiji Takei
Executive Adviser to President, National
Cancer Center Japan
Tokyo

Dr Tatsuya Suzuki
Deputy Director, Strategic Planning
Bureau
National Cancer Center Japan
Tokyo

Dr Tomohiro Matsuda
Head, Office of International Affairs
National Cancer Center Japan
Tokyo

Ms Kay Ohara
Manager, Office of International Affairs
National Cancer Center Japan
Tokyo

MOROCCO
Dr Rachid Bekkali (unable to attend)
Directeur général, Fondation Lalla
Salma – Prévention et traitement des
cancers
Rabat

Dr Latifa Belakhel
Chef de la Division des Maladies Non
Transmissibles
Direction de l'Epidémiologie et de Lutte
contre les Maladies
Ministère de la Santé
Rabat

Dr Loubna Abousselham
Chef de Service de la Prévention et de
Contrôle du Cancer
Direction de l'Epidémiologie et de Lutte
contre les Maladies
Ministère de la Santé
Rabat

NETHERLANDS

Ms Renske van Tol
Coordinator, Early Detection and
Screening Unit, Public Health
Directorate
Ministry of Health, Welfare and Sport
The Hague

Mr Jeroen Hulleman
Senior Policy Advisor, Public Health
Directorate
Ministry of Health, Welfare and Sport
The Hague

NORWAY

Professor Pål Richard Romundstad
Norwegian University of Science and
Technology (NTNU)
Trondheim

Dr Karianne Solaas
Special Adviser, The Research Council
of Norway
Lysaker

QATAR

Dr Al-Hareth M. Al-Khater
Deputy Medical Director, National
Center for Cancer Care and Research
Chairperson, Corporate Healthcare
Ethics Committee
Hamad Medical Corporation
Doha

REPUBLIC OF KOREA

Dr Eun Sook Lee
President, National Cancer Center of
Korea
Goyang-si Gyeonggi-do

Dr Jae Kwan Jun
Head, Division of Cancer Prevention
and Early Detection
National Cancer Center of Korea
Goyang-si Gyeonggi-do

RUSSIAN FEDERATION

Dr Igor Korobko
Director, Department of Science and
Health Innovations Development
Ministry of Health
Moscow

Dr Sergey Muraviov
Director, Department of International
Cooperation and Public Affairs
Ministry of Health
Moscow

Dr Oleg Sonin
Deputy Director, Department of
International Cooperation and Public
Affairs
Ministry of Health
Moscow

Dr Eduard Salakhov
Health Attaché
Permanent Mission of the Russian
Federation to the United Nations in
Geneva
Geneva, Switzerland

SPAIN

Dr Gonzalo Arevalo
Instituto de Salud Carlos III
Madrid

Dr Maria José González de Suso
Instituto de Salud Carlos III
Madrid

TURKEY

No Representative

UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND

Dr Mark Palmer
Director of International Relations
Medical Research Council
London

Dr Mariana Delfino-Machin
Programme Manager for Cancer
Medical Research Council
Swindon

UNITED STATES OF AMERICA

Dr Mara Burr
Director, Multilateral Relations Office
Office of Global Affairs
Department of Health and Human
Services
Washington, DC

Dr Krycia Cowling
Global Health Officer, Multilateral
Relations Office
Office of Global Affairs
Department of Health and Human
Services
Washington, DC

Dr Robert Hawkins
Foreign Service Officer, Bureau of
International Organizations
Department of State
Washington, DC

Ms Gabrielle Lamourelle
Deputy Director, Multilateral Relations
Office
Office of Global Affairs
Department of Health and Human
Services
Washington, DC

Dr Jamie Miller
Deputy Director, Bureau of International
Organizations
Department of State
Washington, DC

Dr Amy Norris
Senior Health Advisor, Bureau of
International Organizations
Department of State
Washington, DC

Dr Margaret Paton
Multilateral Economic and Political
Affairs Advisor, Permanent Mission of
the United States to the United Nations
and other international organizations in
Geneva
Geneva, Switzerland

Dr Phillip Riblett
Legal Advisor, Permanent Mission of
the United States to the United Nations
and other international organizations in
Geneva
Geneva, Switzerland

Dr Larry Wright
Management and Reform Senior
Advisor, Bureau of International
Organizations
Department of State
Washington, DC

WORLD HEALTH ORGANIZATION

Dr Soumya Swaminathan
Executive Director/Chief Scientist
WHO headquarters
Geneva, Switzerland

Ms Sigrid Kranawetter
Principal Legal Officer
WHO headquarters
Geneva, Switzerland

OBSERVERS

SCIENTIFIC COUNCIL

Dr Christine Friedenreich
Chairperson

UNION FOR INTERNATIONAL CANCER CONTROL (UICC)

Dr Sonali Johnson
Head, Knowledge, Advocacy and Policy
Geneva, Switzerland

CHINA

Dr Yang Zhang
Director-General, Department of
International Cooperation
National Health Commission
Beijing

Dr Jie He
President, National Cancer Center of
China
Beijing

Dr Xinhua Li
Professor in Epidemiology, Deputy
Director-General
Chinese Center for Disease Control and
Prevention
Beijing

Dr Min Dai
Director, Department of International
Communications
National Cancer Center of China
Beijing

EXTERNAL AUDIT

Mr Lito Q. Martin (unable to attend)
Director, International Audit and
Relations Office
Commission on Audit
Quezon City, Philippines

PARTICIPATING STATES AND REPRESENTATIVES AT IARC GOVERNING COUNCIL'S
SIXTY-THIRD SESSION, 17–18 MAY 2021 (HELD REMOTELY)

CANADA

Dr Stephen M. Robbins, Chairperson
Scientific Director, Institute of Cancer
Research
Canadian Institutes of Health Research
Ottawa, Ontario

Ms Lucero Hernández
Manager, Multilateral Relations Division
Office of International Affairs for the
Health Portfolio
Ottawa, Ontario

Ms Johanna Krüger
Counsellor, Permanent Mission of
Canada to the United Nations
Geneva, Switzerland

Ms Jennifer Izaguirre
Policy Analyst, Multilateral Relations
Division
Office of International Affairs for the
Health Portfolio
Ottawa, Ontario

Mr William Wang
Policy Analyst, Multilateral Relations
Division
Office of International Affairs for the
Health Portfolio
Ottawa, Ontario

NORWAY

Professor Pål Richard Romundstad,
Vice-Chairperson
Norwegian University of Science and
Technology (NTNU)
Trondheim

Dr Karianne Solaas (unable to attend)
Special Adviser, The Research Council
of Norway
Lysaker

SWITZERLAND

Dr Diane Steber Büchli, Rapporteur
Senior Advisor, Federal Office of Public
Health
Division of International Affairs
Bern

AUSTRALIA

Professor Dorothy Keefe
Chief Executive Office, Cancer Australia
New South Wales

Dr David Meredyth
Director, Australian Government
Department of Health
Canberra

Mr Agastya Bharadwaj
Acting Director, Australian Government
Department of Health
Canberra

Ms Christine Sturrock
Counsellor, Health and Environment
Australia Permanent Mission to the
United Nations
Geneva, Switzerland

Mr Jeff Roach
Deputy Permanent Representative to
the United Nations
Australia Permanent Mission to the
United Nations
Geneva, Switzerland

AUSTRIA

Ms Elisabeth Tischelmayer
Austrian Federal Ministry of Education,
Science and Research
Vienna

BELGIUM

Mr Lieven De Raedt
Conseiller Stratégiques, Relations
Internationales
SPF Santé publique, Sécurité de la
Chaîne Alimentaire et Environnement
Brussels

Dr Marc Van den Bulcke
Chef du Centre du Cancer
Brussels

BRAZIL

Dr Ana Cristina Pinho Mendes Pereira
Director-General, National Cancer
Institute (INCA)
Rio de Janeiro

Dr Livia De Oliveira Pasqualin
International Affairs Analyst, National
Cancer Institute (INCA)
Rio de Janeiro

Dr João Ricardo Rodrigues Viegas
International Affairs Analyst, National
Cancer Institute (INCA)
Rio de Janeiro

Mr Igor Barbosa
Mission permanente du Brésil auprès
des Nations unies à Genève
Geneva, Switzerland

CHINA

Professor Jie He
President, National Cancer Center of
China
Beijing

Dr Min Dai
Director, Department of International
Communications
National Cancer Center of China
Beijing

Dr Ze Cong
Second Secretary, Permanent Mission
of China to the United Nations
Geneva, Switzerland

Dr Wei Wang
Division Director, Bureau of Disease
Prevention and Control
National Health Commission
Beijing

Dr Xiaochen Yang
Deputy Division Director, Division of
International Organizations
Department of International
Cooperation, National Health
Commission
Beijing

DENMARK

Professor Anders Hviid
Statens Serum Institute
Copenhagen

FINLAND

Dr Markku Tervahauta
Director General, National Institute for
Health and Welfare (THL)
Helsinki

Ms Tuula Helander
Director, Department for Safety, Security
and Health
Ministry of Social Affairs and Health
Helsinki



Dr Eero Lahtinen
Minister Counsellor
Geneva, Switzerland

FRANCE

Professor Norbert Ifrac
President, Institut national du Cancer (INCa)
Boulogne-Billancourt

Mr Thomas Dubois
Responsable du Département des Relations internationales
Institut national du Cancer (INCa)
Boulogne-Billancourt

Dr Jocelyne Bérille
Chargée de mission
Ministère de l'Enseignement supérieur, de la Recherche et de l'Innovation
Direction générale de la recherche et de l'innovation
Paris

Mr Jérémie Petit
Ministère de l'Europe et des affaires étrangères
Chef de pôle « Affaires économiques et enjeux globaux »
Direction des Nations unies, des organisations internationales, des droits de l'Homme et de la francophonie
Sous-direction des affaires économiques et budgétaires (NUOI/EB)
Paris

Mr Bernard Derebergue
Ministère de l'Europe et des affaires étrangères
Conseiller politique, Santé
Représentation permanente de la France auprès des Nations unies à Genève et des organisations internationales en Suisse
Geneva, Switzerland

Mr Serge Tomasi
Ambassadeur, Conseiller diplomatique
Préfet de la région Auvergne-Rhône-Alpes, préfet de la zone de défense et de sécurité sud-est
Préfet du Rhône
Lyon

Mr François Rivasseau
Ambassadeur, Représentant Permanent
Ministère de l'Europe et des affaires étrangères
Représentation permanente de la France auprès des Nations unies à Genève et des organisations internationales en Suisse
Geneva, Switzerland

Ms Christine Berling
Cheffe, Mission des affaires européennes et internationales
Direction générale de la Santé (DGS/MAEI)
Ministère des Solidarités et de la Santé
Paris

GERMANY

Ms Elisabeth Schulte
Senior Adviser, Federal Ministry of Health
Berlin

Mr Thomas Ifland
Senior Adviser, Federal Ministry of Health
Bonn

Dr Chris Braun
Federal Ministry of Health
Berlin

HUNGARY

Professor Ildikó Horváth
Secretary of State for Health
Ministry of Human Capacities
Budapest

Dr Péter Nagy
Scientific Director, National Institute of Oncology
Budapest

INDIA

Mr Vishal Chauhan
Joint Secretary (Noncommunicable Diseases), Ministry of Health and Family Welfare
New Delhi

Dr Pradeep Khasnobis
Chief Medical Officer
(Noncommunicable Diseases), Ministry
of Health and Family Welfare
New Delhi

Dr Rupinder Singh Dhaliwal
Scientist, Indian Council of Medical
Research
New Delhi

Mr Vimarsh Aryan
First Secretary, Permanent Mission of
India to the United Nations in Geneva
Geneva, Switzerland

IRAN (ISLAMIC REPUBLIC OF)

Professor Reza Malekzadeh (unable to
attend)
Digestive Diseases Research Institute
Tehran University of Medical Sciences
Tehran

IRELAND

Mr Ciarán Murphy (unable to attend)
Department of Health
Dublin

ITALY

Professor Silvio Brusaferrò
President, Istituto Superiore di Sanità
Rome

Dr Mauro Biffoni
Director, Department of Oncology and
Molecular Medicine
Istituto Superiore di Sanità
Rome

JAPAN

Dr Kazunori Umeki
Senior Coordinator for Global Health,
International Affairs Division, Minister's
Secretariat
Ministry of Health, Labour and Welfare
Tokyo

Dr Hisayo Horiuchi
Deputy Director, International Affairs
Division, Minister's Secretariat
Ministry of Health, Labour and Welfare
Tokyo

Dr Hitoshi Nakagama
President, National Cancer Center
Japan
Tokyo

Dr Masahiro Kaminota
Executive Advisor to President, National
Cancer Center Japan
Tokyo

Dr Tatsuya Suzuki
Deputy Director, Strategic Planning
Bureau
National Cancer Center Japan
Tokyo

Dr Tomohiro Matsuda
Head, Office of International Affairs
National Cancer Center Japan
Tokyo

Ms Kay Ohara
Manager, Office of International Affairs
National Cancer Center Japan
Tokyo

Dr Yukio Saita
Minister, Permanent Mission of Japan
to the International Organizations in
Geneva
Geneva, Switzerland

Dr Takato Koizumi
First Secretary, Permanent Mission of
Japan to the International Organizations
in Geneva
Geneva, Switzerland

Dr Kenji Fujita
Researcher, Global Health Policy
Division
International Cooperation Bureau,
Ministry of Foreign Affairs
Tokyo

MOROCCO

Dr Latifa Belakhel
Chef de la Division des Maladies Non
Transmissibles
Direction de l'Epidémiologie et de Lutte
contre les Maladies
Ministère de la Santé
Rabat

Dr Loubna Abousselham
Chef de Service de la Prévention et de
Contrôle du Cancer
Direction de l'Epidémiologie et de Lutte
contre les Maladies
Ministère de la Santé
Rabat

NETHERLANDS

Ms Florien van der Windt
Member MT Directorate Public Health
Ministry of Health, Welfare and Sport
The Hague

Mr Jeroen Hulleman
Senior Policy Advisor, Public Health
Directorate
Ministry of Health, Welfare and Sport
The Hague

QATAR

Dr Al-Hareth M. Al-Khater
Deputy Medical Director, National
Center for Cancer Care and Research
Chairperson, Corporate Healthcare
Ethics Committee
Hamad Medical Corporation
Doha

Ms Maha Ahmad Al-Ansari
International Relations Coordinator,
International Health Relations
Department
Ministry of Public Health
Doha

REPUBLIC OF KOREA

Dr Sangkyun Han
Director, Division of Disease Control
Policy
Bureau of Public Health Policy, Office
for Healthcare Policy
Ministry of Health and Welfare
Sejong-si

Dr Jinhyuk Yang
Senior Deputy Director, Division of
Disease Control Policy
Bureau of Public Health Policy, Office
for Healthcare Policy
Ministry of Health and Welfare
Sejong-si

Dr Chongwoo Yoo
Director, Office of Public Relations and
Collaboration
National Cancer Center of Korea
Goyang-si Gyeonggi-do

Dr Jae Kwan Jun
Head, Cancer Knowledge and
Information Center
National Cancer Control Institute,
National Cancer Center of Korea
Goyang-si Gyeonggi-do

RUSSIAN FEDERATION

Dr Igor Korobko
Director, Department of Science and Health Innovations Development
Ministry of Health
Moscow

Dr Sergey Muraviov
Director, Department of International Cooperation and Public Affairs
Ministry of Health
Moscow

Dr Oleg Sonin
Deputy Director, Department of International Cooperation and Public Affairs
Ministry of Health
Moscow

Dr Eduard Salakhov
Health Attaché
Permanent Mission of the Russian Federation to the United Nations in Geneva
Geneva, Switzerland

SPAIN

Dr Gonzalo Arevalo Nieto
Vice-Director, International Research Programmes and Institutional Relations
Instituto de Salud Carlos III
Madrid

Dr Maria José González de Suso
(unable to attend)
Programmes Director, Instituto de Salud Carlos III
Madrid

SWEDEN

Professor Madeleine Durbeej-Hjalt
Secretary-General, Medicine and Health Swedish Research Council
Stockholm

Dr Karin Schmekel
Head, Office for Research and Postgraduate Education
Karolinska Institutet
Stockholm

UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND

Dr Mark Palmer
Director of International Relations
Medical Research Council
London

Dr Mariana Delfino-Machin
Programme Manager for Cancer Medical Research Council
Swindon

Ms Esther Lawrence
Deputy Head of Health Team,
Permanent Mission of the United Kingdom to the United Nations and other international organizations in Geneva
Geneva, Switzerland

UNITED STATES OF AMERICA

Dr Mara Burr
Director, Multilateral Relations Office
Office of Global Affairs
Department of Health and Human Services
Washington, DC

Ms Amy Norris
Senior Health Advisor, Bureau of International Organizations
Department of State
Washington, DC

Ms Tracy Carson
Health Attaché, Permanent Mission of the United States to the United Nations and other international organizations in Geneva
Geneva, Switzerland

Dr Ann Chao
National Cancer Institute, National Institutes of Health
Bethesda, Maryland

Ms Carrie Denver
Peace and Security Unit Chief,
Permanent Mission of the United States to the United Nations and other international organizations in Geneva
Geneva, Switzerland

Dr Satish Gopal
Director, Center for Global Health
National Cancer Institute, National Institutes of Health
Bethesda, Maryland

Ms Brittany Hayes
Global Health Officer, Multilateral Relations Office
Office of Global Affairs
Department of Health and Human Services
Washington, DC

Ms Gabrielle Lamourelle
Deputy Director, Multilateral Relations Office
Office of Global Affairs
Department of Health and Human Services
Washington, DC

Mr Gilbert Morton
Senior Advisor, Office of Management, Policy, and Resources
Bureau of International Organization Affairs, Department of State
Washington, DC

Ms Kristen Pisani
Director, Office of Economic and Development Affairs
Bureau of International Organization Affairs, Department of State
Washington, DC

Mr Howard Solomon
Minister Counsellor, Permanent Mission of the United States to the United Nations and other international organizations in Geneva
Geneva, Switzerland

Mr Phillip Riblett
Deputy Legal Advisor, Office of Legal Affairs
Permanent Mission of the United States to the United Nations and other international organizations in Geneva
Geneva, Switzerland

Ms Marie Ricciardone
Program Officer, Center for Global Health
National Cancer Institute, National Institutes of Health
Bethesda, Maryland

Mr James P. Shuster
Management and Reform Advisor,
Office of Management, Policy and Resources
Bureau of International Organizations
Washington, DC

Ms Ann Blackwood
Senior Health Advisor, Cherokee
National
Arlington, Virginia

WORLD HEALTH ORGANIZATION

Dr Agnès Buzyn
Director-General's Envoy for Multilateral
Affairs
WHO headquarters
Geneva, Switzerland

Ms Sigrid Kranawetter
Principal Legal Officer
WHO headquarters
Geneva, Switzerland

Dr Bente Mikkelsen
Director, Noncommunicable Diseases
WHO headquarters
Geneva, Switzerland

OBSERVERS

SCIENTIFIC COUNCIL

Dr Janne Pitkaniemi
Incoming chairperson

Dr Christine Friedenreich
Outgoing chairperson

IARC ETHICS COMMITTEE

Dr Samar Al-Homoud
Chairperson

UNION FOR INTERNATIONAL CANCER CONTROL (UICC)

Dr Sonali Johnson
Head, Knowledge, Advocacy and Policy
Geneva, Switzerland

EXTERNAL AUDIT

Mr Krishnaraju Subramaniam
Director of External Audit (WHO)
Office of the Comptroller and Auditor
General of India
Geneva, Switzerland

SCIENTIFIC COUNCIL MEMBERS (2020)

Dr Christine Friedenreich, Chairperson
Scientific Director for Cancer
Epidemiology and Prevention Research,
Alberta Health Services
Associate Scientific Director, O'Brien
Institute of Public Health
University of Calgary
Calgary, Canada

Dr João P.B. Viola, Vice-Chairperson
Head, Division of Experimental and
Translational Research
National Cancer Institute (INCA)
Rio de Janeiro, Brazil

Dr Karima Bendahhou
Cancer Registry of Casablanca
Centre Mohammed VI pour le traitement
des cancers
Casablanca, Morocco

Professor Tone Bjørge
Head, Epidemiology and Medical
Statistics Section
Department of Global Public Health and
Primary Care
University of Bergen and Cancer
Registry of Norway
Bergen, Norway

Dr Hendriek Boshuizen
Department of Statistics, Informatics
and Mathematical Modelling
National Institute for Public Health and
the Environment (RIVM)
Bilthoven, The Netherlands

Dr Salha M. Bujassoum Al Bader
Director, Medical Oncology, Clinical
Hematology and Hospice Palliative
Medicine Fellowship Program
Hamad Medical Corporation
Doha, Qatar

Dr James Robert Cerhan
(unable to attend)
Chairperson, Department of Health
Sciences Research
Mayo Clinic
Rochester, Minnesota, USA

Dr Jacqueline Clavel
Director of Research
INSERM U1153/EQUIPE 7/EPICEA
Villejuif, France

Professor Gunilla Enblad
Department of Immunology, Genetics
and Pathology
Uppsala University
Uppsala, Sweden

Professor William Gallagher
Director, University College Dublin
Conway Institute
Deputy Director, Precision Oncology
Ireland
Dublin, Ireland

Professor Adèle Green
Senior Scientist
QIMR Berghofer Medical Research
Institute
Brisbane, Australia

Professor Ulrike Haug
Leibniz Institute for Prevention Research
and Epidemiology (BIPS)
Bremen, Germany

Professor Sergey Ivanov
Director, Medical Radiological Research
Centre
National Medical Research Radiological
Centre
Obninsk, Russian Federation



Professor Ravi Mehrotra
Director, National Institute of Cancer
Prevention and Research
Indian Council of Medical Research
Uttar Pradesh, India

Professor Péter Nagy (unable to attend)
Scientific Director, National Institute of
Oncology
Budapest, Hungary

Professor Atsushi Ochiai
Director, Exploratory Oncology
Research and Clinical Trial Center
National Cancer Center Japan
Tokyo, Japan

Professor Jong Bae Park
Dean, National Cancer Center Graduate
School of Cancer Science and Policy
Goyang-si Gyeonggi-do, Republic of
Korea

Dr Pietro Pichierri (unable to attend)
Senior Researcher, Genome Stability
Group
Mechanisms, Biomarkers and Models
Unit
Department of Environment and Health
Istituto Superiore di Sanità
Rome, Italy

Dr Janne Mikael Pitkäniemi
Director of Statistics, Finnish Cancer
Registry
Institute for Statistical and
Epidemiological Cancer Research
Helsinki, Finland

Dr Sabine Rohrmann
Epidemiology, Biostatistics and
Prevention Institute (EBPI)
University of Zurich
Zurich, Switzerland

Dr Roberto Salgado
Breast Cancer Translational Research
Laboratory
Jules Bordet Institute
Brussels, Belgium

Dr Pilar Sánchez Gómez
Head, Neuro-oncology Unit
Chronic Disease Program
Instituto de Salud Carlos III
Madrid, Spain

Professor Maria Sibilía
Institute of Cancer Research
Department of Medicine I
Medical University of Vienna,
Comprehensive Cancer Center
Vienna, Austria

Professor Simon Tavaré
Director, Irving Institute for Cancer
Dynamics
Columbia University
New York, NY, USA

Dr Anne Tjønneland
Danish Cancer Society Research
Center
Copenhagen, Denmark

Dr Kazem Zendehelel
Deputy of Research, Cancer Research
Center
Cancer Institute of Iran
Tehran University of Medical Sciences
Tehran, Islamic Republic of Iran

SCIENTIFIC COUNCIL MEMBERS (2021)

Dr Christine Friedenreich, Chairperson
Scientific Director for Cancer
Epidemiology and Prevention Research,
Alberta Health Services
University of Calgary
Calgary, Canada

Dr Janne Mikael Pitkaniemi,
Vice-Chairperson
Finnish Cancer Registry
Institute for Statistical and
Epidemiological Cancer Research
Helsinki, Finland

Professor William Gallagher, Rapporteur
University College Dublin School of
Biomolecular and Biomedical Science
University College Dublin Conway
Institute
Dublin, Ireland

Dr Marc Arbyn
Coordinator, Cancer Epidemiology Unit
Belgian Cancer Centre
Brussels, Belgium

Dr Karima Bendahhou
Cancer Registry of Casablanca
Centre Mohammed VI pour le traitement
des cancers
Casablanca, Morocco

Professor Tone Bjørge
Head, Epidemiology and Medical
Statistics Section
Department of Global Public Health and
Primary Care
University of Bergen and Cancer
Registry of Norway
Bergen, Norway

Dr Hendriek Boshuizen
Department of Statistics, Informatics
and Mathematical Modelling
National Institute for Public Health and
the Environment (RIVM)
Bilthoven, The Netherlands

Dr Salha M. Bujassoum Al Bader
Director, Medical Oncology, Clinical
Hematology and Hospice Palliative
Medicine Fellowship Program
Hamad Medical Corporation
Doha, Qatar

Dr Ferrán Catalá-López
Department of Health Planning and
Economics
Instituto de Salud Carlos III
Madrid, Spain


Dr James Robert Cerhan
Chairperson, Department of Health
Sciences Research
Mayo Clinic
Rochester, Minnesota, USA

Professor Kalipso Chalkidou (unable to
attend)
Director, Department of Health Finance
The Global Fund
Geneva, Switzerland

Dr Jacqueline Clavel (unable to attend)
Director of Research
INSERM U1153/EQUIPE 7/EPICEA
Villejuif, France

Professor Gunilla Enblad
Department of Immunology, Genetics
and Pathology
Uppsala University
Uppsala, Sweden

Professor Louisa Gordon
QIMR Berghofer Medical Research
Institute
Royal Brisbane Hospital
Brisbane, Australia



Professor Ulrike Haug
Leibniz Institute for Prevention Research
and Epidemiology (BIPS)
Bremen, Germany

Dr Manami Inoue
Chief, Division of Prevention
Center for Public Health Sciences
National Cancer Center Japan
Tokyo, Japan

Professor Sergey Ivanov
Director, Medical Radiological Research
Centre
National Medical Research Radiological
Centre
Obninsk, Russian Federation

Professor Ravi Mehrotra
Director, National Institute of Cancer
Prevention and Research
Indian Council of Medical Research
Uttar Pradesh, India

Professor Péter Nagy (unable to attend)
Scientific Director, National Institute of
Oncology
Budapest, Hungary

Professor Jong Bae Park
National Cancer Center Graduate
School of Cancer Science and Policy
Goyang-si Gyeonggi-do, Republic of
Korea

Dr Pietro Pichierri
Senior Researcher, Genome Stability
Group
Mechanisms, Biomarkers and Models
Unit
Department of Environment and Health
Istituto Superiore di Sanità
Rome, Italy

Dr Sabine Rohrmann
Epidemiology, Biostatistics and
Prevention Institute (EBPI)
University of Zurich
Zurich, Switzerland

Professor Maria Sibilía
Institute of Cancer Research
Department of Medicine I
Medical University of Vienna,
Comprehensive Cancer Center
Vienna, Austria

Dr Anne Tjønneland
Danish Cancer Society Research
Center
Copenhagen, Denmark

Dr João P.B. Viola
Head, Division of Experimental and
Translational Research
National Cancer Institute (INCA)
Rio de Janeiro, Brazil

Professor Kazem Zendehelel
Director, Cancer Biology Research
Center
Cancer Institute of Iran
Tehran University of Medical Sciences
Tehran, Islamic Republic of Iran

IARC STAFF PUBLICATIONS 2020–2021

AS AT 14 DECEMBER 2021

- Abedi-Ardekani B, Nasrollahzadeh D, Egevad L, Banks RE, Vasudev N, Holcatova I, et al. (2021). Morphological findings in frozen non-neoplastic kidney tissues of patients with kidney cancer from large-scale multicentric studies on renal cancer. *Virchows Arch.* 478(6):1099–107. <https://doi.org/10.1007/s00428-020-02986-3> PMID:33403511
- Abrahão R, Perdomo S, Pinto LFR, Nascimento de Carvalho F, Dias FL, de Podestá JRV, et al.; InterCHANGE Group (2020). Predictors of survival after head and neck squamous cell carcinoma in South America: the InterCHANGE Study. *JCO Glob Oncol.* 6(6):486–99. <https://doi.org/10.1200/GO.20.00014> PMID:32213095
- Affi NM, Anisimov SV, Aguilar-Quesada R, Kinkorova J, Marrs S, Nassimbwa S, et al. (2020). Biobanking spotlight on Europe, Middle East, and Africa: presenting the collective experience of the ISBER-EMEA regional ambassadors. *Biopreserv Biobank.* 18(5):471–8. <https://doi.org/10.1089/bio.2020.0013> PMID:32780585
- Aglago EK, Huybrechts I, Murphy N, Casagrande C, Nicolas G, Pischon T, et al. (2020). Consumption of fish and long-chain n-3 polyunsaturated fatty acids is associated with reduced risk of colorectal cancer in a large European cohort. *Clin Gastroenterol Hepatol.* 18(3):654–666. e6. <https://doi.org/10.1016/j.cgh.2019.06.031> PMID:31252190
- Aglago EK, Mayén AL, Knaze V, Freisling H, Fedirko V, Hughes DJ, et al. (2021). Dietary advanced glycation end-products and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. *Nutrients.* 13(9):3132. <https://doi.org/10.3390/nu13093132> PMID:34579010
- Aglago EK, Rinaldi S, Freisling H, Jiao L, Hughes DJ, Fedirko V, et al. (2021). Soluble receptor for advanced glycation end-products (sRAGE) and colorectal cancer risk: a case-control study nested within a European prospective cohort. *Cancer Epidemiol Biomarkers Prev.* 30(1):182–92. <https://doi.org/10.1158/1055-9965.EPI-20-0855> PMID:33082206
- Aglago EK, Schalkwijk CG, Freisling H, Fedirko V, Hughes DJ, Jiao L, et al. (2021). Plasma concentrations of advanced glycation end-products and colorectal cancer risk in the EPIC study. *Carcinogenesis.* 42(5):705–13. <https://doi.org/10.1093/carcin/bgab026> PMID:33780524
- Aisyah DN, Ahmad RA, Artama WT, Adisasmito W, Diva H, Hayward AC, et al. (2020). Knowledge, attitudes, and behaviors on utilizing mobile health technology for TB in Indonesia: a qualitative pilot study. *Front Public Health.* 8:531514. <https://doi.org/10.3389/fpubh.2020.531514> PMID:33123508
- Aisyah DN, Mayadewi CA, Diva H, Kozlakidis Z, Siswanto, Adisasmito W (2020). A spatial-temporal description of the SARS-CoV-2 infections in Indonesia during the first six months of outbreak. *PLoS One.* 15(12):e0243703. <https://doi.org/10.1371/journal.pone.0243703> PMID:33351801
- Aisyah DN, Mayadewi CAA, Igusti G, Manikam L, Adisasmito W, Kozlakidis Z (2021). Laboratory readiness and response for SARS-Cov-2 in Indonesia. *Front Public Health.* 9:705031. <https://doi.org/10.3389/fpubh.2021.705031> PMID:34350153
- Al Knawy B, Kozlakidis Z (2021). 'Quaranta giorni' leadership test: time to transform healthcare. *BMJ Leader.* 5(1):48–50.
- Albani V, Vale LD, Pearce M, Ostroumova E, Liutsko L; SHAMISEN Consortium (2021). Aspects of economic costs and evaluation of health surveillance systems after a radiation accident with a focus on an ultrasound thyroid screening programme for children. *Environ Int.* 156:106571. <https://doi.org/10.1016/j.envint.2021.106571> PMID:33975128
- Alberts CJ, Heard I, Canestri A, Marchand L, Fléjou JF, Piroth L, et al.; ANRS EP57 APACHES Study group (2020a). Incidence and clearance of anal human papillomavirus (HPV)-16 and HPV-18 infection, and their determinants, among human immunodeficiency virus-infected men who have sex with men in France. *J Infect Dis.* 221(9):1488–93. <https://doi.org/10.1093/infdis/jiz623> PMID:31754686
- Alberts CJ, Jeske R, de Martel C, den Hollander WJ, Michel A, Prins M, et al. (2020). *Helicobacter pylori* seroprevalence in six different ethnic groups living in Amsterdam: the HELIUS study. *Helicobacter.* 25(3):e12687. <https://doi.org/10.1111/hel.12687> PMID:32147867
- Albuquerque A, Baptista PV, Clifford GM (2021). For anal cancer, not all women are equal. *Am J Gastroenterol.* 116(10):2140. <https://doi.org/10.14309/ajg.0000000000001298> PMID:34618701
- Albuquerque A, Stirrup O, Nathan M, Clifford GM (2020). Burden of anal squamous cell carcinoma, squamous intraepithelial lesions and HPV16 infection in solid organ transplant recipients: a systematic review and meta-analysis. *Am J Transplant.* 20(12):3520–8. <https://doi.org/10.1111/ajt.15942> PMID:32343489

- Aleksandrova K, Reichmann R, Kaaks R, Jenab M, Bueno-de-Mesquita HB, Dahm CC, et al. (2021). Development and validation of a lifestyle-based model for colorectal cancer risk prediction: the LiFeCRC score. *BMC Med.* 19(1):1. <https://doi.org/10.1186/s12916-020-01826-0> PMID:33390155
- Alfano R, Chadeau-Hyam M, Ghantous A, Keski-Rahkonen P, Chatzi L, Perez AE, et al. (2020). A multi-omic analysis of birthweight in newborn cord blood reveals new underlying mechanisms related to cholesterol metabolism. *Metabolism.* 110:154292. <https://doi.org/10.1016/j.metabol.2020.154292> PMID:32553738
- Allocca CM, Bledsoe MJ, Albert M, Anisimov SV, Bravo E, Castelhanos MG, et al. (2020a). Biobanking in the COVID-19 era and beyond: Part 1. How early experiences can translate into actionable wisdom. *Biopreserv Biobank.* 18(6):533–46. <https://doi.org/10.1089/bio.2020.0082> PMID:33164554
- Allocca CM, Snapes E, Albert M, Bledsoe MJ, Castelhanos MG, De Wilde M, et al. (2020b). Biobanking in the COVID-19 era and beyond: Part 2. A set of tool implementation case studies. *Biopreserv Biobank.* 18(6):547–60. <https://doi.org/10.1089/bio.2020.0083> PMID:33226280
- Almanza-Aguilera E, Ceballos-Sánchez D, Achaintre D, Rothwell JA, Laouali N, Severi G, et al. (2021). Urinary concentrations of (+)-catechin and (-)-epicatechin as biomarkers of dietary intake of flavan-3-ols in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. *Nutrients.* 13(11):4157. <https://doi.org/10.3390/nu13114157> PMID:34836412
- Almonte M, Murillo R, Sánchez GI, González P, Ferrera A, Picconi MA, et al. (2020). Multicentric study of cervical cancer screening with human papillomavirus testing and assessment of triage methods in Latin America: the ESTAMPA screening study protocol. *BMJ Open.* 10(5):e035796. <https://doi.org/10.1136/bmjopen-2019-035796> PMID:32448795
- Altamura G, Tommasino M, Borzacchiello G (2020). Cutaneous vs. mucosal tropism: the papillomavirus paradigm comes to an “end”. *Front Microbiol.* 11:588663. <https://doi.org/10.3389/fmicb.2020.588663> PMID:33162966
- Amadou A, Freisling H, Jenab M, Tsilidis KK, Trichopoulou A, Boffetta P, et al. (2021). Prevalent diabetes and risk of total, colorectal, prostate and breast cancers in an ageing population: meta-analysis of individual participant data from cohorts of the CHANCES consortium. *Br J Cancer.* 124(11):1882–90. <https://doi.org/10.1038/s41416-021-01347-4> PMID:33772152
- Amadou A, Praud D, Coudon T, Danjou AMN, Faure E, Leffondré K, et al. (2020). Chronic long-term exposure to cadmium air pollution and breast cancer risk in the French E3N cohort. *Int J Cancer.* 146(2):341–51. <https://doi.org/10.1002/ijc.32257> PMID:30851122
- Amorrortu RP, Fenske NA, Cherpelis BS, Vijayan L, Zhao Y, Balliu J, et al. (2020). Viruses in Skin Cancer (VIRUSCAN): study design and baseline characteristics of a prospective clinic-based cohort study. *Cancer Epidemiol Biomarkers Prev.* 29(1):39–48. <https://doi.org/10.1158/1055-9965.EPI-19-0446> PMID:31427307
- Amorrortu RP, Zhao Y, Messina JL, Schell MJ, Fenske NA, Cherpelis BS, et al. (2021). Association between human polyomaviruses and keratinocyte carcinomas: a prospective cohort study. *Cancer Epidemiol Biomarkers Prev.* 30(9):1761–4. <https://doi.org/10.1158/1055-9965.EPI-21-0332> PMID:34187857
- Amosa-Lei Sam F, Akinremi A, Mery L, Sarfati D, Stanley J, Gurney J (2021). Cancer incidence in Samoa: a 10-year retrospective survey (2007–2016). *Asia Pac J Public Health.* 33(6–7):700–6. <https://doi.org/10.1177/1010539520975261> PMID:33233921
- Anderson BO, Ilbawi AM, Fidarova E, Weiderpass E, Stevens L, Abdel-Wahab M, et al. (2021). The Global Breast Cancer Initiative: a strategic collaboration to strengthen health care for non-communicable diseases. *Lancet Oncol.* 22(5):578–81. [https://doi.org/10.1016/S1470-2045\(21\)00071-1](https://doi.org/10.1016/S1470-2045(21)00071-1) PMID:33691141
- Andersson TM, Myklebust TÅ, Rutherford MJ, Møller B, Soerjomataram I, Arnold M, et al. (2021). The impact of excluding or including Death Certificate Initiated (DCI) cases on estimated cancer survival: a simulation study. *Cancer Epidemiol.* 71(Pt A):101881. <https://doi.org/10.1016/j.canep.2020.101881> PMID:33440295
- Andersson TM, Rutherford MJ, Myklebust TÅ, Møller B, Soerjomataram I, Arnold M, et al. (2021a). Exploring the impact of cancer registry completeness on international cancer survival differences: a simulation study. *Br J Cancer.* 124(5):1026–32. <https://doi.org/10.1038/s41416-020-01196-7> PMID:33293692
- Angel CZ, Iguacel I, Mullee A, Guha N, Wasson R, McKenna DJ, et al. (2020). Appetite-regulating hormones-leptin, adiponectin and ghrelin-and the development of prostate cancer: a systematic review and exploratory meta-analysis. *Prostate Cancer Prostatic Dis.* 23(1):11–23. <https://doi.org/10.1038/s41391-019-0154-1> PMID:31147627
- Aparecida Silveira E, Vaseghi G, de Carvalho Santos AS, Kliemann N, Masoudkabar F, Noll M, et al. (2020). Visceral obesity and its shared role in cancer and cardiovascular disease: a scoping review of the pathophysiology and pharmacological treatments. *Int J Mol Sci.* 21(23):9042. <https://doi.org/10.3390/ijms21239042> PMID:33261185
- Araghi M, Arnold M, Rutherford MJ, Guren MG, Cabasag CJ, Bardot A, et al. (2021a). Colon and rectal cancer survival in seven high-income countries 2010–2014: variation by age and stage at diagnosis (the ICBP SURVMARK-2 project). *Gut.* 70(1):114–26. <https://doi.org/10.1136/gutjnl-2020-320625> PMID:32482683
- Araghi M, Roshandel G, Hasanpour-Heidari S, Fazel A, Sedaghat SM, Pourkhani A, et al. (2020). Incidence of malignant brain and central nervous system tumors in Golestan, Iran, 2004–2013. *Arch Iran Med.* 23(1):1–6. PMID:31910628
- Arbyn M, Bruni L, Kelly D, Basu P, Poljak M, Gultekin M, et al. (2020). Tackling cervical cancer in Europe amidst the COVID-19 pandemic. *Lancet Public Health.* 5(8):e425. [https://doi.org/10.1016/S2468-2667\(20\)30122-5](https://doi.org/10.1016/S2468-2667(20)30122-5) PMID:32673570
- Arbyn M, Gultekin M, Morice P, Nieminen P, Cruickshank M, Poortmans P, et al. (2021). The European response to the WHO call to eliminate cervical cancer as a public health problem. *Int J Cancer.* 148(2):277–84. <https://doi.org/10.1002/ijc.33189> PMID:32638362
- Arbyn M, Simon M, Peeters E, Xu L, Meijer CJLM, Berkhof J, et al. (2021). 2020 list of human papillomavirus assays suitable for primary cervical cancer screening. *Clin Microbiol Infect.* 27(8):1083–95. <https://doi.org/10.1016/j.cmi.2021.04.031> PMID:33975008

- Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. (2020a). Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. *Lancet Glob Health*. 8(2):e191–203. [https://doi.org/10.1016/S2214-109X\(19\)30482-6](https://doi.org/10.1016/S2214-109X(19)30482-6) PMID:31812369
- Archambault AN, Lin Y, Jeon J, Harrison TA, Bishop DT, Brenner H, et al. (2021). Nongenetic determinants of risk for early-onset colorectal cancer. *JNCI Cancer Spectr*. 5(3):b029. <https://doi.org/10.1093/jncics/pkab029> PMID:34041438
- Archambault AN, Su YR, Jeon J, Thomas M, Lin Y, Conti DV, et al. (2020). Cumulative burden of colorectal cancer-associated genetic variants is more strongly associated with early-onset vs late-onset cancer. *Gastroenterology*. 158(5):1274–1286.e12. <https://doi.org/10.1053/j.gastro.2019.12.012> PMID:31866242
- Aredo JV, Luo SJ, Gardner RM, Sanyal N, Choi E, Hickey TP, et al. (2021). Tobacco smoking and risk of second primary lung cancer. *J Thorac Oncol*. 16(6):968–79. <https://doi.org/10.1016/j.jtho.2021.02.024> PMID:33722709
- Armaroli P, Riggi E, Basu P, Anttila A, Ponti A, Carvalho AL, et al. (2020). Performance indicators in breast cancer screening in the European Union: a comparison across countries of screen positivity and detection rates. *Int J Cancer*. 147(7):1855–63. <https://doi.org/10.1002/ijc.32968> PMID:32159224
- Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA, et al. (2020a). Global burden of 5 major types of gastrointestinal cancer. *Gastroenterology*. 159(1):335–349.e15. <https://doi.org/10.1053/j.gastro.2020.02.068> PMID:32247694
- Arnold M, Ferlay J, van Berge Henegouwen MI, Soerjomataram I (2020b). Global burden of oesophageal and gastric cancer by histology and subsite in 2018. *Gut*. 69(9):1564–71. <https://doi.org/10.1136/gutjnl-2020-321600> PMID:32606208
- Arnold M, Park JY, Camargo MC, Lunet N, Forman D, Soerjomataram I (2020). Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035. *Gut*. 69(5):823–9. <https://doi.org/10.1136/gutjnl-2019-320234> PMID:32001553
- Arouca AB, Meirhaeghe A, Dallongeville J, Moreno LA, Lourenço GJ, Marcos A, et al.; HELENA Study Group (2020). Interplay between the Mediterranean diet and C-reactive protein genetic polymorphisms towards inflammation in adolescents. *Clin Nutr*. 39(6):1919–26. <https://doi.org/10.1016/j.clnu.2019.08.016> PMID:31500937
- Arrossi S, Almonte M, Herrero R, Gago J, Sánchez Antelo V, Szwarz L, et al. (2020). Psycho-social impact of positive human papillomavirus testing in Jujuy, Argentina results from the Psycho-Estampa study. *Prev Med Rep*. 18:101070. <https://doi.org/10.1016/j.pmedr.2020.101070> PMID:32257775
- Arroyave WD, Mehta SS, Guha N, Schwingl P, Taylor KW, Glenn B, et al. (2021). Challenges and recommendations on the conduct of systematic reviews of observational epidemiologic studies in environmental and occupational health. *J Expo Sci Environ Epidemiol*. 31(1):21–30. <https://doi.org/10.1038/s41370-020-0228-0> PMID:32415298
- Assi N, Rinaldi S, Viallon V, Dashti SG, Dossus L, Fournier A, et al. (2020). Mediation analysis of the alcohol-postmenopausal breast cancer relationship by sex hormones in the EPIC cohort. *Int J Cancer*. 146(3):759–68. <https://doi.org/10.1002/ijc.32324> PMID:30968961
- Atun R, Bhakta N, Denburg A, Frazier AL, Friedrich P, Gupta S, et al. (2020). Sustainable care for children with cancer: a *Lancet Oncology* Commission. *Lancet Oncol*. 21(4):e185–224. [https://doi.org/10.1016/S1470-2045\(20\)30022-X](https://doi.org/10.1016/S1470-2045(20)30022-X) PMID:32240612
- Awada Z, Bouaoun L, Nasr R, Tfayli A, Cuenin C, Akika R, et al. (2021). LINE-1 methylation mediates the inverse association between body mass index and breast cancer risk: a pilot study in the Lebanese population. *Environ Res*. 197:111094. <https://doi.org/10.1016/j.envres.2021.111094> PMID:33839117
- Awada Z, Nasr R, Akika R, Ghantous A, Hou L, Zgheib NK (2020). Effect of bisphenols on telomerase expression and activity in breast cancer cell lines. *Mol Biol Rep*. 47(5):3541–9. <https://doi.org/10.1007/s11033-020-05444-0> PMID:32333245
- Ayeni OA, Norris SA, Joffe M, Cubasch H, Galukande M, Zietsman A, et al. (2021). Preexisting morbidity profile of women newly diagnosed with breast cancer in sub-Saharan Africa: African Breast Cancer-Disparities in Outcomes study. *Int J Cancer*. 148(9):2158–70. <https://doi.org/10.1002/ijc.33387> PMID:33180326
- Ayeni OA, Norris SA, Joffe M, Cubasch H, Nietz S, Buccimazza I, et al. (2020). The multimorbidity profile of South African women newly diagnosed with breast cancer. *Int J Cancer*. 147(2):361–74. <https://doi.org/10.1002/ijc.32727> PMID:31600408
- Baaken D, Wollschläger D, Samaras T, Schüz J, Deltour I (2020). Exposure to extremely low-frequency magnetic fields in low- and middle-income countries: an overview. *Radiat Prot Dosimetry*. 191(4):487–500. <https://doi.org/10.1093/rpd/ncaa172> PMID:33232971
- Baena A, De Vuyst H, Meshor D, Kasubi M, Yuma S, Mwaiselage J, et al. (2020). Reproducibility of a rapid human papillomavirus test at different levels of the healthcare system in Tanzania: the AISHA Study. *Cancer Epidemiol Biomarkers Prev*. 29(11):2261–8. <https://doi.org/10.1158/1055-9965.EPI-20-0422> PMID:32856600
- Baker JR, Umesh S, Jenab M, Schomburg L, Tjønneland A, Olsen A, et al. (2021). Prediagnostic blood selenium status and mortality among patients with colorectal cancer in Western European populations. *Biomedicine*. 9(11):1521. <https://doi.org/10.3390/biomedicine9111521> PMID:34829750
- Baldwin DR, Callister ME, Crosbie PA, O'Dowd EL, Rintoul RC, Robbins HA, et al. (2021). Biomarkers in lung cancer screening: the importance of study design. *Eur Respir J*. 57(1):2004367. <https://doi.org/10.1183/13993003.04367-2020> PMID:33446580
- Ballout N, Garcia C, Viallon V (2021). Sparse estimation for case-control studies with multiple disease subtypes. *Biostatistics*. 22(4):738–55. <https://doi.org/10.1093/biostatistics/kxz063> PMID:31977036
- Bandolin L, Borsetto D, Fussey J, Da Mosto MC, Nicolai P, Menegaldo A, et al. (2020). Beta human papillomaviruses infection and skin carcinogenesis. *Rev Med Virol*. 30(4):e2104. <https://doi.org/10.1002/rmv.2104> PMID:32232924
- Bansal S, Deshpande V, Zhao X, Lauer JA, Meheus F, Ilbawi A, et al. (2020). Analysis of mammography screening schedules under varying resource constraints for planning breast cancer control programs in low- and middle-income countries: a mathematical study. *Med Decis Making*. 40(3):364–78. <https://doi.org/10.1177/0272989X20910724> PMID:32160823

- Barahona Ponce C, Scherer D, Boekstegers F, Garate-Calderon V, Jenab M, Aleksandrova K, et al. (2020). Arsenic and gallbladder cancer risk: Mendelian randomization analysis of European prospective data. *Int J Cancer*. 146(9):2648–50. <https://doi.org/10.1002/ijc.32837> PMID:31846055
- Barahona Ponce C, Scherer D, Brinster R, Boekstegers F, Marcelain K, Gárate-Calderón V, et al. (2021). Gallstones, body mass index, C-reactive protein, and gallbladder cancer: Mendelian randomization analysis of Chilean and European genotype data. *Hepatology*. 73(5):1783–96. <https://doi.org/10.1002/hep.31537> PMID:32893372
- Barchuk A, Belyaev A, Gretsova O, Tursun-Zade R, Moshina N, Znaor A (2021a). History and current status of cancer registration in Russia. *Cancer Epidemiol*. 73:101963. <https://doi.org/10.1016/j.canep.2021.101963> PMID:34089992
- Barchuk A, Tursun-Zade R, Belayev A, Moore M, Komarov Y, Moshina N, et al. (2021). Comparability and validity of cancer registry data in the northwest of Russia. *Acta Oncol*. 60(10):1264–71. <https://doi.org/10.1080/02841816X.2021.1967443> PMID:34424113
- Barr RD, Ries LAG, Trama A, Gatta G, Steliarova-Foucher E, Stiller CA, et al. (2020). A system for classifying cancers diagnosed in adolescents and young adults. *Cancer*. 126(21):4634–59. <https://doi.org/10.1002/cncr.33041> PMID:32901932
- Barupal DK, Schubauer-Berigan MK, Korenjak M, Zavadil J, Guyton KZ (2021). Prioritizing cancer hazard assessments for IARC Monographs using an integrated approach of database fusion and text mining. *Environ Int*. 156:106624. <https://doi.org/10.1016/j.envint.2021.106624> PMID:33984576
- Basu M, Gupta P, Dutta A, Jana K, Ukil A (2020). Increased host ATP efflux and its conversion to extracellular adenosine is crucial for establishing *Leishmania* infection. *J Cell Sci*. 133(7):jcs239939. <https://doi.org/10.1242/jcs.239939> PMID:32079656
- Basu P, Alhomoud S, Taghavi K, Carvalho AL, Lucas E, Baussano I (2021a). Cancer screening in the coronavirus pandemic era: adjusting to a new situation. *JCO Glob Oncol*. 7(7):416–24. <https://doi.org/10.1200/GO.21.00033> PMID:33784177
- Basu P, Lucas E, Zhang L, Muwonge R, Murillo R, Nessa A (2021b). Leveraging vertical COVID-19 investments to improve monitoring of cancer screening programme – a case study from Bangladesh. *Prev Med*. 151:106624. <https://doi.org/10.1016/j.yjmed.2021.106624> PMID:34023359
- Basu P, Malvi SG, Joshi S, Bhatla N, Muwonge R, Lucas E, et al. (2021c). Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study. *Lancet Oncol*. 22(11):1518–29. [https://doi.org/10.1016/S1470-2045\(21\)00453-8](https://doi.org/10.1016/S1470-2045(21)00453-8) PMID:34634254
- Basu P, Tripathi R, Mehrotra R, Ray K, Srivastava A, Srivastava A (2021). Role of integrative medicine in the continuum of care of breast cancer patients in the Indian context. *Cancer Causes Control*. 32(5):429–40. <https://doi.org/10.1007/s10552-021-01399-0> PMID:33528692
- Baumeister SE, Baurecht H, Nolde M, Alayash Z, Gläser S, Johansson M, et al.; International Lung Cancer Consortium (2021). Cannabis use, pulmonary function, and lung cancer susceptibility: a Mendelian randomization study. *J Thorac Oncol*. 16(7):1127–35. <https://doi.org/10.1016/j.jtho.2021.03.025> PMID:33852959
- Baussano I, Sankaranarayanan R, Weiderpass E (2020). Prevention is life- and cost-saving. *Prev Med*. 138:106150. <https://doi.org/10.1016/j.yjmed.2020.106150> PMID:32473263
- Baussano I, Sayinzoga F, Tshomo U, Tenet V, Vorsters A, Heideman DAM, et al. (2021). Impact of human papillomavirus vaccination, Rwanda and Bhutan. *Emerg Infect Dis*. 27(1):1–9. <https://doi.org/10.3201/eid2701.191364> PMID:33350922
- Baussano I, Tshomo U, Tenet V, Heideman DAM, Wangden T, Franceschi S, et al. (2020a). Prevalence of human papillomavirus and estimation of human papillomavirus vaccine effectiveness in Thimphu, Bhutan, in 2011–2012 and 2018: a cross-sectional study. *Ann Intern Med*. 173(11):888–94. <https://doi.org/10.7326/M20-2849> PMID:32956600
- Baxter JS, Johnson N, Tomczyk K, Gillespie A, Maguire S, Brough R, et al.; NBCS Collaborators; kConFab Investigators; ABCTB Investigators (2021). Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. *Am J Hum Genet*. 108(7):1190–203. <https://doi.org/10.1016/j.ajhg.2021.05.013> PMID:34146516
- Bell JA, Bull CJ, Gunter MJ, Carslake D, Mahajan A, Davey Smith G, et al. (2020). Early metabolic features of genetic liability to type 2 diabetes: cohort study with repeated metabolomics across early life. *Diabetes Care*. 43(7):1537–45. <https://doi.org/10.2337/dc19-2348> PMID:32345654
- Berns A, Ringborg U, Celis JE, Heitor M, Aaronson NK, Abou-Zeid N, et al. (2020). Towards a cancer mission in Horizon Europe: recommendations. *Mol Oncol*. 14(8):1589–615. <https://doi.org/10.1002/1878-0261.12763> PMID:32749074
- Bhatla N, Meena J, Gupta K, Pal B, Divakar H, Bhalerao S, et al.; FOGSI Expert Group (2020). Human papillomavirus vaccination: good clinical practice recommendations from the Federation of Obstetric and Gynecological Societies of India. *J Obstet Gynaecol Res*. 46(9):1651–60. <https://doi.org/10.1111/jog.14345> PMID:32627278
- Bhatla N, Nessa A, Oswal K, Vashist S, Sebastian P, Basu P (2021). Program organization rather than choice of test determines success of cervical cancer screening: case studies from Bangladesh and India. *Int J Gynaecol Obstet*. 152(1):40–7. <https://doi.org/10.1002/ijgo.13486> PMID:33205399
- Bhatla N, Singhal S, Saraiya U, Srivastava S, Bhalerao S, Shamsunder S, et al.; on behalf of FOGSI Expert Group (2020). Screening and management of preinvasive lesions of the cervix: good clinical practice recommendations from the Federation of Obstetrics and Gynaecological Societies of India (FOGSI). *J Obstet Gynaecol Res*. 46(2):201–14. PMID:31814222
- Boekstegers F, Marcelain K, Barahona Ponce C, Baez Benavides PF, Müller B, de Toro G, et al. (2020). *ABCB1/4* gallbladder cancer risk variants identified in India also show strong effects in Chileans. *Cancer Epidemiol*. 65:101643. <https://doi.org/10.1016/j.canep.2019.101643> PMID:32058310

- Boffetta P, Donato F, Gouas D, da Costa AN, Abedi-Ardekani B, Hainaut P (2020). Cancers of the intestine, the liver, and the biliary tract. In: Anttila S, Boffetta P, editors. Occupational cancers, 2nd ed. Basel, Switzerland: Springer Nature Switzerland AG; pp. 179–191.
- Bond TA, Karhunen V, Wielscher M, Auvinen J, Männikkö M, Keinänen-Kiukaanniemi S, et al. (2020). Exploring the role of genetic confounding in the association between maternal and offspring body mass index: evidence from three birth cohorts. *Int J Epidemiol.* 49(1):233–43. <https://doi.org/10.1093/ije/dyz095> PMID:31074781
- Bondonno CP, Bondonno NP, Dalgaard F, Murray K, Gardener SL, Martins RN, et al. (2021). Flavonoid intake and incident dementia in the Danish Diet, Cancer, and Health cohort. *Alzheimers Dement (N Y).* 7(1):e12175. <https://doi.org/10.1002/trc2.12175> PMID:34027025
- Bondonno NP, Dalgaard F, Murray K, Davey RJ, Bondonno CP, Cassidy A, et al. (2021). Higher habitual flavonoid intakes are associated with a lower incidence of diabetes. *J Nutr.* 151(11):3533–42. PMID:34313759
- Bondonno NP, Murray K, Bondonno CP, Lewis JR, Croft KD, Kyrø C, et al. (2020). Flavonoid intake and its association with atrial fibrillation. *Clin Nutr.* 39(12):3821–8. <https://doi.org/10.1016/j.clnu.2020.04.025> PMID:32386860
- Bonjour M, Charvat H, Franco EL, Piñeros M, Clifford GM, Bray F, et al. (2021). Global estimates of expected and preventable cervical cancers among girls born between 2005 and 2014: a birth cohort analysis. *Lancet Public Health.* 6(7):e510–21. [https://doi.org/10.1016/S2468-2667\(21\)00046-3](https://doi.org/10.1016/S2468-2667(21)00046-3) PMID:33864738
- Bossé Y, Li Z, Xia J, Manem V, Carreras-Torres R, Gabriel A, et al. (2020). Transcriptome-wide association study reveals candidate causal genes for lung cancer. *Int J Cancer.* 146(7):1862–78. <https://doi.org/10.1002/ijc.32771> PMID:31696517
- Botteri E, Berstad P, Sandin S, Weiderpass E (2021). Lifestyle changes and risk of cancer: experience from the Swedish Women's Lifestyle and Health Cohort Study. *Acta Oncol.* 60(7):827–34. <https://doi.org/10.1080/0284186X.2021.1919756> PMID:33988490
- Boucheron P, Anele A, Zietsman A, Galukande M, Parham G, Pinder LF, et al. (2021). Self-reported arm and shoulder problems in breast cancer survivors in Sub-Saharan Africa: the African Breast Cancer-Disparities in Outcomes cohort study. *Breast Cancer Res.* 23(1):109. <https://doi.org/10.1186/s13058-021-01486-9> PMID:34819118
- Bouvard V, Wentzensen N, Mackie A, Berkhof J, Brotherton J, Giorgi-Rossi P, et al. (2021). The IARC perspective on cervical cancer screening. *N Engl J Med.* 385(20):1908–18. <https://doi.org/10.1056/NEJMs2030640> PMID:34758259
- Bradbury KE, Murphy N, Key TJ (2020). Diet and colorectal cancer in UK Biobank: a prospective study. *Int J Epidemiol.* 49(1):246–58. <https://doi.org/10.1093/ije/dyz064> PMID:30993317
- Brancaccio RN, Robitaille A, Dutta S, Rollison DE, Tommasino M, Gheit T (2021). MinION nanopore sequencing and assembly of a complete human papillomavirus genome. *J Virol Methods.* 294:114180. <https://doi.org/10.1016/j.jviromet.2021.114180> PMID:33965458
- Brancher S, Ribeiro AE, Toporcov TN, Weiderpass E (2021). The role of metformin on lung cancer survival: the first systematic review and meta-analysis of observational studies and randomized clinical trials. *J Cancer Res Clin Oncol.* 147(10):2819–36. <https://doi.org/10.1007/s00432-021-03728-x> PMID:34264392
- Brancher S, Stør NC, Weiderpass E, Damhuis RAM, Johannesen TB, Botteri E, et al. (2021). Metformin use and lung cancer survival: a population-based study in Norway. *Br J Cancer.* 124(5):1018–25. <https://doi.org/10.1038/s41416-020-01186-9> PMID:33262518
- Bray F, Laversanne M, Cao B, Varghese C, Mikkelsen B, Weiderpass E, et al. (2021b). Comparing cancer and cardiovascular disease trends in 20 middle- or high-income countries 2000–19: a pointer to national trajectories towards achieving Sustainable Development goal target 3.4. *Cancer Treat Rev.* 100:102290. <https://doi.org/10.1016/j.ctrv.2021.102290> PMID:34536729
- Bray F, Laversanne M, Weiderpass E, Arbyn M (2020a). Geographic and temporal variations in the incidence of vulvar and vaginal cancers. *Int J Cancer.* 147(10):2764–71. <https://doi.org/10.1002/ijc.33055> PMID:32410226
- Bray F, Laversanne M, Weiderpass E, Soerjomataram I (2021a). The ever-increasing importance of cancer as a leading cause of premature death worldwide. *Cancer.* 127(16):3029–30. <https://doi.org/10.1002/cncr.33587> PMID:34086348
- Bray MJ, Chen LS, Fox L, Hancock DB, Culverhouse RC, Hartz SM, et al. (2020). Dissecting the genetic overlap of smoking behaviors, lung cancer, and chronic obstructive pulmonary disease: a focus on nicotinic receptors and nicotine metabolizing enzyme. *Genet Epidemiol.* 44(7):748–58. <https://doi.org/10.1002/gepi.22331> PMID:32803792
- Brhane Y, Yang P, Christiani DC, Liu G, McLaughlin JR, Brennan P, et al. (2020). Genetic determinants of lung cancer prognosis in never smokers: a pooled analysis in the International Lung Cancer Consortium. *Cancer Epidemiol Biomarkers Prev.* 29(10):1983–92. <https://doi.org/10.1158/1055-9965.EPI-20-0248> PMID:32699080
- Brisson M, Kim JJ, Canfell K, Drolet M, Gingras G, Burger EA, et al. (2020). Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. *Lancet.* 395(10224):575–90. [https://doi.org/10.1016/S0140-6736\(20\)30068-4](https://doi.org/10.1016/S0140-6736(20)30068-4) PMID:32007141
- Brotherton JML, Wheeler C, Clifford GM, Elfström M, Saville M, Kaldor J, et al. (2021). Surveillance systems for monitoring cervical cancer elimination efforts: focus on HPV infection, cervical dysplasia, cervical screening and treatment. *Prev Med.* 144:106293. <https://doi.org/10.1016/j.ypmed.2020.106293> PMID:33075352
- Buexm LA, Soares-Lima SC, Brennan P, Fernandes PV, de Souza Almeida Lopes M, Nascimento de Carvalho F, et al. (2020). HPV impact on oropharyngeal cancer patients treated at the largest cancer center from Brazil. *Cancer Lett.* 477:70–5. <https://doi.org/10.1016/j.canlet.2020.02.023> PMID:32087309
- Bull CJ, Bell JA, Murphy N, Sanderson E, Davey Smith G, Timpson NJ, et al. (2020). Adiposity, metabolites, and colorectal cancer risk: Mendelian randomization study. *BMC Med.* 18(1):396. <https://doi.org/10.1186/s12916-020-01855-9> PMID:33327948

- Butt J, Jenab M, Pawlita M, Tjønneland A, Kyrø C, Boutron-Ruault MC, et al. (2020). Antibody responses to *Helicobacter pylori* and risk of developing colorectal cancer in a European cohort. *Cancer Epidemiol Biomarkers Prev.* 29(7):1475–81. <https://doi.org/10.1158/1055-9965.EPI-19-1545> PMID:32332031
- Butt J, Jenab M, Werner J, Fedirko V, Weiderpass E, Dahm CC, et al. (2021). Association of pre-diagnostic antibody responses to *Escherichia coli* and *Bacteroides fragilis* toxin proteins with colorectal cancer in a European cohort. *Gut Microbes.* 13(1):1–14. <https://doi.org/10.1080/19490976.2021.1903825> PMID:33874856
- Byun J, Han Y, Ostrom QT, Edelson J, Walsh KM, Pettit RW, et al.; for INTEGRAL-ILCCO (2021). The shared genetic architectures between lung cancer and multiple polygenic phenotypes in genome-wide association studies. *Cancer Epidemiol Biomarkers Prev.* 30(6):1156–64. <https://doi.org/10.1158/1055-9965.EPI-20-1635> PMID:33771847
- Cabasag CJ, Arnold M, Butler J, Inoue M, Trabert B, Webb PM, et al. (2020). The influence of birth cohort and calendar period on global trends in ovarian cancer incidence. *Int J Cancer.* 146(3):749–58. <https://doi.org/10.1002/ijc.32322> PMID:30968402
- Cabasag CJ, Arnold M, Piñeros M, Morgan E, Brierley J, Hofferkamp J, et al. (2021). Population-based cancer staging for oesophageal, gastric, and pancreatic cancer 2012–2014: International Cancer Benchmarking Partnership SurvMark-2. *Int J Cancer.* 149(6):1239–46. <https://doi.org/10.1002/ijc.33679> PMID:33990959
- Cabasag CJ, Butler J, Arnold M, Rutherford M, Bardot A, Ferlay J, et al. (2020a). Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): a population-based study. *Gynecol Oncol.* 157(1):234–44. <https://doi.org/10.1016/j.ygyno.2019.12.047> PMID:32005583
- Caicedo-Martínez M, Fernández-Deaza G, Ordóñez-Reyes C, Olejua P, Nuche-Berenguer B, Mello MB, et al. (2021). High-risk human papillomavirus infection among women living with HIV in Latin America and the Caribbean: a systematic review and meta-analysis. *Int J STD AIDS.* 32(14):1278–89. <https://doi.org/10.1177/09564624211037498> PMID:34488503
- Cairat M, Al Rahmoun M, Gunter MJ, Heudel PE, Severi G, Dossus L, et al. (2021). Use of systemic glucocorticoids and risk of breast cancer in a prospective cohort of postmenopausal women. *BMC Med.* 19(1):186. <https://doi.org/10.1186/s12916-021-02004-6> PMID:34340701
- Cairat M, Al Rahmoun M, Gunter MJ, Severi G, Dossus L, Fournier A (2020). Use of nonsteroidal anti-inflammatory drugs and breast cancer risk in a prospective cohort of postmenopausal women. *Breast Cancer Res.* 22(1):118. <https://doi.org/10.1186/s13058-020-01343-1> PMID:33129324
- Cairat M, Al Rahmoun M, Gunter MJ, Severi G, Dossus L, Fournier A (2021). Antiplatelet drug use and breast cancer risk in a prospective cohort of postmenopausal women. *Cancer Epidemiol Biomarkers Prev.* 30(4):643–52. <https://doi.org/10.1158/1055-9965.EPI-20-1292> PMID:33531438
- Callister MEJ, Sasieni P, Robbins HA (2021). Overdiagnosis in lung cancer screening. *Lancet Respir Med.* 9(1):7–9. [https://doi.org/10.1016/S2213-2600\(20\)30553-1](https://doi.org/10.1016/S2213-2600(20)30553-1) PMID:33412118
- Campbell PT, Lin Y, Bien SA, Figueiredo JC, Harrison TA, Guinter MA, et al. (2021). Association of body mass index with colorectal cancer risk by genome-wide variants. *J Natl Cancer Inst.* 113(1):38–47. <https://doi.org/10.1093/jnci/djaa058> PMID:32324875
- Camuzi D, Buexm LA, Lourenço SQC, Esposti DD, Cuenin C, Lopes MSA, et al. (2021). HPV infection leaves a DNA methylation signature in oropharyngeal cancer affecting both coding genes and transposable elements. *Cancers (Basel).* 13(14):3621. <https://doi.org/10.3390/cancers13143621> PMID:34298834
- Canfell K, Kim JJ, Brisson M, Keane A, Simms KT, Caruana M, et al. (2020). Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. *Lancet.* 395(10224):591–603. [https://doi.org/10.1016/S0140-6736\(20\)30157-4](https://doi.org/10.1016/S0140-6736(20)30157-4) PMID:32007142
- Casabonne D, Benavente Y, Seifert J, Costas L, Armesto M, Arestin M, et al. (2020). Serum levels of hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study. *Int J Cancer.* 147(5):1315–24. <https://doi.org/10.1002/ijc.32894> PMID:32012253
- Castle PE, Pierz AJ, Adcock R, Aslam S, Basu PS, Belinson JL, et al. (2020). A pooled analysis to compare the clinical characteristics of human papillomavirus-positive and -negative cervical precancers. *Cancer Prev Res (Phila).* 13(10):829–40. <https://doi.org/10.1158/1940-6207.CAPR-20-0182> PMID:32655005
- Castro-Espin C, Agudo A, Bonet C, Katzke V, Turzanski-Fortner R, Aleksandrova K, et al. (2021). Inflammatory potential of the diet and risk of breast cancer in the European Investigation into Cancer and Nutrition (EPIC) study. *Eur J Epidemiol.* 36(9):953–64. <https://doi.org/10.1007/s10654-021-00772-2> PMID:34148186
- Cervenka I, Al Rahmoun M, Mahamat-Saleh Y, Fournier A, Boutron-Ruault MC, Severi G, et al. (2020). Exogenous hormone use and cutaneous melanoma risk in women: the European Prospective Investigation into Cancer and Nutrition. *Int J Cancer.* 146(12):3267–80. <https://doi.org/10.1002/ijc.32674> PMID:31506954
- Chaby LE, Lasseter HC, Contrepois K, Salek RM, Turck CW, Thompson A, et al. (2021). Cross-platform evaluation of commercially targeted and untargeted metabolomics approaches to optimize the investigation of psychiatric disease. *Metabolites.* 11(9):609. <https://doi.org/10.3390/metabo11090609> PMID:34564425
- Chang K, Khandpur N, Neri D, Touvier M, Huybrechts I, Millett C, et al. (2021). Association between childhood consumption of ultraprocessed food and adiposity trajectories in the Avon Longitudinal Study of Parents and Children birth cohort. *JAMA Pediatr.* 175(9):e211573. <https://doi.org/10.1001/jamapediatrics.2021.1573> PMID:34125152
- Charaka H, Khalis M, Elfakir S, Huybrechts I, Khazraji YC, Lyoussi B, et al. (2021). Knowledge, perceptions, and satisfaction of Moroccan women towards a new breast cancer screening program in Morocco. *J Cancer Educ.* 36(4):657–63. <https://doi.org/10.1007/s13187-019-01680-6> PMID:31873856
- Chasimpha SJD, Mclean EM, Dube A, McCormack V, Dos-Santos-Silva I, Glynn JR (2020). Assessing the validity of and factors that influence accurate self-reporting of HIV status after testing: a population-based study. *AIDS.* 34(6):931–41. <https://doi.org/10.1097/QAD.0000000000002513> PMID:32073446

- Chauvel C, Novoloaca A, Veyre P, Reynier F, Becker J (2020). Evaluation of integrative clustering methods for the analysis of multi-omics data. *Brief Bioinform.* 21(2):541–52. <https://doi.org/10.1093/bib/bbz015> PMID:31220206
- Chazelas E, Druesne-Pecollo N, Esseddik Y, de Edelenyi FS, Agaesse C, De Sa A, et al. (2021). Exposure to food additive mixtures in 106,000 French adults from the NutriNet-Santé cohort. *Sci Rep.* 11(1):19680. <https://doi.org/10.1038/s41598-021-98496-6> PMID:34608173
- Chen C, Lohavanichbutr P, Zhang Y, Houck JR, Upton MP, Abedi-Ardekani B, et al. (2020). Prediction of survival of HPV16-negative, p16-negative oral cavity cancer patients using a 13-gene signature: a multicenter study using FFPE samples. *Oral Oncol.* 100:104487. <https://doi.org/10.1016/j.oraloncology.2019.104487> PMID:31835136
- Chen H, Majumdar A, Wang L, Kar S, Brown KM, Feng H, et al.; Breast Cancer Association Consortium (BCAC); Colorectal Transdisciplinary Study (CORECT); Colon Cancer Family Registry Study (CCFR); Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO); Endometrial Cancer Association Consortium (ECAC); Esophageal Cancer GWAS Consortium; Glioma International Case Control Consortium (GICC); Head-Neck Cancer GWAS Consortium; International Lung Cancer Consortium (ILCCO); Melanoma GWAS Consortium; Ovarian Cancer Association Consortium (OCAC); Pancreatic Cancer Case-Control Consortium (PANC4); Pancreatic Cancer Cohort Consortium (PanScan); PRACTICAL consortium, CRUK, BPC3, CAPS, PEGASUS; Renal Cancer GWAS Consortium (2021). Large-scale cross-cancer fine-mapping of the 5p15.33 region reveals multiple independent signals. *HGG Adv.* 2(3):100041. <https://doi.org/10.1016/j.xhgg.2021.100041> PMID:34355204
- Chen MH, Raffield LM, Mousas A, Sakaue S, Huffman JE, Moscati A, et al.; VA Million Veteran Program (2020). Trans-ethnic and ancestry-specific blood-cell genetics in 746,667 individuals from 5 global populations. *Cell.* 182(5):1198–1213. e14. <https://doi.org/10.1016/j.cell.2020.06.045> PMID:32888493
- Chen SLF, Braaten T, Borch KB, Ferrari P, Sandanger TM, Nøst TH (2021). Combined lifestyle behaviors and the incidence of common cancer types in the Norwegian Women and Cancer Study (NOWAC). *Clin Epidemiol.* 13:721–34. <https://doi.org/10.2147/CLEP.S312864> PMID:34429658
- Cheung LC, Ramadas K, Muwonge R, Katki HA, Thomas G, Graubard BI, et al. (2021). Risk-based selection of individuals for oral cancer screening. *J Clin Oncol.* 39(6):663–74. <https://doi.org/10.1200/JCO.20.02855> PMID:33449824
- Chow ZL, Indave BI, Lokuhetty MDS, Ochiai A, Cree IA, White VA (2021). Misleading terminology in pathology: lack of definitions hampers communication. *Virchows Arch.* 479(2):425–30. <https://doi.org/10.1007/s00428-021-03069-7> PMID:33796909
- Christakoudi S, Kakourou A, Markozannes G, Tzoulaki I, Weiderpass E, Brennan P, et al. (2020). Blood pressure and risk of cancer in the European Prospective Investigation into Cancer and Nutrition. *Int J Cancer.* 146(10):2680–93. <https://doi.org/10.1002/ijc.32576> PMID:31319002
- Christakoudi S, Pagoni P, Ferrari P, Cross AJ, Tzoulaki I, Muller DC, et al. (2021). Weight change in middle adulthood and risk of cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. *Int J Cancer.* 148(7):1637–51. <https://doi.org/10.1002/ijc.33339> PMID:33038275
- Christakoudi S, Tsilidis KK, Muller DC, Freisling H, Weiderpass E, Overvad K, et al. (2020). A Body Shape Index (ABSI) achieves better mortality risk stratification than alternative indices of abdominal obesity: results from a large European cohort. *Sci Rep.* 10(1):14541. <https://doi.org/10.1038/s41598-020-71302-5> PMID:32883969
- Chung FF, Herceg Z (2020). The promises and challenges of toxico-epigenomics: environmental chemicals and their impacts on the epigenome. *Environ Health Perspect.* 128(1):15001. <https://doi.org/10.1289/EHP6104> PMID:31950866
- Chung MH, De Vuyst H, Greene SA, Mugo NR, Querec TD, Nyongesa-Malava E, et al. (2021b). Human papillomavirus persistence and association with recurrent cervical intraepithelial neoplasia after cryotherapy vs loop electrosurgical excision procedure among HIV-positive women: a secondary analysis of a randomized clinical trial. *JAMA Oncol.* 7(10):1514–20. <https://doi.org/10.1001/jamaoncol.2021.2683> PMID:34351377
- Chung MH, De Vuyst H, Greene SA, Topazian HM, Sayed S, Moloo Z, et al. (2021a). Loop electrosurgical excision procedure (LEEP) plus top hat for HIV-infected women with endocervical intraepithelial neoplasia in Kenya. *Int J Gynaecol Obstet.* 152(1):118–24. <https://doi.org/10.1002/ijgo.13466> PMID:33145753
- Claeys L, Romano C, De Ruyck K, Wilson H, Fervers B, Korenjak M, et al. (2020). Mycotoxin exposure and human cancer risk: a systematic review of epidemiological studies. *Compr Rev Food Sci Food Saf.* 19(4):1449–64. <https://doi.org/10.1111/1541-4337.12567> PMID:33337079
- Clasen JL, Heath AK, Scelo G, Muller DC (2020). Components of one-carbon metabolism and renal cell carcinoma: a systematic review and meta-analysis. *Eur J Nutr.* 59(8):3801–13. <https://doi.org/10.1007/s00394-020-02211-6> PMID:32162043
- Clasen JL, Heath AK, Van Puyvelde H, Huybrechts I, Park JY, Ferrari P, et al. (2021). A comparison of complementary measures of vitamin B6 status, function, and metabolism in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. *Am J Clin Nutr.* 114(1):338–47. <https://doi.org/10.1093/ajcn/nqab045> PMID:33829249
- Cléro E, Ostroumova E, Demoury C, Grosche B, Kesminiene A, Liutsko L, et al. (2021). Lessons learned from Chernobyl and Fukushima on thyroid cancer screening and recommendations in case of a future nuclear accident. *Environ Int.* 146:106230. <https://doi.org/10.1016/j.envint.2020.106230> PMID:33171378
- Clifford GM, Alberts CJ (2021). Molecular risk stratification for anal cancer prevention. *Clin Infect Dis.* 72(12):2164–6. <https://doi.org/10.1093/cid/ciaa399> PMID:32266927
- Clifford GM, Combes JD (2020). Hopes for prevention of anal cancer in women. *J Infect Dis.* 221(8):1210–2. <https://doi.org/10.1093/infdis/jiz191> PMID:31100126
- Clifford GM, Georges D, Shiels MS, Engels EA, Albuquerque A, Poynten IM, et al. (2021). A meta-analysis of anal cancer incidence by risk group: toward a unified anal cancer risk scale. *Int J Cancer.* 148(1):38–47. <https://doi.org/10.1002/ijc.33185> PMID:32621759
- Cohen D, Ghosh S, Shimakawa Y, Ramou N, Garcia PS, Dubois A, et al. (2020). Hepatitis B virus preS2Δ38–55 variants: a newly identified risk factor for hepatocellular carcinoma. *JHEP Rep.* 2(5):100144. <https://doi.org/10.1016/j.jhepr.2020.100144> PMID:32904132

- Combes JD, Clifford GM, Günthard HF, Hauser C, Darling KEA, Valladares P, et al.; Swiss HIV Cohort Study (2020). Antibodies against HPV16E6 oncoprotein in the Swiss HIV Cohort Study: kinetics and anal cancer risk prediction. *Int J Cancer*. 147(3):757–65. <https://doi.org/10.1002/ijc.32784> PMID:31722114
- Combes JD, Voisin N, Périé S, Malard O, Jegoux F, Nadjingar R, et al. (2021). History of tonsillectomy and risk of oropharyngeal cancer. *Oral Oncol*. 117:105302. <https://doi.org/10.1016/j.oraloncology.2021.105302> PMID:33905915
- Conway DI, Hovanec J, Ahrens W, Ross A, Holcatova I, Lagiou P, et al. (2021). Occupational socioeconomic risk associations for head and neck cancer in Europe and South America: individual participant data analysis of pooled case-control studies within the INHANCE Consortium. *J Epidemiol Community Health*. 75(8):779–87. <https://doi.org/10.1136/jech-2020-214913> PMID:33622804
- Cordova R, Kliemann N, Huybrechts I, Rauber F, Vamos EP, Levy RB, et al. (2021). Consumption of ultra-processed foods associated with weight gain and obesity in adults: a multi-national cohort study. *Clin Nutr*. 40(9):5079–88. <https://doi.org/10.1016/j.clnu.2021.08.009> PMID:34455267
- Cordova R, Knaze V, Viallon V, Rust P, Schalkwijk CG, Weiderpass E, et al. (2020). Dietary intake of advanced glycation end products (AGEs) and changes in body weight in European adults. *Eur J Nutr*. 59(7):2893–904. <https://doi.org/10.1007/s00394-019-02129-8> PMID:31701336
- Cree IA, Indave Ruiz BI, Zavadij J, McKay J, Olivier M, Kozlakidis Z, et al.; IC³R participants (2021a). The International Collaboration for Cancer Classification and Research. *Int J Cancer*. 148(3):560–71. <https://doi.org/10.1002/ijc.33260> PMID:32818326
- Cree IA, Tan PH, Travis WD, Wesseling P, Yagi Y, White VA, et al. (2021). Counting mitoses: Sl(ze) matters! *Mod Pathol*. 34(9):1651–7. <https://doi.org/10.1038/s41379-021-00825-7> PMID:34079071
- Cree IA, White VA, Indave BI, Lokuhetty D (2020). Revising the WHO classification: female genital tract tumours. *Histopathology*. 76(1):151–6. <https://doi.org/10.1111/his.13977> PMID:31846528
- Cristiano S, McKean D, Carey J, Bracci P, Brennan P, Chou M, et al. (2020). Bayesian copy number detection and association in large-scale studies. *BMC Cancer*. 20(1):856. <https://doi.org/10.1186/s12885-020-07304-3> PMID:32894098
- Crocetti E, Mattioli V, Buzzoni C, Franceschi S, Serraino D, Vaccarella S, et al.; for AIRTUM working group (2021). Risk of thyroid as a first or second primary cancer. A population-based study in Italy, 1998–2012. *Cancer Med*. 10(19):6855–67. <https://doi.org/10.1002/cam4.4193> PMID:34533289
- Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A (2020). Recent global patterns in prostate cancer incidence and mortality rates. *Eur Urol*. 77(1):38–52. <https://doi.org/10.1016/j.eururo.2019.08.005> PMID:31493960
- Cuzick J, Adcock R, Carozzi F, Gillio-Tos A, De Marco L, Del Mistro A, et al.; New Technologies for Cervical Cancer Screening Working Group (2020). Combined use of cytology, p16 immunostaining and genotyping for triage of women positive for high-risk human papillomavirus at primary screening. *Int J Cancer*. 147(7):1864–73. <https://doi.org/10.1002/ijc.32973> PMID:32170961
- da Silva M, Laaksonen MA, Lissner L, Weiderpass E, Rylander C (2021). Preventable fractions of cancer incidence attributable to 7-years weight gain in the Norwegian Women and Cancer (NOWAC) study. *Sci Rep*. 11(1):3800. <https://doi.org/10.1038/s41598-021-83027-0> PMID:33589669
- Dagnino S, Bodinier B, Grigoryan H, Rappaport SM, Karimi M, Guida F, et al. (2020). Agnostic Cys34-albumin adductomics and DNA methylation: implication of N-acetylcysteine in lung carcinogenesis years before diagnosis. *Int J Cancer*. 146(12):3294–303. <https://doi.org/10.1002/ijc.32680> PMID:31513294
- Dagnino S, Bodinier B, Guida F, Smith-Byrne K, Petrovic D, Whitaker MD, et al. (2021). Prospective identification of elevated circulating CDPC1 in patients years before onset of lung cancer. *Cancer Res*. 81(13):3738–48. <https://doi.org/10.1158/0008-5472.CAN-20-3454> PMID:33574093
- Dahlin AM, Wibom C, Andersson U, Bybjerg-Grauholm J, Deltour I, Hougaard DM, et al.; Cefalo Study Group (2020). A genome-wide association study on medulloblastoma. *J Neurooncol*. 147(2):309–15. <https://doi.org/10.1007/s11060-020-03424-9> PMID:32056145
- Dai J, Huang M, Amos CI, Hung RJ, Tardon A, Andrew A, et al. (2020). Genome-wide association study of INDELS identified four novel susceptibility loci associated with lung cancer risk. *Int J Cancer*. 146(10):2855–64. <https://doi.org/10.1002/ijc.32698> PMID:31577861
- Dal Maso L, Panato C, De Paoli A, Mattioli V, Serraino D, Elisei R, et al.; DEPTH Working Group (2021). Trends in thyroid function testing, neck ultrasound, thyroid fine needle aspiration, and thyroidectomies in North-eastern Italy. *J Endocrinol Invest*. 44(8):1679–88. <https://doi.org/10.1007/s40618-020-01475-3> PMID:33460012
- Danjou AMN, Pérol O, Coste A, Faure E, Béranger R, Boyle H, et al.; TESTIS study group (2021). Domestic use of pesticides during early periods of development and risk of testicular germ cell tumors in adulthood: a French nationwide case-control study. *Environ Health*. 20(1):111. <https://doi.org/10.1186/s12940-021-00795-y> PMID:34706722
- Dashti SG, English DR, Simpson JA, Karahalios A, Moreno-Betancur M, Biessy C, et al. (2021). Adiposity and endometrial cancer risk in postmenopausal women: a sequential causal mediation analysis. *Cancer Epidemiol Biomarkers Prev*. 30(1):104–13. <https://doi.org/10.1158/1055-9965.EPI-20-0965> PMID:33008875
- Dashti SG, Simpson JA, Karahalios A, Viallon V, Moreno-Betancur M, Gurrin LC, et al. (2020). Adiposity and estrogen receptor-positive, postmenopausal breast cancer risk: quantification of the mediating effects of fasting insulin and free estradiol. *Int J Cancer*. 146(6):1541–52. <https://doi.org/10.1002/ijc.32504> PMID:31187481
- Dashti SG, Viallon V, Simpson JA, Karahalios A, Moreno-Betancur M, English DR, et al. (2020). Explaining the link between adiposity and colorectal cancer risk in men and postmenopausal women in the UK Biobank: a sequential causal mediation analysis. *Int J Cancer*. 147(7):1881–94. <https://doi.org/10.1002/ijc.32980> PMID:32181888
- Davila-Batista V, Molina AJ, Fernández-Villa T, Romaguera D, Pérez-Gómez B, Vilorio-Marqués L, et al.; on behalf of MCC-Spain study group (2020). The relation of CUN-BAE index with body mass index and waist circumference in adults aged 50 to 85 years: the MCC-Spain study. *Nutrients*. 12(4):12. <https://doi.org/10.3390/nu12040996> PMID:32260185

- de Carvalho AC, Perdomo S, Dos Santos W, Fernandes GC, de Jesus LM, Carvalho RS, et al. (2020). Impact of genetic variants in clinical outcome of a cohort of patients with oropharyngeal squamous cell carcinoma. *Sci Rep.* 10(1):9970. <https://doi.org/10.1038/s41598-020-66741-z> PMID:32561788
- de Martel C, Georges D, Bray F, Ferlay J, Clifford GM (2020). Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. *Lancet Glob Health.* 8(2):e180–90. [https://doi.org/10.1016/S2214-109X\(19\)30488-7](https://doi.org/10.1016/S2214-109X(19)30488-7) PMID:31862245
- De Ruyck K, Huybrechts I, Yang S, Arcella D, Claeys L, Abbeddou S, et al. (2020). Mycotoxin exposure assessments in a multi-center European validation study by 24-hour dietary recall and biological fluid sampling. *Environ Int.* 137:105539. <https://doi.org/10.1016/j.envint.2020.105539> PMID:32035364
- Del Pozo MDP, Lope V, Criado-Navarro I, Pastor-Barriso R, Fernández de Larrea N, Ruiz E, et al. (2020). Serum phospholipid fatty acids levels, anthropometric variables and adiposity in Spanish premenopausal women. *Nutrients.* 12(6):16. <https://doi.org/10.3390/nu12061895> PMID:32630591
- Delhomme TM, Avogbe PH, Gabriel AAG, Alcalá N, Leblay N, Voegelé C, et al. (2020). Needlestack: an ultra-sensitive variant caller for multi-sample next generation sequencing data. *NAR Genom Bioinform.* 2(2):a021. <https://doi.org/10.1093/nargab/lqaa021> PMID:32363341
- Delrieu L, Bouaoun L, Fatouhi DE, Dumas E, Bouhnik AD, Noelle H, et al. (2021). Patterns of sequelae in women with a history of localized breast cancer: results from the French VICAN survey. *Cancers (Basel).* 13(5):1161. <https://doi.org/10.3390/cancers13051161> PMID:33800346
- Deoula MS, El Kinany K, Huybrechts I, Gunter MJ, Hatime Z, Boudouaya HA, et al. (2020). Consumption of meat, traditional and modern processed meat and colorectal cancer risk among the Moroccan population: a large-scale case-control study. *Int J Cancer.* 146(5):1333–45. <https://doi.org/10.1002/ijc.32689> PMID:31525258
- Deschasaux M, Huybrechts I, Julia C, Hercberg S, Egnell M, Srour B, et al. (2020). Association between nutritional profiles of foods underlying Nutri-Score front-of-pack labels and mortality: EPIC cohort study in 10 European countries. *BMJ.* 370:m3173. <https://doi.org/10.1136/bmj.m3173> PMID:32938660
- Di Credico G, Polesel J, Dal Maso L, Pauli F, Torelli N, Luce D, et al. (2020). Alcohol drinking and head and neck cancer risk: the joint effect of intensity and duration. *Br J Cancer.* 123(9):1456–63. <https://doi.org/10.1038/s41416-020-01031-z> PMID:32830199
- Di Lorenzo G, Buonerba L, Ingenito C, Crocetto F, Buonerba C, Libroia A, et al. (2020a). Clinical characteristics of metastatic prostate cancer patients infected with COVID-19 in South Italy. *Oncology.* 98(10):743–7. <https://doi.org/10.1159/000509434> PMID:32570240
- Di Lorenzo G, Di Troilo R, Kozlakidis Z, Busto G, Ingenito C, Buonerba L, et al. (2020b). COVID 19 therapies and anti-cancer drugs: a systematic review of recent literature. *Crit Rev Oncol Hematol.* 152:102991. <https://doi.org/10.1016/j.critrevonc.2020.102991> PMID:32544802
- Dianatinasab M, Wesselius A, de Loeij T, Salehi-Abargouei A, Yu EYW, Fararouei M, et al. (2021). The association between meat and fish consumption and bladder cancer risk: a pooled analysis of 11 cohort studies. *Eur J Epidemiol.* 36(8):781–92. <https://doi.org/10.1007/s10654-021-00762-4> PMID:34036467
- Dianatinasab M, Wesselius A, Salehi-Abargouei A, Yu EYW, Brinkman M, Fararouei M, et al. (2020). Adherence to a Western dietary pattern and risk of bladder cancer: a pooled analysis of 13 cohort studies of the Bladder Cancer Epidemiology and Nutritional Determinants international study. *Int J Cancer.* 147(12):3394–403. <https://doi.org/10.1002/ijc.33173> PMID:32580241
- Diaz A, Soerjomataram I, Moore S, Whop LJ, Bray F, Hoberg H, et al. (2020). Collection and reporting of Indigenous status information in cancer registries around the world. *JCO Glob Oncol.* 6(6):133–42. <https://doi.org/10.1200/JGO.19.00119> PMID:32031453
- Dillner J, Elfström KM, Baussano I (2021). Prospects for accelerated elimination of cervical cancer. *Prev Med.* 153:106827. <https://doi.org/10.1016/j.yjmed.2021.106827> PMID:34599922
- Dimou N, Mori N, Harlid S, Harbs J, Martin RM, Smith-Byrne K, et al. (2021). Circulating levels of testosterone, sex hormone binding globulin and colorectal cancer risk: observational and Mendelian randomization analyses. *Cancer Epidemiol Biomarkers Prev.* 30(7):1336–48. <https://doi.org/10.1158/1055-9965.EPI-20-1690> PMID:33879453
- Dimou N, Yarmolinsky J, Bouras E, Tsilidis KK, Martin RM, Lewis SJ, et al. (2021). Causal effects of lifetime smoking on breast and colorectal cancer risk: Mendelian randomization study. *Cancer Epidemiol Biomarkers Prev.* 30(5):953–64. <https://doi.org/10.1158/1055-9965.EPI-20-1218> PMID:33653810
- Dimou NL, Papadimitriou N, Mariosa D, Johansson M, Brennan P, Peters U, et al.; CCFR, Endometrial Cancer Association Consortium (2021). Circulating adipokine concentrations and risk of five obesity-related cancers: a Mendelian randomization study. *Int J Cancer.* 148(7):1625–36. <https://doi.org/10.1002/ijc.33338> PMID:33038280
- Doganis D, Katsimpris A, Panagopoulou P, Bouka P, Bouka E, Moschovi M, et al. (2020). Maternal lifestyle characteristics and Wilms tumor risk in the offspring: a systematic review and meta-analysis. *Cancer Epidemiol.* 67:101769. <https://doi.org/10.1016/j.canep.2020.101769> PMID:32659726
- Dooley J, Lagou V, Goveia J, Ulrich A, Rohlenova K, Heirman N, et al. (2020). Heterogeneous effects of calorie content and nutritional components underlie dietary influence on pancreatic cancer susceptibility. *Cell Rep.* 32(2):107880. <https://doi.org/10.1016/j.celrep.2020.107880> PMID:32668252
- Dossus L, Kouloura E, Biessy C, Viallon V, Siskos AP, Dimou N, et al. (2021). Prospective analysis of circulating metabolites and endometrial cancer risk. *Gynecol Oncol.* 162(2):475–81. <https://doi.org/10.1016/j.ygyno.2021.06.001> PMID:34099314
- Drolet M, Laprise JF, Martin D, Jit M, Bénard É, Gingras G, et al. (2021). Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis. *Lancet Infect Dis.* 21(11):1598–610. [https://doi.org/10.1016/S1473-3099\(20\)30860-4](https://doi.org/10.1016/S1473-3099(20)30860-4) PMID:34245682
- Drozdovitch V, Kesminiene A, Moissonnier M, Veyalkin I, Ostroumova E (2020). Uncertainties in radiation doses for a case-control study of thyroid cancer among persons exposed in childhood to ¹³¹I from Chernobyl fallout. *Health Phys.* 119(2):222–35. <https://doi.org/10.1097/HP.0000000000001206> PMID:33290004

- Drozdvovich V, Minenko V, Kukhta T, Trofimik S, Grakovitch R, Hatch M, et al. (2020). Thyroid dose estimates for a cohort of Belarusian persons exposed *in utero* and during early life to Chernobyl fallout. *Health Phys.* 118(2):170–84. <https://doi.org/10.1097/HP.0000000000001135> PMID:31869316
- Duan R, Qiao Y, Clifford G, Zhao F (2020). Cancer burden attributable to human papillomavirus infection by sex, cancer site, age, and geographical area in China. *Cancer Med.* 9(1):374–84. <https://doi.org/10.1002/cam4.2697> PMID:31714036
- Dube Mandishora RS, Rounge TB, Fitzpatrick M, Christiansen IK, Ambur OH, Lagström S, et al. (2021). Self-collected and clinician-collected anal swabs show modest agreement for HPV genotyping. *PLoS One.* 16(4):e0250426. <https://doi.org/10.1371/journal.pone.0250426> PMID:33901223
- Duffell E, Cortez-Pinto H, Simonova M, Dalgard O, Dahl EH, de Martel C, et al. (2021). Estimating the attributable fraction of cirrhosis and hepatocellular carcinoma due to hepatitis B and C. *J Viral Hepat.* 28(8):1177–89. <https://doi.org/10.1111/jvh.13545> PMID:34003542
- Dyba T, Randi G, Bray F, Martos C, Giusti F, Nicholson N, et al. (2021). The European cancer burden in 2020: incidence and mortality estimates for 40 countries and 25 major cancers. *Eur J Cancer.* 157:308–47. <https://doi.org/10.1016/j.ejca.2021.07.039> PMID:34560371
- Easom NJW, Marks M, Jobe D, Gillmore R, Meyer T, Maini MK, et al. (2020). ULBP1 is elevated in human hepatocellular carcinoma and predicts outcome. *Front Oncol.* 10:971. <https://doi.org/10.3389/fonc.2020.00971> PMID:32656081
- Ecke TH, Otto T, Le Calvez-Kelm F (2020). Evaluating the utility of combined bladder cancer biomarkers, the molecular prognostication of tumor subtypes, or what else is needed to illuminate our vision? *Int J Mol Sci.* 21(24):3. <https://doi.org/10.3390/ijms21249657> PMID:33352845
- Eichler SE, Hopperton AP, Alava JJ, Pereira A Jr, Ahmed R, Kozlakidis Z, et al. (2020). A Citizen science facemask experiment and educational modules to improve coronavirus safety in communities and schools. *Front Med (Lausanne).* 7:486. <https://doi.org/10.3389/fmed.2020.00486> PMID:33015086
- Eklund N, Andrianarisoa NH, van Enckevort E, Anton G, Debucquoy A, Müller H, et al. (2020). Extending the Minimum Information About Blobank Data Sharing terminology to describe samples, sample donors, and events. *Biopreserv Biobank.* 18(3):155–64. <https://doi.org/10.1089/bio.2019.0129> PMID:32302498
- El Kinany K, Mint Sidi Decoula M, Hatime Z, Boudouaya HA, Huybrechts I, El Asri A, et al. (2020). Consumption of modern and traditional Moroccan dairy products and colorectal cancer risk: a large case control study. *Eur J Nutr.* 59(3):953–63. <https://doi.org/10.1007/s00394-019-01954-1> PMID:30929068
- Elder DE, Bastian BC, Cree IA, Massi D, Scolyer RA (2020). The 2018 World Health Organization classification of cutaneous, mucosal, and uveal melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary pathway. *Arch Pathol Lab Med.* 144(4):500–22. <https://doi.org/10.5858/arpa.2019-0561-RA> PMID:32057276
- Ellingjord-Dale M, Papadimitriou N, Katsoulis M, Yee C, Dimou N, Gill D, et al. (2021). Coffee consumption and risk of breast cancer: a Mendelian randomization study. *PLoS One.* 16(1):e0236904. <https://doi.org/10.1371/journal.pone.0236904> PMID:33465101
- Engberg E, Figueiredo RAO, Rounge TB, Weiderpass E, Viljakainen H (2020). Heavy screen use on weekends in childhood predicts increased body mass index in adolescence: a three-year follow-up study. *J Adolesc Health.* 66(5):559–66. <https://doi.org/10.1016/j.jadohealth.2019.09.002> PMID:31704105
- Erdmann F, Wellbrock M, Trübenbach C, Spix C, Schrappe M, Schüz J, et al. (2021). Impact of the COVID-19 pandemic on incidence, time of diagnosis and delivery of healthcare among paediatric oncology patients in Germany in 2020: evidence from the German Childhood Cancer Registry and a qualitative survey. *Lancet Reg Health Eur.* 9:100188. <https://doi.org/10.1016/j.lanepe.2021.100188> PMID:34514453
- Ervik M, Napolitano G, Yeung K, Fox C, Hawkins S, Bray F, et al. (2021). CanStaging*. Available from: <https://canstaging.org/tool>.
- Escriva-Boulley G, Mandrik O, Préau M, Herrero R, Villain P (2021). Cognitions and behaviours of general practitioners in France regarding HPV vaccination: a theory-based systematic review. *Prev Med.* 143:106323. <https://doi.org/10.1016/j.yjmed.2020.106323> PMID:33171178
- Eshriqui I, Viljakainen HT, Ferreira SRG, Raju SC, Weiderpass E, Figueiredo RAO (2020). Breastfeeding may have a long-term effect on oral microbiota: results from the Fin-HIT cohort. *Int Breastfeed J.* 15(1):42. <https://doi.org/10.1186/s13006-020-00285-w> PMID:32414385
- Espina C, Yared W, Ritchie D, Lipponen S, Anttila A, Tamminiemi K, et al. (2021). Sustainability and monitoring of the European Code Against Cancer: recommendations. *Cancer Epidemiol.* 72:101933. <https://doi.org/10.1016/j.canep.2021.101933> PMID:33838462
- Etemadi A, Poustchi H, Calafat AM, Blount BC, De Jesús VR, Wang L, et al. (2020). Opiate and tobacco use and exposure to carcinogens and toxicants in the Golestan Cohort Study. *Cancer Epidemiol Biomarkers Prev.* 29(3):650–8. <https://doi.org/10.1158/1055-9965.EPI-19-1212> PMID:31915141
- Eze IC, Jeong A, Schaffner E, Rezwani FI, Ghantous A, Foraster M, et al. (2020). Genome-wide DNA methylation in peripheral blood and long-term exposure to source-specific transportation noise and air pollution: the SAPALDIA study. *Environ Health Perspect.* 128(6):67003. <https://doi.org/10.1289/EHP6174> PMID:32484729
- Farquhar DR, Coniglio AJ, Masood MM, Lenze N, Brennan P, Anantharaman D, et al. (2020). Evaluation of pathologic staging using number of nodes in p16-negative head and neck cancer. *Oral Oncol.* 108:104800. <https://doi.org/10.1016/j.oraloncology.2020.104800> PMID:32492516
- Faure MC, Khoueiry R, Quanicco J, Aclouque H, Guerquin MJ, Bertoldo MJ, et al. (2021). *In utero* exposure to metformin reduces the fertility of male offspring in adulthood. *Front Endocrinol (Lausanne).* 12:750145. <https://doi.org/10.3389/fendo.2021.750145> PMID:34745014
- Fernandez-Cuesta L, Mangiante L, Alcalá N, Foll M (2021). Challenges in lung and thoracic pathology: molecular advances in the classification of pleural mesotheliomas. *Virchows Arch.* 478(1):73–80. <https://doi.org/10.1007/s00428-020-02980-9> PMID:33411030
- Ferreiro-Iglesias A, McKay JD, Brenner N, Virani S, Lesseur C, Gaborieau V, et al. (2021). Germline determinants of humoral immune response to HPV-16 protect against oropharyngeal cancer. *Nat Commun.* 12(1):5945. <https://doi.org/10.1038/s41467-021-26151-9> PMID:34642315

- Fidler-Benaoudia MM, Torre LA, Bray F, Ferlay J, Jemal A (2020). Lung cancer incidence in young women vs. young men: a systematic analysis in 40 countries. *Int J Cancer*. 147(3):811–9. <https://doi.org/10.1002/ijc.32809> PMID:32020598
- Figueiredo RAO, Kajantie E, Neuvonen PJ, Rounge TB, Weiderpass E, Viljakainen H (2021). Lifetime antimicrobial use is associated with weight status in early adolescence – a register-based cohort study. *Pediatr Obes*. 16(3):e12727. <https://doi.org/10.1111/jipo.12727> PMID:32959492
- Fliet SM, Miguel-Berges ML, González-Gil EM, Gottrand F, Censi L, Widhalm K, et al. (2021). The association between portion sizes from high-energy-dense foods and body composition in European adolescents: the HELENA study. *Nutrients*. 13(3):954. <https://doi.org/10.3390/nu13030954> PMID:33809476
- Florio AA, Ferlay J, Znaor A, Ruggieri D, Alvarez CS, Laversanne M, et al. (2020). Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012. *Cancer*. 126(11):2666–78. <https://doi.org/10.1002/cncr.32803> PMID:32129902
- Foerster M, Anele A, Adisa C, Galukande M, Parham G, Zietsman A, et al. (2020a). Few losses to follow-up in a sub-Saharan African cancer cohort via active mobile health follow-up. *Am J Epidemiol*. 189(10):1185–96. <https://doi.org/10.1093/aje/kwaa070> PMID:32383449
- Foerster M, McKenzie F, Zietsman A, Galukande M, Anele A, Adisa C, et al. (2021). Dissecting the journey to breast cancer diagnosis in sub-Saharan Africa: findings from the multicountry ABC-DO cohort study. *Int J Cancer*. 148(2):340–51. <https://doi.org/10.1002/ijc.33209> PMID:32663320
- Foerster M, Schreiber I, Luch A, Schüz J (2020b). Tattoo inks and cancer. *Cancer Epidemiol*. 65:101655. <https://doi.org/10.1016/j.canep.2019.101655> PMID:31836426
- Foll M, Fernandez-Cuesta L (2020). Impact clinique des études moléculaires des tumeurs neuroendocrines pulmonaires. *Correspondances en Onco-Thoracique*. 1(1):41–2.
- Fortner RT, Hüsing A, Dossus L, Tjønneland A, Overvad K, Dahm CC, et al. (2020). Theoretical potential for endometrial cancer prevention through primary risk factor modification: estimates from the EPIC cohort. *Int J Cancer*. 147(5):1325–33. <https://doi.org/10.1002/ijc.32901> PMID:32011733
- Fortner RT, Rice MS, Knutsen SF, Orlich MJ, Visvanathan K, Patel AV, et al. (2020). Ovarian cancer risk factor associations by primary anatomic site: the Ovarian Cancer Cohort Consortium. *Cancer Epidemiol Biomarkers Prev*. 29(10):2010–8. <https://doi.org/10.1158/1055-9965.EPI-20-0354> PMID:32732252
- Foy JP, Bertolus C, Boutolleau D, Agut H, Gessain A, Herczeg Z, et al. (2020). Arguments to support a viral origin of oral squamous cell carcinoma in non-smoker and non-drinker patients. *Front Oncol*. 10:822. <https://doi.org/10.3389/fonc.2020.00822> PMID:32528893
- Fraser K, Kodali V, Yanamala N, Birch ME, Cena L, Casuccio G, et al. (2020). Physicochemical characterization and genotoxicity of the broad class of carbon nanotubes and nanofibers used or produced in U.S. facilities. *Part Fibre Toxicol*. 17(1):62. <https://doi.org/10.1186/s12989-020-00392-w> PMID:33287860
- Freisling H, Seyed Khoei N, Viallon V, Wagner KH (2020). Gilbert's syndrome, circulating bilirubin and lung cancer: a genetic advantage? *Thorax*. 75(11):916–7. <https://doi.org/10.1136/thoraxjnl-2020-215642> PMID:33023993
- Freisling H, Viallon V, Lennon H, Bagnardi V, Ricci C, Butterworth AS, et al. (2020a). Lifestyle factors and risk of multimorbidity of cancer and cardiometabolic diseases: a multinational cohort study. *BMC Med*. 18(1):5. <https://doi.org/10.1186/s12916-019-1474-7> PMID:31918762
- Fuhrman BJ, Moore SC, Byrne C, Makhoul I, Kitahara CM, Berrington de González A, et al. (2021). Association of the age at menarche with site-specific cancer risks in pooled data from nine cohorts. *Cancer Res*. 81(8):2246–55. <https://doi.org/10.1158/0008-5472.CAN-19-3093> PMID:33820799
- Gabriel AAG, Mathian E, Mangiante L, Voegelé C, Cahais V, Ghantous A, et al. (2020). A molecular map of lung neuroendocrine neoplasms. *Gigascience*. 9(11):giaa112. <https://doi.org/10.1093/gigascience/giaa112> PMID:33124659
- Gadgil A, Sauvaget C, Roy N, Muwonge R, Lucas E, Sankaranarayanan R (2020). Setting up a breast cancer awareness project in Mumbai: methodology, experiences and challenges. *J Cancer Educ*. 35(3):579–88. <https://doi.org/10.1007/s13187-019-01500-x> PMID:30863980
- Galateau Salle F, Le Stang N, Tirode F, Courtiol P, Nicholson AG, Tsao MS, et al. (2020). Comprehensive molecular and pathologic evaluation of transitional mesothelioma assisted by deep learning approach: a multi-institutional study of the International Mesothelioma Panel from the MESOPATH Reference Center. *J Thorac Oncol*. 15(6):1037–53. <https://doi.org/10.1016/j.jtho.2020.01.025> PMID:32165206
- Galati L, Brancaccio RN, Gupta P, Lohmann E, Robitaille A, Mandishora RSD, et al. (2021). Diversity of human papillomavirus in the anal canal of HIV-positive and HIV-negative men. *J Infect*. 82(1):112–6. <https://doi.org/10.1016/j.jinf.2020.11.030> PMID:33253726
- Galati L, Brancaccio RN, Robitaille A, Cuenin C, Luzi F, Fiorucci G, et al. (2020a). Detection of human papillomaviruses in paired healthy skin and actinic keratosis by next generation sequencing. *Papillomavirus Res*. 9:100196. <https://doi.org/10.1016/j.pvr.2020.100196> PMID:32222599
- Galati L, Combes JD, Gupta P, Sen R, Robitaille A, Brancaccio RN, et al. (2020). Detection of a large spectrum of viral infections in conjunctival premalignant and malignant lesions. *Int J Cancer*. 147(10):2862–70. <https://doi.org/10.1002/ijc.33149> PMID:32525572
- Galimberti M, Leuenberger C, Wolf B, Szilágyi SM, Foll M, Wegmann D (2020). Detecting selection from linked sites using an *F*-model. *Genetics*. 216(4):1205–15. <https://doi.org/10.1534/genetics.120.303780> PMID:33067324
- Galukande M, Schüz J, Anderson BO, Zietsman A, Adisa C, Anele A, et al. (2021). Maternally orphaned children and intergenerational concerns associated with breast cancer deaths among women in sub-Saharan Africa. *JAMA Oncol*. 7(2):285–9. <https://doi.org/10.1001/jamaoncol.2020.6583> PMID:33355599
- Gama RR, Arantes LMRB, Sorroche BP, De Marchi P, Melendez ME, Carvalho RS, et al. (2021). Evaluation of acetylation and methylation in oral rinse of patients with head and neck cancer history exposed to valproic acid. *Sci Rep*. 11(1):16415. <https://doi.org/10.1038/s41598-021-95845-3> PMID:34385507
- Garcia DL, Kozlakidis Z (2021). Letter to the editor: ISBER two decades and beyond: honoring our past, celebrating the present, and envisioning our future. *Biopreserv Biobank*. 19(4):353–4. <https://doi.org/10.1089/bio.2021.29088.dlg> PMID:34129381

- Garro-Aguilar Y, Cayssials V, Achaintre D, Boeing H, Mancini FR, Mahamat-Saleh Y, et al. (2020). Correlations between urinary concentrations and dietary intakes of flavonols in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. *Eur J Nutr.* 59(4):1481–92. <https://doi.org/10.1007/s00394-019-02005-5> PMID:31119398
- Gasenko E, Leja M, Polaka I, Hegmane A, Murillo R, Bordin D, et al. (2020). How do international gastric cancer prevention guidelines influence clinical practice globally? *Eur J Cancer Prev.* 29(5):400–7. <https://doi.org/10.1097/CEJ.0000000000000580> PMID:32740165
- Gbenonsi G, Boucham M, Belhiti Z, Nejari C, Huybrechts I, Khalis M (2021). Health system factors that influence diagnostic and treatment intervals in women with breast cancer in sub-Saharan Africa: a systematic review. *BMC Public Health.* 21(1):1325. <https://doi.org/10.1186/s12889-021-11296-5> PMID:34229634
- Ge C, Peters S, Olsson A, Portengen L, Schüz J, Almansa J, et al. (2020a). Diesel engine exhaust exposure, smoking, and lung cancer subtype risks. A pooled exposure-response analysis of 14 case-control Studies. *Am J Respir Crit Care Med.* 202(3):402–11. <https://doi.org/10.1164/rccm.201911-2101OC> PMID:32330395
- Ge C, Peters S, Olsson A, Portengen L, Schüz J, Almansa J, et al. (2020b). Respirable crystalline silica exposure, smoking, and lung cancer subtype risks. A pooled analysis of case-control studies. *Am J Respir Crit Care Med.* 202(3):412–21. <https://doi.org/10.1164/rccm.201910-1926OC> PMID:32330394
- Geijsen AJMR, Kok DE, van Zutphen M, Keski-Rahkonen P, Achaintre D, Gicquiau A, et al. (2021). Diet quality indices and dietary patterns are associated with plasma metabolites in colorectal cancer patients. *Eur J Nutr.* 60(6):3171–84. PMID:33544207
- Geijsen AJMR, van Roekel EH, van Duijnhoven FJB, Achaintre D, Bachleitner-Hofmann T, Baierl A, et al. (2020). Plasma metabolites associated with colorectal cancer stage: findings from an international consortium. *Int J Cancer.* 146(12):3256–66. <https://doi.org/10.1002/ijc.32666> PMID:31495913
- Genere N, El Kawki OM, Giblon RE, Vaccarella S, Morris JC, Hay ID, et al. (2021). Incidence of clinically relevant thyroid cancers remains stable for almost a century: a population-based study. *Mayo Clin Proc.* 96(11):2823–30. <https://doi.org/10.1016/j.mayocp.2021.04.028> PMID:34736609
- Gentiluomo M, Katzke VA, Kaaks R, Tjønneland A, Severi G, Perduca V, et al. (2020). Mitochondrial DNA copy-number variation and pancreatic cancer risk in the prospective EPIC cohort. *Cancer Epidemiol Biomarkers Prev.* 29(3):681–6. <https://doi.org/10.1158/1055-9965.EPI-19-0868> PMID:31932413
- Genua F, Raghunathan V, Jenab M, Gallagher WM, Hughes DJ (2021). The role of gut barrier dysfunction and microbiome dysbiosis in colorectal cancer development. *Front Oncol.* 11:626349. <https://doi.org/10.3389/fonc.2021.626349> PMID:33937029
- Georgiou AN, Ntritsos G, Papadimitriou N, Dimou N, Evangelou E (2021). Cigarette smoking, coffee consumption, alcohol intake, and risk of Crohn's disease and ulcerative colitis: a Mendelian randomization study. *Inflamm Bowel Dis.* 27(2):162–8. <https://doi.org/10.1093/ibd/izaa152> PMID:32628751
- Ghantous A, Novoloaca A, Bouaoun L, Cuenin C, Cros MP, Xu Y, et al. (2021). Aflatoxin exposure during early life is associated with differential DNA methylation in two-year-old Gambian children. *Int J Mol Sci.* 22(16):8967. <https://doi.org/10.3390/ijms22168967> PMID:34445674
- Ghasemi-Kebria F, Amiriani T, Fazel A, Naimi-Tabiei M, Norouzi A, Khoshnia M, et al. (2020). Trends in the incidence of stomach cancer in Golestan Province, a high-risk area in Northern Iran, 2004–2016. *Arch Iran Med.* 23(6):362–8. <https://doi.org/10.34172/aim.2020.28> PMID:32536172
- Ghasemi-Kebria F, Jafari-Delouie N, Amiriani T, Norouzi A, Abedi-Ardekani B, Nasrollahzadeh D, et al. (2021). Building a cancer biobank in a low-resource setting in northern Iran: the Golestan Cancer Biobank. *Arch Iran Med.* 24(7):526–33. <https://doi.org/10.34172/aim.2021.75> PMID:34488317
- Gheyt T, Rollo F, Brancaccio RN, Robitaille A, Galati L, Giuliani M, et al. (2020). Oral infection by mucosal and cutaneous human papillomaviruses in the men who have sex with men from the OHMAR study. *Viruses.* 12(8):15. <https://doi.org/10.3390/v12080899> PMID:32824507
- Ghiesvand R, Green AC, Sandanger TM, Weiderpass E, Robsahm TE, Veierød MB (2021). Phenotypic characteristics and melanoma thickness in women. *Acta Derm Venereol.* 101(4):adv00446. <https://doi.org/10.2340/00015555-3806> PMID:33880571
- Ghoneim DH, Zhu J, Zheng W, Long J, Murff HJ, Ye F, et al. (2020). Mendelian randomization analysis of n-6 polyunsaturated fatty acid levels and pancreatic cancer risk. *Cancer Epidemiol Biomarkers Prev.* 29(12):2735–9. <https://doi.org/10.1158/1055-9965.EPI-20-0651> PMID:32967863
- Gibbs DC, Bostick RM, McCullough ML, Um CY, Flanders WD, Jenab M, et al. (2020). Association of prediagnostic vitamin D status with mortality among colorectal cancer patients differs by common, inherited vitamin D-binding protein isoforms. *Int J Cancer.* 147(10):2725–34. <https://doi.org/10.1002/ijc.33043> PMID:32391587
- Ginsburg O, Ashton-Prolla P, Cantor A, Mariosa D, Brennan P (2021a). The role of genomics in global cancer prevention. *Nat Rev Clin Oncol.* 18(2):116–28. <https://doi.org/10.1038/s41571-020-0428-5> PMID:32973296
- Ginsburg O, Basu P, Kapambwe S, Canfell K (2021). Eliminating cervical cancer in the COVID-19 era. *Nat Can.* 2(2):133–4. <https://doi.org/10.1038/s43018-021-00178-9>
- Ginsburg O, Weiderpass E (2020). What will it take to eliminate cervical cancer in the USA? *Lancet Public Health.* 5(4):e182–3. [https://doi.org/10.1016/S2468-2667\(20\)30028-1](https://doi.org/10.1016/S2468-2667(20)30028-1) PMID:32057316
- Ginsburg O, Yip CH, Brooks A, Cabanes A, Caleffi M, Dunstan Yataco JA, et al. (2020). Breast cancer early detection: a phased approach to implementation. *Cancer.* 126(Suppl 10):2379–93. <https://doi.org/10.1002/cncr.32887> PMID:32348566
- Gonzalez-Ericsson PI, Stovgaard ES, Sua LF, Reisenbichler E, Kos Z, Carter JM, et al.; International Immuno-Oncology Biomarker Working Group (2020). The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. *J Pathol.* 250(5):667–84. <https://doi.org/10.1002/path.5406> PMID:32129476

- González-Gil EM, Huybrechts I, Aguilera CM, Béghin L, Breidenassel C, Gesteiro E, et al. (2021). Cardiometabolic risk is positively associated with underreporting and inversely associated with overreporting of energy intake among European adolescents: the Healthy Lifestyle in Europe by Nutrition in Adolescence (HELENA) Study. *J Nutr.* 151(3):675–84. <https://doi.org/10.1093/jn/nxaa389> PMID:33484148
- Gormley M, Dudding T, Sanderson E, Martin RM, Thomas S, Tyrrell J, et al. (2020). A multivariable Mendelian randomization analysis investigating smoking and alcohol consumption in oral and oropharyngeal cancer. *Nat Commun.* 11(1):6071. <https://doi.org/10.1038/s41467-020-19822-6> PMID:33247085
- Gormley M, Yarmolinsky J, Dudding T, Burrows K, Martin RM, Thomas S, et al. (2021). Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: a Mendelian randomization study. *PLoS Genet.* 17(4):e1009525. <https://doi.org/10.1371/journal.pgen.1009525> PMID:33886544
- Gredner T, Mons U, Niedermaier T, Brenner H, Soerjomataram I (2021). Impact of tobacco control policies implementation on future lung cancer incidence in Europe: an international, population-based modeling study. *Lancet Reg Health Eur.* 4:100074. <https://doi.org/10.1016/j.lanepe.2021.100074> PMID:34029359
- Grimsrud TK, Pukkala E, Weiderpass E (2020). The use of register data in occupational cancer control. In: Anttila S, Boffetta P, editors. *Occupational cancers*, 2nd ed. Basel, Switzerland: Springer Nature Switzerland AG; pp. 619–626.
- Guha N, Bouaoun L, Kromhout H, Vermeulen R, Brüning T, Behrens T, et al. (2021). Lung cancer risk in painters: results from the SYNERGY pooled case-control study consortium. *Occup Environ Med.* 78(4):269–78. <https://doi.org/10.1136/oemed-2020-106770> PMID:33115922
- Guida F, Tan VY, Corbin LJ, Smith-Byrne K, Alcalá K, Langenberg C, et al. (2021). The blood metabolome of incident kidney cancer: a case-control study nested within the MetKid consortium. *PLoS Med.* 18(9):e1003786. <https://doi.org/10.1371/journal.pmed.1003786> PMID:34543281
- Gumpenberger T, Brezina S, Keski-Rahkonen P, Baierl A, Robinot N, Leeb G, et al. (2021). Untargeted metabolomics reveals major differences in the plasma metabolome between colorectal cancer and colorectal adenomas. *Metabolites.* 11(2):119. <https://doi.org/10.3390/metabo11020119> PMID:33669644
- Guo X, Lin W, Wen W, Huyghe J, Bien S, Cai Q, et al. (2021). Identifying novel susceptibility genes for colorectal cancer risk from a transcriptome-wide association study of 125,478 subjects. *Gastroenterology.* 160(4):1164–1178. e6. <https://doi.org/10.1053/j.gastro.2020.08.062> PMID:33058866
- Gupta P, Shahzad N, Harold A, Shuda M, Venuti A, Romero-Medina MC, et al. (2020a). Merkel cell polyomavirus downregulates N-myc downstream-regulated gene 1, leading to cellular proliferation and migration. *J Virol.* 94(3):e00899–00819. <https://doi.org/10.1128/JVI.00899-19> PMID:31694959
- Gupta S, Aitken J, Bartels U, Bhakta N, Bucurenci M, Brierley JD, et al. (2020). Development of paediatric non-stage prognosticator guidelines for population-based cancer registries and updates to the 2014 Toronto Paediatric Cancer Stage Guidelines. *Lancet Oncol.* 21(9):e444–51. [https://doi.org/10.1016/S1470-2045\(20\)30320-X](https://doi.org/10.1016/S1470-2045(20)30320-X) PMID:32888473
- Gupta S, Harper A, Ruan Y, Barr R, Frazier AL, Ferlay J, et al. (2020). International trends in the incidence of cancer among adolescents and young adults. *J Natl Cancer Inst.* 112(11):1105–17. <https://doi.org/10.1093/jnci/djaa007> PMID:32016323
- Guseva Canu I, Gaillen-Guedy A, Wild P, Straif K, Luce D (2020). Lung cancer mortality in the French cohort of titanium dioxide workers: some aetiological insights. *Occup Environ Med.* 77(11):795–7. <https://doi.org/10.1136/oemed-2020-106522> PMID:32737152
- Guyton KZ, Schubauer-Berigan MK (2021). Invited perspective: prioritizing chemical testing and evaluation using validated *in vitro* assays relevant to key characteristics. *Environ Health Perspect.* 129(7):71303. <https://doi.org/10.1289/EHP9507> PMID:34287027
- Hadji M, Rashidian H, Marzban M, Gholipour M, Naghibzadeh-Tahami A, Mohebbi E, et al. (2021). The Iranian Study of Opium and Cancer (IROPICAN): rationale, design, and initial findings. *Arch Iran Med.* 24(3):167–76. <https://doi.org/10.34172/aim.2021.27> PMID:33878874
- Hageman S, Pennells L, Ojeda F, Kaptoge S, Kuulasmaa K, de Vries T, et al.; SCORE2 working group and ESC Cardiovascular risk collaboration (2021). SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. *Eur Heart J.* 42(25):2439–54. <https://doi.org/10.1093/eurheartj/ehab309> PMID:34120177
- Halaburkova A, Cahais V, Novoloaca A, Araujo MGDS, Khoueiry R, Ghantous A, et al. (2020). Pan-cancer multi-omics analysis and orthogonal experimental assessment of epigenetic driver genes. *Genome Res.* 30(10):1517–32. <https://doi.org/10.1101/gr.268292.120> PMID:32963031
- Hall AL, Kromhout H, Schüz J, Peters S, Portengen L, Vermeulen R, et al. (2020). Laryngeal cancer risks in workers exposed to lung carcinogens: exposure-effect analyses using a quantitative job exposure matrix. *Epidemiology.* 31(1):145–54. <https://doi.org/10.1097/EDE.0000000000001120> PMID:31577634
- Hana CA, Tran LV, Mölzer C, Müllner E, Hörmann-Wallner M, Franzke B, et al. (2021). Serum metabolomics analysis reveals increased lipid catabolism in mildly hyperbilirubinemic Gilbert's syndrome individuals. *Metabolism.* 125:154913. <https://doi.org/10.1016/j.metabol.2021.154913> PMID:34653509
- Handakas E, Keski-Rahkonen P, Chatzi L, Alfano R, Roumeliotaki T, Plusquin M, et al. (2021). Cord blood metabolic signatures predictive of childhood overweight and rapid growth. *Int J Obes (Lond).* 45(10):2252–60. <https://doi.org/10.1038/s41366-021-00888-1> PMID:34253844
- Hanley-Cook GT, Huybrechts I, Biessy C, Remans R, Kennedy G, Deschasaux-Tanguy M, et al. (2021). Food biodiversity and total and cause-specific mortality in 9 European countries: an analysis of a prospective cohort study. *PLoS Med.* 18(10):e1003834. <https://doi.org/10.1371/journal.pmed.1003834> PMID:34662340
- Hanly P, Ortega Ortega M, Pearce A, Soerjomataram I, Sharp L (2020). Advances in the methodological approach to friction period estimation: a European perspective. *Soc Sci Med.* 264:113289. <https://doi.org/10.1016/j.socscimed.2020.113289> PMID:32836019
- Hantikainen E, Löf M, Grotta A, Trolle Lagerros Y, Serafini M, Bellocco R, et al. (2020). Dietary non-enzymatic antioxidant capacity and risk of stroke: the Swedish Women's Lifestyle and Health Cohort. *Nutrition.* 73:110723. <https://doi.org/10.1016/j.nut.2020.110723> PMID:32135416

- Hardikar S, Albrechtsen RD, Achaintre D, Lin T, Pauleck S, Playdon M, et al. (2020). Impact of pre-blood collection factors on plasma metabolomic profiles. *Metabolites*. 10(5):14. <https://doi.org/10.3390/metabo10050213> PMID:32455751
- Hariri S, Sharafi H, Sheikh M, Merat S, Hashemi F, Azimian F, et al. (2020). Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era. *Harm Reduct J*. 17(1):80. <https://doi.org/10.1186/s12954-020-00431-x> PMID:33081794
- Harlid S, Gunter MJ, Van Guelpen B (2021). Risk-predictive and diagnostic biomarkers for colorectal cancer; a systematic review of studies using pre-diagnostic blood samples collected in prospective cohorts and screening settings. *Cancers (Basel)*. 13(17):4406. <https://doi.org/10.3390/cancers13174406> PMID:34503217
- Harlid S, Harbs J, Myte R, Brunius C, Gunter MJ, Palmqvist R, et al. (2021). A two-tiered targeted proteomics approach to identify pre-diagnostic biomarkers of colorectal cancer risk. *Sci Rep*. 11(1):5151. <https://doi.org/10.1038/s41598-021-83968-6> PMID:33664295
- Harms LM, Scalbert A, Zamora-Ros R, Rinaldi S, Jenab M, Murphy N, et al. (2020). Plasma polyphenols associated with lower high-sensitivity C-reactive protein concentrations: a cross-sectional study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. *Br J Nutr*. 123(2):198–208. <https://doi.org/10.1017/S0007114519002538> PMID:31583990
- Hashemian M, Merat S, Poustchi H, Jafari E, Radmard AR, Kamangar F, et al. (2021). Red meat consumption and risk of nonalcoholic fatty liver disease in a population with low meat consumption: the Golestan Cohort Study. *Am J Gastroenterol*. 116(8):1667–75. <https://doi.org/10.14309/ajg.0000000000001229> PMID:33767101
- Hassler MR, Bray F, Catto JWF, Grollman AP, Hartmann A, Margulis V, et al. (2020). Molecular characterization of upper tract urothelial carcinoma in the era of next-generation sequencing: a systematic review of the current literature. *Eur Urol*. 78(2):209–20. <https://doi.org/10.1016/j.eururo.2020.05.039> PMID:32571725
- Hatime Z, El Kinany K, Huybrechts I, Gunter MJ, Khalis M, Deoula M, et al. (2021). Extended healthy lifestyle index and colorectal cancer risk in the Moroccan population. *Eur J Nutr*. 60(2):1013–22. <https://doi.org/10.1007/s00394-020-02311-3> PMID:32572618
- Heath AK, Clasen JL, Jayanth NP, Jenab M, Tjønneland A, Petersen KEN, et al. (2021). Soft drink and juice consumption and renal cell carcinoma incidence and mortality in the European Prospective Investigation into Cancer and Nutrition. *Cancer Epidemiol Biomarkers Prev*. 30(6):1270–4. <https://doi.org/10.1158/1055-9965.EPI-20-1726> PMID:33849969
- Heath AK, Muller DC, van den Brandt PA, Papadimitriou N, Critselis E, Gunter M, et al. (2020). Nutrient-wide association study of 92 foods and nutrients and breast cancer risk. *Breast Cancer Res*. 22(1):5. <https://doi.org/10.1186/s13058-019-1244-7> PMID:31931881
- Heer E, Harper A, Escandor N, Sung H, McCormack V, Fidler-Benaoudia MM (2020). Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. *Lancet Glob Health*. 8(8):e1027–37. [https://doi.org/10.1016/S2214-109X\(20\)30215-1](https://doi.org/10.1016/S2214-109X(20)30215-1) PMID:32710860
- Hejazi J, Ghanavati M, Hejazi E, Poustchi H, Sepanlou SG, Khoshnia M, et al. (2020). Habitual dietary intake of flavonoids and all-cause and cause-specific mortality: Golestan Cohort Study. *Nutr J*. 19(1):108. <https://doi.org/10.1186/s12937-020-00627-8> PMID:32988395
- Henderson MK, Afifi N, Kozlakidis Z (2021). Zooming along through the pandemic: our experiences with virtual biobanking conferences and workshops. *Biopreserv Biobank*. 19(4):247–9. <https://doi.org/10.1089/bio.2021.29091.mkh> PMID:34348044
- Henderson MK, Kozlakidis Z (2020). Coronavirus and biobanking: the collective global experiences of the first wave and bracing during the second. *Biopreserv Biobank*. 18(6):481–2. <https://doi.org/10.1089/bio.2020.29077.mjk> PMID:33147072
- Henderson MK, Kozlakidis Z, Fachiroh J, Wiafe Addai B, Xu X, Ezzat S, et al. (2020). The responses of biobanks to COVID-19. *Biopreserv Biobank*. 18(6):483–91. <https://doi.org/10.1089/bio.2020.29074.mkh> PMID:32871085
- Herrero R, Heise K, Acevedo J, Cook P, Gonzalez C, Gahona J, et al.; ENIGMA Chile study group (2020). Regional variations in *Helicobacter pylori* infection, gastric atrophy and gastric cancer risk: the ENIGMA study in Chile. *PLoS One*. 15(9):e0237515. <https://doi.org/10.1371/journal.pone.0237515> PMID:32898138
- Hidaka A, Harrison TA, Cao Y, Sakoda LC, Barfield R, Giannakis M, et al. (2020). Intake of dietary fruit, vegetables, and fiber and risk of colorectal cancer according to molecular subtypes: a pooled analysis of 9 studies. *Cancer Res*. 80(20):4578–90. <https://doi.org/10.1158/0008-5472.CAN-20-0168> PMID:32816852
- Hii LW, Chung FF, Mai CW, Yee ZY, Chan HH, Raja VJ, et al. (2020). Sphingosine kinase 1 regulates the survival of breast cancer stem cells and non-stem breast cancer cells by suppression of STAT1. *Cells*. 9(4):23. <https://doi.org/10.3390/cells9040886> PMID:32260399
- Hii LW, Chung FF, Soo JS, Tan BS, Mai CW, Leong CO (2020). Histone deacetylase (HDAC) inhibitors and doxorubicin combinations target both breast cancer stem cells and non-stem breast cancer cells simultaneously. *Breast Cancer Res Treat*. 179(3):615–29. <https://doi.org/10.1007/s10549-019-05504-5> PMID:31784862
- His M, Biessy C, Torres-Mejía G, Ángeles-Llerenas A, Alvarado-Cabrero I, Sánchez GI, et al.; PRECAMA team (2020). Anthropometry, body shape in early-life and risk of premenopausal breast cancer among Latin American women: results from the PRECAMA study. *Sci Rep*. 10(1):2294. <https://doi.org/10.1038/s41598-020-59056-6> PMID:32042008
- His M, Lajous M, Gómez-Flores-Ramos L, Monge A, Dossus L, Viallon V, et al. (2021a). Biomarkers of mammographic density in premenopausal women. *Breast Cancer Res*. 23(1):75. <https://doi.org/10.1186/s13058-021-01454-3> PMID:34301304
- His M, Viallon V, Dossus L, Schmidt JA, Travis RC, Gunter MJ, et al. (2021b). Lifestyle correlates of eight breast cancer-related metabolites: a cross-sectional study within the EPIC cohort. *BMC Med*. 19(1):312. <https://doi.org/10.1186/s12916-021-02183-2> PMID:34886862

- Holowatyj AN, Gigic B, Herpel E, Scalbert A, Schneider M, Ulrich CM; MetaboCCC Consortium; ColoCare Study (2020). Distinct molecular phenotype of sporadic colorectal cancers among young patients based on multiomics analysis. *Gastroenterology*. 158(4):1155–1158. e2. <https://doi.org/10.1053/j.gastro.2019.11.012> PMID:31730769
- Holowatyj AN, Haffa M, Lin T, Scherer D, Gigic B, Ose J, et al. (2020). Multi-omics analysis reveals adipose-tumor crosstalk in patients with colorectal cancer. *Cancer Prev Res (Phila)*. 13(10):817–28. <https://doi.org/10.1158/1940-6207.CAPR-19-0538> PMID:32655010
- Honaryar MK, Tarasenko Y, Almonte M, Smelov V (2020). Epidemiology of cancers in men who have sex with men (MSM): a protocol for umbrella review of systematic reviews. *Int J Environ Res Public Health*. 17(14):4954. <https://doi.org/10.3390/ijerph17144954> PMID:32660003
- Hornigold N, Dunn KR, Craven RA, Zougman A, Trainor S, Shreeve R, et al. (2020). Dysregulation at multiple points of the kynurenine pathway is a ubiquitous feature of renal cancer: implications for tumour immune evasion. *Br J Cancer*. 123(1):137–47. <https://doi.org/10.1038/s41416-020-0874-y> PMID:32390008
- Hosen MI, Forey N, Durand G, Voegelé C, Bilici S, Avogbe PH, et al. (2020). Development of sensitive droplet digital PCR assays for detecting urinary *TERT* promoter mutations as non-invasive biomarkers for detection of urothelial cancer. *Cancers (Basel)*. 12(12):3541. <https://doi.org/10.3390/cancers12123541> PMID:33260905
- Hosen MI, Sheikh M, Zvereva M, Scelo G, Forey N, Durand G, et al. (2020a). Urinary *TERT* promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: evidence from the Golestan Cohort Study. *EBioMedicine*. 53:102643. <https://doi.org/10.1016/j.ebiom.2020.102643> PMID:32081602
- Hosseini B, Hall AL, Zendejdel K, Kromhout H, Onyije FM, Moradzadeh R, et al. (2021). Occupational exposure to carcinogens and occupational epidemiological cancer studies in Iran: a review. *Cancers (Basel)*. 13(14):3581. <https://doi.org/10.3390/cancers13143581> PMID:34298794
- Hovanec J, Siemiatycki J, Conway DI, Olsson A, Guenel P, Luce D, et al. (2021). Application of two job indices for general occupational demands in a pooled analysis of case-control studies on lung cancer. *Scand J Work Environ Health*. 47(6):475–81. <https://doi.org/10.5271/sjweh.3967> PMID:33942106
- Howe CG, Cox B, Fore R, Jungius J, Kvist T, Lent S, et al. (2020). Maternal gestational diabetes mellitus and newborn DNA methylation: findings from the Pregnancy and Childhood Epigenetics Consortium. *Diabetes Care*. 43(1):98–105. <https://doi.org/10.2337/dc19-0524> PMID:31601636
- Howe LJ, Hemani G, Lesseur C, Gaborieau V, Ludwig KU, Mangold E, et al. (2020). Evaluating shared genetic influences on nonsyndromic cleft lip/palate and oropharyngeal neoplasms. *Genet Epidemiol*. 44(8):924–33. <https://doi.org/10.1002/gepi.22343> PMID:32710482
- Hua X, Dai JY, Lindström S, Harrison TA, Lin Y, Alberts SR, et al. (2021). Genetically predicted circulating C-reactive protein concentration and colorectal cancer survival: a Mendelian randomization consortium study. *Cancer Epidemiol Biomarkers Prev*. 30(7):1349–58. <https://doi.org/10.1158/1055-9965.EPI-20-1848> PMID:33972368
- Huang JY, Larose TL, Luu HN, Wang R, Fanidi A, Alcalá K, et al. (2020). Circulating markers of cellular immune activation in prediagnostic blood sample and lung cancer risk in the Lung Cancer Cohort Consortium (LC3). *Int J Cancer*. 146(9):2394–405. <https://doi.org/10.1002/ijc.32555> PMID:31276202
- Huang T, Townsend MK, Wentzensen N, Trabert B, White E, Arslan AA, et al. (2020). Reproductive and hormonal factors and risk of ovarian cancer by tumor dominance: results from the Ovarian Cancer Cohort Consortium (OC3). *Cancer Epidemiol Biomarkers Prev*. 29(1):200–7. <https://doi.org/10.1158/1055-9965.EPI-19-0734> PMID:31719062
- Hubert JN, Suybeng V, Vallée M, Delhomme TM, Maubec E, Boland A, et al. (2021). The PI3K/mTOR pathway is targeted by rare germline variants in patients with both melanoma and renal cell carcinoma. *Cancers (Basel)*. 13(9):2243. <https://doi.org/10.3390/cancers13092243> PMID:34067022
- Humphrey OS, Middleton DRS, Ahmad S, Cocerva T, Dowell SM, Garza-Galindo R, et al. (2021). The Society for Environmental Geochemistry and Health (SEGH): building for the future of early career researchers. *Environ Geochem Health*. 43(7):2455–8. <https://doi.org/10.1007/s10653-020-00620-4> PMID:32613477
- Hung RJ, Warkentin MT, Brhane Y, Chatterjee N, Christiani DC, Landi MT, et al. (2021). Assessing lung cancer absolute risk trajectory based on a polygenic risk model. *Cancer Res*. 81(6):1607–15. <https://doi.org/10.1158/0008-5472.CAN-20-1237> PMID:33472890
- Huybrechts I, Kliemann N, Perol O, Cattetey-Javouhey A, Benech N, Maire A, et al. (2021). Feasibility study to assess the impact of a lifestyle intervention during colorectal cancer screening in France. *Nutrients*. 13(11):3685. <https://doi.org/10.3390/nu13113685> PMID:34835941
- Huybrechts I, Miglio R, Mistura L, Grioni S, Pozzebon I, Odorifero C, et al. (2021). Relative validity of an Italian EPIC food frequency questionnaire for dietary factors in children and adolescents. A Rizzoli Orthopedic Institute Study. *Nutrients*. 13(4):1245. <https://doi.org/10.3390/nu13041245> PMID:33918879
- Huybrechts I, Zouiouich S, Loobuyck A, Vandembulcke Z, Vogtmann E, Pisanu S, et al. (2020). The human microbiome in relation to cancer risk: a systematic review of epidemiologic studies. *Cancer Epidemiol Biomarkers Prev*. 29(10):1856–68. <https://doi.org/10.1158/1055-9965.EPI-20-0288> PMID:32727720
- Huyghe JR, Harrison TA, Bien SA, Hampel H, Figueiredo JC, Schmit SL, et al. (2021). Genetic architectures of proximal and distal colorectal cancer are partly distinct. *Gut*. 70(7):1325–34. <https://doi.org/10.1136/gutjnl-2020-321534> PMID:33632709
- IARC Monographs Vol 126 group (2020). Carcinogenicity of opium consumption. *Lancet Oncol*. 21(11):1407–8. [https://doi.org/10.1016/S1470-2045\(20\)30611-2](https://doi.org/10.1016/S1470-2045(20)30611-2) PMID:33038940
- Ibsen DB, Steur M, Imamura F, Overvad K, Schulze MB, Bendinelli B, et al. (2020). Replacement of red and processed meat with other food sources of protein and the risk of type 2 diabetes in European populations: the EPIC-InterAct study. *Diabetes Care*. 43(11):2660–7. <https://doi.org/10.2337/dc20-1038> PMID:32868270

- ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium (2020). Pan-cancer analysis of whole genomes. *Nature*. 578(7793):82–93. <https://doi.org/10.1038/s41586-020-1969-6> PMID:32025007
- Idahl A, Le Cornet C, González Maldonado S, Waterboer T, Bender N, Tjønneland A, et al. (2020). Serologic markers of *Chlamydia trachomatis* and other sexually transmitted infections and subsequent ovarian cancer risk: results from the EPIC cohort. *Int J Cancer*. 147(8):2042–52. <https://doi.org/10.1002/ijc.32999> PMID:32243586
- Iguacel I, Börnhorst C, Michels N, Breidenassel C, Dallongeville J, González-Gross M, et al. (2021). Socioeconomically disadvantaged groups and metabolic syndrome in European adolescents: the HELENA study. *J Adolesc Health*. 68(1):146–54. <https://doi.org/10.1016/j.jadohealth.2020.05.027> PMID:32636143
- Iguacel I, Huybrechts I, Moreno LA, Michels N (2021). Vegetarianism and veganism compared with mental health and cognitive outcomes: a systematic review and meta-analysis. *Nutr Rev*. 79(4):361–81. <https://doi.org/10.1093/nutrit/nuaa030> PMID:32483598
- Iguacel I, Schmidt JA, Perez-Cornago A, Van Puyvelde H, Travis R, Stepien M, et al. (2021). Associations between dietary amino acid intakes and blood concentration levels. *Clin Nutr*. 40(6):3772–9. <https://doi.org/10.1016/j.clnu.2021.04.036> PMID:34130023
- Ilbawi A, Dhaene G, Meheus F, Bertram M (2020). Opportunities to improve cancer control and progress towards universal health coverage in Commonwealth nations. *Lancet Oncol*. 21(7):876–9. [https://doi.org/10.1016/S1470-2045\(20\)30245-X](https://doi.org/10.1016/S1470-2045(20)30245-X) PMID:32615104
- Irvin SR, Weiderpass E, Stanczyk FZ, Brinton LA, Trabert B, Langseth H, et al. (2020). Association of anti-Müllerian hormone, follicle-stimulating hormone, and inhibin B with risk of ovarian cancer in the Janus Serum Bank. *Cancer Epidemiol Biomarkers Prev*. 29(3):636–42. <https://doi.org/10.1158/1055-9965.EPI-19-0675> PMID:31932414
- Islami F, Poustchi H, Pourshams A, Khoshnia M, Gharavi A, Kamangar F, et al. (2020). A prospective study of tea drinking temperature and risk of esophageal squamous cell carcinoma. *Int J Cancer*. 146(1):18–25. <https://doi.org/10.1002/ijc.32220> PMID:30891750
- Jackson SS, Adami HO, Andreotti G, Beane-Freeman LE, de González AB, Buring JE, et al. (2020). Associations between reproductive factors and biliary tract cancers in women from the Biliary Tract Cancers Pooling Project. *J Hepatol*. 73(4):863–72. <https://doi.org/10.1016/j.jhep.2020.04.046> PMID:32437829
- Jacobs I, Taljaard-Krugell C, Wicks M, Cubasch H, Joffe M, Laubscher R, et al. (2021). Dietary patterns and breast cancer risk in black urban South African women: the SABC study. *Nutrients*. 13(11):4106. <https://doi.org/10.3390/nu13114106> PMID:34836361
- Jafari-Delouei N, Naeimi-Tabiei M, Fazel A, Ashaari M, Hatami E, Sedaghat SM, et al. (2020). Descriptive epidemiology of lymphoma in northern Iran: results from the Golestan Registry 2004–2013. *Arch Iran Med*. 23(3):150–4. PMID:32126782
- Jafri A, Mathe N, Aglago EK, Konyole SO, Ouedraogo M, Audain K, et al. (2021). Food availability, accessibility and dietary practices during the COVID-19 pandemic: a multi-country survey. *Public Health Nutr*. 24(7):1798–805. <https://doi.org/10.1017/S1368980021000987> PMID:33663623
- Jakszyn P, Cayssials V, Buckland G, Perez-Cornago A, Weiderpass E, Boeing H, et al. (2020). Inflammatory potential of the diet and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition study. *Int J Cancer*. 147(4):1027–39. <https://doi.org/10.1002/ijc.32870> PMID:31945199
- Jang HH, Noh H, Kim HW, Cho SY, Kim HJ, Lee SH, et al. (2020). Metabolic tracking of isoflavones in soybean products and biosamples from healthy adults after fermented soybean consumption. *Food Chem*. 330:127317. <https://doi.org/10.1016/j.foodchem.2020.127317> PMID:32569934
- Jayasekara H, MacInnis RJ, Lujan-Barroso L, Mayen-Chacon AL, Cross AJ, Wallner B, et al. (2021). Lifetime alcohol intake, drinking patterns over time and risk of stomach cancer: a pooled analysis of data from two prospective cohort studies. *Int J Cancer*. 148(11):2759–73. <https://doi.org/10.1002/ijc.33504> PMID:33554339
- Jazieh AR, Kozlakidis Z (2020). Healthcare transformation in the post-coronavirus pandemic era. *Front Med (Lausanne)*. 7:429. <https://doi.org/10.3389/fmed.2020.00429> PMID:32850915
- Ji X, Mukherjee S, Landi MT, Bosse Y, Joubert P, Zhu D, et al. (2020a). Protein-altering germline mutations implicate novel genes related to lung cancer development. *Nat Commun*. 11(1):2220. <https://doi.org/10.1038/s41467-020-15905-6> PMID:32393777
- Ji XW, Jiang Y, Wu H, Zhou P, Tan YT, Li HL, et al. (2020). Long-term liver cancer incidence and mortality trends in the Changning District of Shanghai, China. *J Dig Dis*. 21(4):230–6. <https://doi.org/10.1111/1751-2980.12855> PMID:32124559
- Jia M, Lin X, Zhou X, Yan H, Chen Y, Liu P, et al. (2020). Diagnostic performance of automated breast ultrasound and handheld ultrasound in women with dense breasts. *Breast Cancer Res Treat*. 181(3):589–97. <https://doi.org/10.1007/s10549-020-05625-2> PMID:32338323
- Jiang X, Dimou NL, Zhu Z, Bonilla C, Lewis SJ, Lindström S, et al.; PRACTICAL, CRUK, BPC3, CAPS and PEGASUS consortia (2020). Allergy, asthma, and the risk of breast and prostate cancer: a Mendelian randomization study. *Cancer Causes Control*. 31(3):273–82. <https://doi.org/10.1007/s10552-020-01271-7> PMID:32006205
- Jimenez RC, Casajuana-Martin N, García-Recio A, Alcántara L, Pardo L, Campillo M, et al. (2021). The mutational landscape of human olfactory G protein-coupled receptors. *BMC Biol*. 19(1):21. <https://doi.org/10.1186/s12915-021-00962-0> PMID:33546694
- Jobard E, Dossus L, Baglietto L, Fornili M, Lécuyer L, Mancini FR, et al. (2021). Investigation of circulating metabolites associated with breast cancer risk by untargeted metabolomics: a case-control study nested within the French E3N cohort. *Br J Cancer*. 124(10):1734–43. <https://doi.org/10.1038/s41416-021-01304-1> PMID:33723391
- Jochems SHJ, Reulen RC, van Osch FHM, Witlox WJA, Goossens ME, Brinkman M, et al. (2020). Fruit consumption and the risk of bladder cancer: a pooled analysis by the Bladder Cancer Epidemiology and Nutritional Determinants study. *Int J Cancer*. 147(8):2091–100. <https://doi.org/10.1002/ijc.33008> PMID:32285440
- Johnson S, Tittenbrun Z, Romero Y, Torode J, Frech S, Abdel-Wahab M, et al. (2021). The World Cancer Declaration: time to consolidate wins and work towards 2025. *Lancet Oncol*. 22(3):296–8. [https://doi.org/10.1016/S1470-2045\(21\)00012-7](https://doi.org/10.1016/S1470-2045(21)00012-7) PMID:33548178

- Johnston WT, Erdmann F, Newton R, Steliarova-Foucher E, Schüz J, Roman E (2021). Childhood cancer: estimating regional and global incidence. *Cancer Epidemiol.* 71(Pt B):101662. <https://doi.org/10.1016/j.canep.2019.101662> PMID:31924557
- Joko-Fru WY, Jedy-Agba E, Korir A, Ogunbiyi O, Dzamalala CP, Chokunonga E, et al. (2020). The evolving epidemic of breast cancer in sub-Saharan Africa: results from the African Cancer Registry Network. *Int J Cancer.* 147(8):2131–41. <https://doi.org/10.1002/ijc.33014> PMID:32306390
- Joko-Fru WY, Miranda-Filho A, Soerjomataram I, Egue M, Akele-Akpo MT, N'da G, et al. (2020). Breast cancer survival in sub-Saharan Africa by age, stage at diagnosis and human development index: a population-based registry study. *Int J Cancer.* 146(5):1208–18. <https://doi.org/10.1002/ijc.32406> PMID:31087650
- Jordan SJ, Na R, Weiderpass E, Adami HO, Anderson KE, van den Brandt PA, et al. (2021). Pregnancy outcomes and risk of endometrial cancer: a pooled analysis of individual participant data in the Epidemiology of Endometrial Cancer Consortium. *Int J Cancer.* 148(9):2068–78. <https://doi.org/10.1002/ijc.33360> PMID:33105052
- Joshi S, Mane A, Muwonge R, Divate U, Padbidri V, Kulkarni V, et al. (2020). Prevalence and predictors of bacterial vaginosis in HIV-infected women in Maharashtra, India. *Int J STD AIDS.* 31(6):541–52. <https://doi.org/10.1177/0956462419878333> PMID:32233718
- Joshi S, Muwonge R, Kulkarni V, Lucas E, Kulkarni S, Kand S, et al. (2021). Mobile screening unit (MSU) for the implementation of the 'screen and treat' programme for cervical cancer prevention in Pune, India. *Asian Pac J Cancer Prev.* 22(2):413–8. <https://doi.org/10.31557/APJCP.2021.22.2.413> PMID:33639655
- Julián-Serrano S, Yuan F, Wheeler W, Benyamin B, Machiela MJ, Arslan AA, et al. (2021). Hepcidin-regulating iron metabolism genes and pancreatic ductal adenocarcinoma: a pathway analysis of genome-wide association studies. *Am J Clin Nutr.* 114(4):1408–17. <https://doi.org/10.1093/ajcn/nqab217> PMID:34258619
- Kachuri L, Graff RE, Smith-Byrne K, Meyers TJ, Rashkin SR, Ziv E, et al. (2020). Pan-cancer analysis demonstrates that integrating polygenic risk scores with modifiable risk factors improves risk prediction. *Nat Commun.* 11(1):6084. <https://doi.org/10.1038/s41467-020-19600-4> PMID:33247094
- Kachuri L, Johansson M, Rashkin SR, Graff RE, Bossé Y, Manem V, et al. (2020). Immune-mediated genetic pathways resulting in pulmonary function impairment increase lung cancer susceptibility. *Nat Commun.* 11(1):27. <https://doi.org/10.1038/s41467-019-13855-2> PMID:31911640
- Kamangar F, Nasrollahzadeh D, Safiri S, Sepanlou SG, Fitzmaurice C, Ikuta KS, et al.; GBD 2017 Oesophageal Cancer Collaborators (2020). The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Gastroenterol Hepatol.* 5(6):582–97. [https://doi.org/10.1016/S2468-1253\(20\)30007-8](https://doi.org/10.1016/S2468-1253(20)30007-8) PMID:32246941
- Kantelhardt EJ, Assefa M, McCormack V, Cubasch H, Jemal A, Pace LE (2020). Expert discussion: breast cancer in low-resource countries. *Breast Care (Basel).* 15(3):310–3. <https://doi.org/10.1159/000508693> PMID:32774226
- Karabegović I, Portilla-Fernandez E, Li Y, Ma J, Maas SCE, Sun D, et al. (2021). Epigenome-wide association meta-analysis of DNA methylation with coffee and tea consumption. *Nat Commun.* 12(1):2830. <https://doi.org/10.1038/s41467-021-22752-6> PMID:33990564
- Karalexi MA, Dessypris N, Ma X, Spector LG, Marcotte E, Clavel J, et al.; NARECHEM-ST Group; FRECCLE Group (2020). Age-, sex- and disease subtype-related foetal growth differentials in childhood acute myeloid leukaemia risk: a Childhood Leukemia International Consortium analysis. *Eur J Cancer.* 130:1–11. <https://doi.org/10.1016/j.ejca.2020.01.018> PMID:32163883
- Karalexi MA, Tagkas CF, Markozannes G, Tseretopoulou X, Hernández AF, Schüz J, et al. (2021). Exposure to pesticides and childhood leukemia risk: a systematic review and meta-analysis. *Environ Pollut.* 285:117376. <https://doi.org/10.1016/j.envpol.2021.117376> PMID:34380208
- Katzke VA, Le Cornet C, Mahfouz R, Brauer B, Johnson T, Canzian F, et al. (2021). Are circulating immune cells a determinant of pancreatic cancer risk? A prospective study using epigenetic cell count measures. *Cancer Epidemiol Biomarkers Prev.* 30(12):2179–87. <https://doi.org/10.1158/1055-9965.EPI-21-0169> PMID:34548327
- Kay CD, Clifford MN, Mena P, McDougall GJ, Andres-Lacueva C, Cassidy A, et al. (2020). Recommendations for standardizing nomenclature for dietary (poly)phenol catabolites. *Am J Clin Nutr.* 112(4):1051–68. <https://doi.org/10.1093/ajcn/nqaa204> PMID:32936878
- Kelly-Reif K, Sandler DP, Shore D, Schubauer-Berigan MK, Troester MA, Nylander-French L, et al. (2020). Radon and cancer mortality among underground uranium miners in the Příbram region of the Czech Republic. *Am J Ind Med.* 63(10):859–67. <https://doi.org/10.1002/ajim.23167> PMID:33448434
- Khalis M, Dossus L, Rinaldi S, Biessy C, Moskal A, Charaka H, et al. (2020). Body size, silhouette trajectory and the risk of breast cancer in a Moroccan case-control study. *Breast Cancer.* 27(4):748–58. <https://doi.org/10.1007/s12282-020-01072-5> PMID:32144737
- Khalis M, Garcia-Larsen V, Charaka H, Deoula MMS, El Kinany K, Benslimane A, et al. (2020). Update of the Moroccan food composition tables: towards a more reliable tool for nutrition research. *J Food Compos Anal.* 87:5. <https://doi.org/10.1016/j.jfca.2019.103397>
- Khankari NK, Banbury BL, Borges MC, Haycock P, Albanes D, Arndt V, et al. (2020). Mendelian randomization of circulating polyunsaturated fatty acids and colorectal cancer risk. *Cancer Epidemiol Biomarkers Prev.* 29(4):860–70. <https://doi.org/10.1158/1055-9965.EPI-19-0891> PMID:32051193
- Kim YI, Lee JY, Kim CG, Park B, Park JY, Choi IJ (2021). Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the *Helicobacter pylori* infection in Korea: a randomized open-label trial. *BMC Gastroenterol.* 21(1):95. <https://doi.org/10.1186/s12876-021-01680-1> PMID:33653284
- Kleinstern G, Camp NJ, Berndt SI, Birmann BM, Nieters A, Bracci PM, et al. (2020). Lipid trait variants and the risk of non-Hodgkin lymphoma subtypes: a Mendelian randomization study. *Cancer Epidemiol Biomarkers Prev.* 29(5):1074–8. <https://doi.org/10.1158/1055-9965.EPI-19-0803> PMID:32108027

- Kleinstern G, Yan H, Hildebrandt MAT, Vijai J, Berndt SI, Ghesquières H, et al. (2020). Inherited variants at 3q13.33 and 3p24.1 are associated with risk of diffuse large B-cell lymphoma and implicate immune pathways. *Hum Mol Genet.* 29(1):70–9. <https://doi.org/10.1093/hmg/ddz228> PMID:31600786
- Kliemann N, Murphy N, Viallon V, Freisling H, Tsilidis KK, Rinaldi S, et al. (2020). Predicted basal metabolic rate and cancer risk in the European Prospective Investigation into Cancer and Nutrition. *Int J Cancer.* 147(3):648–61. <https://doi.org/10.1002/ijc.32753> PMID:31652358
- Kliemann N, Viallon V, Murphy N, Beeken RJ, Rothwell JA, Rinaldi S, et al. (2021). Metabolic signatures of greater body size and their associations with risk of colorectal and endometrial cancers in the European Prospective Investigation into Cancer and Nutrition. *BMC Med.* 19(1):101. <https://doi.org/10.1186/s12916-021-01970-1> PMID:33926456
- Knuppel A, Fensom GK, Watts EL, Gunter MJ, Murphy N, Papier K, et al. (2020). Circulating insulin-like growth factor-I concentrations and risk of 30 cancers: prospective analyses in UK Biobank. *Cancer Res.* 80(18):4014–21. <https://doi.org/10.1158/0008-5472.CAN-20-1281> PMID:32709735
- Koczkodaj P, Felú A, Picão E, Schüz J (2020). Youth Ambassadors for the European Code Against Cancer Initiative: a call to action. *Cancer Epidemiol.* 69:101854. <https://doi.org/10.1016/j.canep.2020.101854> PMID:33168480
- Kojimahara N, Yoshitake T, Ono K, Kai M, Bynes G, Schüz J, et al. (2020). Computed tomography of the head and the risk of brain tumours during childhood and adolescence: results from a case-control study in Japan. *J Radiol Prot.* 40(4):1010–23. <https://doi.org/10.1088/1361-6498/abacff> PMID:32759481
- Kontou P, Pavlopoulou A, Dimou N, Theodoropoulou M, Braliou G, Tsaousis G, et al. (2021). The human GPCR signal transduction network. *Netw Model Anal Health Inform Bioinform.* 10(1):12. <https://doi.org/10.1007/s13721-020-00278-z>
- Kontou PI, Braliou GG, Dimou NL, Nikolopoulos G, Bagos PG (2020). Antibody tests in detecting SARS-CoV-2 infection: a meta-analysis. *Diagnostics (Basel).* 10(5):15. <https://doi.org/10.3390/diagnostics10050319> PMID:32438677
- Koroknai V, Szász I, Hernandez-Vargas H, Fernandez-Jimenez N, Cuenin C, Herceg Z, et al. (2020). DNA hypermethylation is associated with invasive phenotype of malignant melanoma. *Exp Dermatol.* 29(1):39–50. <https://doi.org/10.1111/exd.14047> PMID:31602702
- Kowalski LP, Sanabria A, Ridge JA, Ng WT, de Bree R, Rinaldo A, et al. (2020). COVID-19 pandemic: effects and evidence-based recommendations for otolaryngology and head and neck surgery practice. *Head Neck.* 42(6):1259–67. <https://doi.org/10.1002/hed.26164> PMID:32270581
- Kozlakidis Z (2020). Biobanks and biobank-based artificial intelligence (AI) implementation through an international lens. In: Holzinger A, Goebel R, Mengel M, Müller H, editors. *Artificial intelligence and machine learning for digital pathology: state-of-the-art and future challenges.* Cham, Switzerland: Springer International Publishing; pp. 195–203. <https://doi.org/10.1007/978-3-030-50402-1>
- Kozlakidis Z, Abduljawad J, Al Khathaami AM, Schaper L, Stelling J (2020). Global health and data-driven policies for emergency responses to infectious disease outbreaks. *Lancet Glob Health.* 8(11):e1361–3. [https://doi.org/10.1016/S2214-109X\(20\)30361-2](https://doi.org/10.1016/S2214-109X(20)30361-2) PMID:32791118
- Kozlakidis Z, Nigam A (2020). Ten minutes with Zisis Kozlakidis, Head of Laboratory Services and Biobanking at the International Agency for Research on Cancer, World Health Organization. *BMJ Leader.* 4(3):160–1. <https://doi.org/10.1136/leader-2020-000282>
- Kozlakidis Z, Vandenberg O, Stelling J (2020). Editorial: clinical microbiology in low resource settings. *Front Med (Lausanne).* 7:258. <https://doi.org/10.3389/fmed.2020.00258> PMID:32587861
- Kreimer AR, Chaturvedi AK, Alemany L, Anantharaman D, Bray F, Carrington M, et al. (2020). Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI. *Oral Oncol.* 108:104736. <https://doi.org/10.1016/j.oraloncology.2020.104736> PMID:32502860
- Kreimer AR, Sampson JN, Porras C, Schiller JT, Kemp T, Herrero R, et al.; Costa Rica HPV Vaccine Trial (CVT) Group (2020a). Evaluation of durability of a single dose of the bivalent HPV vaccine: the CVT trial. *J Natl Cancer Inst.* 112(10):1038–46. <https://doi.org/10.1093/jnci/djaa011> PMID:32091594
- Kühn T, Stepien M, López-Nogueroles M, Damms-Machado A, Sookthai D, Johnson T, et al. (2020). Prediagnostic plasma bile acid levels and colon cancer risk: a prospective study. *J Natl Cancer Inst.* 112(5):516–24. <https://doi.org/10.1093/jnci/djz166> PMID:31435679
- Kulhánová I, Forman D, Vignat J, Espina C, Brenner H, Storm HH, et al. (2020). Tobacco-related cancers in Europe: the scale of the epidemic in 2018. *Eur J Cancer.* 139:27–36. <https://doi.org/10.1016/j.ejca.2020.07.024> PMID:32957011
- Kulhánová I, Znaor A, Shield KD, Arnold M, Vignat J, Charafeddine M, et al. (2020). Proportion of cancers attributable to major lifestyle and environmental risk factors in the Eastern Mediterranean region. *Int J Cancer.* 146(3):646–56. <https://doi.org/10.1002/ijc.32284> PMID:30882889
- Kulkarni O, Sugier PE, Guibon J, Boland-Augé A, Lonjou C, Bacq-Daïan D, et al. (2021). Gene network and biological pathways associated with susceptibility to differentiated thyroid carcinoma. *Sci Rep.* 11(1):8932. <https://doi.org/10.1038/s41598-021-88253-0> PMID:33903625
- Kumar S, Khanduri A, Sidibe A, Morgan C, Torode J, Basu P, et al. (2021). Acting on the call: a framework for action for rapid acceleration of access to the HPV vaccination in low- and lower-middle-income countries. *Int J Gynaecol Obstet.* 152(1):32–9. <https://doi.org/10.1002/ijgo.13482> PMID:33185283
- La Merrill MA, Vandenberg LN, Smith MT, Goodson W, Browne P, Patisaul HB, et al. (2020). Consensus on the key characteristics of endocrine-disrupting chemicals as a basis for hazard identification. *Nat Rev Endocrinol.* 16(1):45–57. <https://doi.org/10.1038/s41574-019-0273-8> PMID:31719706
- Labadie JD, Harrison TA, Banbury B, Amtay EL, Bernd S, Brenner H, et al. (2020). Postmenopausal hormone therapy and colorectal cancer risk by molecularly defined subtypes and tumor location. *JNCI Cancer Spectr.* 4(5):a042. <https://doi.org/10.1093/jncics/pkaa042> PMID:32923935
- Labrèche F, Goldberg MS, Hashim D, Weiderpass E (2020). Breast cancer. In: Anttila S, Boffetta P, editors. *Occupational cancers*, 2nd ed. Basel, Switzerland: Springer Nature Switzerland AG; pp. 417–438.

- Laine JE, Bodinier B, Robinson O, Plusquin M, Scalbert A, Keski-Rahkonen P, et al. (2020). Prenatal exposure to multiple air pollutants, mediating molecular mechanisms, and shifts in birthweight. *Environ Sci Technol*. 54(22):14502–13. <https://doi.org/10.1021/acs.est.0c02657> PMID:33124810
- Lambert PC, Andersson TM, Rutherford MJ, Myklebust TA, Møller B (2020). Reference-adjusted and standardized all-cause and crude probabilities as an alternative to net survival in population-based cancer studies. *Int J Epidemiol*. 49(5):1614–23. <https://doi.org/10.1093/ije/dyaa112> PMID:32829393
- Lambert PF, Münger K, Rösl F, Hasche D, Tommasino M (2020a). Beta human papillomaviruses and skin cancer. *Nature*. 588(7838):E20–1. <https://doi.org/10.1038/s41586-020-3023-0> PMID:33328661
- Lamurias A, Jesus S, Neveu V, Salek RM, Couto FM (2021). Information retrieval using machine learning for biomarker curation in the Exposome-Explorer. *Front Res Metr Anal*. 6:689264. <https://doi.org/10.3389/frma.2021.689264> PMID:34490412
- Lantuejoul S, Fernandez-Cuesta L, Damiola F, Girard N, McLeer A (2020). New molecular classification of large cell neuroendocrine carcinoma and small cell lung carcinoma with potential therapeutic impacts. *Transl Lung Cancer Res*. 9(5):2233–44. <https://doi.org/10.21037/tlcr-20-269> PMID:33209646
- Larose TL, Meheus F, Brennan P, Johansson M, Robbins HA (2020). Assessment of biomarker testing for lung cancer screening eligibility. *JAMA Netw Open*. 3(3):e200409. <https://doi.org/10.1001/jamanetworkopen.2020.0409> PMID:32134462
- Laskar R, Ferreira-Iglesias A, Bishop DT, Iles MM, Kanetsky PA, Armstrong BK, et al.; Australian Melanoma Family Study Investigators; Leeds Case-Control Study Investigators (2021). Risk factors for melanoma by anatomical site: an evaluation of aetiological heterogeneity. *Br J Dermatol*. 184(6):1085–93. <https://doi.org/10.1111/bjd.19705> PMID:33270213
- Laskar RS, Li P, Ecsedi S, Abedi-Ardekani B, Durand G, Robinot N, et al. (2021). Sexual dimorphism in cancer: insights from transcriptional signatures in kidney tissue and renal cell carcinoma. *Hum Mol Genet*. 30(5):343–55. <https://doi.org/10.1093/hmg/ddab031> PMID:33527138
- Lebrett MB, Balata H, Evison M, Colligan D, Duerden R, Elton P, et al. (2020). Analysis of lung cancer risk model (PLCO_{M2012} and LLP_{v2}) performance in a community-based lung cancer screening programme. *Thorax*. 75(8):661–8. <https://doi.org/10.1136/thoraxjnl-2020-214626> PMID:32631933
- Lécuyer L, Dalle C, Lefevre-Arbogast S, Micheau P, Lyan B, Rossary A, et al. (2020). Diet-related metabolomic signature of long-term breast cancer risk using penalized regression: an exploratory study in the SU.VI.MAX cohort. *Cancer Epidemiol Biomarkers Prev*. 29(2):396–405. <https://doi.org/10.1158/1055-9965.EPI-19-0900> PMID:31767565
- Leske H, Dalgleish R, Lazar AJ, Reifengerger G, Cree IA (2021). A common classification framework for histone sequence alterations in tumours: an expert consensus proposal. *J Pathol*. 254(2):109–20. <https://doi.org/10.1002/path.5666> PMID:33779999
- Lesueur C, Ferreira-Iglesias A, McKay JD, Bossé Y, Johansson M, Gaborieau V, et al. (2021). Genome-wide association meta-analysis identifies pleiotropic risk loci for aerodigestive squamous cell cancers. *PLoS Genet*. 17(3):e1009254. <https://doi.org/10.1371/journal.pgen.1009254> PMID:33667223
- Leuraud K, Richardson DB, Cardis E, Daniels RD, Gillies M, Haylock R, et al. (2021). Risk of cancer associated with low-dose radiation exposure: comparison of results between the INWORKS nuclear workers study and the A-bomb survivors study. *Radiat Environ Biophys*. 60(1):23–39. <https://doi.org/10.1007/s00411-020-00890-7> PMID:33479781
- Li C, Stoma S, Lotta LA, Warner S, Albrecht E, Allione A, et al. (2020). Genome-wide association analysis in humans links nucleotide metabolism to leukocyte telomere length. *Am J Hum Genet*. 106(3):389–404. <https://doi.org/10.1016/j.ajhg.2020.02.006> PMID:32109421
- Li M, Brito JP, Vaccarella S (2020a). Long-term declines of thyroid cancer mortality: an international age-period-cohort analysis. *Thyroid*. 30(6):838–46. <https://doi.org/10.1089/thy.2019.0684> PMID:31964280
- Li M, Dal Maso L, Vaccarella S (2020b). Global trends in thyroid cancer incidence and the impact of overdiagnosis. *Lancet Diabetes Endocrinol*. 8(6):468–70. [https://doi.org/10.1016/S2213-8587\(20\)30115-7](https://doi.org/10.1016/S2213-8587(20)30115-7) PMID:32445733
- Li M, Delafosse P, Meheus F, Borson-Chazot F, Lifante JC, Simon R, et al.; Thyroid Cancer Group FRANCIM (2021). Temporal and geographical variations of thyroid cancer incidence and mortality in France during 1986–2015: the impact of overdiagnosis. *Cancer Epidemiol*. 75:102051. <https://doi.org/10.1016/j.canep.2021.102051> PMID:34743057
- Li M, Sun Y, Yang J, de Martel C, Charvat H, Clifford GM, et al. (2020). Time trends and other sources of variation in *Helicobacter pylori* infection in mainland China: a systematic review and meta-analysis. *Helicobacter*. 25(5):e12729. <https://doi.org/10.1111/hel.12729> PMID:32686261
- Li M, Zheng R, Dal Maso L, Zhang S, Wei W, Vaccarella S (2021a). Mapping overdiagnosis of thyroid cancer in China. *Lancet Diabetes Endocrinol*. 9(6):330–2. [https://doi.org/10.1016/S2213-8587\(21\)00083-8](https://doi.org/10.1016/S2213-8587(21)00083-8) PMID:33891886
- Li SX, Hodge AM, MacInnis RJ, Bassett JK, Ueland PM, Midttun Ø, et al. (2021). Inflammation-related marker profiling of dietary patterns and all-cause mortality in the Melbourne Collaborative Cohort Study. *J Nutr*. 151(10):2908–16. <https://doi.org/10.1093/jn/nxab231> PMID:34320210
- Liew K, Yu GQS, Wei Pua LJ, Wong LZ, Tham SY, Hii LW, et al. (2021). Parallel genome-wide RNAi screens identify lymphocyte-specific protein tyrosine kinase (LCK) as a targetable vulnerability of cell proliferation and chemoresistance in nasopharyngeal carcinoma. *Cancer Lett*. 504:81–90. <https://doi.org/10.1016/j.canlet.2021.02.006> PMID:33587980
- Linseisen J, Grundmann N, Zoller D, Kühn T, Jansen EHJM, Chajès V, et al. (2021). Red blood cell fatty acids and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Cancer Epidemiol Biomarkers Prev*. 30(5):874–85. <https://doi.org/10.1158/1055-9965.EPI-20-1426> PMID:33619024
- Lipenga T, Matumba L, Vidal A, Herceg Z, McCormack V, De Saeger S, et al. (2021). A concise review towards defining the exposome of oesophageal cancer in sub-Saharan Africa. *Environ Int*. 157:106880. <https://doi.org/10.1016/j.envint.2021.106880> PMID:34543937
- Liu Y, Xia J, McKay J, Tsavachidis S, Xiao X, Spitz MR, et al. (2021). Rare deleterious germline variants and risk of lung cancer. *NPJ Precis Oncol*. 5(1):12. <https://doi.org/10.1038/s41698-021-00146-7> PMID:33594163

- Liu Z, Lin C, Mu L, Suo C, Ye W, Jin L, et al. (2020). The disparities in gastrointestinal cancer incidence among Chinese populations in Shanghai compared to Chinese immigrants and indigenous non-Hispanic white populations in Los Angeles, USA. *Int J Cancer*. 146(2):329–40. <https://doi.org/10.1002/ijc.32251> PMID:30838637
- Lofffield E, Gunter MJ, Sinha R (2020). Coffee and colorectal cancer: is improved survival a “perk” of coffee drinking? *JAMA Oncol*. 6(11):1721–2. <https://doi.org/10.1001/jamaoncol.2020.3313> PMID:32940627
- Lofffield E, Herzig KH, Caporaso JG, Derkach A, Wan Y, Byrd DA, et al. (2020). Association of body mass index with fecal microbial diversity and metabolites in the Northern Finland Birth Cohort. *Cancer Epidemiol Biomarkers Prev*. 29(11):2289–99. <https://doi.org/10.1158/1055-9965.EPI-20-0824> PMID:32855266
- Lofffield E, Rothwell JA, Sinha R, Keski-Rahkonen P, Robinot N, Albanes D, et al. (2020). Prospective investigation of serum metabolites, coffee drinking, liver cancer incidence, and liver disease mortality. *J Natl Cancer Inst*. 112(3):286–94. <https://doi.org/10.1093/jnci/djz122> PMID:31168595
- Lofffield E, Stepien M, Viallon V, Trijsburg L, Rothwell JA, Robinot N, et al. (2021). Novel biomarkers of habitual alcohol intake and associations with risk of pancreatic and liver cancers and liver disease mortality. *J Natl Cancer Inst*. 113(11):1542–50. <https://doi.org/10.1093/jnci/djab078> PMID:34010397
- Löfvenborg JE, Carlsson S, Andersson T, Hampe CS, Koulman A, Chirlaque Lopez MD, et al. (2021). Interaction between GAD65 antibodies and dietary fish intake or plasma phospholipid n-3 polyunsaturated fatty acids on incident adult-onset diabetes: the EPIC-InterAct study. *Diabetes Care*. 44(2):416–24. <https://doi.org/10.2337/dc20-1463> PMID:33303636
- Lokuhetty MDS, Wijesinghe HD, Damen JAAG, Lee T, Whiter VA, Cree IA, et al. (2020). Prognostic value of the androgen receptor in addition to the established hormone receptors and HER2 status for predicting survival in women with early breast cancer. *Cochrane Database Syst Rev*. (11):18. <https://doi.org/10.1002/14651858.CD013784>
- Londoño C, Cayssials V, de Villasante I, Crous-Bou M, Scalbert A, Weiderpass E, et al. (2021). Polyphenol intake and epithelial ovarian cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. *Antioxidants (Basel)*. 10(8):1249. <https://doi.org/10.3390/antiox10081249> PMID:34439497
- Longatto-Filho A, Fregnani JH, Mafra da Costa A, de Araujo-Souza PS, Scapulatempo-Neto C, Herbster S, et al. (2021). Evaluation of Elafin immunohistochemical expression as marker of cervical cancer severity. *Acta Cytol*. 65(2):165–74. <https://doi.org/10.1159/000512010> PMID:33271565
- Looi CK, Hii LW, Chung FF, Mai CW, Lim WM, Leong CO (2021). Roles of inflammasomes in Epstein-Barr virus-associated nasopharyngeal cancer. *Cancers (Basel)*. 13(8):1786. <https://doi.org/10.3390/cancers13081786> PMID:33918087
- Lope V, Del Pozo MDP, Criado-Navarro I, Pérez-Gómez B, Pastor-Barruso R, Ruiz E, et al. (2020). Serum phospholipid fatty acids and mammographic density in premenopausal women. *J Nutr*. 150(9):2419–28. <https://doi.org/10.1093/jn/nxaa168> PMID:32584993
- López de Maturana E, Rodríguez JA, Alonso L, Lao O, Molina-Montes E, Martín-Antoniano IA, et al.; PanGenEU Investigators; SBC/EPICURO Investigators (2021). A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. *Genome Med*. 13(1):15. <https://doi.org/10.1186/s13073-020-00816-4> PMID:33517887
- Lorenzoni CF, Ferro J, Carrilho C, Colombet M, Parkin DM (2020). Cancer in Mozambique: results from two population-based cancer registries. *Int J Cancer*. 147(6):1629–37. <https://doi.org/10.1002/ijc.32953> PMID:32142162
- Lortet-Tieulent J, Georges D, Bray F, Vaccarella S (2020). Profiling global cancer incidence and mortality by socioeconomic development. *Int J Cancer*. 147(11):3029–36. <https://doi.org/10.1002/ijc.33114> PMID:32449164
- Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. (2021). The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. *Neuro Oncol*. 23(8):1231–51. <https://doi.org/10.1093/neuonc/noab106> PMID:34185076
- Louis DN, Wesseling P, Aldape K, Brat DJ, Capper D, Cree IA, et al. (2020). cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. *Brain Pathol*. 30(4):844–56. <https://doi.org/10.1111/bpa.12832> PMID:32307792
- Louvanto K, Eriksson T, Gray P, Apter D, Baussano I, Bly A, et al. (2020). Baseline findings and safety of infrequent vs. frequent screening of human papillomavirus vaccinated women. *Int J Cancer*. 147(2):440–7. <https://doi.org/10.1002/ijc.32802> PMID:31749143
- Lozar T, Nagvekar R, Rohrer C, Dube Mandishora RS, Ivanus U, Fitzpatrick MB (2021). Cervical cancer screening postpandemic: self-sampling opportunities to accelerate the elimination of cervical cancer. *Int J Womens Health*. 13:841–59. <https://doi.org/10.2147/IJWH.S288376> PMID:34566436
- Lujan-Barroso L, Botteri E, Caini S, Ljungberg B, Roswall N, Tjønneland A, et al. (2020). Menstrual factors, reproductive history, hormone use, and urothelial carcinoma risk: a prospective study in the EPIC cohort. *Cancer Epidemiol Biomarkers Prev*. 29(8):1654–64. <https://doi.org/10.1158/1055-9965.EPI-20-0184> PMID:32467345
- Mafra da Costa A, Ribeiro AL, Ribeiro AG, Gini A, Cabasag C, Reis RM, et al. (2021). Impact of COVID-19 pandemic on cancer-related hospitalizations in Brazil. *Cancer Control*. 28:10732748211038736. <https://doi.org/10.1177/10732748211038736> PMID:34406894
- Magnotti F, Valsesia S, Gupta P, Flechtenmacher C, Contard P, Viarisio D, et al. (2021). The inflammasome adaptor ASC delays UV-induced skin tumorigenesis in beta HPV38 E6 and E7 transgenic mice. *J Invest Dermatol*. 141(1):236–238.e2. <https://doi.org/10.1016/j.jid.2020.04.028> PMID:32470340
- Mahamat-Saleh Y, Cervenka I, Al-Rahmoun M, Mancini FR, Severi G, Ghiasvand R, et al. (2020). Citrus intake and risk of skin cancer in the European Prospective Investigation into Cancer and Nutrition cohort (EPIC). *Eur J Epidemiol*. 35(11):1057–67. <https://doi.org/10.1007/s10654-020-00666-9> PMID:32710289

- Mahmood H, Shaban M, Indave BI, Santos-Silva AR, Rajpoot N, Khurram SA (2020). Use of artificial intelligence in diagnosis of head and neck precancerous and cancerous lesions: a systematic review. *Oral Oncol.* 110:104885. <https://doi.org/10.1016/j.oraloncology.2020.104885> PMID:32674040
- Maitre M, Croüail P, Schneider T, Kuroda Y, Miyazaki M, Tanigawa K, et al. (2021). Living conditions and health status of populations living in territories impacted by nuclear accidents – some lessons for developing health surveillance programme. *Environ Int.* 147:106294. <https://doi.org/10.1016/j.envint.2020.106294> PMID:33360722
- Mafflet A, Quiroz Marnef A, Nijs J, Clarys P, Huybrechts I, Elma Ö, et al. (2021). Obesity hurts: the why and how of integrating weight reduction with chronic pain management. *Phys Ther.* 101(11):pzab198. <https://doi.org/10.1093/ptj/pzab198> PMID:34403478
- Mandal R, Ghosh I, Banerjee D, Mittal S, Muwonge R, Roy C, et al. (2020). Correlation between p16/Ki-67 expression and the grade of cervical intraepithelial neoplasias. *Int J Gynecol Pathol.* 39(4):384–90. <https://doi.org/10.1097/PGP.0000000000000617> PMID:32515923
- Mandrik O, Tolma E, Zielonke N, Meheus F, Ordóñez-Reyes C, Severens JL, et al. (2021). Systematic reviews as a “lens of evidence”: determinants of participation in breast cancer screening. *J Med Screen.* 28(2):70–9. <https://doi.org/10.1177/0969141320930743> PMID:32517538
- Marant Micallef C, Paul A, Charvat H, Vignat J, Houot M, Pilorget C, et al. (2021). An innovative method to estimate lifetime prevalence of carcinogenic occupational circumstances: the example of painters and workers of the rubber manufacturing industry in France. *J Expo Sci Environ Epidemiol.* 31(4):769–76. <https://doi.org/10.1038/s41370-020-00272-7> PMID:33144638
- Mariz FC, Bender N, Anantharaman D, Basu P, Bhatla N, Pillai MR, et al. (2020). Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines. *NPJ Vaccines.* 5(1):14. <https://doi.org/10.1038/s41541-020-0165-x> PMID:32128255
- Maruvada P, Lampe JW, Wishart DS, Barupal D, Chester DN, Dodd D, et al. (2020). Perspective: dietary biomarkers of intake and exposure – exploration with omics approaches. *Adv Nutr.* 11(2):200–15. <https://doi.org/10.1093/advances/nmz075> PMID:31386148
- Matos LL, Forster CHQ, Marta GN, Castro Junior G, Ridge JA, Hirata D, et al. (2021). The hidden curve behind COVID-19 outbreak: the impact of delay in treatment initiation in cancer patients and how to mitigate the additional risk of dying – the head and neck cancer model. *Cancer Causes Control.* 32(5):459–71. <https://doi.org/10.1007/s10552-021-01411-7> PMID:33704627
- Matta M, Huybrechts I, Biessy C, Casagrande C, Yammine S, Fournier A, et al. (2021). Dietary intake of trans fatty acids and breast cancer risk in 9 European countries. *BMC Med.* 19(1):81. <https://doi.org/10.1186/s12916-021-01952-3> PMID:33781249
- Mattosio D, Gheit T, Strati K, Venuti A (2021). Editorial: HPV and host interaction. *Front Cell Infect Microbiol.* 11:638005. <https://doi.org/10.3389/fcimb.2021.638005> PMID:33777848
- McCormack V, Aggarwal A (2021). Early cancer diagnosis: reaching targets across whole populations amidst setbacks. *Br J Cancer.* 124(7):1181–2. <https://doi.org/10.1038/s41416-021-01276-2> PMID:33558710
- McCormack V, Kaimila B, Mmbaga BT, Schüz J (2021). Esophageal cancer in Tanzania: a welcome stimulus in primary prevention research. *Cancer Epidemiol Biomarkers Prev.* 30(2):248–51. <https://doi.org/10.1158/1055-9965.EPI-20-1518> PMID:33547145
- McCormack V, McKenzie F, Foerster M, Zietsman A, Galukande M, Adisa C, et al. (2020). Breast cancer survival and survival gap apportionment in sub-Saharan Africa (ABC-DO): a prospective cohort study. *Lancet Glob Health.* 8(9):e1203–12. [https://doi.org/10.1016/S2214-109X\(20\)30261-8](https://doi.org/10.1016/S2214-109X(20)30261-8) PMID:32827482
- Melki PN, Korenjak M, Zavadij J (2020). Experimental investigations of carcinogen-induced mutation spectra: innovation, challenges and future directions. *Mutat Res Genet Toxicol Environ Mutagen.* 853:503195. <https://doi.org/10.1016/j.mrgentox.2020.503195> PMID:32522347
- Mendes-Santos C, Andersson G, Weiderpass E, Santana R (2020). Mitigating COVID-19 impact on the Portuguese population mental health: the opportunity that lies in digital mental health. *Front Public Health.* 8:553345. <https://doi.org/10.3389/fpubh.2020.553345> PMID:33313033
- Mendes-Santos C, Weiderpass E, Santana R, Andersson G (2020). Portuguese psychologists’ attitudes toward internet interventions: exploratory cross-sectional study. *JMIR Ment Health.* 7(4):e16817. <https://doi.org/10.2196/16817> PMID:32250273
- Merid SK, Novoloaca A, Sharp GC, Küpers LK, Kho AT, Roy R, et al. (2020). Epigenome-wide meta-analysis of blood DNA methylation in newborns and children identifies numerous loci related to gestational age. *Genome Med.* 12(1):25. <https://doi.org/10.1186/s13073-020-0716-9> PMID:32114984
- Merritt MA, Strickler HD, Hutson AD, Einstein MH, Rohan TE, Xue X, et al. (2021). Sex hormones, insulin, and insulin-like growth factors in recurrence of high-stage endometrial cancer. *Cancer Epidemiol Biomarkers Prev.* 30(4):719–26. <https://doi.org/10.1158/1055-9965.EPI-20-1613> PMID:33622671
- Mhatre S, Rajaraman P, Chatterjee N, Bray F, Goel M, Patkar S, et al. (2020). Mustard oil consumption, cooking method, diet and gallbladder cancer risk in high- and low-risk regions of India. *Int J Cancer.* 147(6):1621–8. <https://doi.org/10.1002/ijc.32952> PMID:32142159
- Michalek IM, Kinnunen TI, Kjaerheim K, Lyng E, Martinsen JI, Sørensen P, et al. (2020). Smoking-adjusted risk of kidney cancer by occupation: a population-based cohort study of Nordic men. *Acta Oncol.* 59(5):582–7. <https://doi.org/10.1080/0284186X.2020.1714722> PMID:32009517
- Michels N, De Backer F, Dimakopoulou M, Mane K, Indave I, Huybrechts I (2021). Eating disorders and the risk of developing cancer: a systematic review. *Eat Weight Disord.* 26(4):1021–35. <https://doi.org/10.1007/s40519-020-01020-4> PMID:33025526
- Michels N, Specht IO, Heitmann BL, Chajès V, Huybrechts I (2021). Dietary trans-fatty acid intake in relation to cancer risk: a systematic review and meta-analysis. *Nutr Rev.* 79(7):758–76. <https://doi.org/10.1093/nutrit/nuaa061> PMID:34104953

- Michels N, van Aart C, Morisse J, Mullee A, Huybrechts I (2021). Chronic inflammation towards cancer incidence: a systematic review and meta-analysis of epidemiological studies. *Crit Rev Oncol Hematol*. 157:103177. <https://doi.org/10.1016/j.critrevonc.2020.103177> PMID:33264718
- Middleton DRS, McCormack VA, Watts MJ, Schüz J (2020). Environmental geochemistry and cancer: a pertinent global health problem requiring interdisciplinary collaboration. *Environ Geochem Health*. 42(4):1047–56. <https://doi.org/10.1007/s10653-019-00303-9> PMID:31054071
- Middleton DRS, Mmbaga BT, O'Donovan M, Abedi-Ardekani B, DeBiram-Beecham I, Nyakunga-Marro G, et al. (2021). Minimally invasive esophageal sponge cytology sampling is feasible in a Tanzanian community setting. *Int J Cancer*. 148(5):1208–18. <https://doi.org/10.1002/ijc.33366> PMID:33128785
- Minoni L, Romero-Medina MC, Venuti A, Sirand C, Robitaille A, Altamura G, et al. (2020). Transforming properties of beta-3 human papillomavirus E6 and E7 proteins. *mSphere*. 5(4):e00398-20. <https://doi.org/10.1128/mSphere.00398-20> PMID:32669468
- Mint Sidi Ould Deoula M, Huybrechts I, El Kinany K, Boudouaya H, Hatime Z, El Asri A, et al. (2020). Behavioral, nutritional, and genetic risk factors of colorectal cancers in Morocco: protocol for a multicenter case-control study. *JMIR Res Protoc*. 9(1):e13998. <https://doi.org/10.2196/13998> PMID:31929106
- Miranda-Filho A, Bray F (2020). Global patterns and trends in cancers of the lip, tongue and mouth. *Oral Oncol*. 102:104551. <https://doi.org/10.1016/j.oraloncology.2019.104551> PMID:31986342
- Miranda-Filho A, Bray F, Charvat H, Rajaraman S, Soerjomataram I (2020). The World Cancer Patient Population (WCPP): an updated standard for international comparisons of population-based survival. *Cancer Epidemiol*. 69:101802. <https://doi.org/10.1016/j.canep.2020.101802> PMID:32942139
- Miranda-Filho A, Charvat H, Bray F, Migowski A, Cheung LC, Vaccarella S, et al. (2021). A modeling analysis to compare eligibility strategies for lung cancer screening in Brazil. *EClinical Medicine*. 42:101176. <https://doi.org/10.1016/j.eclinm.2021.101176> PMID:34765952
- Miranda-Filho A, Lortet-Tieulent J, Bray F, Cao B, Franceschi S, Vaccarella S, et al. (2021a). Thyroid cancer incidence trends by histology in 25 countries: a population-based study. *Lancet Diabetes Endocrinol*. 9(4):225–34. [https://doi.org/10.1016/S2213-8587\(21\)00027-9](https://doi.org/10.1016/S2213-8587(21)00027-9) PMID:33662333
- Miranda-Filho A, Piñeros M, Ferreccio C, Adsay V, Soerjomataram I, Bray F, et al. (2020). Gallbladder and extrahepatic bile duct cancers in the Americas: incidence and mortality patterns and trends. *Int J Cancer*. 147(4):978–89. <https://doi.org/10.1002/ijc.32863> PMID:31922259
- Mocci E, Kundu P, Wheeler W, Arslan AA, Beane-Freeman LE, Bracci PM, et al. (2021). Smoking modifies pancreatic cancer risk loci on 2q21.3. *Cancer Res*. 81(11):3134–43. <https://doi.org/10.1158/0008-5472.CAN-20-3267> PMID:33574088
- Mohebbi E, Hadji M, Rashidian H, Rezaianzadeh A, Marzban M, Haghdoost AA, et al. (2021). Opium use and the risk of head and neck squamous cell carcinoma. *Int J Cancer*. 148(5):1066–76. <https://doi.org/10.1002/ijc.33289> PMID:32895947
- Montealegre-Paez AL, Pacheco-Orozco R, Martinez-Gregorio H, Vaca-Paniagua F, Ardila J, Cayol F, et al. (2020). Liquid biopsy in the diagnosis and monitoring of cancer patients: opportunities and challenges in Latin America. *Rev Colomb Cancerol*. 24(4):164–77. <https://doi.org/10.35509/01239015.44>
- Moody S, Senkin S, Islam SMA, Wang J, Nasrollahzadeh D, Cortez Cardoso Penha R, et al. (2021). Mutational signatures in esophageal squamous cell carcinoma from eight countries with varying incidence. *Nat Genet*. 53(11):1553–63. <https://doi.org/10.1038/s41588-021-00928-6> PMID:34663923
- Moore A, Machiela MJ, Machado M, Wang SS, Kane E, Slager SL, et al. (2021). Genome-wide homozygosity and risk of four non-Hodgkin lymphoma subtypes. *J Transl Genet Genom*. 5:200–17. <https://doi.org/10.20517/jtgg.2021.08> PMID:34622145
- Morgan E, Arnold M, Rutherford MJ, Bardot A, Ferlay J, De P, et al. (2021a). The impact of reclassifying cancers of unspecified histology on international differences in survival for small cell and non-small cell lung cancer (ICBP SurvMark-2 project). *Int J Cancer*. 149(5):1013–20. <https://doi.org/10.1002/ijc.33620> PMID:33932300
- Morgan E, Soerjomataram I, Gavin AT, Rutherford MJ, Gatenby P, Bardot A, et al. (2021). International trends in oesophageal cancer survival by histological subtype between 1995 and 2014. *Gut*. 70(2):234–42. <https://doi.org/10.1136/gutjnl-2020-321089> PMID:32554620
- Mori N, Sawada N, Ishihara J, Kotemori A, Takachi R, Murai U, et al. (2021). Validity of a food frequency questionnaire for the estimation of total polyphenol intake estimates and its major food sources in the Japanese population: the JPHC FFQ Validation Study. *J Nutr Sci*. 10:e35. <https://doi.org/10.1017/jns.2021.25> PMID:34094515
- Morra A, Escala-Garcia M, Beesley J, Keeman R, Canisius S, Ahearn TU, et al.; NBCS Collaborators; ABCTB Investigators; kConFab Investigators (2021). Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. *Breast Cancer Res*. 23(1):86. <https://doi.org/10.1186/s13058-021-01450-7> PMID:34407845
- Mpunga T, Chantal Umulisa M, Tenet V, Rugwizangoga B, Milner DA Jr, Munyanshongore C, et al. (2020). Human papillomavirus genotypes in cervical and other HPV-related anogenital cancer in Rwanda, according to HIV status. *Int J Cancer*. 146(6):1514–22. <https://doi.org/10.1002/ijc.32491> PMID:31173641
- Mrabti H, Sauvaget C, Benider A, Bendahhou K, Selmouni F, Muwonge R, et al. (2021). Patterns of care of breast cancer patients in Morocco – a study of variations in patient profile, tumour characteristics and standard of care over a decade. *Breast*. 59:193–202. <https://doi.org/10.1016/j.breast.2021.07.009> PMID:34280610
- Mullee A, Dimou N, Allen N, O'Mara T, Gunter MJ, Murphy N (2021). Testosterone, sex hormone-binding globulin, insulin-like growth factor-1 and endometrial cancer risk: observational and Mendelian randomization analyses. *Br J Cancer*. 125(9):1308–17. <https://doi.org/10.1038/s41416-021-01518-3> PMID:34363033
- Mullee A, Gunter MJ, Murphy N (2020). Hypertension and unlikely causality in the association between soft drink consumption and mortality – reply. *JAMA Intern Med*. 180(2):336–7. <https://doi.org/10.1001/jamainternmed.2019.6127> PMID:32011637

- Mullins N, Forstner AJ, O'Connell KS, Coombes B, Coleman JRI, Qiao Z, et al.; HUNT All-In Psychiatry (2021). Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. *Nat Genet.* 53(6):817–29. <https://doi.org/10.1038/s41588-021-00857-4> PMID:34002096
- Munishi OM, McCormack V, Mchome B, Mangi G, Zullig LL, Bartlett J, et al. (2020). Awareness of cancer risk factors and its signs and symptoms in Northern Tanzania: a cross-sectional survey in the general population and in people living with HIV. *J Cancer Educ.* 35(4):696–704. <https://doi.org/10.1007/s13187-019-01513-6> PMID:30915669
- Murphy N, Campbell PT, Gunter MJ (2021). Are sugar-sweetened beverages contributing to the rising occurrence of colorectal cancer in young adults? *Gut.* 70(12):2222–3. <https://doi.org/10.1136/gutjnl-2021-324614> PMID:34016645
- Murphy N, Campbell PT, Gunter MJ (2021a). Unraveling the etiology of early-onset colorectal cancer. *J Natl Cancer Inst.* 113(5):505–6. <https://doi.org/10.1093/jnci/djaa165> PMID:33136122
- Murphy N, Carreras-Torres R, Song M, Chan AT, Martin RM, Papadimitriou N, et al. (2020a). Circulating levels of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 associate with risk of colorectal cancer based on serologic and Mendelian randomization analyses. *Gastroenterology.* 158(5):1300–1312. e20. <https://doi.org/10.1053/j.gastro.2019.12.020> PMID:31884074
- Murphy N, Knuppel A, Papadimitriou N, Martin RM, Tsilidis KK, Smith-Byrne K, et al. (2020b). Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, and breast cancer risk: observational and Mendelian randomization analyses with ~430 000 women. *Ann Oncol.* 31(5):641–9. <https://doi.org/10.1016/j.annonc.2020.01.066> PMID:32169310
- Musetti C, Garau M, Alonso R, Piñeros M, Soerjomataram I, Barrios E (2021). Colorectal cancer in young and older adults in Uruguay: changes in recent incidence and mortality trends. *Int J Environ Res Public Health.* 18(15):8232. <https://doi.org/10.3390/ijerph18158232> PMID:34360522
- Muwonge R, Basu P, Gheyt T, Anantharaman D, Verma Y, Bhatla N, et al.; Indian HPV vaccine study group (2020). Acquisition, prevalence and clearance of type-specific human papillomavirus infections in young sexually active Indian women: a community-based multicentric cohort study. *PLoS One.* 15(12):e0244242. <https://doi.org/10.1371/journal.pone.0244242> PMID:33373380
- Myklebust TA, Andersson T, Bardot A, Vernon S, Gavin A, Fitzpatrick D, et al. (2020). Can different definitions of date of cancer incidence explain observed international variation in cancer survival? An ICBP SURVMARK-2 study. *Cancer Epidemiol.* 67:101759. <https://doi.org/10.1016/j.canep.2020.101759> PMID:32544801
- Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al.; WHO Classification of Tumours Editorial Board (2020). The 2019 WHO classification of tumours of the digestive system. *Histopathology.* 76(2):182–8. <https://doi.org/10.1111/his.13975> PMID:31433515
- Nakata K, Colombet M, Stiller CA, Pritchard-Jones K, Steliarova-Foucher E; IICC-3 Contributors (2020). Incidence of childhood renal tumours: an international population-based study. *Int J Cancer.* 147(12):3313–27. <https://doi.org/10.1002/ijc.33147> PMID:32902866
- Nalairndran G, Hassan Abdul Razack A, Mai CW, Fei-Lei Chung F, Chan KK, Hii LW, et al. (2020). Phosphoinositide-dependent kinase-1 (PDK1) regulates serum/glucocorticoid-regulated kinase 3 (SGK3) for prostate cancer cell survival. *J Cell Mol Med.* 24(20):12188–98. <https://doi.org/10.1111/jcmm.15876> PMID:32926495
- Nalini M, Khoshnia M, Kamangar F, Sharafkhan M, Poustchi H, Pourshams A, et al. (2021). Joint effect of diabetes and opiate use on all-cause and cause-specific mortality: the Golestan Cohort Study. *Int J Epidemiol.* 50(1):314–24. <https://doi.org/10.1093/ije/dyaa126> PMID:32810213
- Nalini M, Shakeri R, Poustchi H, Pourshams A, Etemadi A, Islami F, et al. (2021). Long-term opiate use and risk of cardiovascular mortality: results from the Golestan Cohort Study. *Eur J Prev Cardiol.* 28(1):98–106. <https://doi.org/10.1093/eurjpc/zwaa006> PMID:33624066
- Narh CT, Dzamalala CP, Mmbaga BT, Menya D, Mlombe Y, Finch P, et al.; ESCCAPE team (2021). Geophagia and risk of squamous cell esophageal cancer in the African esophageal cancer corridor: findings from the ESCCAPE multicountry case-control studies. *Int J Cancer.* 149(6):1274–83. <https://doi.org/10.1002/ijc.33688> PMID:34004024
- Nasrollahzadeh D, Roshandel G, Delhomme TM, Avogbe PH, Foll M, Saidi F, et al. (2021). TP53 targeted deep sequencing of cell-free DNA in esophageal squamous cell carcinoma using low-quality serum: concordance with tumor mutation. *Int J Mol Sci.* 22(11):5627. <https://doi.org/10.3390/ijms22115627> PMID:34073316
- Naudin S, Solans Margalef M, Saberi Hosnijeh F, Nieters A, Kyrø C, Tjønneland A, et al. (2020). Healthy lifestyle and the risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition study. *Int J Cancer.* 147(6):1649–56. <https://doi.org/10.1002/ijc.32977> PMID:32176325
- Naudin S, Viallon V, Hashim D, Freisling H, Jenab M, Weiderpass E, et al. (2020). Healthy lifestyle and the risk of pancreatic cancer in the EPIC study. *Eur J Epidemiol.* 35(10):975–86. <https://doi.org/10.1007/s10654-019-00559-6> PMID:31564045
- Nazarzadeh M, Bidel Z, Canoy D, Copland E, Wamil M, Majert J, et al.; Blood Pressure Lowering Treatment Trialists' Collaboration (2021). Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis. *Lancet.* 398(10313):1803–10. [https://doi.org/10.1016/S0140-6736\(21\)01920-6](https://doi.org/10.1016/S0140-6736(21)01920-6) PMID:34774144
- NCD Risk Factor Collaboration (NCD-RisC) (2020). National trends in total cholesterol obscure heterogeneous changes in HDL and non-HDL cholesterol and total-to-HDL cholesterol ratio: a pooled analysis of 458 population-based studies in Asian and Western countries. *Int J Epidemiol.* 49(1):173–92. <https://doi.org/10.1093/ije/dyz099> PMID:31321439
- NCD Risk Factor Collaboration (NCD-RisC) (2020). Repositioning of the global epicentre of non-optimal cholesterol. *Nature.* 582(7810):73–7. <https://doi.org/10.1038/s41586-020-2338-1> PMID:32494083
- NCD Risk Factor Collaboration (NCD-RisC) (2021). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. *Lancet.* 398(10304):957–80. [https://doi.org/10.1016/S0140-6736\(21\)01330-1](https://doi.org/10.1016/S0140-6736(21)01330-1) PMID:34450083

- NCD Risk Factor Collaboration (NCD-RisC) (2021). Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight. *Elife*. 10:e60060. <https://doi.org/10.7554/eLife.60060> PMID:33685583
- Neveu V, Nicolas G, Salek RM, Wishart DS, Scalbert A (2020). Exposome-Explorer 2.0: an update incorporating candidate dietary biomarkers and dietary associations with cancer risk. *Nucleic Acids Res*. 48 D1:D908–12. <https://doi.org/10.1093/nar/gkz1009> PMID:31724701
- Nicholson AG, Sauter JL, Nowak AK, Kindler HL, Gill RR, Remy-Jardin M, et al. (2020). EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach. *J Thorac Oncol*. 15(1):29–49. <https://doi.org/10.1016/j.jtho.2019.08.2506> PMID:31546041
- Noh H, Charvat H, Freisling H, Ólafsdóttir GH, Ólafsdóttir EJ, Tryggvadóttir L, et al. (2020). Cumulative exposure to premenopausal obesity and risk of postmenopausal cancer: a population-based study in Icelandic women. *Int J Cancer*. 147(3):793–802. <https://doi.org/10.1002/ijc.32805> PMID:31755107
- Noh H, Jang HH, Kim G, Zouiouich S, Cho SY, Kim HJ, et al. (2021). Taxonomic composition and diversity of the gut microbiota in relation to habitual dietary intake in Korean adults. *Nutrients*. 13(2):366. <https://doi.org/10.3390/nu13020366> PMID:33530330
- Norell CH, Butler J, Farrell R, Altman A, Bentley J, Cabasag CJ, et al. (2020). Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of care. *Int J Gynecol Cancer*. 30(11):1748–56. <https://doi.org/10.1136/ijgc-2020-001403> PMID:32784203
- Nøst TH, Alcalá K, Urbarova I, Byrne KS, Guida F, Sandanger TM, et al. (2021). Systemic inflammation markers and cancer incidence in the UK Biobank. *Eur J Epidemiol*. 36(8):841–8. <https://doi.org/10.1007/s10654-021-00752-6> PMID:34036468
- Nounu A, Greenhough A, Heesom KJ, Richmond RC, Zheng J, Weinstein SJ, et al. (2021). A combined proteomics and Mendelian randomization approach to investigate the effects of aspirin-targeted proteins on colorectal cancer. *Cancer Epidemiol Biomarkers Prev*. 30(3):564–75. <https://doi.org/10.1158/1055-9965.EPI-20-1176> PMID:33318029
- Nounu A, Richmond RC, Stewart ID, Surendran P, Wareham NJ, Butterworth A, et al. (2021). Salicylic acid and risk of colorectal cancer: a two-sample Mendelian randomization study. *Nutrients*. 13(11):4164. <https://doi.org/10.3390/nu13114164> PMID:34836419
- Nyitray AG, D'Souza G, Stier EA, Clifford G, Chiao EY (2020). The utility of digital anal rectal examinations in a public health screening program for anal cancer. *J Low Genit Tract Dis*. 24(2):192–6. <https://doi.org/10.1097/LGT.0000000000000508> PMID:31972661
- O'Donoghue S, Byrne JA, Green C, Hill K, Kozlakidis Z, De Wilde A, et al. (2020). The experts speak on biobank education. *Biopreserv Biobank*. 18(1):14–7. <https://doi.org/10.1089/bio.2020.29064.sod> PMID:32069096
- Obón-Santacana M, Luján-Barroso L, Freisling H, Naudin S, Boutron-Ruault MC, Mancini FR, et al. (2020). Consumption of nuts and seeds and pancreatic ductal adenocarcinoma risk in the European Prospective Investigation into Cancer and Nutrition. *Int J Cancer*. 146(1):76–84. <https://doi.org/10.1002/ijc.32415> PMID:31107546
- Olsson A, Kovalevskiy EV, Talibov M, Moissonnier M, Byrnes G, Bouaoun L, et al. (2020). Tobacco smoking among chrysotile asbestos workers in Asbest in the Russian Federation. *Occup Environ Med*. 77(9):623–7. <https://doi.org/10.1136/oemed-2019-106263> PMID:32398292
- Olsson A, Kromhout H (2021). Occupational cancer burden: the contribution of exposure to process-generated substances at the workplace. *Mol Oncol*. 15(3):753–63. <https://doi.org/10.1002/1878-0261.12925> PMID:33544948
- Onyije FM, Hosseini B, Togawa K, Schüz J, Olsson A (2021). Cancer incidence and mortality among petroleum industry workers and residents living in oil producing communities: a systematic review and meta-analysis. *Int J Environ Res Public Health*. 18(8):4343. <https://doi.org/10.3390/ijerph18084343> PMID:33923944
- Ortmann O, Torode J, Schmiegel W, Thomssen C, Hakama M, Basu P, et al.; participants of the ERTM (2020). Knowledge transfer as a tool towards improvement of cancer care in low- and middle-income countries. 6th European Roundtable Meeting (ERTM), June 14th, 2019, Berlin, Germany. *J Cancer Res Clin Oncol*. 146(7):1813–8. <https://doi.org/10.1007/s00432-020-03209-7> PMID:32270287
- Ose J, Gigic B, Brezina S, Lin T, Baiert A, Geijsen AJMR, et al. (2021). Targeted plasma metabolic profiles and risk of recurrence in stage II and III colorectal cancer patients: results from an international cohort consortium. *Metabolites*. 11(3):129. <https://doi.org/10.3390/metabo11030129> PMID:33668370
- Ose J, Holowatyj AN, Nattenmüller J, Gigic B, Lin T, Himbert C, et al. (2020). Metabolomics profiling of visceral and abdominal subcutaneous adipose tissue in colorectal cancer patients: results from the ColoCare study. *Cancer Causes Control*. 31(8):723–35. <https://doi.org/10.1007/s10552-020-01312-1> PMID:32430684
- Ostroumova E, Schüz J, Kesminiene A (2020). Future of Chernobyl research: the urgency for consolidated action. *Lancet*. 395(10229):1037–8. [https://doi.org/10.1016/S0140-6736\(20\)30675-9](https://doi.org/10.1016/S0140-6736(20)30675-9) PMID:32199076
- Oudjehih M, Deltour I, Bouhidel ML, Bouhidel A, Marref A, Luzon V, et al. (2020). Smokeless tobacco use, cigarette smoking, and upper aerodigestive tract cancers: a case-control study in the Batna Region, Algeria, 2008–2011. *Tob Use Insights*. 13:X20902239. <https://doi.org/10.1177/1179173X20902239> PMID:32076371
- Outzen M, Tjønneland A, Hughes DJ, Jenab M, Frederiksen K, Schomburg L, et al. (2021). Toenail selenium, plasma selenoprotein P and risk of advanced prostate cancer: a nested case-control study. *Int J Cancer*. 148(4):876–83. <https://doi.org/10.1002/ijc.33267> PMID:32838475
- Pacheco-Orozco RA, Montealegre-Páez L, Cayol F, Martínez-Gregorio H, Oliver J, Frecha C, et al. (2020). AR-V7 as a biomarker for resistance to treatment with abiraterone/enzalutamide in three Latin American countries: a hypothetical cost-saving analysis. *Oncologist*. 25(12):e1990–5. <https://doi.org/10.1634/theoncologist.2020-0043> PMID:32721059
- Pan K, Chlebowski RT, Mortimer JE, Gunter MJ, Rohan T, Vitolins MZ, et al. (2020). Insulin resistance and breast cancer incidence and mortality in postmenopausal women in the Women's Health Initiative. *Cancer*. 126(16):3638–47. <https://doi.org/10.1002/cncr.33002> PMID:32530506
- Panato C, Vaccarella S, Dal Maso L, Basu P, Franceschi S, Serraino D, et al. (2020). Thyroid cancer incidence in India between 2006 and 2014 and impact of overdiagnosis. *J Clin Endocrinol Metab*. 105(8):2507–14. <https://doi.org/10.1210/clinem/dgaa192> PMID:32297630

- Papadimitriou N, Dimou N, Gill D, Tzoulaki I, Murphy N, Riboli E, et al. (2021). Genetically predicted circulating concentrations of micronutrients and risk of breast cancer: a Mendelian randomization study. *Int J Cancer*. 148(3):646–53. <https://doi.org/10.1002/ijc.33246> PMID:32761610
- Papadimitriou N, Dimou N, Tsilidis KK, Banbury B, Martin RM, Lewis SJ, et al. (2020). Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis. *Nat Commun*. 11(1):597. <https://doi.org/10.1038/s41467-020-14389-8> PMID:32001714
- Papadimitriou N, Gunter MJ, Murphy N, Gicquiau A, Achaintre D, Brezina S, et al. (2021a). Circulating tryptophan metabolites and risk of colon cancer: results from case-control and prospective cohort studies. *Int J Cancer*. 149(9):1659–69. <https://doi.org/10.1002/ijc.33725> PMID:34196970
- Papadimitriou N, Markozannes G, Kanellopoulou A, Critselis E, Alhardan S, Karafousia V, et al. (2021). An umbrella review of the evidence associating diet and cancer risk at 11 anatomical sites. *Nat Commun*. 12(1):4579. <https://doi.org/10.1038/s41467-021-24861-8> PMID:34321471
- Papadimitriou N, Muller D, van den Brandt PA, Geybels M, Patel CJ, Gunter MJ, et al. (2020). A nutrient-wide association study for risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition and the Netherlands Cohort Study. *Eur J Nutr*. 59(7):2929–37. <https://doi.org/10.1007/s00394-019-02132-z> PMID:31705265
- Park JY, Herrero R (2021). Recent progress in gastric cancer prevention. *Best Pract Res Clin Gastroenterol*. 50–51:101733. <https://doi.org/10.1016/j.bpg.2021.101733> PMID:33975687
- Parkin DM, Hämmerl L, Ferlay J, Kantelhardt EJ (2020). Cancer in Africa 2018: the role of infections. *Int J Cancer*. 146(8):2089–103. <https://doi.org/10.1002/ijc.32538> PMID:31254479
- Parmenter BH, Croft KD, Hodgson JM, Dalggaard F, Bondonno CP, Lewis JR, et al. (2020). An overview and update on the epidemiology of flavonoid intake and cardiovascular disease risk. *Food Funct*. 11(8):6777–806. <https://doi.org/10.1039/D0FO01118E> PMID:32725042
- Parmenter BH, Dalggaard F, Murray K, Cassidy A, Bondonno CP, Lewis JR, et al. (2021). Habitual flavonoid intake and ischemic stroke incidence in the Danish Diet, Cancer, and Health Cohort. *Am J Clin Nutr*. 114(1):348–57. <https://doi.org/10.1093/ajcn/nqab138> PMID:33963737
- Pashayan N, Antoniou AC, Ivanus U, Esserman LJ, Easton DF, French D, et al. (2020). Personalized early detection and prevention of breast cancer: ENVISION consensus statement. *Nat Rev Clin Oncol*. 17(11):687–705. <https://doi.org/10.1038/s41571-020-0388-9> PMID:32555420
- Pasqual E, Turner MC, Gracia-Lavedan E, Casabonne D, Benavente Y, Chef IT, et al. (2020). Association of ionizing radiation dose from common medical diagnostic procedures and lymphoma risk in the Epilymph case-control study. *PLoS One*. 15(7):e0235658. <https://doi.org/10.1371/journal.pone.0235658> PMID:32649712
- Patel DM, Jones RR, Booth BJ, Olsson AC, Kromhout H, Straif K, et al.; International Childhood Cancer Cohort Consortium (2020). Parental occupational exposure to pesticides, animals and organic dust and risk of childhood leukemia and central nervous system tumors: findings from the International Childhood Cancer Cohort Consortium (I4C). *Int J Cancer*. 146(4):943–52. <https://doi.org/10.1002/ijc.32388> PMID:31054169
- Pearson-Stuttard J, Papadimitriou N, Markozannes G, Cividini S, Kakourou A, Gill D, et al. (2021). Type 2 diabetes and cancer: an umbrella review of observational and Mendelian randomization studies. *Cancer Epidemiol Biomarkers Prev*. 30(6):1218–28. <https://doi.org/10.1158/1055-9965.EPI-20-1245> PMID:33737302
- Peplowska B, Janasik B, McCormack V, Bukowska-Damska A, Kałużny P (2020). Cadmium and volumetric mammographic density: a cross-sectional study in Polish women. *PLoS One*. 15(5):e0233369. <https://doi.org/10.1371/journal.pone.0233369> PMID:32433664
- Perera SK, Jacob S, Wilson BE, Ferlay J, Bray F, Sullivan R, et al. (2021). Global demand for cancer surgery and an estimate of the optimal surgical and anaesthesia workforce between 2018 and 2040: a population-based modelling study. *Lancet Oncol*. 22(2):182–9. [https://doi.org/10.1016/S1470-2045\(20\)30675-6](https://doi.org/10.1016/S1470-2045(20)30675-6) PMID:33485458
- Perez-Cornago A, Crowe FL, Appleby PN, Bradbury KE, Wood AM, Jakobsen MU, et al. (2021). Plant foods, dietary fibre and risk of ischaemic heart disease in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. *Int J Epidemiol*. 50(1):212–22. <https://doi.org/10.1093/ije/dyaa155> PMID:33245137
- Perez-Cornago A, Huybrechts I, Appleby PN, Schmidt JA, Crowe FL, Overvad K, et al. (2020). Intake of individual fatty acids and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition. *Int J Cancer*. 146(1):44–57. <https://doi.org/10.1002/ijc.32233> PMID:30807653
- Perez-Guzman PN, Chung MH, De Vuyst H, Dalal S, Mutai KK, Muthoni K, et al. (2020). The impact of scaling up cervical cancer screening and treatment services among women living with HIV in Kenya: a modelling study. *BMJ Glob Health*. 5(3):e001886. <https://doi.org/10.1136/bmjgh-2019-001886> PMID:32337077
- Perrier F, Ghiasvand R, Lergenmuller S, Robsahm TE, Green AC, Borch KB, et al. (2021). Physical activity and cutaneous melanoma risk: a Norwegian population-based cohort study. *Prev Med*. 153:106556. <https://doi.org/10.1016/j.ypmed.2021.106556> PMID:33862033
- Peters S, Broberg K, Gallo V, Levi M, Kippler M, Vineis P, et al. (2021). Blood metal levels and amyotrophic lateral sclerosis risk: a prospective cohort. *Ann Neurol*. 89(1):125–33. <https://doi.org/10.1002/ana.25932> PMID:33068316
- Peters S, Gallo V, Vineis P, Middleton LT, Forsgren L, Sacerdote C, et al. (2020). Alcohol consumption and risk of Parkinson's disease: data from a large prospective European cohort. *Mov Disord*. 35(7):1258–63. <https://doi.org/10.1002/mds.28039> PMID:32357270
- Petrick JL, Florio AA, Znaor A, Ruggieri D, Laversanne M, Alvarez CS, et al. (2020). International trends in hepatocellular carcinoma incidence, 1978–2012. *Int J Cancer*. 147(2):317–30. <https://doi.org/10.1002/ijc.32723> PMID:31597196
- Pettit RW, Byun J, Han Y, Ostrom QT, Edelson J, Walsh KM, et al. (2021). The shared genetic architecture between epidemiological and behavioral traits with lung cancer. *Sci Rep*. 11(1):17559. <https://doi.org/10.1038/s41598-021-96685-x> PMID:34475455

- Phiri FP, Ander EL, Lark RM, Bailey EH, Chilima B, Gondwe J, et al. (2020). Urine selenium concentration is a useful biomarker for assessing population level selenium status. *Environ Int.* 134:105218. <https://doi.org/10.1016/j.envint.2019.105218> PMID:31715489
- Pilleron S, Cabasag CJ, Ferlay J, Bray F, Luciani S, Almonte M, et al. (2020). Cervical cancer burden in Latin America and the Caribbean: where are we? *Int J Cancer.* 147(6):1638–48. <https://doi.org/10.1002/ijc.32956> PMID:32150288
- Pilleron S, Charvat H, Araghi M, Arnold M, Fidler-Benaoudia MM, Bardot A, et al. (2021). Age disparities in stage-specific colon cancer survival across seven countries: an International Cancer Benchmarking Partnership SURVMARK-2 population-based study. *Int J Cancer.* 148(7):1575–85. <https://doi.org/10.1002/ijc.33326> PMID:33006395
- Pilleron S, Maringe C, Charvat H, Atkinson J, Morris E, Sarfati D (2021). Age disparities in lung cancer survival in New Zealand: the role of patient and clinical factors. *Lung Cancer.* 157:92–9. <https://doi.org/10.1016/j.lungcan.2021.05.015> PMID:34006378
- Pilleron S, Maringe C, Charvat H, Atkinson J, Morris EJA, Sarfati D (2021). The impact of timely cancer diagnosis on age disparities in colon cancer survival. *J Geriatr Oncol.* 12(7):1044–51. <https://doi.org/10.1016/j.jgo.2021.04.003> PMID:33863698
- Pilleron S, Soto-Perez-de-Celis E, Vignat J, Ferlay J, Soerjomataram I, Bray F, et al. (2021). Estimated global cancer incidence in the oldest adults in 2018 and projections to 2050. *Int J Cancer.* 148(3):601–8. <https://doi.org/10.1002/ijc.33232> PMID:32706917
- Pimenoff VN, Elfström M, Baussano I, Björnstedt M, Dillner J (2021). Estimating total excess mortality during a coronavirus disease 2019 outbreak in Stockholm, Sweden. *Clin Infect Dis.* 72(11):e890–2. <https://doi.org/10.1093/cid/ciaa1593> PMID:33070183
- Pinder LF, Parham GP, Basu P, Muwonge R, Lucas E, Nyambe N, et al. (2020). Thermal ablation versus cryotherapy or loop excision to treat women positive for cervical precancer on visual inspection with acetic acid test: pilot phase of a randomised controlled trial. *Lancet Oncol.* 21(1):175–84. [https://doi.org/10.1016/S1473-2045\(19\)30635-7](https://doi.org/10.1016/S1473-2045(19)30635-7) PMID:31734069
- Piñeros M, Abriata MG, de Vries E, Barrios E, Bravo LE, Cueva P, et al. (2021a). Progress, challenges and ways forward supporting cancer surveillance in Latin America. *Int J Cancer.* 149(1):12–20. <https://doi.org/10.1002/ijc.33407> PMID:33231289
- Piñeros M, Mery L, Soerjomataram I, Bray F, Steliarova-Foucher E (2021c). Scaling up the surveillance of childhood cancer: a global roadmap. *J Natl Cancer Inst.* 113(1):9–15. <https://doi.org/10.1093/jnci/djaa069> PMID:32433739
- Piñeros M, Saraiya M, Baussano I, Bonjour M, Chao A, Bray F (2021b). The role and utility of population-based cancer registries in cervical cancer surveillance and control. *Prev Med.* 144:106237. <https://doi.org/10.1016/j.yjmed.2020.106237> PMID:33678223
- Pinheiro M, Gage JC, Clifford GM, Demarco M, Cheung LC, Chen Z, et al. (2020). Association of HPV35 with cervical carcinogenesis among women of African ancestry: evidence of viral-host interaction with implications for disease intervention. *Int J Cancer.* 147(10):2677–86. <https://doi.org/10.1002/ijc.33033> PMID:32363580
- Pisanu S, Deledda A, Loviselli A, Huybrechts I, Velluzzi F (2020). Validity of accelerometers for the evaluation of energy expenditure in obese and overweight individuals: a systematic review. *J Nutr Metab.* 2020:2327017. <https://doi.org/10.1155/2020/2327017> PMID:32832147
- Polaka I, Razuka-Ebela D, Park JY, Leja M (2021). Taxonomy-based data representation for data mining: an example of the magnitude of risk associated with *H. pylori* infection. *BioData Min.* 14(1):43. <https://doi.org/10.1186/s13040-021-00271-w> PMID:34454568
- Poli UR, Muwonge R, Bhoopal T, Lucas E, Basu P (2020). Feasibility, acceptability, and efficacy of a community health worker-driven approach to screen hard-to-reach periurban women using self-sampled HPV detection test in India. *JCO Glob Oncol.* 6(6):658–66. <https://doi.org/10.1200/GO.20.00061> PMID:32343627
- Ponti A, Basu P, Ritchie D, Anttila A, Carvalho AL, Senore C, et al. (2020). Key issues that need to be considered while revising the current annex of the European Council Recommendation (2003) on cancer screening. *Int J Cancer.* 147(1):9–13. <https://doi.org/10.1002/ijc.32885> PMID:31970768
- Porras C, Tsang SH, Herrero R, Guillén D, Darragh TM, Stoler MH, et al.; Costa Rica Vaccine Trial Group (2020). Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial. *Lancet Oncol.* 21(12):1643–52. [https://doi.org/10.1016/S1473-2045\(20\)30524-6](https://doi.org/10.1016/S1473-2045(20)30524-6) PMID:33271093
- PouralijanAmiri M, Khoshkam M, Madadi R, Kamali K, Faghanzadeh Ganji G, Salek R, et al. (2020). NMR-based plasma metabolic profiling in patients with unstable angina. *Iran J Basic Med Sci.* 23(3):311–20. <https://doi.org/10.22038/IJBMS.2020.39979.9475> PMID:32440317
- Preti M, Rotondo JC, Holzinger D, Micheletti L, Gallio N, McKay-Chopin S, et al. (2020). Role of human papillomavirus infection in the etiology of vulvar cancer in Italian women. *Infect Agent Cancer.* 15(1):20. <https://doi.org/10.1186/s13027-020-00286-8> PMID:32266002
- Pukkala E, Peltomaa M, Mäkitie A, Heikkinen S, Kjærheim K, Martinsen JI, et al. (2021). Cancer incidence among musicians: 45 years of follow-up in four Nordic countries. *Acta Oncol.* 60(7):835–41. <https://doi.org/10.1080/0284186X.2021.1924403> PMID:34162315
- Purdue MP, Rhee J, Moore L, Gao X, Sun X, Kirk E, et al. (2021). Differences in risk factors for molecular subtypes of clear cell renal cell carcinoma. *Int J Cancer.* 149(7):1448–54. <https://doi.org/10.1002/ijc.33701> PMID:34058014
- Purdue MP, Song L, Scélo G, Houlston RS, Wu X, Sakoda LC, et al. (2020). Pathway analysis of renal cell carcinoma genome-wide association studies identifies novel associations. *Cancer Epidemiol Biomarkers Prev.* 29(10):2065–9. <https://doi.org/10.1158/1055-9965.EPI-20-0472> PMID:32732251
- Puyol M, Seoane J, Aguilar E, Voza LB, Orbe I, Crawford KH, et al. (2021). World Cancer Research Day: a call to action for a coordinated international research effort to prevent, diagnose, and treat cancer. *Clin Cancer Res.* 27(4):963–6. <https://doi.org/10.1158/1078-0432.CCR-20-2978> PMID:33257425
- Qendri V, Bogaards JA, Baussano I, Lazzarato F, Vänskä S, Berkhof J (2020). The cost-effectiveness profile of sex-neutral HPV immunisation in European tender-based settings: a model-based assessment. *Lancet Public Health.* 5(11):e592–603. [https://doi.org/10.1016/S2468-2667\(20\)30209-7](https://doi.org/10.1016/S2468-2667(20)30209-7) PMID:33120045

- Quezada-Marín JI, Lam AK, Ochiai A, Odze RD, Washington KM, Fukayama M, et al. (2020). Gastrointestinal tissue-based molecular biomarkers: a practical categorisation based on the 2019 World Health Organization classification of epithelial digestive tumours. *Histopathology*. 77(3):340–50. <https://doi.org/10.1111/his.14120> PMID:32320495
- Rage E, Richardson DB, Demers PA, Do M, Fenske N, Kreuzer M, et al. (2020). PUMA – Pooled Uranium Miners Analysis: cohort profile. *Occup Environ Med*. 77(3):194–200. <https://doi.org/10.1136/oemed-2019-105981> PMID:32005674
- Raglan O, Assi N, Nautiyal J, Lu H, Gabra H, Gunter MJ, et al. (2020). Proteomic analysis of malignant and benign endometrium according to obesity and insulin-resistance status using reverse phase protein array. *Transl Res*. 218: 57–72. <https://doi.org/10.1016/j.trsl.2019.12.003> PMID:31954096
- Raglan O, MacIntyre DA, Mitra A, Lee YS, Smith A, Assi N, et al. (2021). The association between obesity and weight loss after bariatric surgery on the vaginal microbiota. *Microbiome*. 9(1):124. <https://doi.org/10.1186/s40168-021-01011-2> PMID:34049596
- Raju SC, Viljakainen H, Figueiredo RAO, Neuvonen PJ, Eriksson JG, Weiderpass E, et al. (2020). Antimicrobial drug use in the first decade of life influences saliva microbiota diversity and composition. *Microbiome*. 8(1):121. <https://doi.org/10.1186/s40168-020-00893-y> PMID:32825849
- Ramakrishnan R, Doherty A, Smith-Byrne K, Rahimi K, Bennett D, Woodward M, et al. (2021). Accelerometer measured physical activity and the incidence of cardiovascular disease: evidence from the UK Biobank cohort study. *PLoS Med*. 18(1):e1003487. <https://doi.org/10.1371/journal.pmed.1003487> PMID:33434193
- Ramírez AT, Sánchez GI, Nedjai B, Agudelo MC, Brentnall AR, Cuschieri K, et al.; ASC-US-COL Trial Group (2021). Effective methylation triage of HPV positive women with abnormal cytology in a middle-income country. *Int J Cancer*. 148(6):1383–93. <https://doi.org/10.1002/ijc.33314> PMID:33006394
- Rao AKDM, Arvinden VR, Ramasamy D, Patel K, Meenakumari B, Ramanathan P, et al. (2021). Identification of novel dysregulated circular RNAs in early-stage breast cancer. *J Cell Mol Med*. 25(8):3912–21. <https://doi.org/10.1111/jcmm.16324> PMID:33544410
- Razuka-Ebela D, Polaka I, Parshutin S, Santare D, Ebela I, Murillo R, et al. (2020). Sociodemographic, lifestyle and medical factors associated with *Helicobacter pylori* infection. *J Gastrointest Liver Dis*. 29(3):319–27. <https://doi.org/10.15403/jgld-870> PMID:32919416
- Razuka-Ebela D, Zile I, Tzivian L, Ebela I, Polaka I, Parshutin S, et al. (2020). Does family history of cancer influence undergoing screening and gastrointestinal investigations? *J Gastrointest Liver Dis*. 29(4):523–8. <https://doi.org/10.15403/jgld-813> PMID:33118535
- Recalde M, Davila-Batista V, Díaz Y, Leitzmann M, Romieu I, Freisling H, et al. (2021). Body mass index and waist circumference in relation to the risk of 26 types of cancer: a prospective cohort study of 3.5 million adults in Spain. *BMC Med*. 19(1):10. <https://doi.org/10.1186/s12916-020-01877-3> PMID:33441148
- Recalde M, Pistillo A, Fernandez-Bertolin S, Roel E, Aragon M, Freisling H, et al. (2021). Body mass index and risk of COVID-19 diagnosis, hospitalization, and death: a cohort study of 2 524 926 Catalans. *J Clin Endocrinol Metab*. 106(12):e5030–42. <https://doi.org/10.1210/clinem/dgab546> PMID:34297116
- Rehm J, Shield KD, Weiderpass E (2020). Alcohol consumption. A leading risk factor for cancer. *Chem Biol Interact*. 331:109280. <https://doi.org/10.1016/j.cbi.2020.109280> PMID:33010221
- Reynolds RR, Davies MJ, Buffam FV, Dolman PJ, White VA (2021). Differences in 7th and 8th edition American Joint Committee on Cancer staging for periocular sebaceous carcinoma. *Can J Ophthalmol*. 56(1):31–6. <https://doi.org/10.1016/j.jcjo.2020.07.017> PMID:32822657
- Ricci C, Freisling H, Leitzmann MF, Taljaard-Krugell C, Jacobs I, Kruger HS, et al. (2020). Diet and sedentary behaviour in relation to cancer survival. A report from the National Health and Nutrition Examination Survey linked to the U.S. mortality registry. *Clin Nutr*. 39(11):3489–96. <https://doi.org/10.1016/j.clnu.2020.03.013> PMID:32229168
- Ricci C, Leitzmann MF, Freisling H, Schutte AE, Schutte R, Kruger SH, et al. (2020). Diet and sedentary behaviour in relation to mortality in US adults with a cardiovascular condition: results from the National Health and Nutrition Examination Survey linked to the US mortality registry. *Br J Nutr*. 124(12):1329–37. <https://doi.org/10.1017/S0007114520002391> PMID:32600485
- Richardson DB, Rage E, Demers PA, Do MT, DeBono N, Fenske N, et al. (2021). Mortality among uranium miners in North America and Europe: the Pooled Uranium Miners Analysis (PUMA). *Int J Epidemiol*. 50(2):633–43. <https://doi.org/10.1093/ije/dyaa195> PMID:33232447
- Ringborg U, Berns A, Celis JE, Heitor M, Tabernero J, Schüz J, et al. (2021). The Porto European Cancer Research Summit 2021. *Mol Oncol*. 15(10):2507–43. <https://doi.org/10.1002/1878-0261.13078> PMID:34515408
- Ritchie D, Mallafré-Larrosa M, Ferro G, Schüz J, Espina C (2021). Evaluation of the impact of the European Code against Cancer on awareness and attitudes towards cancer prevention at the population and health promoters' levels. *Cancer Epidemiol*. 71(Pt A):101898. <https://doi.org/10.1016/j.canep.2021.101898> PMID:33611135
- Robbins HA, Alcalá K, Swerdlow AJ, Schoemaker MJ, Wareham N, Travis RC, et al. (2021). Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom. *Br J Cancer*. 124(12):2026–34. <https://doi.org/10.1038/s41416-021-01278-0> PMID:33846525
- Robbins HA, Johansson M (2020). Defining equity in eligibility for cancer screening. *JAMA Oncol*. 6(1):156. <https://doi.org/10.1001/jamaoncol.2019.4598> PMID:31697333
- Robitaille A, Brancaccio RN, Dutta S, Rollison DE, Leja M, Fischer N, et al. (2020). PVAmpliconFinder: a workflow for the identification of human papillomaviruses from high-throughput amplicon sequencing. *BMC Bioinformatics*. 21(1):233. <https://doi.org/10.1186/s12859-020-03573-8> PMID:32513098
- Rodríguez-Aguilera JR, Ecsedi S, Goldsmith C, Cros MP, Domínguez-López M, Guerrero-Celis N, et al. (2020). Genome-wide 5-hydroxymethylcytosine (5hmC) emerges at early stage of *in vitro* differentiation of a putative hepatocyte progenitor. *Sci Rep*. 10(1):7822. <https://doi.org/10.1038/s41598-020-64700-2> PMID:32385352

- Roel E, Pistillo A, Recalde M, Sena AG, Fernández-Bertolín S, Aragón M, et al. (2021). Characteristics and outcomes of over 300,000 patients with COVID-19 and history of cancer in the United States and Spain. *Cancer Epidemiol Biomarkers Prev.* 30(10):1884–94. <https://doi.org/10.1158/1055-9965.EPI-21-0266> PMID:34272262
- Rohner E, Bütikofer L, Schmidlin K, Sengaly M, Maskew M, Giddy J, et al. (2020). Cervical cancer risk in women living with HIV across four continents: a multicohort study. *Int J Cancer.* 146(3):601–9. <https://doi.org/10.1002/ijc.32260> PMID:31215037
- Rojas-Jiménez E, Mejía-Gómez JC, Díaz-Velásquez C, Quezada-Urban R, Martínez Gregorio H, Vallejo-Lecuona F, et al. (2020). Comprehensive genomic profile of heterogeneous long follow-up triple-negative breast cancer and its clinical characteristics shows DNA repair deficiency has better prognostic. *Genes (Basel).* 11(11):21. <https://doi.org/10.3390/genes11111367> PMID:33227964
- Rolandsson O, Hampe CS, Sharp SJ, Ardanaz E, Boeing H, Fagherazzi G, et al. (2020). Autoimmunity plays a role in the onset of diabetes after 40 years of age. *Diabetologia.* 63(2):266–77. <https://doi.org/10.1007/s00125-019-05016-3> PMID:31713011
- Rollison DE, Amorrortu RP, Zhao Y, Messina JL, Schell MJ, Fenske NA, et al. (2021). Cutaneous human papillomaviruses and the risk of keratinocyte carcinomas. *Cancer Res.* 81(17):4628–38. <https://doi.org/10.1158/0008-5472.CAN-21-0805> PMID:34266893
- Romero-Medina MC, Venuti A, Melita G, Robitaille A, Ceraolo MG, Pacini L, et al. (2020). Human papillomavirus type 38 alters wild-type p53 activity to promote cell proliferation via the downregulation of integrin alpha 1 expression. *PLoS Pathog.* 16(8):e1008792. <https://doi.org/10.1371/journal.ppat.1008792> PMID:32813746
- Romieu I, Biessy C, Joffe M, Cubasch H, Norris S, Vorster HH, et al. (2021). Reproductive factors and risk of breast cancer in black South African women. *Cancer Causes Control.* 32(4):415–22. <https://doi.org/10.1007/s10552-021-01390-9> PMID:33471235
- Rosato V, Negri E, Bosetti C, Malats N, Gomez-Rubio P, PanGenEU Consortium, et al. (2020). Gallbladder disease, cholecystectomy, and pancreatic cancer risk in the International Pancreatic Cancer Case-Control Consortium (PanC4). *Eur J Cancer Prev.* 29(5):408–15. <https://doi.org/10.1097/CEJ.0000000000000572> PMID:32740166
- Roshandel G, Ferlay J, Ghanbari-Motlagh A, Partovipour E, Salavati F, Aryan K, et al. (2021). Cancer in Iran 2008 to 2025: recent incidence trends and short-term predictions of the future burden. *Int J Cancer.* 149(3):594–605. <https://doi.org/10.1002/ijc.33574> PMID:33884608
- Roshandel G, Ferlay J, Semnani S, Fazel A, Naeimi-Tabiei M, Ashaari M, et al. (2020). Recent cancer incidence trends and short-term predictions in Golestan, Iran 2004–2025. *Cancer Epidemiol.* 67:101728. <https://doi.org/10.1016/j.canep.2020.101728> PMID:32554298
- Rostron BL, Wang J, Etemadi A, Thakur S, Chang JT, Bhandari D, et al. (2021). Associations between biomarkers of exposure and lung cancer risk among exclusive cigarette smokers in the Golestan Cohort Study. *Int J Environ Res Public Health.* 18(14):7349. <https://doi.org/10.3390/ijerph18147349> PMID:34299799
- Roux J, Zeghidi M, Villar S, Kozlakidis Z (2021). Biosafety and biobanking: current understanding and knowledge gaps. *Biosaf Health.* 3(5):244–8. <https://doi.org/10.1016/j.bsheal.2021.06.003> PMID:34179747
- Rovira P, Kilian C, Neufeld M, Rumgay H, Soerjomataram I, Ferreira-Borges C, et al. (2021). Fewer cancer cases in 4 countries of the WHO European Region in 2018 through increased alcohol excise taxation: a modelling study. *Eur Addict Res.* 27(3):189–97. <https://doi.org/10.1159/000511899> PMID:33271557
- Rumgay H, Arnold M, Lavarsanne M, Whiteman DC, Thrift AP, Wei W, et al. (2021b). International trends in esophageal squamous cell carcinoma and adenocarcinoma incidence. *Am J Gastroenterol.* 116(5):1072–6. <https://doi.org/10.14309/ajg.0000000000001121> PMID:33929382
- Rumgay H, Murphy N, Ferrari P, Soerjomataram I (2021). Alcohol and cancer: epidemiology and biological mechanisms. *Nutrients.* 13(9):3173. <https://doi.org/10.3390/nu13093173> PMID:34579050
- Rumgay H, Shield K, Charvat H, Ferrari P, Sompaisarn B, Obot I, et al. (2021a). Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study. *Lancet Oncol.* 22(8):1071–80. [https://doi.org/10.1016/S1470-2045\(21\)00279-5](https://doi.org/10.1016/S1470-2045(21)00279-5) PMID:34270924
- Rushton L, Hutchings SJ, Straif K (2020). Occupational cancer burden. In: Anttila S, Boffetta P, editors. *Occupational cancers*, 2nd ed. Basel, Switzerland: Springer Nature Switzerland AG; pp. 561–578.
- Rusyn I, Arzuaga X, Cattley RC, Corton JC, Ferguson SS, Godoy P, et al. (2021). Key characteristics of human hepatotoxicants as a basis for identification and characterization of the causes of liver toxicity. *Hepatology.* 74(6):3486–96. <https://doi.org/10.1002/hep.31999> PMID:34105804
- Rusyn I, Belpoggi F, Camacho L, Käfferlein HU, Cattley R, Estill CF, et al.; IARC Monographs Vol 125 group (2020). Carcinogenicity of some industrial chemical intermediates and solvents. *Lancet Oncol.* 21(1):25–6. [https://doi.org/10.1016/S1470-2045\(19\)30779-X](https://doi.org/10.1016/S1470-2045(19)30779-X) PMID:31787538
- Rutherford MJ, Arnold M, Bardot A, Ferlay J, De P, Tervonen H, et al. (2021). Comparison of liver cancer incidence and survival by subtypes across seven high-income countries. *Int J Cancer.* 149(12):2020–31. <https://doi.org/10.1002/ijc.33767> PMID:34460109
- Rydz E, Hall AL, Peters CE (2020). Prevalence and recent trends in exposure to night shiftwork in Canada. *Ann Work Expo Health.* 64(3):270–81. <https://doi.org/10.1093/annweh/wxaa001> PMID:32020159
- Ryzhov A, Bray F, Ferlay J, Fedorenko Z, Goulak L, Gorokh Y, et al. (2020). Recent cancer incidence trends in Ukraine and short-term predictions to 2022. *Cancer Epidemiol.* 65:101663. <https://doi.org/10.1016/j.canep.2019.101663> PMID:31882366
- Ryzhov A, Corbex M, Piñeros M, Barchuk A, Andreyan D, Djanklich S, et al. (2021). Comparison of breast cancer and cervical cancer stage distributions in ten newly independent states of the former Soviet Union: a population-based study. *Lancet Oncol.* 22(3):361–9. [https://doi.org/10.1016/S1470-2045\(20\)30674-4](https://doi.org/10.1016/S1470-2045(20)30674-4) PMID:33556324

- Saberi Hosnijeh F, Casabonne D, Nieters A, Solans M, Naudin S, Ferrari P, et al. (2021). Association between anthropometry and lifestyle factors and risk of B-cell lymphoma: an exposome-wide analysis. *Int J Cancer*. 148(9):2115–28. <https://doi.org/10.1002/ijc.33369> PMID:33128820
- Saberi Hosnijeh F, Koliijn PM, Casabonne D, Nieters A, Solans M, Naudin S, et al. (2020). Mediating effect of soluble B-cell activation immune markers on the association between anthropometric and lifestyle factors and lymphoma development. *Sci Rep*. 10(1):13814. <https://doi.org/10.1038/s41598-020-70790-9> PMID:32796953
- Salamat F, Khandashpour M, Naeimi-Tabiei M, Ariannia A, Ashaari M, Sedaghat S, et al. (2020). Increasing trends of lung cancer in Golestan province, Northern Iran (2004–2016). *Cancer Epidemiol*. 65:101687. <https://doi.org/10.1016/j.canep.2020.101687> PMID:32087554
- Salgado R, Bellizzi AM, Rimm D, Bartlett JMS, Nielsen T, Holger M, et al. (2020). How current assay approval policies are leading to unintended imprecision medicine. *Lancet Oncol*. 21(11):1399–401. [https://doi.org/10.1016/S1470-2045\(20\)30592-1](https://doi.org/10.1016/S1470-2045(20)30592-1) PMID:33098760
- Samet JM, Chiu WA, Cogliano V, Jinot J, Kriebel D, Lunn RM, et al. (2020). The IARC Monographs: updated procedures for modern and transparent evidence synthesis in cancer hazard identification. *J Natl Cancer Inst*. 112(1):30–7. <https://doi.org/10.1093/jnci/djz169> PMID:31498409
- Sangrajrang S, Laversanne M, Bausom R, Mery L, Bray F (2020). Cancer incidence and cancer control in Bangkok, Thailand: results from the cancer registry 2011–15 and projections to 2035. *Cancer Epidemiol*. 67:101765. <https://doi.org/10.1016/j.canep.2020.101765> PMID:32585431
- Sanikini H, Muller DC, Chadeau-Hyam M, Murphy N, Gunter MJ, Cross AJ (2020). Anthropometry, body fat composition and reproductive factors and risk of oesophageal and gastric cancer by subtype and subsite in the UK Biobank cohort. *PLoS One*. 15(10):e0240413. <https://doi.org/10.1371/journal.pone.0240413> PMID:33079929
- Sanikini H, Muller DC, Sophiea M, Rinaldi S, Agudo A, Duell EJ, et al. (2020). Anthropometric and reproductive factors and risk of esophageal and gastric cancer by subtype and subsite: results from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. *Int J Cancer*. 146(4):929–42. <https://doi.org/10.1002/ijc.32386> PMID:31050823
- Saraiya V, Bradshaw P, Meyer K, Gammon M, Slade G, Brennan P, et al. (2020). The association between diet quality and cancer incidence of the head and neck. *Cancer Causes Control*. 31(2):193–202. <https://doi.org/10.1007/s10552-019-01261-4> PMID:31894494
- Sayinzoga F, Umulisa MC, Sibomana H, Tenet V, Baussano I, Clifford GM (2020). Human papillomavirus vaccine coverage in Rwanda: a population-level analysis by birth cohort. *Vaccine*. 38(24):4001–5. <https://doi.org/10.1016/j.vaccine.2020.04.021> PMID:32336599
- Schmidt JA, Fensom GK, Rinaldi S, Scalbert A, Appleby PN, Achaintre D, et al. (2020). Patterns in metabolite profile are associated with risk of more aggressive prostate cancer: a prospective study of 3,057 matched case-control sets from EPIC. *Int J Cancer*. 146(3):720–30. <https://doi.org/10.1002/ijc.32314> PMID:30951192
- Schmidt JA, Fensom GK, Rinaldi S, Scalbert A, Gunter MJ, Holmes MV, et al. (2021). NMR metabolite profiles in male meat-eaters, fish-eaters, vegetarians and vegans, and comparison with MS metabolite profiles. *Metabolites*. 11(2):121. <https://doi.org/10.3390/metabo11020121> PMID:33672542
- Schoemaker MJ, Nichols HB, Wright LB, Brook MN, Jones ME, O'Brien KM, et al. (2020). Adult weight change and premenopausal breast cancer risk: a prospective pooled analysis of data from 628,463 women. *Int J Cancer*. 147(5):1306–14. <https://doi.org/10.1002/ijc.32892> PMID:32012248
- Schubauer-Berigan MK (2020). Hazards at 10 000 m: studies of aircrew and their importance in understanding cancer risks from cosmic radiation and circadian disruption. *Occup Environ Med*. 77(5):283–4. <https://doi.org/10.1136/oemed-2020-106432> PMID:32179634
- Schüz J, Bukhtiyarov I, Olsson A, Moissonnier M, Ostroumova E, Feletto E, et al. (2020a). Occupational cohort study of current and former workers exposed to chrysotile in mine and processing facilities in Asbest, the Russian Federation: cohort profile of the Asbest Chrysotile Cohort study. *PLoS One*. 15(7):e0236475. <https://doi.org/10.1371/journal.pone.0236475> PMID:32726334
- Schüz J, Espina C (2021). The eleventh hour to enforce rigorous primary cancer prevention. *Mol Oncol*. 15(3):741–3. <https://doi.org/10.1002/1878-0261.12927> PMID:33660939
- Schüz J, Kovalevskiy E, Moissonnier M, Olsson A, Hashim D, Kromhout H, et al. (2020b). Comparison of two information sources for cause-of-death follow-up in the Russian Federation: the Asbest Chrysotile Cohort Study. *Methods Inf Med*. 59(1):9–17. <https://doi.org/10.1055/s-0040-1710381> PMID:32535878
- Schüz J, Kromhout H (2020). Re Ferrante et al (2020). Mortality and mesothelioma incidence among chrysotile asbestos miners in Balangero, Italy: a cohort study. *Am J Ind Med*. 63(9):834–5. <https://doi.org/10.1002/ajim.23154> PMID:32648970
- Schüz J, Roman E (2021). Childhood cancer: a global perspective. *Cancer Epidemiol*. 71(Pt B):101878. <https://doi.org/10.1016/j.canep.2020.101878> PMID:33358343
- Seferidi P, Scrinis G, Huybrechts I, Woods J, Vineis P, Millett C (2020). The neglected environmental impacts of ultra-processed foods. *Lancet Planet Health*. 4(10):e437–8. [https://doi.org/10.1016/S2542-5196\(20\)30177-7](https://doi.org/10.1016/S2542-5196(20)30177-7) PMID:33038314
- Sengayi-Muchengeti M, Joko-Fru WY, Miranda-Filho A, Egue M, Akele-Akpo MT, N'da G, et al. (2020). Cervical cancer survival in sub-Saharan Africa by age, stage at diagnosis and Human Development Index: a population-based registry study. *Int J Cancer*. 147(11):3037–48. <https://doi.org/10.1002/ijc.33120> PMID:32449157
- Senkin S (2021). MSA: reproducible mutational signature attribution with confidence based on simulations. *BMC Bioinformatics*. 22(1):540. <https://doi.org/10.1186/s12859-021-04450-8> PMID:34736398

- Seyed Khoei N, Anton G, Peters A, Freisling H, Wagner KH (2020). The association between serum bilirubin levels and colorectal cancer risk: results from the Prospective Cooperative Health Research in the Region of Augsburg (KORA) study in Germany. *Antioxidants (Basel)*. 9(10):908. <https://doi.org/10.3390/antiox9100908> PMID:32987702
- Seyed Khoei N, Carreras-Torres R, Murphy N, Gunter MJ, Brennan P, Smith-Byrne K, et al. (2021). Genetically raised circulating bilirubin levels and risk of ten cancers: a Mendelian randomization study. *Cells*. 10(2):394. <https://doi.org/10.3390/cells10020394> PMID:33671849
- Seyed Khoei N, Jenab M, Murphy N, Banbury BL, Carreras-Torres R, Viallon V, et al. (2020a). Circulating bilirubin levels and risk of colorectal cancer: serological and Mendelian randomization analyses. *BMC Med*. 18(1):229. <https://doi.org/10.1186/s12916-020-01703-w> PMID:32878631
- Sfera A, Osorio C, Rahman L, Zapata-Martín Del Campo CM, Maldonado JC, Jafri N, et al. (2021). PTSD as an endothelial disease: insights from COVID-19. *Front Cell Neurosci*. 15:770387. <https://doi.org/10.3389/fncel.2021.770387> PMID:34776871
- Sharp GC, Alfano R, Ghantous A, Urquiza J, Rifas-Shiman SL, Page CM, et al.; 36 other members of the Pregnancy and Childhood Epigenetics (PACE) consortium (2021). Paternal body mass index and offspring DNA methylation: findings from the PACE consortium. *Int J Epidemiol*. 50(4):1297–315. <https://doi.org/10.1093/ije/dyaa267> PMID:33517419
- Sheikh M, Kamangar F, Malekzadeh R (2020). Fifty years of research and one conclusion: opium causes cancer. *Arch Iran Med*. 23(11):757–60. <https://doi.org/10.34172/aim.2020.95> PMID:33220692
- Sheikh M, Masoudi S, Bakhshandeh R, Moayyedkazemi A, Zamani F, Nikfam S, et al. (2020). Survival features, prognostic factors, and determinants of diagnosis and treatment among Iranian patients with pancreatic cancer, a prospective study. *PLoS One*. 15(12):e0243511. <https://doi.org/10.1371/journal.pone.0243511> PMID:33275621
- Sheikh M, Mukeriyaa A, Shangina O, Brennan P, Zaridze D (2021). Postdiagnosis smoking cessation and reduced risk for lung cancer progression and mortality: a prospective cohort study. *Ann Intern Med*. 174(9):1232–9. <https://doi.org/10.7326/M21-0252> PMID:34310171
- Sheikh M, Poustchi H, Pourshams A, Khoshnia M, Gharavi A, Zahedi M, et al. (2020). Household fuel use and the risk of gastrointestinal cancers: the Golestan Cohort Study. *Environ Health Perspect*. 128(6):67002. <https://doi.org/10.1289/EHP5907> PMID:32609005
- Sheikh M, Shakeri R, Poustchi H, Pourshams A, Etemadi A, Islami F, et al. (2020). Opium use and subsequent incidence of cancer: results from the Golestan Cohort Study. *Lancet Glob Health*. 8(5):e649–60. [https://doi.org/10.1016/S2214-109X\(20\)30059-0](https://doi.org/10.1016/S2214-109X(20)30059-0) PMID:32353313
- Sheth S, Farquhar DR, Lenze NR, Mazul A, Brennan P, Anantharaman D, et al. (2021). Decreased overall survival in black patients with HPV-associated oropharyngeal cancer. *Am J Otolaryngol*. 42(1):102780. <https://doi.org/10.1016/j.amjoto.2020.102780> PMID:33152576
- Shiko Y, Konno R, Konishi H, Sauvaget C, Ohashi Y, Kakizoe T (2020). Effectiveness of HPV vaccination against the development of high-grade cervical lesions in young Japanese women. *BMC Infect Dis*. 20(1):808. <https://doi.org/10.1186/s12879-020-05513-6> PMID:33153446
- Shimakawa Y, Ndow G, Njie R, Njai HF, Takahashi K, Akbar SMF, et al. (2020). Hepatitis B core-related antigen: an alternative to hepatitis B virus DNA to assess treatment eligibility in Africa. *Clin Infect Dis*. 70(7):1442–52. <https://doi.org/10.1093/cid/ciz412> PMID:31102406
- Shin A, Cho S, Sandin S, Lof M, Oh MY, Weiderpass E (2020). Omega-3 and -6 fatty acid intake and colorectal cancer risk in Swedish Women's Lifestyle and Health Cohort. *Cancer Res Treat*. 52(3):848–54. <https://doi.org/10.4143/crt.2019.550> PMID:32138465
- Sieri S, Agnoli C, Grioni S, Weiderpass E, Mattiello A, Sluijs I, et al. (2020). Glycemic index, glycemic load, and risk of coronary heart disease: a pan-European cohort study. *Am J Clin Nutr*. 112(3):631–43. <https://doi.org/10.1093/ajcn/nqaa157> PMID:32619242
- Silveira EA, Klieemann N, Noll M, Sarrafzadegan N, de Oliveira C (2021). Visceral obesity and incident cancer and cardiovascular disease: an integrative review of the epidemiological evidence. *Obes Rev*. 22(1):e13088. <https://doi.org/10.1111/obr.13088> PMID:32692447
- Simoens C, Gorbasljeva I, Gheit T, Holzinger D, Lucas E, Ridder R, et al.; HPV-AHEAD study group (2021). HPV DNA genotyping, HPV E6*1 mRNA detection, and p16^{INK4a}/Ki-67 staining in Belgian head and neck cancer patient specimens, collected within the HPV-AHEAD study. *Cancer Epidemiol*. 72:101925. <https://doi.org/10.1016/j.canep.2021.101925> PMID:33839457
- Singleton RK, Heath AK, Clasen JL, Scelo G, Johansson M, Calvez-Kelm FL, et al. (2021). Risk prediction for renal cell carcinoma: results from the European Prospective Investigation into Cancer and Nutrition (EPIC) prospective cohort study. *Cancer Epidemiol Biomarkers Prev*. 30(3):507–12. <https://doi.org/10.1158/1055-9965.EPI-20-1438> PMID:33335022
- Sklias A, Halaburkova A, Vanzan L, Jimenez NF, Cuenin C, Bouaoun L, et al. (2021). Epigenetic remodelling of enhancers in response to estrogen deprivation and re-stimulation. *Nucleic Acids Res*. 49(17):9738–54. <https://doi.org/10.1093/nar/gkab697> PMID:34403459
- Smith MT, Guyton KZ, Kleinstreuer N, Borrel A, Cardenas A, Chiu WA, et al. (2020). The key characteristics of carcinogens: relationship to the hallmarks of cancer, relevant biomarkers, and assays to measure them. *Cancer Epidemiol Biomarkers Prev*. 29(10):1887–903. <https://doi.org/10.1158/1055-9965.EPI-19-1346> PMID:32152214
- Snijders R, Fukinsia A, Claeys Y, Hasker E, Mpanya A, Miaka E, et al. (2021). Costs and outcomes of integrated human African trypanosomiasis surveillance system using rapid diagnostic tests, Democratic Republic of the Congo. *Emerg Infect Dis*. 27(8):2144–53. <https://doi.org/10.3201/eid2708.202399> PMID:34287133
- Snijders R, Fukinsia A, Claeys Y, Mpanya A, Hasker E, Meheus F, et al. (2020). Cost of a new method of active screening for human African trypanosomiasis in the Democratic Republic of the Congo. *PLoS Negl Trop Dis*. 14(12):e0008832. <https://doi.org/10.1371/journal.pntd.0008832> PMID:33315896

- Soares-Lima SC, Gonzaga IM, Camuzi D, Nicolau-Neto P, Vieira da Silva R, Guaraldi S, et al. (2021). IL6 and BCL3 expression are potential biomarkers in esophageal squamous cell carcinoma. *Front Oncol.* 11:722417. <https://doi.org/10.3389/fonc.2021.722417> PMID:34422669
- Soares-Lima SC, Mehanna H, Camuzi D, de Souza-Santos PT, Simão TA, Nicolau-Neto P, et al. (2021). Upper aerodigestive tract squamous cell carcinomas show distinct overall DNA methylation profiles and different molecular mechanisms behind WNT signaling disruption. *Cancers (Basel)*. 13(12):19. <https://doi.org/10.3390/cancers13123014> PMID:34208581
- Soerjomataram I, Bray F (2021). Planning for tomorrow: global cancer incidence and the role of prevention 2020–2070. *Nat Rev Clin Oncol.* 18(10):663–72. <https://doi.org/10.1038/s41571-021-00514-z> PMID:34079102
- Soerjomataram I, Ervik M, Fox C, Hawkins S, Yeung K, Napolitano G, et al. (2021b). CanStaging[®]: an electronic staging tool for population-based cancer registries. *Lancet Oncol.* 22(8):1069. [https://doi.org/10.1016/S1470-2045\(21\)00188-1](https://doi.org/10.1016/S1470-2045(21)00188-1) PMID:34339643
- Solans M, Benavente Y, Saez M, Agudo A, Jakszyn P, Naudin S, et al. (2020). Inflammatory potential of diet and risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition. *Eur J Nutr.* 59(2):813–23. <https://doi.org/10.1007/s00394-019-01947-0> PMID:30903361
- Sorroche BP, Talukdar FR, Lima SCS, Melendez ME, de Carvalho AC, de Almeida GC, et al. (2021). DNA methylation markers from negative surgical margins can predict recurrence of oral squamous cell carcinoma. *Cancers (Basel)*. 13(12):17. <https://doi.org/10.3390/cancers13122915> PMID:34207933
- Steenland K, Schubauer-Berigan MK, Vermeulen R, Lunn RM, Straif K, Zahm S, et al. (2020). Risk of bias assessments and evidence syntheses for observational epidemiologic studies of environmental and occupational exposures: strengths and limitations. *Environ Health Perspect.* 128(9):95002. <https://doi.org/10.1289/EHP6980> PMID:32924579
- Stelzle D, Tanaka LF, Lee KK, Ibrahim Khalil A, Baussano I, Shah ASV, et al. (2021). Estimates of the global burden of cervical cancer associated with HIV. *Lancet Glob Health.* 9(2):e161–9. [https://doi.org/10.1016/S2214-109X\(20\)30459-9](https://doi.org/10.1016/S2214-109X(20)30459-9) PMID:33212031
- Stepien M, Keski-Rahkonen P, Kiss A, Robinot N, Duarte-Salles T, Murphy N, et al. (2021). Metabolic perturbations prior to hepatocellular carcinoma diagnosis: findings from a prospective observational cohort study. *Int J Cancer.* 148(3):609–25. <https://doi.org/10.1002/ijc.33236> PMID:32734650
- Stockdale AJ, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I, de Martel C, et al. (2020). The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. *J Hepatol.* 73(3):523–32. <https://doi.org/10.1016/j.jhep.2020.04.008> PMID:32335166
- Støer NC, Botteri E, Thoresen GH, Karlstad Ø, Weiderpass E, Friis S, et al. (2021). Drug use and cancer risk: a drug-wide association study (DWAS) in Norway. *Cancer Epidemiol Biomarkers Prev.* 30(4):682–9. <https://doi.org/10.1158/1055-9965.EPI-20-1028> PMID:33144282
- Sun R, Xu M, Li X, Gaynor S, Zhou H, Li Z, et al. (2021). Integration of multiomic annotation data to prioritize and characterize inflammation and immune-related risk variants in squamous cell lung cancer. *Genet Epidemiol.* 45(1):99–114. <https://doi.org/10.1002/gepi.22358> PMID:32924180
- Sun YQ, Richmond RC, Suderman M, Min JL, Battram T, Flatberg A, et al. (2021). Assessing the role of genome-wide DNA methylation between smoking and risk of lung cancer using repeated measurements: the HUNT study. *Int J Epidemiol.* 50(5):1482–97. <https://doi.org/10.1093/ije/dyab044> PMID:33729499
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 71(3):209–49. <https://doi.org/10.3322/caac.21660> PMID:33538338
- Taghavi K, Moono M, Mwanahamuntu M, Basu P, Limacher A, Tembo T, et al. (2020). Screening test accuracy to improve detection of precancerous lesions of the cervix in women living with HIV: a study protocol. *BMJ Open.* 10(12):e037955. <https://doi.org/10.1136/bmjopen-2020-037955> PMID:33371015
- Taghavi K, Rohner E, Basu P, Low N, Rutjes A, Bohlus J (2020). Screening test accuracy of portable devices that can be used to perform colposcopy for detecting CIN2+ in low- and middle-income countries: a systematic review and meta-analysis. *BMC Womens Health.* 20(1):253. <https://doi.org/10.1186/s12905-020-01121-3> PMID:33198721
- Tagliabue M, Mena M, Maffini F, Gheir T, Quirós Blasco B, Holzinger D, et al.; HPV-AHEAD Study Group (2020). Role of human papillomavirus infection in head and neck cancer in Italy: the HPV-AHEAD study. *Cancers (Basel)*. 12(12):3567. <https://doi.org/10.3390/cancers12123567> PMID:33260360
- Tahiri I, Garro-Aguilar Y, Cayssials V, Achaintre D, Mancini FR, Mahamat-Saleh Y, et al. (2020). Urinary flavanone concentrations as biomarkers of dietary flavanone intakes in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. *Br J Nutr.* 123(6):691–8. <https://doi.org/10.1017/S0007114519003131> PMID:31791423
- Talibov M, Hansen J, Heikkinen S, Martinsen JI, Sparen P, Tryggvadottir L, et al. (2020). RE: “Comment on: “Occupational exposures and male breast cancer: a nested case-control study in the Nordic countries””. *Breast.* 50:151–2. <https://doi.org/10.1016/j.breast.2019.10.014> PMID:31704090
- Talukdar FR, Soares Lima SC, Khoueiry R, Laskar RS, Cuenin C, Sorroche BP, et al. (2021). Genome-wide DNA methylation profiling of esophageal squamous cell carcinoma from global high-incidence regions identifies crucial genes and potential cancer markers. *Cancer Res.* 81(10):2612–24. <https://doi.org/10.1158/0008-5472.CAN-20-3445> PMID:33741694
- Tan PH, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S, et al.; WHO Classification of Tumours Editorial Board (2020). The 2019 World Health Organization classification of tumours of the breast. *Histopathology.* 77(2):181–5. <https://doi.org/10.1111/his.14091> PMID:32056259
- Tang H, Jiang L, Stolzenberg-Solomon RZ, Arslan AA, Beane Freeman LE, Bracci PM, et al. (2020). Genome-wide gene-diabetes and gene-obesity interaction scan in 8,255 cases and 11,900 controls from PanScan and PanC4 consortia. *Cancer Epidemiol Biomarkers Prev.* 29(9):1784–91. <https://doi.org/10.1158/1055-9965.EPI-20-0275> PMID:32546605

- Tettamanti G, Auvinen A, Åkerstedt T, Kojo K, Ahlbom A, Heinävaara S, et al.; COSMOS Study Group (2020). Long-term effect of mobile phone use on sleep quality: results from the Cohort Study of Mobile Phone Use and Health (COSMOS). *Environ Int.* 140:105687. <https://doi.org/10.1016/j.envint.2020.105687> PMID:32276731
- Thierry-Chef I, Ferro G, Le Cornet L, Dabin J, Istad TS, Jahnen A, et al. (2021). Dose estimation for the European Epidemiological Study on Pediatric Computed Tomography (EPI-CT). *Radiat Res.* 196(1):74–99. <https://doi.org/10.1667/RADE-20-00231.1> PMID:33914893
- Thomas CE, Wang R, Adams-Haduch J, Murphy SE, Ueland PM, Middtun Ø, et al. (2020). Urinary cotinine is as good a biomarker as serum cotinine for cigarette smoking exposure and lung cancer risk prediction. *Cancer Epidemiol Biomarkers Prev.* 29(1):127–32. <https://doi.org/10.1158/1055-9965.EPI-19-0653> PMID:31685561
- Thomas HJD, Bjorkman AD, Myers-Smith IH, Elmendorf SC, Kattge J, Diaz S, et al. (2020). Global plant trait relationships extend to the climatic extremes of the tundra biome. *Nat Commun.* 11(1):1351. <https://doi.org/10.1038/s41467-020-15014-4> PMID:32165619
- Thomas M, Sakoda LC, Hoffmeister M, Rosenthal EA, Lee JK, van Duijnhoven FJB, et al. (2020). Genome-wide modeling of polygenic risk score in colorectal cancer risk. *Am J Hum Genet.* 107(3):432–44. <https://doi.org/10.1016/j.ajhg.2020.07.006> PMID:32758450
- Thomas M, Sakoda LC, Hoffmeister M, Rosenthal EA, Lee JK, van Duijnhoven FJB, et al. (2021). Response to Li and Hopper. *Am J Hum Genet.* 108(3):527–9. <https://doi.org/10.1016/j.ajhg.2021.02.003> PMID:33667396
- Thompson HJ, Levitt JO, McGinley JN, Chandler P, Guenther PM, Huybrechts I, et al. (2021). Measuring dietary botanical diversity as a proxy for phytochemical exposure. *Nutrients.* 13(4):1295. <https://doi.org/10.3390/nu13041295> PMID:33919845
- Togawa K, Anderson BO, Foerster M, Galukande M, Zietsman A, Pontac J, et al. (2021a). Geospatial barriers to healthcare access for breast cancer diagnosis in sub-Saharan African settings: the African Breast Cancer-Disparities in Outcomes cohort study. *Int J Cancer.* 148(9):2212–26. <https://doi.org/10.1002/ijc.33400> PMID:33197280
- Togawa K, Leon ME, Lebailly P, Beane Freeman LE, Nordby KC, Baldi I, et al. (2021b). Cancer incidence in agricultural workers: findings from an international consortium of agricultural cohort studies (AGRICOH). *Environ Int.* 157:106825. <https://doi.org/10.1016/j.envint.2021.106825> PMID:34461377
- Togawa K, Ma H, Smith AW, Neuhaus ML, George SM, Baumgartner KB, et al. (2021). Self-reported symptoms of arm lymphedema and health-related quality of life among female breast cancer survivors. *Sci Rep.* 11(1):10701. <https://doi.org/10.1038/s41598-021-89055-0> PMID:34021179
- Tong TYN, Appleby PN, Key TJ, Dahm CC, Overvad K, Olsen A, et al. (2020). The associations of major foods and fibre with risks of ischaemic and haemorrhagic stroke: a prospective study of 418 329 participants in the EPIC cohort across nine European countries. *Eur Heart J.* 41(28):2632–40. <https://doi.org/10.1093/eurheartj/ehaa007> PMID:32090257
- Tota JE, Struyf F, Sampson JN, Gonzalez P, Ryser M, Herrero R, et al.; Costa Rica Vaccine Trial and PATRICIA Study (2020). Efficacy of the AS04-adjuvanted HPV16/18 vaccine: pooled analysis of the Costa Rica Vaccine and PATRICIA randomized controlled trials. *J Natl Cancer Inst.* 112(8):818–28. <https://doi.org/10.1093/jnci/djz222> PMID:31697384
- Trabert B, Tworoger SS, O'Brien KM, Townsend MK, Fortner RT, Iversen ES, et al.; Ovarian Cancer Cohort Consortium (OC3) (2020). The risk of ovarian cancer increases with an increase in the lifetime number of ovulatory cycles: an analysis from the Ovarian Cancer Cohort Consortium (OC3). *Cancer Res.* 80(5):1210–8. <https://doi.org/10.1158/0008-5472.CAN-19-2850> PMID:31932455
- Truong T, Lesueur F, Sugier PE, Guibon J, Xhaard C, Karimi M, et al. (2021). Multiethnic genome-wide association study of differentiated thyroid cancer in the EPITHYR consortium. *Int J Cancer.* 148(12):2935–46. <https://doi.org/10.1002/ijc.33488> PMID:33527407
- Tsang SH, Basu P, Bender N, Herrero R, Kemp TJ, Kreimer AR, et al.; Costa Rica Vaccine Trial (CVT) Group (2020). Evaluation of serological assays to monitor antibody responses to single-dose HPV vaccines. *Vaccine.* 38(38):5997–6006. <https://doi.org/10.1016/j.vaccine.2020.07.017> PMID:32713678
- Tsang SH, Sampson JN, Schussler J, Porras C, Wagner S, Boland J, et al.; Costa Rica HPV Vaccine Trial (CVT) Group (2020). Durability of cross-protection by different schedules of the bivalent HPV vaccine: the CVT Trial. *J Natl Cancer Inst.* 112(10):1030–7. <https://doi.org/10.1093/jnci/djaa010> PMID:32091596
- Tsilidis KK, Papadimitriou N, Dimou N, Gill D, Lewis SJ, Martin RM, et al. (2021). Genetically predicted circulating concentrations of micronutrients and risk of colorectal cancer among individuals of European descent: a Mendelian randomization study. *Am J Clin Nutr.* 113(6):1490–502. PMID:33740060
- Turck CW, Mak TD, Goudarzi M, Salek RM, Cheema AK (2020). The ABRF Metabolomics Research Group 2016 exploratory study: investigation of data analysis methods for untargeted metabolomics. *Metabolites.* 10(4):128. <https://doi.org/10.3390/metabo10040128> PMID:32230777
- Ugelvig Petersen K, Pukkala E, Martinsen JI, Lynge E, Tryggvadottir L, Weiderpass E, et al. (2020). Cancer incidence among seafarers and fishermen in the Nordic countries. *Scand J Work Environ Health.* 46(5):461–8. <https://doi.org/10.5271/sjweh.3879> PMID:31917456
- Urrea Cosme Y, Córdoba Sánchez V, Sánchez GI, Baena A, Ruiz Osorio MA, Rodríguez Zabala D, et al. (2020). Health-related quality of life of women after HPV testing as triage strategy for an abnormal Pap smear: a nested randomized pragmatic trial in a middle-income country. *Qual Life Res.* 29(11):2999–3008. <https://doi.org/10.1007/s11136-020-02563-w> PMID:32617889
- Usyk M, Zolnik CP, Castle PE, Porras C, Herrero R, Gradissimo A, et al.; Costa Rica HPV Vaccine Trial (CVT) Group (2020). Cervicovaginal microbiome and natural history of HPV in a longitudinal study. *PLoS Pathog.* 16(3):e1008376. <https://doi.org/10.1371/journal.ppat.1008376> PMID:32214382
- Uttley L, Indave BI, Hyde C, White V, Lokuhetty D, Cree I (2020). Invited commentary – WHO Classification of Tumours: how should tumors be classified? Expert consensus, systematic reviews or both? *Int J Cancer.* 146(12):3516–21. <https://doi.org/10.1002/ijc.32975> PMID:32170735

- Vaccarella S, Bray F (2020). Are U.S. trends a barometer of future cancer transitions in emerging economies? *Int J Cancer*. 146(6):1499–502. <https://doi.org/10.1002/ijc.32485> PMID:31162837
- Vaccarella S, Dal Maso L (2021). Challenges in investigating risk factors for thyroid cancer. *Lancet Diabetes Endocrinol*. 9(2):57–9. [https://doi.org/10.1016/S2213-8587\(20\)30426-5](https://doi.org/10.1016/S2213-8587(20)30426-5) PMID:33347808
- Vaccarella S, Ginsburg O, Bray F (2021). Gender inequalities in cancer among young adults. *Lancet Oncol*. 22(2):166–7. [https://doi.org/10.1016/S1470-2045\(21\)00001-2](https://doi.org/10.1016/S1470-2045(21)00001-2) PMID:33539738
- Vaccarella S, Lortet-Tieulent J, Colombet M, Davies L, Stiller CA, Schüz J, et al.; IICC-3 contributors (2021a). Global patterns and trends in incidence and mortality of thyroid cancer in children and adolescents: a population-based study. *Lancet Diabetes Endocrinol*. 9(3):144–52. [https://doi.org/10.1016/S2213-8587\(20\)30401-0](https://doi.org/10.1016/S2213-8587(20)30401-0) PMID:33482107
- van den Brandt PA, Ziegler RG, Wang M, Hou T, Li R, Adami HO, et al. (2021). Body size and weight change over adulthood and risk of breast cancer by menopausal and hormone receptor status: a pooled analysis of 20 prospective cohort studies. *Eur J Epidemiol*. 36(1):37–55. <https://doi.org/10.1007/s10654-020-00688-3> PMID:33128203
- Van Puyvelde H, Papadimitriou N, Clasen J, Muller D, Biessy C, Ferrari P, et al. (2021). Dietary methyl-group donor intake and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Nutrients*. 13(6):15. <https://doi.org/10.3390/nu13061843> PMID:34071317
- Van Puyvelde H, Perez-Cornago A, Casagrande C, Nicolas G, Versele V, Skeie G, et al. (2020). Comparing calculated nutrient intakes using different food composition databases: results from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. *Nutrients*. 12(10):2906. <https://doi.org/10.3390/nu12102906> PMID:32977480
- Van Puyvelde H, Versele V, De Backer M, Casagrande C, Nicolas G, Clasen JL, et al.; EPIC collaborators (2020). Methodological approaches to compile and validate a food composition database for methyl-group carriers in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. *Food Chem*. 330:127231. <https://doi.org/10.1016/j.foodchem.2020.127231> PMID:32535317
- van Roekel EH, Bours MJL, van Delden L, Breukink SO, Aquarius M, Keulen ETP, et al. (2021). Longitudinal associations of physical activity with plasma metabolites among colorectal cancer survivors up to 2 years after treatment. *Sci Rep*. 11(1):13738. <https://doi.org/10.1038/s41598-021-92279-9> PMID:34215757
- Vandenberg O, Durand G, Hallin M, Diefenbach A, Gant V, Murray P, et al. (2020). Consolidation of clinical microbiology laboratories and introduction of transformative technologies. *Clin Microbiol Rev*. 33(2):e00057–00019. <https://doi.org/10.1128/CMR.00057-19> PMID:32102900
- Vänskä S, Luostarinen T, Baussano I, Apter D, Eriksson T, Natunen K, et al. (2020). Vaccination with moderate coverage eradicates oncogenic human papillomaviruses if a gender-neutral strategy is applied. *J Infect Dis*. 222(6):948–56. <https://doi.org/10.1093/infdis/jiaa099> PMID:32161969
- Viallon V, His M, Rinaldi S, Breeur M, Gicquiau A, Hemon B, et al. (2021). A new pipeline for the normalization and pooling of metabolomics data. *Metabolites*. 11(9):631. <https://doi.org/10.3390/metabo11090631> PMID:34564446
- Viljakainen J, Raju SC, Viljakainen H, Figueiredo RAO, Roos E, Weiderpass E, et al. (2020). Meal regularity plays a role in shaping the saliva microbiota. *Front Microbiol*. 11:757. <https://doi.org/10.3389/fmicb.2020.00757> PMID:32390990
- Villain P, Carvalho AL, Lucas E, Mosquera I, Zhang L, Muwonge R, et al.; IARC COVID-19 Impact Study Group (2021). Cross-sectional survey of the impact of the COVID-19 pandemic on cancer screening programs in selected low- and middle-income countries: study from the IARC COVID-19 Impact Study Group. *Int J Cancer*. 149(1):97–107. <https://doi.org/10.1002/ijc.33500> PMID:33533501
- Vineis P, Huybrechts I, Millett C, Weiderpass E (2021). Climate change and cancer: converging policies. *Mol Oncol*. 15(3):764–9. <https://doi.org/10.1002/1878-0261.12781> PMID:32964631
- Virani S, Baiocchi G, Bowtell D, Cabasag CJ, Cho KR, Fortner RT, et al. (2021). Joint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research. *Carcinogenesis*. 42(6):785–93. <https://doi.org/10.1093/carcin/bgab043> PMID:34037709
- Vlaanderen J, de Hoogh K, Hoek G, Peters A, Probst-Hensch N, Scalbert A, et al. (2021). Developing the building blocks to elucidate the impact of the urban exposome on cardiometabolic-pulmonary disease: the EU EXPANSE project. *Environ Epidemiol*. 5(4):e162. <https://doi.org/10.1097/EE9.0000000000000162> PMID:34414346
- Vodosin P, Jorgensen AK, Mendy M, Kozlakidis Z, Caboux E, Zawati MH (2021). A review of regulatory frameworks governing biobanking in the low and middle income member countries of BCNet. *Biopreserv Biobank*. 19(5):444–52. <https://doi.org/10.1089/bio.2020.0101> PMID:33945303
- Vuckovic D, Bao EL, Akbari P, Lareau CA, Mousas A, Jiang T, et al.; VA Million Veteran Program (2020). The polygenic and monogenic basis of blood traits and diseases. *Cell*. 182(5):1214–1231. e11. <https://doi.org/10.1016/j.cell.2020.08.008> PMID:32888494
- Wang C, Plusquin M, Ghantous A, Herceg Z, Alfano R, Cox B, et al. (2020). DNA methylation of insulin-like growth factor 2 and H19 cluster in cord blood and prenatal air pollution exposure to fine particulate matter. *Environ Health*. 19(1):129. <https://doi.org/10.1186/s12940-020-00677-9> PMID:33287817
- Wang X, Amitay E, Harrison TA, Banbury BL, Berndt SI, Brenner H, et al. (2021). Association between smoking and molecular subtypes of colorectal cancer. *JNCI Cancer Spectr*. 5(4):b056. <https://doi.org/10.1093/jncics/pkab056> PMID:34377935
- Wang Y, Gorlova OY, Gorlov IP, Zhu M, Dai J, Albanes D, et al. (2020). Association analysis of driver gene-related genetic variants identified novel lung cancer susceptibility loci with 20,871 lung cancer cases and 15,971 controls. *Cancer Epidemiol Biomarkers Prev*. 29(7):1423–9. <https://doi.org/10.1158/1055-9965.EPI-19-1085> PMID:32277007
- Washington MK, Goldberg RM, Chang GJ, Limburg P, Lam AK, Salto-Tellez M, et al.; WHO Classification of Tumours Editorial Board (2021). Diagnosis of digestive system tumours. *Int J Cancer*. 148(5):1040–50. <https://doi.org/10.1002/ijc.33210> PMID:32674220
- Waszak SM, Robinson GW, Gudenas BL, Smith KS, Forget A, Kojic M, et al. (2020). Germline Elongator mutations in Sonic Hedgehog medulloblastoma. *Nature*. 580(7803):396–401. <https://doi.org/10.1038/s41586-020-2164-5> PMID:32296180

- Waterboer T, Brenner N, Klussmann JP, Brennan P, Wieland U, Robbins HA (2020). Study results and related evidence do not support use of HPV16 L1 DRH1 antibodies as a cancer screening test. *EBioMedicine*. 62:103143. <https://doi.org/10.1016/j.ebiom.2020.103143> PMID:33249381
- Watts EL, Fensom GK, Smith Byrne K, Perez-Cornago A, Allen NE, Knuppel A, et al. (2021). Circulating insulin-like growth factor-I, total and free testosterone concentrations and prostate cancer risk in 200 000 men in UK Biobank. *Int J Cancer*. 148(9):2274–88. <https://doi.org/10.1002/ijc.33416> PMID:33252839
- Watts MJ, An T, Argyraki A, Arhin E, Brown A, Button M, et al. (2020). The Society for Environmental Geochemistry and Health (SEGH): building for the future. *Environ Geochem Health*. 42(2):343–7. <https://doi.org/10.1007/s10653-019-00381-9> PMID:31376045
- Watts MJ, Humphrey OS, Middleton DRS (2021). SEGH Live and beyond. *Environ Geochem Health*. 43(8):2799–801. <https://doi.org/10.1007/s10653-020-00722-z> PMID:32970295
- Watts MJ, Menya D, Humphrey OS, Middleton DS, Hamilton E, Marriott A, et al. (2021). Human urinary biomonitoring in Western Kenya for micronutrients and potentially harmful elements. *Int J Hyg Environ Health*. 238:113854. <https://doi.org/10.1016/j.ijheh.2021.113854> PMID:34624595
- Watts MJ, Middleton DRS, Marriott A, Humphrey OS, Hamilton E, McCormack V, et al. (2020). Iodine status in western Kenya: a community-based cross-sectional survey of urinary and drinking water iodine concentrations. *Environ Geochem Health*. 42(4):1141–51. <https://doi.org/10.1007/s10653-019-00352-0> PMID:31190125
- Wedekind R, Keski-Rahkonen P, Robinot N, Mercier F, Engel E, Huybrechts I, et al. (2020). Metabolic signatures of 10 processed and non-processed meat products after in vitro digestion. *Metabolites*. 10(7):14. <https://doi.org/10.3390/metabo10070272> PMID:32635215
- Wedekind R, Keski-Rahkonen P, Robinot N, Viallon V, Rothwell JA, Boutron-Ruault MC, et al. (2021). Pepper alkaloids and processed meat intake: results from a randomized trial and the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. *Mol Nutr Food Res*. 65(7):e2001141. <https://doi.org/10.1002/mnfr.202001141> PMID:33592132
- Wedekind R, Kiss A, Keski-Rahkonen P, Viallon V, Rothwell JA, Cross AJ, et al. (2020). A metabolomic study of red and processed meat intake and acylcarnitine concentrations in human urine and blood. *Am J Clin Nutr*. 112(2):381–8. <https://doi.org/10.1093/ajcn/nqaa140> PMID:32492168
- Wei F, Gaisa MM, D'Souza G, Xia N, Giuliano AR, Hawes SE, et al. (2021a). Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29 900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies. *Lancet HIV*. 8(9):e531–43. [https://doi.org/10.1016/S2352-3018\(21\)00108-9](https://doi.org/10.1016/S2352-3018(21)00108-9) PMID:34339628
- Wei LQ, Cheong IH, Yang GH, Li XG, Kozlakidis Z, Ding L, et al. (2021b). The application of high-throughput technologies for the study of microbiome and cancer. *Front Genet*. 12:699793. <https://doi.org/10.3389/fgene.2021.699793> PMID:34394190
- Wei W, Zeng H, Zheng R, Zhang S, An L, Chen R, et al. (2020). Cancer registration in China and its role in cancer prevention and control. *Lancet Oncol*. 21(7):e342–9. [https://doi.org/10.1016/S1470-2045\(20\)30073-5](https://doi.org/10.1016/S1470-2045(20)30073-5) PMID:32615118
- Weiderpass E (2021). Aménagement des villes et santé publique : une vision internationale. In: Képénékian G, Aubelle V, Bosc S, editors. Hippocrate et les territoires : perspectives pour la santé globale. Avignon, France: Editions de l'Aube; pp. 143–153.
- Weiderpass E, Hashim D, Labrèche F (2020). Malignant tumors of the female reproductive system. In: Anttila S, Boffetta P, editors. Occupational cancers, 2nd ed. Basel, Switzerland: Springer Nature Switzerland AG; pp. 439–453.
- Whitworth HS, Gallagher KE, Howard N, Mounier-Jack S, Mbwanji G, Kreimer AR, et al. (2020). Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: a systematic review of evidence from clinical trials. *Vaccine*. 38(6):1302–14. <https://doi.org/10.1016/j.vaccine.2019.12.017> PMID:31870572
- Wisnuwardani RW, De Henauw S, Ferrari M, Forsner M, Gottrand F, Huybrechts I, et al. (2020). Total polyphenol intake is inversely associated with a pro/anti-inflammatory biomarker ratio in European adolescents of the HELENA Study. *J Nutr*. 150(6):1610–8. <https://doi.org/10.1093/jn/nxaa064> PMID:32221603
- Wisnuwardani RW, De Henauw S, Forsner M, Gottrand F, Huybrechts I, Knaze V, et al. (2020). Polyphenol intake and metabolic syndrome risk in European adolescents: the HELENA study. *Eur J Nutr*. 59(2):801–12. <https://doi.org/10.1007/s00394-019-01946-1> PMID:30903362
- Witlox WJA, van Osch FHM, Brinkman M, Jochems S, Goossens ME, Weiderpass E, et al. (2020). An inverse association between the Mediterranean diet and bladder cancer risk: a pooled analysis of 13 cohort studies. *Eur J Nutr*. 59(1):287–96. <https://doi.org/10.1007/s00394-019-01907-8> PMID:30737562
- Woo HD, Herceg Z (2021). A method to investigate the *Helicobacter pylori*-associated DNA methylome. *Methods Mol Biol*. 2283:75–81. https://doi.org/10.1007/978-1-0716-1302-3_9 PMID:33765311
- Wu Y, Huang R, Wang M, Bernstein L, Bethea TN, Chen C, et al. (2021). Dairy foods, calcium, and risk of breast cancer overall and for subtypes defined by estrogen receptor status: a pooled analysis of 21 cohort studies. *Am J Clin Nutr*. 114(2):450–61. <https://doi.org/10.1093/ajcn/nqab097> PMID:33964859
- Xia C, Xu X, Zhao X, Hu S, Qiao Y, Zhang Y, et al. (2021). Effectiveness and cost-effectiveness of eliminating cervical cancer through a tailored optimal pathway: a modeling study. *BMC Med*. 19(1):62. <https://doi.org/10.1186/s12916-021-01930-9> PMID:33653331
- Xia Z, Su YR, Petersen P, Qi L, Kim AE, Figueiredo JC, et al. (2020). Functional informed genome-wide interaction analysis of body mass index, diabetes and colorectal cancer risk. *Cancer Med*. 9(10):3563–73. <https://doi.org/10.1002/cam4.2971> PMID:32207560
- Xie S, Wang S, Xue L, Middleton DRS, Guan C, Hao C, et al. (2020). *Helicobacter pylori* is associated with precancerous and cancerous lesions of the gastric cardia mucosa: results of a large population-based study in China. *Front Oncol*. 10:205. <https://doi.org/10.3389/fonc.2020.00205> PMID:32195175
- Yammine S, Huybrechts I, Biessy C, Dossus L, Aglago EK, Naudin S, et al. (2020). Dietary and circulating fatty acids and ovarian cancer risk in the European Prospective Investigation into Cancer and Nutrition. *Cancer Epidemiol Biomarkers Prev*. 29(9):1739–49. <https://doi.org/10.1158/1055-9965.EPI-19-1477> PMID:32616494

- Yang J, Zhou M, Li M, Yin P, Hu J, Zhang C, et al. (2020). Fine particulate matter constituents and cause-specific mortality in China: a nationwide modelling study. *Environ Int.* 143:105927. <https://doi.org/10.1016/j.envint.2020.105927> PMID:32619910
- Yang JJ, Yu D, Xiang YB, Blot W, White E, Robien K, et al. (2020). Association of dietary fiber and yogurt consumption with lung cancer risk: a pooled analysis. *JAMA Oncol.* 6(2):e194107. <https://doi.org/10.1001/jamaoncol.2019.4107> PMID:31647500
- Yang L, Kartsonaki C, Yao P, de Martel C, Plummer M, Chapman D, et al.; China Kadoorie Biobank Collaborative Group (2021). The relative and attributable risks of cardia and non-cardia gastric cancer associated with *Helicobacter pylori* infection in China: a case-cohort study. *Lancet Public Health.* 6(12):e888–96. [https://doi.org/10.1016/S2468-2667\(21\)00164-X](https://doi.org/10.1016/S2468-2667(21)00164-X) PMID:34838195
- Yang T, Tang H, Risch HA, Olson SH, Peterson G, Bracci PM, et al. (2020). Incorporating multiple sets of eQTL weights into gene-by-environment interaction analysis identifies novel susceptibility loci for pancreatic cancer. *Genet Epidemiol.* 44(8):880–92. <https://doi.org/10.1002/gepi.22348> PMID:32779232
- Yang Z, Yang J, Li MM, Chen JJ, Ou CQ (2021). Nonlinear and lagged meteorological effects on daily levels of ambient PM_{2.5} and O₃: evidence from 284 Chinese cities. *J Clean Prod.* 278:10. <https://doi.org/10.1016/j.jclepro.2020.123931>
- Yauseyenko V, Drozdovitch V, Ostroumova E, Polyanskaya O, Minenko V, Brenner A, et al. (2020). Belarusian *in utero* cohort: a new opportunity to evaluate the health effects of prenatal and early-life exposure to ionising radiation. *J Radiol Prot.* 40(1):280–95. <https://doi.org/10.1088/1361-6498/ab5c08> PMID:31770737
- Yu EY, Wesselius A, Mehrkanoon S, Goosens M, Brinkman M, van den Brandt P, et al. (2021). Vegetable intake and the risk of bladder cancer in the BLadder Cancer Epidemiology and Nutritional Determinants (BLEND) international study. *BMC Med.* 19(1):56. <https://doi.org/10.1186/s12916-021-01931-8> PMID:33685459
- Yu EYW, Dai Y, Wesselius A, van Osch F, Brinkman M, van den Brandt P, et al. (2020). Coffee consumption and risk of bladder cancer: a pooled analysis of 501,604 participants from 12 cohort studies in the BLadder Cancer Epidemiology and Nutritional Determinants (BLEND) international study. *Eur J Epidemiol.* 35(6):523–35. <https://doi.org/10.1007/s10654-019-00597-0> PMID:31927701
- Yu EYW, Wesselius A, Mehrkanoon S, Brinkman M, van den Brandt P, White E, et al. (2020). Grain and dietary fiber intake and bladder cancer risk: a pooled analysis of prospective cohort studies. *Am J Clin Nutr.* 112(5):1252–66. <https://doi.org/10.1093/ajcn/nqaa215> PMID:32778880
- Yu EYW, Wesselius A, Sinhart C, Wolk A, Stern MC, Jiang X, et al. (2020). A data mining approach to investigate food groups related to incidence of bladder cancer in the BLadder cancer Epidemiology and Nutritional Determinants international study. *Br J Nutr.* 124(6):611–9. <https://doi.org/10.1017/S0007114520001439> PMID:32321598
- Yuan F, Hung RJ, Walsh N, Zhang H, Platz EA, Wheeler W, et al. (2020). Genome-wide association study data reveal genetic susceptibility to chronic inflammatory intestinal diseases and pancreatic ductal adenocarcinoma risk. *Cancer Res.* 80(18):4004–13. <https://doi.org/10.1158/0008-5472.CAN-20-0447> PMID:32641412
- Zahed H, Johansson M, Ueland PM, Midttun Ø, Milne RL, Giles GG, et al. (2021). Epidemiology of 40 blood biomarkers of one-carbon metabolism, vitamin status, inflammation, and renal and endothelial function among cancer-free older adults. *Sci Rep.* 11(1):13805. <https://doi.org/10.1038/s41598-021-93214-8> PMID:34226613
- Zamora-Ros R, Cayssials V, Franceschi S, Kyrø C, Weiderpass E, Hennings J, et al. (2020). Polyphenol intake and differentiated thyroid cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. *Int J Cancer.* 146(7):1841–50. <https://doi.org/10.1002/ijc.32589> PMID:31342519
- Zhang YD, Hurson AN, Zhang H, Choudhury PP, Easton DF, Milne RL, et al.; Breast Cancer Association Consortium (BCAC); Barrett's and Esophageal Adenocarcinoma Consortium (BEACON); Colon Cancer Family Registry (CCFR); Transdisciplinary Studies of Genetic Variation in Colorectal Cancer (CORECT); Endometrial Cancer Association Consortium (ECAC); Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO); Melanoma Genetics Consortium (GenoMEL); Glioma International Case-Control Study (GICC); International Lung Cancer Consortium (ILCCO); Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Consortium; International Consortium of Investigators Working on Non-Hodgkin's Lymphoma Epidemiologic Studies (InterLymph); Ovarian Cancer Association Consortium (OCAC); Oral Cancer GWAS; Pancreatic Cancer Case-Control Consortium (PanC4); Pancreatic Cancer Cohort Consortium (PanScan); Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL); Renal Cancer GWAS; Testicular Cancer Consortium (TECAC) (2020). Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. *Nat Commun.* 11(1):3353. <https://doi.org/10.1038/s41467-020-16483-3> PMID:32620889
- Zhao LG, Li ZY, Feng GS, Ji XW, Tan YT, Li HL, et al. (2020). Coffee drinking and cancer risk: an umbrella review of meta-analyses of observational studies. *BMC Cancer.* 20(1):101. <https://doi.org/10.1186/s12885-020-6561-9> PMID:32024485
- Zhao LG, Li ZY, Feng GS, Ji XW, Tan YT, Li HL, et al. (2021). Tea drinking and risk of cancer incidence: a meta-analysis of prospective cohort studies and evidence evaluation. *Adv Nutr.* 12(2):402–12. <https://doi.org/10.1093/advances/nmaa117> PMID:33002099
- Zhao XL, Liu ZH, Zhao S, Hu SY, Muwonge R, Duan XZ, et al. (2021). Efficacy of point-of-care thermal ablation among high-risk human papillomavirus positive women in China. *Int J Cancer.* 148(6):1419–27. <https://doi.org/10.1002/ijc.33290> PMID:32895912
- Zhao XL, Xu XQ, Duan XZ, Rezhake R, Hu SY, Wang Y, et al. (2020a). Comparative performance evaluation of different HPV tests and triaging strategies using self-samples and feasibility assessment of thermal ablation in 'colposcopy and treat' approach: a population-based study in rural China. *Int J Cancer.* 147(5):1275–85. <https://doi.org/10.1002/ijc.32881> PMID:31970767

- Zhao Y, Amorrortu RP, Fenske NA, Cherpelis B, Messina JL, Sondak VK, et al. (2021). Cutaneous viral infections associated with ultraviolet radiation exposure. *Int J Cancer*. 148(2):448–58. <https://doi.org/10.1002/ijc.33263> PMID:32818302
- Zheng JS, Luan J, Sofianopoulou E, Imamura F, Stewart ID, Day FR, et al. (2021). Plasma vitamin C and type 2 diabetes: genome-wide association study and Mendelian randomization analysis in European populations. *Diabetes Care*. 44(1):98–106. <https://doi.org/10.2337/dc20-1328> PMID:33203707
- Zheng JS, Luan J, Sofianopoulou E, Sharp SJ, Day FR, Imamura F, et al. (2020). The association between circulating 25-hydroxyvitamin D metabolites and type 2 diabetes in European populations: a meta-analysis and Mendelian randomisation analysis. *PLoS Med*. 17(10):e1003394. <https://doi.org/10.1371/journal.pmed.1003394> PMID:33064751
- Zheng JS, Sharp SJ, Imamura F, Chowdhury R, Gundersen TE, Steur M, et al. (2020). Association of plasma biomarkers of fruit and vegetable intake with incident type 2 diabetes: EPIC-InterAct case-cohort study in eight European countries. *BMJ*. 370:m2194. <https://doi.org/10.1136/bmj.m2194> PMID:32641421
- Zhong J, Jermusyk A, Wu L, Hoskins JW, Collins I, Mocchi E, et al. (2020). A transcriptome-wide association study identifies novel candidate susceptibility genes for pancreatic cancer. *J Natl Cancer Inst*. 112(10):1003–12. <https://doi.org/10.1093/jnci/djz246> PMID:31917448
- Zhou W, Liu G, Hung RJ, Haycock PC, Aldrich MC, Andrew AS, et al. (2021). Causal relationships between body mass index, smoking and lung cancer: univariable and multivariable Mendelian randomization. *Int J Cancer*. 148(5):1077–86. <https://doi.org/10.1002/ijc.33292> PMID:32914876
- Zhu B, Xiao Y, Yeager M, Clifford G, Wentzensen N, Cullen M, et al. (2020). Mutations in the HPV16 genome induced by APOBEC3 are associated with viral clearance. *Nat Commun*. 11(1):886. <https://doi.org/10.1038/s41467-020-14730-1> PMID:32060290
- Zhu D, Chung HF, Dobson AJ, Pandeya N, Brunner EJ, Kuh D, et al. (2020). Type of menopause, age of menopause and variations in the risk of incident cardiovascular disease: pooled analysis of individual data from 10 international studies. *Hum Reprod*. 35(8):1933–43. <https://doi.org/10.1093/humrep/deaa124> PMID:32563191
- Zhu J, Shu X, Guo X, Liu D, Bao J, Milne RL, et al. (2020). Associations between genetically predicted blood protein biomarkers and pancreatic cancer risk. *Cancer Epidemiol Biomarkers Prev*. 29(7):1501–8. <https://doi.org/10.1158/1055-9965.EPI-20-0091> PMID:32439797
- Znaor A, Fouad H, Majnoni d'Intignano F, Hammerich A, Slama S, Pourghazian N, et al. (2021a). Use of cancer data for cancer control in the Eastern Mediterranean Region: results of a survey among population-based cancer registries. *Int J Cancer*. 148(3):593–600. <https://doi.org/10.1002/ijc.33223> PMID:32683692
- Znaor A, Ryzhov A, Corbex M, Piñeros M, Bray F (2021b). Cervical cancer in the Newly Independent States of the former Soviet Union: incidence will remain high without action. *Cancer Epidemiol*. 73:101944. <https://doi.org/10.1016/j.canep.2021.101944> PMID:33975255
- Znaor A, Skakkebaek NE, Rajpert-De Meyts E, Laversanne M, Kuliš T, Gurney J, et al. (2020). Testicular cancer incidence predictions in Europe 2010–2035: a rising burden despite population ageing. *Int J Cancer*. 147(3):820–8. <https://doi.org/10.1002/ijc.32810> PMID:31773729
- Zouiouich S, Lofffield E, Huybrechts I, Viallon V, Louca P, Vogtman E, et al. (2021). Markers of metabolic health and gut microbiome diversity: findings from two population-based cohort studies. *Diabetologia*. 64(8):1749–59. <https://doi.org/10.1007/s00125-021-05464-w> PMID:34110438
- Zupunski L, Yaumenenka A, Ryzhov A, Veyalkin I, Drozdovitch V, Masiuk S, et al. (2021). Breast cancer incidence in the regions of Belarus and Ukraine most contaminated by the Chernobyl accident: 1978 to 2016. *Int J Cancer*. 148(8):1839–49. <https://doi.org/10.1002/ijc.33346> PMID:33064313
- Zvereva M, Pisarev E, Hosen I, Kisil O, Matskeplishvili S, Kubareva E, et al. (2020a). Activating telomerase *TERT* promoter mutations and their application for the detection of bladder cancer. *Int J Mol Sci*. 21(17):18. <https://doi.org/10.3390/ijms21176034> PMID:32839402
- Zvereva M, Roberti G, Durand G, Voegelé C, Nguyen MD, Delhomme TM, et al. (2020). Circulating tumour-derived *KRAS* mutations in pancreatic cancer cases are predominantly carried by very short fragments of cell-free DNA. *EBioMedicine*. 55:102462. <https://doi.org/10.1016/j.ebiom.2019.09.042> PMID:32249202
- Zwakenberg SR, Burgess S, Sluijs I, Weiderpass E, Beulens JWW, van der Schouw YT; EPIC-CVD consortium (2020). Circulating phylloquinone, inactive Matrix Gla protein and coronary heart disease risk: a two-sample Mendelian randomization study. *Clin Nutr*. 39(4):1131–6. <https://doi.org/10.1016/j.clnu.2019.04.024> PMID:31103344

SECTION OF CANCER SURVEILLANCE (CSU)

The Section of Cancer Surveillance (CSU) is grateful to the following for their collaboration:

Maihan Abdullah, Marym Ramzia Mohammady, Afghanistan; Lamia Kara, Algeria; Graciela Abriata, Betty Carballo, Maria Cristina Diumenjo, Florencia Moreno, Graciela Nicolás, Argentina; Joanne Aitken, Karen Canfell, Katina D'Onise, Jeff Dunn, Sue Evans, Gail Garvey, Suzanne Moore, Alison Pearce, David Roder, Hanna Tervonen, Richard Trevithick, David Whiteman, Danny Youlden, Australia; Luca Li-Bassi, Lisa Stevens, Austria; Daisy Gibson, Bahamas; Nabila Purno, Bangladesh; Marc Arbyn, Delphine Heenen, Belgium; Ugyen Tshomo, Bhutan; Marianna Camargo, Marceli Santos, Brazil; Monirath Hav, Cambodia; Ronald Barr, James Brierley, Angela Eckstrand, Miranda Fidler-Benaoudia, Cindy Gauvreau, Mary Gospodarowicz, Sumit Gupta, Prabhat Jha, Serena Kozie, Carol McClure, Brian O'Sullivan, Jürgen Rehm, Lorraine Shack, Kevin Shield, Bundit Sornpaisarn, Nathalie St-Jacques, Ryan Woods, Walter Zoss, Canada; Katy Heise, Chile; Meng Meng Li, Wenqiang Wei, Rongshou Zheng, China; Luis Eduardo Bravo, Esther de Vries, Constanza Pardo, Claudia Uribe, Carolina Wiesner, Colombia; Line Couitchéré, Leticia Fernández, Côte d'Ivoire; Tomislav Kuliš, Croatia; Yaima Galán, Cuba; Marilys Corbex, Gerda Engholm, Lina Steinrud Mørch, Niels Erik Skakkebæk, Hans Storm, Jeannette Falck Winther, Denmark; Patricia Cueva, Wilmer Tarupi, Ecuador; Heba Fouad, Amal Samy Ibrahim, Slim Slama, Egypt; Soad Linneth Fuentes-Alabí, El Salvador; Chris Bates, Luisa Cikamatana, Fiji; Sanna Heikkinen, Eero Pukkala, Finland; Françoise Borson-Chazot, Jacqueline Clavel, Marc Colonna, Cyrille Delpierre, Antoine Duclos, Brigitte Lacour, Sébastien Lamy, Jean-Christophe Lifante, Brenda Mallon, Gwenn Menvielle, Sophie Pilleron, Corinne Pilorget, Agnes Rogel, France; Konstantine Kazanjan, Alexander Turdziladze, Georgia; Hermann Brenner, Friederike Erdmann, Thomas Gredner, Peter Kaatsch, Carolin Killian, Germany; Fred Kwame Awittor, Baffour Awuah, Ghana; Annette David, Guam; Budukh Atul, Rajesh Dikshit, Prashant Mathur, Venkatraman Radhakrishnan, Rama Ranganathan, Rajamaram Swaminathan, India; Susanna Hilda Hutajulu, Herindita Puspitaningtyas, Indonesia; Marzieh Araghi, Hamideh Rashidian, Gholamreza Roshandel, Kazem Zendehtdel, Islamic Republic of Iran; Julianne Byrne, Paul Hanly, Colette O'Neill, Paul Walsh, Ireland; Manola Bettio, Luigino Dal Maso, Silvano Gallus, Gemma Gatta, Ivano Iavarone, Alessandra Lugo, Ciaran Nicholl, Fulvio Ricceri, Stefano Rosso, Carlotta Sacerdote, Annalisa Trama, Dario Trapani, Roberto Zanetti, Italy; Tomohiro Matsuda, Kayo Nakata, Japan; Omar Nimri, Jordan; Gladys Chesumbai Onyango, Kenya; Elena Ten, Kyrgyzstan; Marcis Leja, Latvia; Adel Attia, Waled Masaud, Libya; Azizah Manan, Malaysia; Yelda Leal, Abelardo Meneses, Alejandro Mohar, Alexandra Palafox, Nancy Reinoso, Mexico; Karima Bendahou, Morocco; Htoo Kyaw Lynn, Kaung Myat Shwe, Soe Aung, Soe Myat, Myanmar; Ranjeeta Subedi, Nepal; Jan Willem Coebergh, Valery Lemmens, Wilma Nusselder, Sabine Siesling, Mark van Berge Henegouwen, Rob Verhoeven, Otto Visser, The Netherlands; Hazem Abd Elkader, Sunia Foliaki, Jason Gurney, Diana Sarfati, New Zealand; Isidore Obot, Nigeria; Bjorn Moller, Jan Nygard, Giske Ursin, Norway; Enrique Gil, Eduardo Payet, Patricia Perez, Ebert Poquioma, Peru; Laudico Adriano, Rica Lumague, The Philippines; Fatima Cardoso, Portugal; Seri Hong, Min Kyung, Hee Young Shin, Young-Joo Won, Republic of Korea; Anton Barchuk, Carina Ferreira-Borges, Maria Neufeld, Mikhail Valkov, Russian Federation; Marc Hagenimana, Rwanda; Filipina Aмоса-Lei Sam, Samoa; Lejla Paripovic, Serbia; Elvira Singh, Ross Soo, Lanying Wang, Singapore; Vesna Zadnik, Tina Žagar, Slovenia; Natasha Abraham, Peter Hesseling, Elvira Singh, South Africa; Paul Dickman, Adela Cañete Nieto, Marta Ortega-Ortega, Spain; Eshani Fernando, Suraj Perera, Sudath Samaraweera, Sri Lanka; Lars Hjorth, Monica Persson, Sven Sandin, Par Sparen, Sweden; Cary Adams, Bochen Cao, Elena Fidarova, Andre Ilbawi, Robert Jakob, Sonali Johnson, Claudia Kuehni, Keith McGregor, Felipe Roitberg, Rolf Stahel, Zuzanna Tittenbrun, Zuzana Tomášiková, Julie Torode, Switzerland; Malcolm Moore, Donsuk Pongnikorn, Piya Rujkijyananont, Suleeporn Sangrajrang, Patumrat Sripan, Surapon Wiangnon, Thailand; Glennis Andall-Breton, Corey George, Sarah Quesnel-Crooks, Trinidad and Tobago; Sultan Eser, Murat Gultekin, Turkey; Francis Okongo, Uganda; Anton Ryzhov, Ukraine; Wael Shelpai, United Arab Emirates; Helen Coleman, David Conway, Tim Eden, Richard Feltbower, Anna Gavin, Lucy Irwin, Tom Johnston, Andrew Kunzmann, Paul Lambert, Biying Liu, Michael Marmot, Amy McKeon, Max Parkin, Kathy Pritchard-Jones, Eve Roman, Brian Rous, Mark Rutherford, Peter Sasieni, Linda Sharp, Charles Stiller, Richard Sullivan, Sally Vernon, Paolo Vineis, United Kingdom; Martin Matu, United Republic of Tanzania; Rafael Alonso, Enrique Barrios, Mariela Garau, Carina Musetti, Uruguay; Rifat Atun, Nickhill Bhakta, Archie Bleyer, Nancy Bolous, Juan Brito, Constanza Camargo, Ann Chao, Louise Davies, Edward Dee, Susan Devesa, Mini Devidas, Brenda Edwards, Lindsay Frazier, Paola Friedrich, Leeanna Fox Irwin, Ophira Ginsburg, Lou Gonsalves, Julie Gralow, Jim Hofferkamp, Sharmeen Hussain, Farhad Islami, Ahmedin Jemal, Betsy Kohler, Jill Koshiol, Catherine Lam, Silvana Luciani, Aju Mathew, Katherine McGlynn, Daniel Moreira, Serban Negoita, Magdalena Paczkowski, Lynn Ries, Julie Ritter, Carlos Rodriguez-Galindo, Victor Santana, Mona Saraiya, Meredith Shiels, Aaron Thrift, Kevin Ward, USA; Dilfuza Alieva, Sayde Djanklic, Uzbekistan; Bui Duc Tung, Tran Thanh Hung, Viet Nam.

The IARC Monographs Group (IMO) is grateful to the following for their collaboration:

Working Group members

Volume 126: Deirdre Cronin-Fenton, Denmark; Nazir Ahmad Dar, India; Arash Etemadi, USA; Paola Fortini, Italy; Deborah Glass, Australia; Jennifer Jinot, Canada; Farin Kamangar, USA; Narges Khanjani, Islamic Republic of Iran; Ruri Kikura-Hanajiri, Japan; Nuria Malats, Spain; Reza Malekzadeh, Islamic Republic of Iran; Akram Pourshams, Islamic Republic of Iran; Afarin Rahimi-Movaghar, Islamic Republic of Iran; David Richardson, USA; Vikash Sewram, South Africa; Saman Warnakulasuriya, United Kingdom.

Volume 127: Mohamed Abdallah (withdrew), United Kingdom; Tina Bahadori, USA; Gloria Calaf, Chile; Tania Carreón-Valencia, USA; Guosheng Chen, Canada; Aline De Conti, USA; David DeMarini, USA; Lin Fritschi, Australia; Min Gi, Japan; William Gwinn, USA; Nancy Hopf, Switzerland; David Josephy, Canada; Jorunn Kirkeleit, Norway; Kristina Kjaerheim, Norway; Sophie Langouët, France; Damien McElvenny, United Kingdom; David McLean (withdrew), New Zealand; Martha Sandy, USA; Consolato Sergi, Canada; Leslie Stayner, USA; Takeshi Toyoda, Japan.

Volume 128: Frederick Beland, USA; Fung Lung Chung, USA; David Dorman, USA; Sarah Elmore, USA; Katharine Hammond, USA; Srmena Krstev, Serbia; Dirk Lachenmeier, Germany; Igor Linhart, Czechia; Alexandra Long, Canada; Daniele Mandrioli, Italy; Matilde Marques, Portugal; Kumiko Ogawa, Japan; Jane Pappas, Canada; Juan Parra Morte, Italy; David Phillips, United Kingdom; Glenn Talaska, USA; Moon-Shong Tang, USA; Nisha Thakur, India; Martie Van Tongeren, United Kingdom; Paolo Vineis, United Kingdom.

Volume 129: Wendy C. Andersen, USA; Guosheng Chen, Canada; Gisela de Aragão Umbuzeiro, Brazil; Jia-Long Fang, USA; Julia Gohlke, USA; Frank Le Curieux, Finland; Kamila Mitrowska, Poland; Anjoeka Pronk, The Netherlands; Pascal Sanders, France; Meng Sun, USA; Takashi Umemura, Japan.

Volume 130: Marc Aubert, France; Fiorella Belpoggi, Italy; Russell C. Cattley, USA; Julie Cox, Canada; Calvin Ge, The Netherlands; Per Gustavsson, Sweden; Heiko Käfferlein, Germany; Lawrence Lash, USA; Annie Lumen, USA; Michiharu Matsumoto, Japan; María Teresa Muñoz-Quezada, Chile; Cheryl Peters, Canada; Mark Purdue, USA; Brad Reisfeld, USA; Patricia Stewart, USA; Camilla Svendsen, Norway; Michelle Turner, Spain; Abbas Virji, USA; Marianna G. Yakubovskaya, Russian Federation; James Yiin, USA.

Representatives

Volume 128: John Stanek, United States Environmental Protection Agency, USA; Irina Zastenskaya, WHO European Centre for Environment and Health, Germany.

Volume 129: Rosalie Elespuru, Center for Devices and Radiological Health, United States Food and Drug Administration, USA.

The IARC Handbooks Group (IHB) is grateful to the following for their collaboration:

Working Group members

Volume 18: Silvina Arrossi, Buenos Aires, Argentina; Julia Brotherton, Melbourne, Karen Canfell, Woolloomooloo, Australia; Eduardo Franco, Montreal, Rachel Kupets, Toronto, Canada; Fanghui Zhao, Beijing, China; Raúl Murillo, Bogotá, Colombia; Françoise F. Hamers, Saint-Maurice, France; Rengaswamy Sankaranarayanan, New Delhi, India; Paolo Giorgi Rossi, Reggio Emilia, Italy; Chisato Hamashima, Tokyo, Japan; Karima Bendahhou, Casablanca, Morocco; Johannes Berkhof, Amsterdam, The Netherlands; Marta del Pino, Barcelona, Spain; Miriam Elfström, Huddinge, Sweden; Suleeporn Sangrajrang, Bangkok, Thailand; C. Simon Herrington, Edinburgh, Anne Mackie, London, United Kingdom; Michael H. Chung, Mona Saraiya, Robert Smith, Atlanta, Mark Schiffman, Nicolas Wentzensen, Rockville, Silvia de Sanjosé, Seattle, USA; Z. Mike Chirenje, Harare, Zimbabwe.

Volume 19: Newell Johnson, Griffith; Luiz Paulo Kowalski, São Paulo, Alan Roger Santos-Silva, Campinas; Maria E. Leon, Pierre Saintigny, Lyon; Devasena Anantharaman, Kerala, Prakash Gupta, Navi Mumbai, Ravi Mehrotra, New Delhi, Dharendra Narain Sinha, Patna, Kunnambath Ramadas, Trivandrum; Toru Nagao, Nagoya; Rosnah Binti Mohd Zain, Kuala Lumpur; Olalekan Ayo-Yusuf, Pretoria; Wanninayake M. Tilakaratne, Peradeniya; Felipe Roitberg, Geneva and São Paulo; Hsiu-Hsi Chen, Taipei; Patravoot Vatanasapt, Khon Kaen; David Conway, Glasgow, Saman Warnakulasuriya, London, Olena Mandrik, Sheffield; Anil Chaturvedi, Bethesda, Alexander Ross Kerr, New York.

Invited specialists

Volume 18: Marc Arbyn, Brussels, Belgium; Walter Prendiville, Lyon, France.

Volume 19: Rengaswamy Sankaranarayanan, Mumbai; Ann Gillenwater, Houston.

Representatives

Volume 18: Carolina Wiesner, Colombian National Cancer Institute, Bogotá, Colombia.

Volume 19: Carolina Wiesner, National Cancer Institute, Bogotá; Frédéric De Bels, Institut national du cancer, Boulogne-Billancourt; Luciana Neamtii, European Commission, Ispra.

WHO Secretariat

Volume 18: Nathalie Broutet, Elena Fidarova, John Grove, Nancy Santesso, WHO headquarters, Geneva, Switzerland.

Volume 19: Gampo Dorji, Thushara Eraj Indranath Fernando, Jagdish Kaur, WHO Regional Office for South-East Asia, New Delhi; Andre Ilbawi, Rok Ho Kim, Maria Pura Solon, Benoît Varenne, WHO headquarters, Geneva.

The WHO Classification of Tumours Group (WCT) is grateful to the following for their collaboration:

Editorial Board Standing Members of the WHO Classification of Tumours, fifth edition

Fátima Carneiro, Porto, Portugal; John K.C. Chan, Kowloon, Hong Kong Special Administrative Region, China; Annie N.Y. Cheung, Hong Kong Special Administrative Region, China; Erika Denton, Norwich, United Kingdom; Michael Eden, Cambridge, United Kingdom; Andrew Field, Sydney, Australia; Anthony Gill, St Leonards, Australia; Jennelle Hodge, Indianapolis, USA; Joseph Khoury, Houston, USA; Sunil Lakhani, Herston, Australia; Sigurd Lax, Graz, Austria; Alexander Lazar, Houston, USA; Holger Moch, Zurich, Switzerland; Atsushi Ochiai, Tokyo, Japan; Esther Oliva, Boston, USA; Brian Rous, Cambridge, United Kingdom; Rajendra Singh, New York, USA; Fernando Augusto Soares, São Paulo, Brazil; John Srigley, Mississauga, Canada; Puay Hoon Tan, Singapore, Singapore; Lester D.R. Thompson, Woodland Hills, USA; Ming S. Tsao, Toronto, Canada; Toyonori Tsuzuki, Nagakute, Japan; Kay Washington, Nashville, USA.

Editorial Board Expert Members of the WHO Classification of Female Genital Tumours, fifth edition

James Brenton, Cambridge, United Kingdom; C. Blake Gilks, Vancouver, Canada; Lora Hedrick Ellenson, New York, USA; C. Simon Herrington, Edinburgh, United Kingdom; Pei Hui, New Haven, USA; Kyu-Rae Kim, Seoul, Republic of Korea; Teri Longacre, Stanford, USA; Anais Malpica, Houston, USA; Xavier Matias-Guiu, Barcelona, Spain; Glenn McCluggage, Belfast, United Kingdom; Yoshiki Mikami, Kumamoto, Japan; Marisa Nucci, Boston, USA; Jaume Ordi, Barcelona, Spain; Joseph Rabban, San Francisco, USA; le-Ming Shih, Baltimore, USA; Robert Soslow, New York, USA; Karl Tamussino, Graz, Austria.

Editorial Board Expert Members of the WHO Classification of Soft Tissue and Bone Tumours, fifth edition

Cristina Antonescu, New York, USA; Jean-Yves Blay, Lyon, France; Judith Bovée, Leiden, The Netherlands; Julia Bridge, Omaha, USA; Isabela Werneck Cunha, São Paulo, Brazil; Angelo Dei Tos, Treviso, Italy; Adrienne Flanagan, London, United Kingdom; Christopher Fletcher, Boston, USA; Andrew Folpe, Rochester, USA; Jason Hornick, Boston, USA; Fredrik Mertens, Lund, Sweden; Markku Miettinen, Bethesda, USA; Gunnlaugur Petur Nielsen, Boston, USA; Yoshinao Oda, Fukuoka, Japan; Akihiko Yoshida, Tokyo, Japan.

Editorial Board Expert Members of the WHO Classification of Thoracic Tumours, fifth edition

Alain Borczuk, New York, USA; Wendy Cooper, Camperdown, Australia; Sanja Dacic, Pittsburgh, USA; Françoise Galateau-Salle, Lyon, France; Deepali Jain, New Delhi, India; Keith Kerr, Aberdeen, United Kingdom; Sylvie Lantuejoul, Lyon, France; Joseph Maleszewski, Rochester, USA; Alexander Marx, Mannheim, Germany; Andrew Nicholson, London, United Kingdom; Masayuki Noguchi, Tsukuba-shi, Japan; Simon Padley, London, United Kingdom; Giorgio Scagliotti, Orbassano, Italy; William Travis, New York, USA; Paul Van Schil, Edegem, Belgium; Yasushi Yatabe, Tokyo, Japan.

WHO Radiology Advisory Board Members of the WHO Classification of Tumours, fifth edition

Regina Beets-Tan, Amsterdam, The Netherlands; Rajat Chowdhury, Oxford, United Kingdom; Erika Denton, Norwich, United Kingdom; Vicky Goh, London, United Kingdom; Toshinori Hirai, Kumamoto, Japan; Masahiro Jinzaki, Tokyo, Japan; David Liu, Vancouver, Canada; Elisabeth Morris, Sacramento, USA; Deepak Patkar, Mumbai, India; William Poon, Hong Kong Special Administrative Region, China; Sona Pungavkar, Mumbai, India; Andrea Rockall, London, United Kingdom; Christian van der Pol, Hamilton, Canada; Ivan Wong, Hong Kong Special Administrative Region, China.

Editorial Board Standing Members of the International Academy of Cytology (IAC)–IARC Cytopathology Reporting Systems, first edition

Andrew Field, Darlinghurst, Australia; Ravi Mehrotra, New Delhi, India; Martha Bishop Pitman, Boston, USA; Fernando Schmitt, Porto, Portugal.

SECTION OF MECHANISMS OF CARCINOGENESIS (MCA)

The Epigenetics Group (EGE) is grateful to the following for their collaboration:

Richard Saffery, Gabriella Tikellis, Victoria, Australia; Christoph Bock, Vienna, Austria; François Fuks, Brussels, Tim Nawrot, Michelle Plusquin, Diepenbeek, Marthe De Boevre, Sarah De Saeger, Ghent, Belgium; Sheila Lima, Felipe Pinto, Rio de Janeiro, Silvia Rogatto, São Paulo, Brazil; Anastas Gospodinov, Sophia, Bulgaria; Chantal Matar, Ottawa, Canada; Janos Terzic, Katarina Vukojevic, Split, Gordana Lauc, Nino Sincic, Vlatka Zoldos, Zagreb, Croatia; Pavel Soucek, Pilsen, Czechia; Kirsti Husgafvel-Pursiainen, Eeva Kettunen, Helsinki, Finland; Saadi Khochbin, Claire Vourc'h, Grenoble, Jean-Yves Blay, Julie Caramel, Isabelle Chemin, Philippe Clézardin, Henri Gruffat, Evelyne Manet, Patrick Mehlen, Philippe Merle, Maria Ouzounova, Romain Parent, Lyon, Ellen Obberghen-Schilling, Nice, Jacqueline Clavel, Suzette Delalogue, Alain Puisieux, Cécile Zaros, Paris, Cécile Chevrier, Rennes, Marie-Aline Charles, Villejuif, France; Rudolf Kaaks, Christoph Plass, Heidelberg, Germany; Bernardo Bonanni, Milan, Lorenzo Leoncini, Lucia Mundo, Siena, Lorenzo Richiardi, Turin, Italy; Sandra Ghayad, Rihab Nasr, Nathalie K. Zgheib, Beirut, Lebanon; Felicia Chung, Chee-Onn Leong, Kuala Lumpur, Malaysia; Felipe Vaca Paniagua, Mexico City, Mexico; Siri E. Håberg, Vessela

N. Kristensen, Per Magnus, Monica Cheng Munthe-Kaas, Oslo, Norway; Jeongseon Kim, Goyang, Republic of Korea; Manolis Kogevinas, Barcelona, Jose Ramon Bilbao, Bilbao, Spain; Erik Melén, Stockholm, Sweden; Nicole Probst, Basel, Rabih Murr, Geneva, Switzerland; Temduang Limpaboon, Khon Kaen, Thailand; Jean Golding, Bristol, Yun Yun Gong, Michael Routledge, Leeds, Andrew Pretince, Elio Riboli, Paolo Vineis, London, Terry Dwyer, Oxford, United Kingdom; Leslie Stayner, Chicago, Robert A. Waterland, Houston, Steve Horvath, Joseph Wiemels, Los Angeles, Jia Chen, New York, Martha Linet, Mary H. Ward, Rockville, Ruth Patterson, Dorothy Sears, San Diego, Stephanie London, Martyn Smith, San Francisco, USA; Cuong van Duong, Tran Bao Ngoc, Thai Nguyen, Viet Nam.

The Molecular Mechanisms and Biomarkers Group (MMB) is grateful to the following for their collaboration:

Joëlle Nortier, Sandrine Rorive, Thierry Roumeuguère, Brussels, Marthe De Boevre, Sarah De Saeger, Filip Van Nieuwerburgh, Ghent, Belgium; Želimir Stipančić, Odžak, Bosnia and Herzegovina; Damir Dittrich, Krešimir Karlović, Maja Mišić, Karla Tomić, Slavonski Brod, Fran Borovečki, Bojan Jelaković, Sandra Karanović, Neda Slade, Zagreb, Croatia; Tomáš Stopka, Ruth Tachezy, Tereza Turková, Prague, Czechia; Benoit Busser, Lucie Sancey, Grenoble, Barbara Charbotel, Cédric Chaveroux, Isabelle Chemin, Isabelle Daniel, Sophie Deneuve, Béatrice Fervers, Joelle Févotte, Olivia Perol, Pierre Saintigny, Isabelle Treilleux, Pauline Vidican, François Virard, Lyon, Nathalie Rioux-Leclercq, Rennes, France; Tomáš Zikmund, Munich, Germany; Daniele Mandrioli, Bologna, Italy; Min Gi, Shugo Suzuki, Hideki Wanibuchi, Osaka, Yuji Eso, Hiroko Marusawa, Kyoto, Yukari Totsuka, Tokyo, Japan; Leo Schouten, Kim Smits, Maastricht, The Netherlands; Maria Dusinska, Espen Mariussen, Elise Rundén Pran, Kjeller, Norway; Ong Teng Aik, Retnagowri Rajandram, Mun Kein Seong, Kuala Lumpur, Felicia Chung Fei Lei, Abhimanyu Veerakumarasivam, Petaling Jaya, Rozaini Abdullah, Shah Alam, Malaysia; Arnoud Boot, Steve G. Rozen, Bin Tean Teh, Singapore, Singapore; Alvin Ng, Mike Stratton, Cambridge, David Phillips, London, Benjamin Schuster-Böckler, Oxford, United Kingdom; Mark LaBarge, Martha Stampfer, Berkeley, Mia Petljak, Cambridge, Marketa Tomkova, Davis, Frederick A. Beland, Mona Churchwell, Igor Pogribny, Volodymyr Tryndyak, Jefferson City, Ludmil B. Alexandrov, Erik Bergstrom, Burcak Otlu Saritas, Maria Zhivagui, La Jolla, Ahmad Besaratinia, Los Angeles, Silvia Balbo, Madjda Bellamri, Steve Hecht, Lisa Peterson, Natalia Tretyakova, Robert J. Turesky, Karine Vevang, Peter Villalta, Minneapolis, Dinesh Barupal, New York City, Dmitry A. Gordenin, Ronald A. Herbert, Les Klimczak, Research Triangle Park, Kathleen G. Dickman, Arthur P. Grollman, Stony Brook, USA.

SECTION OF INFECTIONS (INF)

The Infections and Cancer Biology Group (ICB) is grateful to the following for their collaboration:

Marc Arbyn, John-Paul Bogers, Antwerp, Michael Herfs, Liege, Belgium; Laura Sichero, Luisa Lina Villa, São Paulo, Brazil; François Coutlée, Montreal, Canada; Jean-Luc Pretet, Besançon, Henri Gruffat, Evelyne Manet, Jacqueline Marvel, Lyon, Jean Lacau de Saint Guily, Paris, Christine Clavel, Véronique Dalstein, Reims, Antoine Touze, Tours, France; Partha Basu, Gary Clifford, Jean-Damien Combes, Zdenko Herceg, Eric Lucas (IARC collaborators), Lyon, France; Nicole Fischer, Daniela Fusco, Adam Grundhoff, Hamburg, Christa Flechtenmacher, Lutz Gissmann, Dana Holzinger, Karin Muller-Decker, Michael Pawlita, Rüdiger Ridder, Daniele Viariso, Heidelberg, Germany; Devasenaa Anantharaman, Radhakrishnan Pillai, Thiruvananthapuram, India; Cara Martini, Dublin, Ireland; Susanna Chiocca, Fausto Maffini, Domenico Mattosio, Milan, Maria Benevolo, Maria V. Chiantore, Paola Di Bonito, Eugenia Dogliotti, Maria Gabriela Dona, Gianna Fiorucci, Paola Fortini, Massimo Giuliani, Giorgio Mangino, Francesca Marcon, Giovanna Romeo, Rome, Mario Preti, Torino, Paolo Boscolo-Rizzo, Trieste, Italy; Oh Choon Chiat, Singapore; Laia Alemany, Silvia de Sanjosé, Belén Lloveras Rubio, Barcelona, Spain; Lesley A. Anderson, Andrew Kunzmann, Belfast, United Kingdom; Megan Burke Fitzpatrick, Madison, David Wada, Salt Lake City, Rosyabelle P. Amorrortu, Anna R. Giuliano, Shalaka S. Hampras, Dana E. Rollison, Tampa, USA.

The Infections and Cancer Epidemiology Group (ICE) is grateful to the following for their collaboration:

Karina Baghdasarova, Marianna Hakobyan, Narine Hayrapetyan, Yerevan, Armenia; Alex Vorsters, Antwerp, Belgium; Ugyen Tshomo, Thimphu, Bhutan; Marc Brisson, Montreal, Canada; Catterina Ferreccio, Santiago, Chile; Rufei Duan, Fang-hui Zhao, Beijing, China; Apollinaire Horo, Abidjan, Côte d'Ivoire; Matti Lehtinen, Tampere, Finland; Isabelle Chemin, Lyon, Pierre Debeaudrap, Isabelle Etienney, Isabelle Heard, Jean Lacau de Saint Guily, Paris, France; Partha Basu, Freddie Bray, Jacques Ferlay, Tarik Gheit, Massimo Tommasino (IARC collaborators), Lyon, France; Dominik Stelzle, Munich, Germany; Rajaraman Swaminathan, Chennai, Rengaswamy Sankaranarayanan, Lopamudra Ray Saraswati, New Delhi, India; Farhad Pourfarzi, Ardabil, Reza Malekzadeh, Tehran, Islamic Republic of Iran; Silvia Franceschi, Aviano, Francesca Carozzi, Florence, Paolo Giorgi Rossi, Reggio Emilia, Fulvio Lazzarato, Franco Merletti, Turin, Italy; Marcis Leja, Riga, Latvia; Hans Berkhof, Daniëlle A.M. Heideman, Chris J.L.M. Meijer, Amsterdam, The Netherlands; Diana Sarfati, Wellington, New Zealand; Il Ju Choi, Jae Kwan Jun, Goyang, Republic of Korea; Tharcisse Mpunga, Butaro, Jean de Dieu Hakizimana, Felix Sayinzoga, Kigali, Rwanda; Joakim Dillner, Stockholm, Sweden; Alexandra U. Scherrer, Zurich, Switzerland; Nathalie Broutet, Shona Dalal, Meg Doherty, Yvan Hutin, Mary Mahy (WHO collaborators), Geneva, Switzerland; Robert Newton, Entebbe, Uganda; Zhengming Chen, Iona Millwood, Richard Peto, Ling Yang, Oxford, Martyn Plummer, Warwick, United Kingdom; Eric A. Engels, Aimee Kreimer, Lisa Mirabello, Meredith Shiels, Bethesda, USA.

The Section of Environment and Radiation (ENV) is grateful to the following for their collaboration:

Eduardo Cazap, Argentina; Eleonora Feletto, Australia; Ilya Veyalkin, Alesya Yaumenenka, Belarus; David Ritchie, Wendy Yared, Belgium; Christoffer Johansen, Denmark; Anssi Auvinen, Eero Pukkala, Antti Tossavainen, Finland; Isabel Baldi, Rémi Béranger, Jacqueline Clavel, Béatrice Fervers, Marcel Goldberg, Pierre Lebailly, Marie Zins, France; Eva Kantelhardt, Susanne Sachs, Birgit Wolz, Germany; Eleni Petridou, Greece; Kazem Zendehtdel, Islamic Republic of Iran; Franco Merletti, Italy; Shoji Nakayama, Shunichi Yamashita, Japan; Diana Menya, Kenya; Charles Dzamalala, Malawi; Annelie Zietsman, Namibia; Hans Kromhout, The Netherlands; Jeroen Douwes, New Zealand; Charles Adisa, Godson Ana, Angelica Anele, Shadrach Offiah, Nigeria; Karl-Christian Nordby, Norway; Igor Bukhtiyarov, Viktor Ivanov, Evgeny Kovalevskiy, Sergey Shinkarev, Russian Federation; Elisabeth Cardis, Spain; Herbert Cubasch, Angela Mathee, Frank Winde, South Africa; Maria Feychting, Sweden; Zhanat Carr, André Ilbawi, Martin Röösl, Switzerland; Moses Galukande, Uganda; Sergei Masiuk, Anton Ryzhov, Mykola Tronko, Ukraine; Isabel dos Santos Silva, Julian Peto, Eve Roman, Michael Watts, United Kingdom; Blandina Mmbaga, United Republic of Tanzania; Christian Abnet, Benjamin Anderson, Laura Beane-Freeman, Sandford Dawsey, Vladimir Drozdovitch, Julia Heck, Catherine Metayer, Daniel Pope, Paul Romitti, Michael Scheurer, Sara Schonfeld, Logan Spector, USA.

SECTION OF NUTRITION AND METABOLISM (NME)

The Biomarkers Group (BMA) is grateful to the following for their collaboration:

Abdul Wahed Wasiq, Kandahar, Afghanistan; Ghazaleh Dashti, Dallas English, Melbourne, Australia; Andrea Gsur, Vienna, Austria; Barbara Vanaelst, Ghent, Belgium; Rui Reis, Fabiana Vazques, Barretos, Brazil; David Wishart, Edmonton, Canada; Eva Bustamante, Maria Luisa Garmendia, Santiago, Chile; Gloria Sanchez, Medellín, Colombia; Carolina Porras, Ana Cecilia Rodriguez, San Jose, Costa Rica; Kim Overvad, Aarhus, Anne Tjønneland, Copenhagen, Denmark; Kati Hanhineva, Kuopio, Finland; Erwan Engel, Claudine Manach, Clermont-Ferrand, David Cox, Béatrice Fervers, Lyon, Marie Christine Boutron-Ruault, Agnès Fournier, Marina Kvaskoff, Fabienne Lesueur, Joseph Rothwell, Gianluca Severi, Mathilde Touvier, Thérèse Truong, Paris, Fabien Jourdan, Toulouse, France; Ute Nothlings, Bonn, Anna Floegel, Bremen, Steffen Neumann, Halle, Renee Fortner, Rudolf Kaaks, Tilman Kühn, Heidelberg, Michael Witting, Munich, Heiner Boeing, Potsdam, Germany; Antonia Trichopoulou, Athens, Greece; Domenico Palli, Florence, Bernardo Bonanni, Vittorio Krogh, Sabina Sieri, Milan, Salvatore Panico, Naples, Rosario Tumino, Ragusa, Italy; Takeshi Kimura, Norie Sawada, Shoichiro Tsugane, Tokyo, Japan; Angelica Angeles Lleneras, Martin Lajous, Ruy Lopez, Gabriela Torres, Cuernavaca, Mexico; Bas Bueno de Mesquita, Bilthoven, Matty Weijnen, Maastricht, Charlotte Onland-Moret, Petra H.M. Peeters, Carla van Gils, Roel Vermeulen, Utrecht, Justin J. J. van der Hoof, Wageningen, The Netherlands; Per Magne Ueland, Bergen, Eiliv Lund, Elisabete Weiderpass, Tromsø, Norway; Francisco Couto, Lisbon, Portugal; Hwan-Hee Jang, Jeonju, Republic of Korea; Herbert Cubasch, Raquel Duarte, Maureen Joffe, Shane Norris, Eunice van den Berg, Johannesburg, Christine Taljaard, Este Vorster, Potchefstroom, John Becker, Pretoria, South Africa; Antonio Agudo, Talita Duarte-Salles, Manolis Kogevinas, Raul Zamora-Ros, Barcelona, Maria José Sánchez, Granada, Carmen Navarro, Murcia, Aurelio Barricarte, Pamplona, Miren Dorronsoro, San Sebastian, Spain; Jonas Manjer, Malmö, Sophia Harlid, Joakim Hennings, Maria Sandström, Anne Zeleniuch-Jacquotte, Umeå, Sweden; Nicole Probst-Hensch, Basel, Switzerland; Kay-Tee Khaw, Cambridge, Marc Chadeau-Hyam, Elio Riboli, Paolo Vineis, London, Tim Key, Ruth Travis, Kostantinos Tsilidis, Oxford, United Kingdom; Mia Gaudet, Atlanta, Cari Kitahara, Rashmi Sinha, Bethesda, Megan Rice, Stephanie Smith-Warner, Boston, Cornelia Ulrich, Salt Lake City, Peggy Porter, Seattle, USA.

The Nutritional Epidemiology Group (NEP) is grateful to the following for their collaboration:

Marthe De Boevre, Karl De Ruyc, Sarah De Saeger, Koen Van Herck, Ghent, Lode Godderis, Leuven, Belgium; Fabiana de Lima Vazquez, Rui Manuel Reis, Barretos, Brazil; Lauren Griffith, Parminder Raina, Hamilton, Robert W. Bruce, Ahmed El-Sohemy, Gail McKeown-Eyssen, Toronto, Canada; Maria Luisa Garmendia, Santiago, Chile; Gloria Inés Sánchez, Medellín, Colombia; Carolina Porras-Gutiérrez, Ana Cecilia Rodriguez, San Jose, Costa Rica; Christina C. Dahm, Kim Overvad, Aarhus, Anja Olsen, Anne Tjønneland, Copenhagen, Berit Lilienthal Heitmann, Ina Olmer Specht, Frederiksberg, Denmark; Gabriel Perlemuter, Clamart, Marie Christine Boutron-Ruault, Françoise Clavel-Chapelon, Gianluca Severi, Thérèse Truong, Villejuif, France; Justo Lorenzo Bermejo, Julia Butt, Renée Fortner, Rudolf Kaaks, Verena Katzke, Tilman Kühn, Michael Pawlita, Tim Waterboer, Heidelberg, Heiner Boeing, Matthias Schulze, Potsdam, Germany; Pagona Lagiou, Antonia Trichopoulou, Athens, Greece; David Hughes, Dublin, Ireland; Giovanna Masala, Domenico Palli, Florence, Vittorio Krogh, Sabina Sieri, Milan, Amalia Mattiello, Salvatore Panico, Naples, Rosario Tumino, Ragusa, Alessio Naccardi, Fulvio Ricceri, Carlotta Sacerdote, Carlo Senore, Paolo Vineis, Turin, Italy; Ann Korir, Nairobi, Kenya; Farah Naja, Lara Nasreddine, Beirut, Lebanon; Gabriela Torres-Mejía, Cuernavaca, Mexico; Leila Alaoui, Hind el Fatemi, Karima el Rhazi, Mohamed Khalis, Fez, Rachid Bekkali, Hind Mrabti, Rabat, Morocco; Bas Bueno de Mesquita, Eugene Jansen, Monique Verschuren, Bilthoven, Petra H.M. Peeters, Roel Vermeulen, Utrecht, Ellen Kampman, Diewertje Kok, Wageningen, The Netherlands; Eiliv Lund, Torkjel M. Sandanger, Guri Skeie, Elisabete Weiderpass, Tromsø, Norway; Herbert Cubasch, Raquel Duarte, Maureen Joffe, Shane Norris, Johannesburg, Christine Taljaard, Este Vorster, Potchefstroom, South Africa; Antonio Agudo, Talita Duarte Salles, Carlos González, Raul Zamora-Ros, Barcelona, Maria José Sánchez, Granada, María Dolores Chirlaque López, Carmen Navarro, Murcia, José Ramón Quirós, Oviedo, Aurelio Barricarte, Pamplona, Pilar Amiano, Miren Dorronsoro, San Sebastian, Marina Lopez, Valencia, Spain; Jonas Manjer, Emily Sonestedt, Malmö, Göran Hallmans, Malin Sund, Umeå, Sweden; Adam Butterworth, Kay-Tee Khaw, Claudia Langenberg, Nick Wareham, Cambridge,

Rebecca Beeken, Amanda Cross, Robert Goldin, Maria Kyrgiou, David Muller, Elio Riboli, Andrew Steptoe, Kostas Tsilidis, Heather Ward, London, Andrew Renehan, Manchester, John E. Hesketh, Newcastle, Andrew Hart, Norwich, Kathryn Bradbury, Tim Key, Ruth Travis, Oxford, Barrie Margetts, Southampton, Robert Newton, York, United Kingdom; Veronika Fedirko, Mia Gaudet, Andrew T. Gewirtz, Atlanta, Demetrius Albanes, Erikka Loftfield, Rashmi Sinha, Stephanie Weinstein, Bethesda, Ed Giovannucci, Boston, Laura Beretta, Houston, Thomas Rohan, Howard Strickler, Sylvia Wassertheil-Smoller, New York, Maria Isabel Waddington Achatz, Rockville, Cornelia Ulrich, Salt Lake City, Liz Donato, Ulrike Peters, Peggy Porter, Seattle, USA.

The Nutritional Methodology and Biostatistics Group (NMB) is grateful to the following for their collaboration:

Ghazaleh Dashti, Dallas English, Harindra Jayasekara, Robert McInnis, Melbourne, Australia; Karl-Heinz Wagner, Vienna, Austria; Christina Dahm, Aarhus, Denmark; Cécile Proust-Lima, Bordeaux, Nadim Ballout, Béatrice Fervers, Lyon, Olivier Bouaziz, Marcel Goldberg, Grégory Nuel, Mathilde Touvier, Paris, Marie-Christine Boutron-Ruault, Marina Kvaskoff, Gianluca Severi, Villejuif, France; Rudolf Kaaks, Tilman Kühn, Heidelberg, Matthias Schultze, Potsdam, Michael Leitzmann, Regensburg, Germany; Enzo Bagnardi, Rino Bellocco, Vittorio Krogh, Milan, Salvatore Panico, Naples, Fulvio Ricceri, Carlotta Sacerdote, Turin, Italy; Roel Vermeulen, Monique Verschuren, Bilthoven, The Netherlands; Edoardo Botteri, Oslo, Torkjel Sandanger, Guri Skeie, Tromsø, Norway; Talita Duarte Salles, Barcelona, Spain; David Richards, Bristol, Adam Butterworth, Nick Wareham, Cambridge, Jack Bowden, Exeter, Marc Chadeau, David Muller, Elio Riboli, Kostas K. Tsilidis, Ioanna Tsoulakis, Paolo Vineis, London, Tim Key, Ruth Travis, Oxford, United Kingdom; Lola Etievant, Neal D. Freedman, Erikka Loftfield, Joshua Sampson, Bethesda, Stephanie Smith-Warner, Boston, Jeanine Genkinger, New York, USA.

SECTION OF GENETICS (GEN)

The Genetic Epidemiology Group (GEP) is grateful to the following for their collaboration:

Federico Jauk, Carlos Vaccaro, Marta Vilensky, Buenos Aires, Argentina; Emily Banks, Canberra, Allison Hodge, Melbourne, Kerrin Bleicher, Karen Canfell, Anne Cust, Louisa Degenhardt, Sallie Pearson, Peter Sarich, Marianne Weber, Sydney, Graham G. Giles, Roger L. Mine, Victoria, Australia; Rui Reis, Barretos, José Carlos de Oliveira, Goiânia, Patricia Ashton-Prolla, Porto Alegre, Luis Felipe Ribeiro Pinto, Rio de Janeiro, Jose Roberto de Podesta, Santa Cecilia, Maria Paula Curado, Vilma Martins, São Paulo, Brazil; Lorenzo Ferri, Michael Pollak, Brent Richards, Montreal, Monique Albert, Steven Gallinger, Rayjean Hung, Geoffrey Liu, Toronto, Canada; Mengmeng Li, Guangzhou, Alisa Goldenstein, Taiyuan, China; Paula Andrea Rodriguez, Antonio Huerta Salgado, Bogotá, Paula Hurtado, Cali, Sandra Aruachan, Norma Serrano, Floridablanca, Gustavo Giraldo, Medellín, Ana Milena Gomez, San Ignacio, Colombia; Lenka Foretova, Brno, Ivana Holcatova, Prague, Czechia; Jaana Rautava, Turku, Finland; Nazim Benzer, Pierre Saintigny, Lyon, Szilvi Ecsedi, Nice, Jean-Philippe Foy, Marcel Goldberg, Paris, France; Noemi Bender, Nicole Brenner, Evangelia Christodoulou, Rudolf Kaaks, Michael Pawlita, Lea Schroeder, Tim Waterboer, Heidelberg, Germany; Mauricio Villegas, Sacatepéquez, Guatemala; Péter Nyirády, Tibor Szarvas, Budapest, Hungary; Rajesh Dikshit, Mumbai, India; Gholamreza Roshandel, Gorgan, Mojgan Asgari, Reza Malekzadeh, Hossein Poustchi, Kazem Zendejdel, Tehran, Islamic Republic of Iran; Hadrien Charvat, Tatsuhiro Shibata, Tokyo, Japan; Diana Menya, Eldoret, Kenya; Sonata Jarmalaite, Vilnius, Lithuania; Charles Dzamalala, Blantyre, Malawi; Janett Caballero Jasso, Felipe Vaca-Paniagua, Mexico City, Abril Bernadette Martínez Rizo, Tepic, Eva María Gómez, Toluca de Lerdo, Mexico; Arnulf Langhammer, Levanger, Hilde Langseth, Mari Nygard, Giske Ursin, Elisabete Weiderpass, Oslo, Torkjel Sandanger, Tromsø, Kristian Hveem, Eivind Ness-Jensen, Trondheim, Norway; María Lucila González Donna, David Olivares Osuna, Capiatá, Paraguay; Carlos Castañeda, Surquillo, Peru; Beata Swiatkowska, Lodz, Jolanta Lissowska, Warsaw, Poland; Dana Mates, Stefan Rascu, Cristian Sima, Jinga Viorel, Bucharest, Romania; Anush Mukerji, David Zaridze, Moscow, Russian Federation; Saša Milosavljević, Belgrade, Serbia; Laia Alemany, Barcelona, Javier Oliver, Málaga, Spain; Anders Målarstig, Solna, Mikael Johansson, Börje Ljungberg, Umeå, Göran Frans Emanuel Laurell, Uppsala, Sweden; Suleeporn Sangrajang, Bangkok, Taned Chitapanarux, Anak Iamaroon, Chiang Mai, Surasak Sangkhathat, Songkhla, Thailand; George Davey-Smith, Tom Dudding, Richard Martin, Andrew Ness, Bristol, Rebecca Fitzgerald, Nick Wareham, Cambridge, Archie Campbell, Edinburgh, David Conway, Nigel Jamieson, Alastair Ross, Glasgow, Rosamonde Banks, Matthew Callister, Leeds, David Muller, Peter Sasieni, London, Haval Balata, Phil Crosbie, Mikey Lebrecht, Manchester, David Baldwin, Nottingham, Ruth C. Travis, Oxford, Laura Humphreys, Sarah Moody, Minouk Schoemaker, Mike Stratton, Anthony Swerdlow, Saffron Walden, Sutton, United Kingdom; Blandina Theophil Mmbaga, Moshi, United Republic of Tanzania; Mauricio Cuello, Montevideo, Uruguay; Ying Wang, Atlanta, Judith Hoffman-Bolton, Farin Kamangar, Betty May, Kala Visvanathan, Baltimore, I-Min Lee, Howard Sesso, Boston, Nicholas F. Schelcht, Buffalo, Katherine Hoadley, Chapel Hill, Christopher I. Amos, Houston, Gypsamber D'Souza, Maryland, Neil Hayes, Memphis, William J. Blot, Qiuyin Cai, Loren Lipworth, Xiao Ou Suh, Wei Zheng, Nashville, Ilir Agalliu, Alan Arslan, Sandra W. Smoller, New York, Brenda Diergaarde, Jian-Min Yuan, Pittsburgh, Demetrius Albanes, Christine D. Berg, Neil Caporaso, Stephen Chanock, Anil K. Chaturvedi, Li C. Cheung, Neal Freedman, Kathy Helzlsouer, Allan Hildesheim, Wen-Yi Huang, Hormuzd Katki, Aimée R. Kreimer, Rebecca Landy, Linda Liao, Mark Purdue, Meredith Shiels, Stephanie J. Weinstein, Rockville, Jose Zavallos, Saint Louis, Ludmil Alexandrov, San Diego, Chu Chen, Seattle, Lesley Tinker, Washington, Meredith C. B. Adams, Chris Gillette, Mara Z. Vitolins, Winston-Salem, USA.

The Genetic Cancer Susceptibility Group (GCS) is grateful to the following for their collaboration:

Ismail Hosen, Dhaka, Bangladesh; Felipe Ribeiro Pinto, Rio de Janeiro, Brazil; Yohan Bossé, Quebec, Rayjean Hung, Toronto, Canada; Jin-Xin Bei, Guangzhou, China; Henrik Hjalgrim, Copenhagen, Denmark; French MESOBANK, French MESOCLIN, French MESOPATH, and

French NETMESO, Lara Chalabreysse, Jean-Michel Maury, Bron, Arnaud Sherpereel, Lille, Jean-Yves Blay, Sandrine Boyault, Christophe Caux, Isabelle Chemin, Liming Chen, Francesca Damiola, Charles Dumontet, Anthony Ferrari, Françoise Galateau-Sallé, Joël Lachuer, Sylvie Lantuejoul, Arnaud Manel, Pierre Martinez, Delphine Maucourt-Boulch, Jean-Michel Maury, Caroline Moyret-Lalle, Séverine Tabone-Eglinger, Emmanuel Vian, Alain Viari, Thomas Walter, Lyon, Anne Boland, Jean Francois Deleuze, Nicolas Girard, Owkin (artificial intelligence company), Paris, France; Thorsten Ecke, Anja Rabien, Berlin, Germany; Jajah Fachiroh, Ery Kus Dwianingsih, Yogyakarta, Indonesia; Reza Malekzadeh, Tehran, Islamic Republic of Iran; Ghislaine Scelo, Turin, Italy; Beena Devi, Kuching, Malaysia; Anke Van Den Berg, Groningen, Jules Derks, Anne-Marie Dingemans, Ernst-Jan Speel, Maastricht, Hans Clevers, Talya Dayton, Utrecht, The Netherlands; Carmen Jeronimo, Porto, Portugal; David Zaridze, Maria Zvereva, Moscow, Russian Federation; Laura Costas-Caudet, Paolo Di Tommaso, Evan Floden, Barcelona, Juan Castaño, Cordoba, Juan Sandoval, Valencia, Spain; Suleeporn Sangrajrang, Bangkok, Thailand; Ruth Jarrett, Glasgow, United Kingdom; Alyssa Clay-Gilmour, Columbia, Lara Sucheston-Campbell, Columbus, Sophia Wang, Duarte, Loïc Le Marchand, Honolulu, Christopher Amos, Houston, Wendy Cozen, Los Angeles, Martha Shrubsole, Nashville, Vijai Joseph, New York, Sonja Berndt, Nat Rothman, Rockville, Susan Slager, Rochester, Ludmil Alexandrov, San Diego, Jaehee Kim, Julia Palacios, Noah Rosenberg, Stanford, USA.

SECTION OF EARLY DETECTION AND PREVENTION (EDP)

The Prevention and Implementation Group (PRI) is grateful to the following for their collaboration:

Silvina Arrossi, Rosa Laudi, Laura Thuyaret, Instituto Nacional de Cancer, Buenos Aires, Laura Fleider, Silvio Tatti, Hospital de Clínicas "José de San Martín", Buenos Aires, Juan Mural, Hospital Posadas, Buenos Aires, Alejandra Picconi, Instituto Malbran, Buenos Aires, Argentina; Aliaksandr Davidzenka, UNFPA Country Office, Minsk, Oleg Dubovik, UNDP Country Office, Minsk, Alesya Evmenenko, Elena Khorevich, Sergey Krasny, Vitaliy Osharin, Svyatoslav Semenov, Aliaksandr Silchanka, Olga Trusova, N.N. Alexandrov National Cancer Center of Belarus, Minsk, Viatcheslav Grankov, Valiantsin Rusovich, WHO Country Office, Minsk, Belarus; Marc Arbyn, Unit Cancer Epidemiology, Belgian Cancer Centre, Brussels, Belgium; Carolina Terán, Universidad San Francisco Xavier de Chuquisaca, Sucre, Bolivia; Felipe Roitberg, Institute of Cancer of State of Sao Paulo/University of São Paulo and Hospital Sírio Libanes, São Paulo, Brazil; Nancy Santesso, McMaster University, Hamilton, Canada; Johanna Acevedo, Paz Cook, Catterina Ferreccio, Marcela Lagos, Javiera Leniz, Vanessa van de Wyngard, Pontificia Universidad Católica, Santiago, Carla Molina, Universidad Nacional, Santiago, Chile; Gloria Sánchez, Universidad de Antioquia, Medellín, Marcela Celis, Sandra Martinez, Yuly Salgado, Carolina Wiesner, Instituto Nacional de Cancerología, Bogota, Colombia; Paula Gonzalez, Carolina Porras, Proyecto Epidemiológico Guanacaste, Guardia, Alejandro Calderón, Emmanuel Gonzalez, Diego Guillen, Caja costarricense de Seguro Social, San Jose, Costa Rica; Marilyns Corbex, Vitaly Smelov, WHO Regional Office for Europe, Denmark; Mauricio Maza, Basic Health International, San Salvador, El Salvador; Francis Mégraud, INSERM, CHU Pellegrin, Bordeaux, Franck Chauvin, Simon Ducarroz, Julie Kalecinski, Véronique Régnier, Fabien Tinquaut, Centre Hygée – Centre Régional de Prévention des Cancers, Saint Priest en Jarez, Anne-Sophie Petit, Marie Préau, Arnaud Simeone, GREPS, Université Lyon 2, France; Umberto D'Alessandro, MRC Unit The Gambia at LSHTM, Fajara, The Gambia; Anabelle Ferrera, Universidad Nacional Autónoma de Honduras, Tegucigalpa, Jackeline Figueroa, Secretaria de Salud, Tegucigalpa, Honduras; Farhad Pourfarzi, Ardabil University of Medical Sciences, Ardabil, Ahad Eshraghian, Shiraz University of Medical Sciences, Shiraz, Reza Malekzadeh, Alireza Sadjadi, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran; Michael Chung, Aga Khan University, Nairobi, Kenya; Sergejs Isajevs, Petra Kriķe, Marcis Leja, Inese Polaka, Daiga Šantare, University of Latvia, Latvia; Aurelio Cruz, Pilar Hernandez, Eduardo Lazcano, Instituto Nacional de Salud Pública, Cuernavaca, Mexico; Wim Quint, Linda Struijk, Leen-Jan van Doorn, DDL Diagnostic Laboratory, Rijswijk, Harry de Koning, Erasmus University, Rotterdam, The Netherlands; Maria Liz Bobadilla, Nelly Maldonado, Veronica Villagra, Laboratorio Central Nacional, Asunción, Elena Kasamatsu, Laura Mendoza, María Isabel Rodríguez, Instituto de Investigaciones en Ciencias de la Salud, Asunción, Ana Soilan, COLPODIG, Asunción, Paraguay; Yenny Bellido, Gino Venegas, Liga Nacional de Lucha contra el Cáncer, Lima, Franco Doimi, Laboratorio Privado de Anatomía Patológica, Lima, Carlos Velarde, Ninoska Macavilca, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Ana Patricia Ortiz, Luis Pericchi, Marievelisse Soto, Erick Suarez, University of Puerto Rico, San Juan, Puerto Rico; Il Ju Choi, Jungnam Joo, Jae Kwan JunByung Ho Nam, Young-Il Kim, Hyun Ji LimMin Kyung Lim, National Cancer Center, Goyang-si Gyeonggi-do, Republic of Korea; Alexey Belyaev, Yuri Komarov, N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Olga Sokolova, S.P. Botkin Clinical Infectious Diseases Hospital, Saint Petersburg, Russian Federation; Mamadou Diop, Institut Africain de Lutte contre le Cancer, CHU Aristide le Dantec, Senegal; Tit Albreht, National Institute of Public Health, Ljubljana, Slovenia; Anna-Lise Williamson, University of Cape Town, Cape Town, Themba Ginindza, Motshedisi Sebitloane, University of Kwazulu-Natal, Durban, Nondumiso Ngxola, Walter Sisulu University, East London, South Africa; Xavier Bosch, Laia Bruni, Xavier Castellsagué, Institut Català d'Oncologia, Barcelona, Spain; Joakim Dillner, Karolinska Institutet, Stockholm, Sweden; Melanie Bertram, Paul Bloem, Nathalie Broutet, Elena Fidarova, Raymond Hutubessy, André Ilbawi, Dario Trapani, World Health Organization, Geneva, Pierre Vassilakos, Hopitaux Universitaires de Genève, Switzerland; Robert Newton, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda; Claire Borelli, Rosalind Given-Wilson, St Georges University Hospital, London, Sue Cohen, Public Health England, London, Janet Seeley, LSHTM, London, Yan Chen, Nottingham University, Nottingham, Louise Wilkinson, Oxford University, Oxford, United Kingdom; Mabula Kasubi, Muhimbili National Hospital, Dar Es Salaam, Yuma Safina, Ministry of Health and Social Welfare, Dar Es Salaam, John Theopista, WHO Country Office, United Republic of Tanzania; Andrea Beracochea, Natalia Perez, Guillermo Rodríguez, Comisión Honoraria de Lucha contra el Cáncer, Montevideo, Uruguay; Prajakta Adsul, University of New Mexico Comprehensive Cancer Center, Albuquerque, Maria Constanza Camargo, Michael Cook, Allan Hildesheim, Hormuzd A. Katki, Aimée R. Kreimer, Douglas R. Lowy, Charles Rabkin, Mark Schiffman, John T. Schiller, Diane Solomon, Sholom Wacholder, National Cancer Institute, Bethesda, Scott Howard, University of Tennessee Health Science Center, Memphis, Catherine Lam, St Jude Children's Research Hospital, Memphis, Teresa Darragh, University of California, San Francisco, Michael Chung, University of Washington, Seattle, Jose Jerónimo, Global Coalition

Against Cervical Cancer, Virginia, Silvana Luciani, Pan American Health Organization (PAHO), Washington DC, Silvia de Sanjosé Llongueras, PATH, Washington DC, USA.

The Screening Group (SCR) is grateful to the following for their collaboration:

Africa

Djima Patrice Dangbeme, CHU Mel, Cotonou, Benin; René Perrin, Fondation Claudine Talon, Cotonou, Benin; Doreen Ramogola-Masire, University of Botswana, Gaborone, Botswana; Lame Seema, Gontse Tshisimogo, Ministry of Health, Gaborone, Botswana; Carla Barbosa, Sonia Ferreira, Ministry of Health, Praia, Cabo Verde; Paul Ndom, Comité National de Lutte contre le Cancer, Yaounde, Cameroon; Nkele Ndeki Ngoh, Women's Health Promotion in Cameroon, Yaounde, Cameroon; Sona Franklin Mukete, National Cancer Control Committee, Yaounde, Cameroon; Jean-Marie Dangou, WHO Regional Office for Africa, Division of Prevention and Control of Noncommunicable Diseases, Brazzaville, Congo; Takelech Asnake, Ministry of Health, Addis Ababa, Ethiopia; Kouassi Dinard, Director, Jacques Kathe Ayerebi, Denise Kpebo, Institut National de Santé Publique, Abidjan, Côte d'Ivoire; Bakare Herve Julius, Adie Yao, Programme National de Lutte contre le Cancer, Abidjan, Côte d'Ivoire; Valerian Mwenda, Mary Nyangasi, Ministry of Health, Nairobi, Kenya; Ismail M. Siala, Tripoli Cancer Center, Tripoli, Libya; Adel A. Attia, Ministry of Health, Benghazi, Libya; Jonathan Chiwanda Banda, Ministry of Health, Lilongwe, Malawi; Rachid Bekkali, Maria Bennani, Youssef Chami, The Lalla Salma Foundation for the Prevention and Treatment of Cancers, Rabat, Morocco; Loubna Abousselham, Latifa Belakhel, Ministry of Health, Rabat, Morocco; Hanane Belcadi, Zakia Ghaffouli, Chakib Nejari, Faculty of Medicine of Fez, Morocco; Rosita Paulo Mugolo, Reginaldo de Alice Miguel Julião, Ministry of Health, Maputo, Mozambique; Charlotte Buys, Rose-Marie De Waldt, Ministry of Health and Social Services, Windhoek, Namibia; Hagenimana Marc, Rwanda Biomedical Centre, Kigali, Rwanda; Inga Mumukunde, Clinton Health Access Initiative, Kigali, Rwanda; Yacine Dieng, Babacar Guèye, Marie Khemesse Ngom Ndiaye, Ministry of Health, Dakar, Senegal; Rokhaya Dada Sy, Gaspard Kamara Center, Dakar, Senegal; Manala Makua, Ministry of Health, Pretoria, South Africa; Lynette Denny, Department of Obstetrics and Gynaecology, Faculty of Health Sciences, Cape Town, South Africa; Bridget Kebirungi, Mugabe Frank Rwabinumi, Ministry of Health, Uganda; Jonas Tairo, Benjamin Mkapa Hospital, Dar es Salaam, United Republic of Tanzania; Sharon Kapambwe, Director, Cervical Cancer Prevention Programme, Lusaka, Zambia; Charlotte Kasempa, Humphrey Mwape, Namakau Nyambe, Centre for Infectious Diseases Research in Zambia, Lusaka, Zambia; Dorothy Lombe, Cancer Disease Hospital, Lusaka, Zambia; Groesbeck P. Parham, UNC Global Projects, Lusaka, Zambia; Lloyd Mulenga, National HIV Programme Coordinator, Zambia Ministry of Health, Lusaka, Zambia; Mike Chirenje, Professor of Obstetrics and Gynaecology, Bothwell Takaingofa Guzha, Anna Nyakabau, University of Zimbabwe, Harare, Zimbabwe.

Asia

Ashrafun Nessa, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh; Youlin Qiao, Fanghui Zhao, Cancer Institute of the Chinese Academy of Medical Sciences, Beijing, China; Nasim Pourgazian, Slim Slama, WHO EMRO, Cairo, Egypt; B.V. Bhat, Krishnanandha Pai, Malabar Cancer Care Society, Kannur, India; Anita Gadgil, BARC Hospital, Mumbai, India; Dipnrita Banerjee, Ranajit Mandal, Chittaranjan National Cancer Institute, Kolkata, India; Ravi Kannan, Director, Cachar Cancer Hospital and Research Centre, Silchar, India; Neerja Bhatla, Shachi Vashist, All India Institute of Medical Sciences, New Delhi, India; Pulikatil Okkaru Esmay, Anil Kumar, Vinod Joseph Mammen, Christian Fellowship Community Health Centre, Ambillikai, India; Rohini Patel, Anand Shah, Gujarat Cancer and Research Institute (GCRI), M.P. Shah Cancer Hospital, Ahmedabad, India; David Remlala, Eric Zomawia, Andy Zorinsanga, Civil Hospital Aizawl, Mizoram, India; Nisha Gautam, Mitu Mukhia, Yogesh Verma, Sikkim Manipal Institute of Medical Sciences, Gangtok, Sikkim, India; Sutapa Biswas, Maqsood Siddiqi, Cancer Foundation of India, Kolkata, India; Rajendra Badwe, Askoh Patil, Sharmila Pimple, Tata Memorial Centre, Mumbai, India; Uma Divate, Radhika Jadhav, Smita Joshi, Jehangir Clinical Development Centre (JCDC) Pvt. Ltd Jehangir Hospital Premises, Pune, India; Usha Rani Reddi Poli, Renuka Poojari, Indian Institute of Public Health, Hyderabad, India; Lopamudra Ray Saraswati, Research Triangle Institute (RTI) Global India, India; Roopa Hariprasad, ICMR-National Institute of Cancer Prevention and Research, New Delhi, India; M.K. Chauhan, Aruna S. Chiwate, Sanjay Hingmire, Kasturi Jayant, Sylla G. Malvi, Yogesh Somani, Anand Sopal, Nargis Dutt Memorial Cancer Hospital, Barshi, India; Devasena Anantharaman, Jinu Austin, Subha Sankaran, Lekshmy SR, Kannan TR, Rajiv Gandhi Centre for Biotechnology, Trivandrum, India; Kirti Jain, Manoj Mahajan, GBH Cancer Memorial Hospital, Udaipur, India; Beela Sara Mathew, Kunnambath Ramadas, Thara Somanathan, Ramani Wesley, Regional Cancer Centre, Trivandrum, India; K. Malliga, V. Shanta, R. Swaminathan, Rajkumar Thangarajan, Cancer Institute (WIA), Chennai, India; Gerard Selvam, Tamil Nadu Health Systems Project Cervical Screening Programme, Chennai, India; Kunal Oswal, Tata Trusts (Alamelu Charitable Foundation), Mumbai, India; Reza Malekzadeh, Hamideh Salimzadeh, Tehran, Islamic Republic of Iran; Kazem Zendejdel, Ministry of Health, Iranian National Cancer Control Committee, Tehran, Islamic Republic of Iran; Kumiko Saika, National Cancer Center, Tokyo, Japan; Jae Kwan Jun, Kyeongmin Lee, National Cancer Center, Goyang-si, Republic of Korea; Samar Al Homoud, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia; Fatina Mohamed Al Tahan, Ministry of Health, Riyadh, Saudi Arabia; Vindya Kumarapeli, Suraj Perera, Sudath Samaraweera, Padmaka Silva, Ministry of Health, Colombo, Sri Lanka; Suleeporn Sangrajrang, National Cancer Institute, Thailand; Wachara Eamratsameekool, Phanomphrai Community Hospital, Roi Et, Thailand; Murat Gültekin, Murat Tuncer, National Cancer Control Programme, Turkey; Fahriye Unlu, Ministry of Health, Ankara, Turkey; Ibtihal Fadhil, Dubai, United Arab Emirates.

Australasia

Natasha Bartlett, Australian Institute of Health and Welfare, Darlinghurst, Australia; Julia Brotherton, Medical Director, VCS Foundation, Melbourne, Australia; Karen Canfell, Director, Cancer Research Division, Cancer Council NSW, Australia; Jane O'Hallahan, National Screening Unit, Ministry of Health, Wellington, New Zealand; Diana Sarfati, Department of Public Health, University of Otago, Wellington, New Zealand.

Europe

Viacheslav Kurchin, N.N. Alexandrov National Cancer Centre, Minsk, Belarus; David Ritchie, Association of European Cancer Leagues (ECL), Brussels, Belgium; Irina Todorova, Nauchno-Uzsledovatel'ski Centre Psihologiya I Zdrave Fondatsiya, Bulgaria; Berit Andersen, Regionshospitalet Randers (RHR), Department of Public Health Programmes, Randers, Denmark; Anneli Uusküla, University of Tartu, Tartu, Estonia; Ahti Anttila, Finnish Cancer Registry, Helsinki, Finland; Gery Lamblin, Karine Le Bail Carval, Hôpital Femme Mère Enfant, Bron, France; Xavier Carcopino, Hôpital Nord, Service de Gynécologie, Marseille, France; Marc Bardou, Allan Lançon, CHU de Dijon, Dijon, France; Christiane Dascher-Nadel, INSERM Transfert SA, Paris, France; Jean-Claude Dupont, Lisa Rochaix, Lucie Sabin, Ecole d'Economie de Paris, Paris, France; Françoise Hamers, Coordinatrice Evaluation des dépistages des cancers, Agence nationale de santé publique, Saint-Maurice, France; Guy Launoy, Université de Caen, Caen, France; Ulrike Helbig, German Cancer Society, Berlin, Germany; Eva Kantelhardt, Martin Luther University of Halle-Wittenberg, Halle, Germany; Noemi Bender, Martin Müller, Kristina Prager, Tim Waterboer, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany; Vanessa Moore, European Institute of Women's Health, Dublin, Ireland; Paolo Giorgi Rossi, Azienda Unità Sanitaria Locale di Reggio Emilia, Montecchio Emilia, Italy; Silvia Deandrea, Paolo Guglielmetti, Joint Research Council, European Commission, Ispra, Italy; Livia Giordano, Antonio Ponti, Guglielmo Ronco, Nereo Segnan, Carlo Senore, CPO Piemonte, Torino, Italy; Harry de Koning, Erasmus MC Foundation, Rotterdam, The Netherlands; Mirza Balaj, Terje Andreas Eikemo, Norwegian University of Science and Technology (NTNU), Norway; Bjørn Morten Hofmann, Norwegian University of Science and Technology, Trondheim, Norway; Trude Andreassen, Norwegian Directorate of Health, Oslo, Norway; Gry Baadstrand Skare, Cancer Registry of Norway, Oslo, Norway; Solveig Hofvind, BreastScreen Norway, Oslo, Norway; Linn Fenna Groeneveld, Kreftregisteret, Oslo, Norway; Nuno Lunet, Instituto de Saúde Pública da Universidade do Porto, Porto, Portugal; Adriana Baban, Universitatea Babeş-Bolyai, Cluj-Napoca, Romania; Florian Nicula, Institutul Oncologic, Cluj-Napoca, Romania; Silvina Arrosi, Consejo Nacional de Investigaciones Científicas y Técnicas, Madrid, Spain; Isabel Portillo, Osakidetza – Servicio Vasco de Salud, Bilbao, Spain; Jone Miren Altzibar, Osakidetza – Servicio Vasco de Salud, San Sebastián, Spain; Edurne Arenaza, Osakidetza – Servicio Vasco de Salud, Vitoria, Spain; Joakim Dillner, Karolinska Hospital, Stockholm, Sweden; Nathalie Broutet, Andre Ilbawi, Surabhi Joshi, Cherian Varghese, WHO, Geneva, Switzerland; Julie Torode, Union for International Cancer Control (UICC), Geneva, Switzerland; Julia Bohlius, Katayoun Taghavi, Institute of Social and Preventive Medicine (ISPM), Bern, Switzerland; Peter Sasieni, Biostatistics and Cancer Epidemiology Group, Cancer Research UK Centre for Epidemiology, Mathematics and Statistics, Clinical Centre at Barts, Wolfson Institute of Preventive Medicine, London, United Kingdom; Ihtesham Rehman, Lancaster University, Lancaster, United Kingdom; Richard Sullivan, Kings College London, United Kingdom; Kelly Howard, Rosa Legood, Deborah Watson-Jones, London School of Hygiene and Tropical Medicine Royal Charter, London, United Kingdom; Clare Bamba, Newcastle University, Newcastle, United Kingdom; Adam Todd, Newcastle University, Newcastle, United Kingdom.

North America

Cindy Law, Jill Tinmouth, Canadian Screening for CRC Research Network, Toronto, Canada; Daniel Sadowski, Alberta Colorectal Cancer Screening Program, Calgary, Canada; Sarah Fournier, Marie-Helene Guertin, Institut national de santé publique du Québec, Canada; Scott Antle, Eastern Health, St John's, Canada; Sarah Fournier, Shelley Polos, Saskatchewan Cancer Agency, Regina, Canada; Simbi Ebenuwah, CancerCare Manitoba, Winnipeg, Canada; Kumar Eshwar, New Brunswick Cancer Network, New Brunswick, Canada; Bronwen McCurdy, CancerCare Ontario, Toronto, Canada; Linda Rabeneck, University of Toronto, Canada; Gitika Panicker, Mona Saraiya, Elizabeth Unger, CDC, Atlanta, USA; Silvana Luciani, Pan American Health Organization, Washington, USA; Houston Baker, Vikram Sahasrabudhe, Stephen Taplin, National Cancer Institute, Bethesda, USA; Ben Anderson, Professor of Surgery, University of Seattle, Seattle, USA; Douglas Puricelli Perin, National Cancer Institute Center for Global Health, USA; Edward L. Trimble, National Cancer Institute, Rockville, USA; Darcy W. Rao, University of Washington, Seattle, USA; Neha Kumar, Soham Pathak, Neo Sense Vector, Allentown, USA; Silvia de Sanjosé, National Cancer Institute and PATH, Seattle, USA; Robert Smith, Senior Vice President, Cancer Screening, American Cancer Society (ACS), Atlanta, USA.

South America

Silvina Arrosi, Programme Manager, National Cervical Screening Programme, Buenos Aires, Argentina; Camille Deleveaux, Ministry of Health, Nassau, Bahamas; Jeanette Andrews-Barr, Constance Ginton-Rolle, Princess Margaret Hospital, Nassau, Bahamas; Marianna de Camargo, Arn Migowski, National Cancer Institute, INCA, Rio de Janeiro, Brazil; Caterina Ferreccio, Pontificia Universidad Católica de Chile, Santiago, Chile; Gina Merino, Juvenal A. Ríos, Ministerio de Salud, Santiago, Chile; Raúl Murillo, Centro Oncológico Javeriano, Hospital Universitario San Ignacio, Bogotá, Colombia; Heidy García, Omaira Isabel Roldán, Teresa del Carmen Moreno, Yolanda Inés Sandoval, Ministerio de Salud y Protección Social, Bogotá, Colombia; Asha Martin, Dominica-China Friendship Hospital, Roseau, Dominica; Marina Andrea Chacón, Reina Oliva Hernández, Mario Morales Velado, Ministerio de Salud, San Salvador, El Salvador; Myanna Charles, Leandra Charles, Ministry of Health, St George's, Grenada; Sorana McLeish, General Hospital, St George's, Grenada; Martin Campbell, Ministry of Health, Georgetown, Guyana; Penelope Layne, Cancer Registry, Georgetown, Guyana; Jacqueline Figueroa, Secretaria de Salud, Tegucigalpa, Honduras; Yasmine Hanna, Londi-ann Ottey, Cathi-Ann Williams, Ministry of Health and Wellness, Kingston, Jamaica; Eduardo Lazcano-Ponce, Instituto Nacional de Salud Pública de México, Mexico; Elías Yused Argüello, Adriana Milano Castillo, Velia Rosas, Secretaría de Salud, Ciudad de México, Mexico; Xiomara Isabel Ruiz, Ministerio de Salud, Managua, Nicaragua; Elsa Arenas, Geneva Mireya González, Oris Mariela Ruiz, Ministerio de Salud, Ciudad de Panamá, Panama; Alicia Pomata, Ministerio de Salud Pública y Bienestar Social, Capiatá, Paraguay; Lourdes Ortega, Ministerio de Salud, Lima, Peru; Arlitha Scott, Ministry of Health, Saint Vincent and the Grenadines; Els Dams, Diakonessen Hospital, Paramaribo, Suriname; Nensy Bandhoe, Lobi Health Center Foundation, Paramaribo, Suriname; Cheshta Sewtahal, Ministry of Health, Paramaribo, Suriname.

The Laboratory Services and Biobank Group (LSB) is grateful to the following for their collaboration:

Tamara Sarkisian, Armenia; Daniel Catchpoole, Australia; Jens Habermann, Lukasz Kozera, Michaela T. Mayrhofer, Christine Ann Mitchell, Karine Sargsyan, Austria; Brent Schacter, Canada; Jason Chen, Io Hong Cheong, Younchang Shao, Hui Wang, Xun Xu, China; Judita Kinkorova, Czechia; Sameera Ezzat, Amany Maher, Ahmed Samir, Egypt; Brenda Bogaert, Emmanuelle Gormally, Marina Rousseau-Tsangaris, Pierre Saintigny, Severine Tabone-Eglinger, France; Lena Krieger, Germany; Wiku Adisasmito, Dewi Nur Aisyah, Jajah Fachiroh, Indonesia; Rita Lawlor, Italy; Koh Furuta, Japan; Chite Asirwa, Kenya; Morten Øien, Norway; Joanna Glenska-Olender, Agnieszka Matera-Witkiewicz, Poland; Nahla Afifi, Qatar; Daniel Simeon-Dubach, Switzerland; Alison Parry-Jones, United Kingdom; Clare Allocca, Marianna Bledsoe, Dayong Gao, Deborah Garcia, Marianne K. Henderson, John Litaker, Adonis Sfera, Jim Vaught, USA.

ACKNOWLEDGEMENTS OF SUPPORT

SECTION OF CANCER SURVEILLANCE (CSU)

The Section of Cancer Surveillance (CSU) gratefully acknowledges financial support from the following:

American Cancer Society (ACS), USA
Australian Government, Australia
Cancer Research UK (CRUK), United Kingdom
Centers for Disease Control and Prevention (CDC), USA
Children with Cancer UK, United Kingdom
European Society for Medical Oncology (ESMO), Switzerland
Institut national du Cancer (INCa), France
Medical Research Council (MRC), United Kingdom
National Cancer Institute (NCI), USA
Nordic Cancer Union
Seventh Framework Programme (FP7/2007–2013) of the European Commission
St. Jude Children's Research Hospital, USA
Susan G. Komen Foundation, USA
Union for International Cancer Control (UICC), Switzerland
Vital Strategies, USA
WHO NCDs, Disability, Violence and Injury Prevention (NVI)
WHO Pan American Health Organization
WHO Regional Office for Europe
WHO Regional Office for the Eastern Mediterranean
World Cancer Research Fund, United Kingdom

SECTION OF EVIDENCE SYNTHESIS AND CLASSIFICATION (ESC)

The IARC Monographs Group (IMO) gratefully acknowledges financial support from the following:

European Commission Directorate-General for Employment, Social Affairs, and Inclusion
National Cancer Institute (NCI), National Institutes of Health (NIH), USA
National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH), USA

The IARC Handbooks Group (IHB) gratefully acknowledges financial support from the following:

American Cancer Society (ACS), USA
Canadian Partnership Against Cancer (CPAC), Canada
Centers for Disease Control and Prevention (CDC), USA
Institut national du Cancer (INCa), France
Medical Research Council (MRC), United Kingdom

SECTION OF MECHANISMS OF CARCINOGENESIS (MCA)

The Epigenetics Group (EGE) gratefully acknowledges financial support from the following:

Agence nationale de recherches sur le sida et les hépatites virales (ANRS), France
American University of Beirut, Lebanon
Association pour la recherche sur le Cancer (ARC), France
Campus France, France
Canadian Institutes of Health Research (CIHR), Canada
Cancéropôle Lyon Auvergne Rhône-Alpes (CLARA), France
European Commission, Belgium
Institut national de la santé et de la recherche médicale (INSERM), France
Institut national du Cancer (INCa), France
King Hussein Cancer Center, Jordan
La Ligue contre le Cancer, France
Ministère de l'Europe et des Affaires étrangères, France
Ministry of Education, Malaysia
National Cancer Institute (NCI), National Institutes of Health (NIH), USA
Research Foundation – Flanders, Belgium
University of Bergen, Norway
University of Ottawa, Canada

The Molecular Mechanisms and Biomarkers Group (MMB) gratefully acknowledges financial support from the following:

Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES), France
Cancer Research UK (CRUK), United Kingdom
Charles University Grant Agency, Czechia
Fondation ARC pour la recherche sur le Cancer, France
Fondation de France, France
Institut national du Cancer (INCa), France
National Cancer Institute (NCI), National Institutes of Health (NIH), USA
National Medical Research Council (NMRC), Singapore
Research Foundation – Flanders (FWO), Belgium
World Cancer Research Fund International, United Kingdom

SECTION OF INFECTIONS (INF)

The Infections and Cancer Biology Group (ICB) gratefully acknowledges financial support from the following:

Cancer Research UK (CRUK), United Kingdom
Comité du Rhône de la Ligue nationale contre le Cancer, France
Fondation ARC pour la recherche sur le Cancer, France
Institut national de la santé et de la recherche médicale (INSERM), France
National Cancer Institute (NCI), National Institutes of Health (NIH), USA

The Infections and Cancer Epidemiology Group (ICE) gratefully acknowledges financial support from the following:

Adera, France
Agence nationale de recherches sur le sida et les hépatites virales (ANRS), France
Bill & Melinda Gates Foundation, USA
Canadian Institutes of Health Research (CIHR), Canada
First Hospital of Lanzhou University, China
Fondation de France, France
Institut national du Cancer (INCa), France
Karolinska Institutet, Sweden
RTI International India, India
Société Nationale Française de Gastro-entérologie, France
Stichting VUmc, The Netherlands
Tampere University, Finland
World Health Organization, Switzerland

SECTION OF ENVIRONMENT AND RADIATION (ENV)

The Section of Environment and Radiation (ENV) gratefully acknowledges financial support from the following:

African Academy of Science, Kenya
Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES), France
Albert Einstein Hospital, Sociedade Beneficente Israelita Brasileira Albert Einstein, Brazil
American Cancer Society (ACS), USA
Cancéropôle Lyon Auvergne Rhône-Alpes (CLARA), France
Children with Cancer UK, United Kingdom
Danish Cancer Society Research Center (DCSRC), Denmark
European Commission – Health and Food Safety (EC Santé), Belgium
Federal Ministry for the Environment, Nature Conservation and Nuclear Safety, Germany
Federal Office for Radiation Protection (BfS), Germany
Fondation de France, France
Fondation Franco-Japonaise Sasakawa, France
Institut national du Cancer (INCa), France
Medical Research Centre (MRC), United Kingdom
Métropole de Lyon, France
Ministère de l'Europe et des Affaires étrangères (MEAE), France
Ministry of the Environment, Japan
Ministry of Health, Russian Federation
National Cancer Institute (NCI), National Institutes of Health (NIH), USA
Susan G. Komen Breast Cancer Foundation, USA
World Cancer Research Fund International, United Kingdom

SECTION OF NUTRITION AND METABOLISM (NME)

The Biomarkers Group (BMA) gratefully acknowledges financial support from the following:

Agence nationale de la Recherche, France
Cancer Research UK (CRUK), United Kingdom
Cancéropôle Lyon Auvergne Rhône-Alpes (CLARA), France
European Commission, Belgium
European Molecular Biology Organization (EMBO), Germany
Fondation pour la Recherche sur le Cancer (ARC), France
Institut national du Cancer (INCa), France
Instituto de Salud Carlos III, Spain
La Ligue nationale contre le Cancer, France
Maastricht University, The Netherlands
National Cancer Institute (NCI), National Institutes of Health (NIH), USA
National Health and Medical Research Council, Australia
Rural Development Administration, Republic of Korea
World Cancer Research Fund (WCRF), United Kingdom

The Nutritional Epidemiology Group (NEP) gratefully acknowledges financial support from the following:

American Cancer Society (ACS), USA
Cancer Research UK (CRUK), United Kingdom
Crohn's and Colitis UK, United Kingdom
European Commission, Belgium
Fondation de France, France
Health Research Board, Ireland
Institut national du Cancer (INCa), France
La Ligue nationale contre le Cancer, France
National Cancer Institute (NCI), National Institutes of Health (NIH), USA
United States Agency for International Development (USAID), USA
World Cancer Research Fund (WCRF), United Kingdom

The Nutritional Methodology and Biostatistics Group (NMB) gratefully acknowledges financial support from the following:

Austrian Science Fund, Austria

Fondation de France, France

Institut national du Cancer (INCa), France

Instituto de Salud Carlos III, Spain

La Ligue nationale contre le Cancer, France

National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH), USA

World Cancer Research Fund (WCRF), United Kingdom

SECTION OF GENETICS (GEN)

The Genetic Epidemiology Group (GEP) gratefully acknowledges financial support from the following:

Cancer Research UK (CRUK), United Kingdom

European Commission, Belgium

Fondation ARC pour la recherche sur le Cancer, France

Institut national du Cancer (INCa), France

International HundredK+ Cohorts Consortium (IHCC), USA

Lung Cancer Research Foundation (LCRF), USA

National Cancer Institute (NCI), National Institutes of Health (NIH), USA

National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), USA

National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health (NIH), USA

World Cancer Research Fund (WCRF), United Kingdom

The Genetic Cancer Susceptibility Group (GCS) gratefully acknowledges financial support from the following:

Dutch Cancer Society (DCS), The Netherlands

Institut national du Cancer (INCa), France

La Ligue nationale contre le Cancer (LNCC), France

Ministry of Science, Innovation, and Universities, Spain

National Cancer Institute (NCI), National Institutes of Health (NIH), USA

National Institute for Medical Research Development (NIMAD), Islamic Republic of Iran

Neuroendocrine Tumor Research Foundation (NETRF), USA

World Cancer Research Fund (WCRF), United Kingdom

SECTION OF EARLY DETECTION AND PREVENTION (EDP)

The Prevention and Implementation Group (PRI) gratefully acknowledges financial support from the following:

Association of Oncologists of the Northwestern Federal District, Russian Federation

Center for Global Health (CGH), National Cancer Institute (NCI), National Institutes of Health (NIH), USA

Department of Reproductive Health and Research, World Health Organization, Switzerland

European Union and United Nations agencies (UNDP, UNICEF, WHO, UNFPA)

Institut national du Cancer (INCa), France

The Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland

WHO Country Office, Belarus

WHO Regional Office for Europe, Denmark

The Screening Group (SCR) gratefully acknowledges financial support from the following:

American Cancer Society (ACS), USA

Bill & Melinda Gates Foundation, USA

Cancer Research UK (CRUK), United Kingdom

Centers for Disease Control and Prevention (CDC), USA

European Commission, Belgium

Grand Lyon – Métropole, France

Institut national du Cancer (INCa), France

Lalla Salma Foundation, Morocco

Medical Research Council (MRC), United Kingdom

Ministry of Health, Government of Thailand

National Cancer Institute, Thailand

National Cancer Institute (NCI), National Institutes of Health (NIH), USA

Research Council of Norway
Union for International Cancer Control (UICC), Switzerland
WHO headquarters, Switzerland
WHO Regional Office for Europe, Denmark

The Laboratory Services and Biobank Group (LSB) gratefully acknowledges financial support from the following:

Biobanking and BioMolecular resources Research Infrastructure Consortium–European Research Infrastructure Consortium (BBMRI-ERIC), Austria
Cancéropôle Lyon Auvergne Rhône-Alpes (CLARA), France
Catholic University of Lyon, France
Center for Global Health, National Cancer Institute (NCI), National Institutes of Health (NIH), USA
Centre Léon Bérard (CLB), France
European Commission, Belgium